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Preface 
This dissertation entitled “Subtype-selective Neuronal Nicotinic Acetylcholine Receptor 
Agonists and Antagonists” describes the research performed as part of the PhD program of 
Pharmaceutical Sciences at the Department of Pharmaceutical Sciences at the University of 
Milan from October 2015 to September 2018, that resulted in three publications. In addition to 
the PhD project, some time was dedicated to green chemistry topics, which are not included in 
this thesis, but resulted in three publications. The chemistry experimental work was performed 
at the department of Pharmaceutical Sciences, University of Milan, and was supervised by 
Researcher Dr. Cristiano Bolchi and Full Professor Marco Pallavicini as Principal Scientist.  
The time period from March 2017 to August 2017 was spent at the department of Drug Design 
and Pharmacology, University of Copenhagen, under the supervision of Professor Bente 
Frølund and Dr. Kasper Harpsøe. The computational work conducted during this period is not 
included as an integrated part of this thesis. Some of the work performed at University of 
Copenhagen is described in the article published in Journal of Medicinal Chemistry. 
The PhD program was financed by The University of Milan. 
The title of the thesis is based on the research conducted at University of Milan. Figures, 
schemes, tables, and references are numbered consecutively through the text. Final compounds 
already described in literature are identified by roman progressive numbers; unreported final 
compounds and intermediate chemical compounds are identified by Arabic progressive 
numbers.  
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Abstract 
This PhD thesis focuses on two specific targets, belonging to the same receptor class of 
Nicotinic Acetylcholine Receptors (nAChRs): the α4β2 subtype and the α7 subtype. This 
elaborate is divided in two parts. The aim of the first part is the design and synthesis of α4β2 
selective partial agonists as potential smoking-cessation agents. The aim of the second part is 
the design and synthesis of α7 antagonists with mitocan properties as antitumoral agents. 
Part 1.  
In the first project, a series of 3-nitrophenyl ethers and 3-hydroxyphenyl ethers of (S)-N-
methylprolinol bearing bulky and lipophilic substituents at the C5 were designed, synthesized 
and assayed as putative selective α4β2 ligands. Two of them, 5-substituted with a 6-hydroxy-
1-hexynyl, had high α4β2 affinity and increased α4β2/α3β4 selectivity when compared with the 
correspondent unsubstituted parent compounds.  
In the second project, each -CH= of the unselective antagonist (S,R)-N-methyl-2-pyrrolidinyl-
1,4-benzodioxane and of its epimer at the benzodioxane stereocenter, was replaced by a 
nitrogen. The resulting four diastereomeric pairs of pyrrolidinyl-pyridodioxanes, also designed 
as the product of rigidification of the flexible scaffolds of pyridyl ethers of N-methyl prolinol, 
were studied for their nicotinic affinity at the α4β2 and α3β4. The isosteric -CH= to N 
substitution was detrimental for all the compounds, with the only exception of N-Methyl-
pyrrolidinyl 5-pyridodioxane, with the nitrogen at position 5. Indeed, this ligand had similar 
affinity to its benzodioxane parent compound, but it had high α4β2/α3β4 selectivity and it was 
shown to be a selective partial agonist.  
In the third project, the unselective antagonist (S,R)-N-methyl-2-pyrrolidinyl-1,4-benzodioxane 
and of its epimer at the benzodioxane stereocenter were substituted at position 5 of the 
benzodioxane moiety, to explore the possibility of introducing selectivity and/or partial agonist 
as previously done with -CH= to N replacement. Among the synthesized compounds, (S,S)-N-
Methyl-pyrrolidinyl-5-amino-benzodioxane had slightly improved affinity at the α4β2 affinity 
and highly enhanced α4β2/α3β4 selectivity than the unsubstituted parent compound, and it was 
shown to be a very potent partial agonist. 
In the fourth project, we applied computational techniques to support the interpretation of the 
biological results regarding N-Methyl-pyrrolidinyl 5-substituted benzodioxanes and 
pyridodioxanes. From these findings, we suggested that partial agonism and α4β2/α3β4 
selectivity could be achieved when the benzodioxane scaffold is appropriately substituted with 
V 
 
an HBA/HBD system, that can displace a water molecule from a small and hydrophilic 
subpocket of the binding site.  
Part 2. 
Adenocarcinoma and glioblastoma cell lines express α7 and α9-α10 nAChRs, whose activation 
promotes tumor cells growth. On these cells, the triethylammoniumethyl ether of 4-stilbenol 
MG624, a known selective antagonist of α7 and α9-α10 nAChRs, has antiproliferative activity. 
The structural analogy of MG624 with the mitocan RDM-4’BTPI, triphenylphosphoniumbutyl 
ether of pterostilbene, suggested us that molecular hybridization among their three 
substructures might result in novel antitumour agents with higher potency and selectivity. We 
found that replacement of ethylene with butylene in the triethylammonium derivatives results 
in more potent and selective toxicity towards adenocarcinoma and glioblastoma cells, which 
was paralleled by increased α7 and α9-α10 nAChR antagonism and improved ability of 
reducing mitochondrial ATP production. Further elongation to octylene (26) provided a 
compound with 40-fold and 10-fold increased antiglioblastoma and antiadenocarcinoma 
activity respectively, when compared to MG624. Elongation of the alkylene linker was greatly 
advantageous also for the triphenylphosphonium derivatives. RDM-4’BTPI did not acquire, as 
expectable, antinicotinic activity by hybridization with MG624 stilbene scaffold, but it was 
surpassed in glioblastoma cell viability reduction by its stilbene analogues with > 4C alkylene 
linker. In particular, the analogue with decylene between stilbenoxyl and 
triphenylphosphonium head (24) was ten-fold and two-fold more potent than RDM-4’BTPI in 
reducing glioblastoma cell viability and in increasing ROS production respectively. Overall, 
the ammonium compound 26 reached antiproliferative activities at glioblastoma and 
adenocarcinoma cells in the same range of the phosphonium 24, but showed good selectivity 
against neuroblastoma and healthy mouse astrocytes.  
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Abbreviations and acronyms 
α-Bgtx   α-Bungarotoxin  
A549   Cell line of adenocarcinomic human alveolar basal epithelial cells 
ACh   Acetylcholine 
AChBP  Acetylcholine Binding Protein 
AChE   Acetylcholine esterase 
ACN   Acetonitrile 
AcOH    Acetic Acid 
ADHD  Attention Deficit Hyperactivity Disorder 
Aq.   Aqueous 
ArIB   α7-specific antagonist α-Conotoxin 
BBB   Blood Brain Barrier 
bFGF   basic Fibroblast Grow Factor 
Bn   Benzyl 
Boc   tert-Butoxycarbonyl 
Bu   Butyl 
Cbz   Carboxybenzyl 
ChAT   Choline Acetyltransferase 
CHRNA7   Gene that encodes for neuronal acetylcholine receptor subunit alpha-7 
CHRNA9  Gene that encodes for neuronal acetylcholine receptor subunit alpha-9 
ChT   Choline Transporter 
CI   Confidence Interval 
CoA   Coenzyme A 
CPu   Caudate nucleus-Putamen 
CryoEM  Cryo Electron Microscopy 
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CTD   C-Terminal Domain 
CV%   Coefficient of Variation Percentage 
DA   Dopamine 
DCM   Dichloromethane 
DEAD   Diethyl Azodicarboxylate 
DIAD   Diisopropyl Azodicarboxylate 
DIPEA  N,N-Diisopropylethylamine 
DME   Dimethoxyethane 
DMSO  Dimethylsulphoxide 
DOM   Direct -orto methallation 
EC50 The molar concentration of an agonist that produces 50% of the maximal 
possible effect of an agonist  
ECD   Extracellular Domain 
EMA   European Medicines Agency 
Epi   Epibatidine 
ERK1 Extracellular signal-regulated kinase 1: protein-serine/threonine kinase 
or mitogen activated kinase 
ERK2 Extracellular signal-regulated kinase 2: protein-serine/threonine kinase 
or mitogen activated kinase 
Et   Ethyl 
FACS   Fluorescence-activated cell sorting 
FDA   US Food and Drug Administration 
FOS   Transcription Factor 
GABA   -aminobutyric acid 
GABA-A    -aminobutyric acid receptor A 
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GABA-C   -aminobutyric acid receptor C 
5-HT3   Serotonin receptor 3 
GH4C1  rat anterior pituitary cell line  
GID   unselective α-Conotoxin (antagonist at the α4β2, α3β4 and α7 subtype) 
GPCR   G-Protein Coupled Receptor 
h   hour    
H1975   Human non-small-cell lung cancer cell line 
HBA   Hydrogen Bond Acceptor 
HBD   Hydrogen Bond Donor 
HEK 243  Human Embryonic Kidney 243 cell line 
HepG2  Human Caucasian hepatocyte carcinoma cell line 
HPLC   High Performance Liquid Chromatography 
HS   High Sensitive 
i-Bu   iso-butyl   
IC50 The molar concentration of an antagonist that inhibits 50% of the 
maximal possible effect of an agonist. 
ICD   Intracellular Domain 
Imax Maximal current elicited by the agonist used as a control in an 
electrophysiologic assay. 
JUN   Transcription Factor 
Ki   The equilibrium dissociation constant of a ligand determined in  
   inhibition studies 
LBD   Ligand Binding Domain 
LGIC   Ligand-Gated Ion Channel 
LS   Low Sensitive 
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mAChR  Muscle Acetylcholine Receptor 
mCPBA  meta-chloroperbenzoic acid 
MEM   2-Methoxyethoxymethyl 
MeOH   Methanol 
Me   Methyl 
Min   Minutes 
MLA   Methyllycaconitine 
MoA   Mechanism of Action  
Ms   Mesyl 
MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium) 
MTS assay Assay that uses MTS to assess methabolic activity 
MW   Microwave irradiation 
MWC   Monod-Wyman-Changeux 
MYC   Transcription factor 
N.D.   Not Detectable 
NAc   Nucleus Accumbens 
nAChR  Nicotinic Acetylcholine Receptors 
NIH   National Institute of Health 
NMDA  N-Methyl-D-Aspartate  
NMR   Nuclear Magnetic Resonance 
NNK   Nikotine-derived Nitrosamine Ketone 
NNN   N-Nitroso Nornicotine 
NRT   Nicotine Replacement Therapy 
NSCLC  Non-Small-Cell Lung Carcinoma 
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NTD   N-Terminal Domain 
OT   Olfactory Tubercle 
pAKT   Phosphorylated AKT 
PAM   Positive Allosteric Modulator 
PDB-ID  Protein DataBank IDentifier 
pERK   Phosphorylated ERK 
Pg   Protecting Group 
Ph   Phenyl 
pic-BH3  Picoline-borane 
PKC   Protein Kinase C 
pLGIC   Pentameric Ligand-Gated Ion Channel 
PNS   Peripheral Nervous System 
Pr   Propyl 
RAF1   Serine/Threonine kinase, Proto-oncogene 
RFU   Reference Fluorescence Units 
RgIA4   α9-specific antagonist α-Conotoxin 
ROS   Reactive Oxygen Species 
Rt   Room Temperature 
SAR   Structure-Activity Relationship 
Sat.   Saturated  
SCLC   Small-Cell Lung Carcinoma 
SEM   Standard Error of Mean 
SH-SY5Y  Human Neuroblastoma cell line 
siRNA   Small Interference RNA 
XI 
 
SN   Substantia Nigra 
t-Bu   tert-butyl    
Td   triplet of doublets 
TEA   Triethylamine 
TFA   Trifluroacetic Acid 
THF   Tetrahydrofuran 
TM   Trans Membrane 
TMD   Trans Membrane Domain 
TNF-α   Tumor Necrosis Factor α 
TPP+   Triphenyl Phosphonium Cation 
Tr   Trytyl 
U87MG  Uppsala-87 Malignant Glioma, human primary glioblastoma cell line 
VAChT  Vesicular Acetylcholine Transporter  
VdW   Van der Waals 
VEGF   Vascular Endothelial Grow Factor 
VTA   Ventral Tegmental Area 
WHO   World Health Organization 
The 3-letter and 1-letter IUPAC nomenclature are used for the 21 proteinogenic amino acids. 
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Nicotinic acetylcholine receptors (nAChRs) 
General structure and function 
Acetylcholine (ACh), one of the most important neurotransmitters both in the central nervous 
system (CNS) and in the peripheral nervous system (PNS), exerts its physiological effects by 
acting on two classes of receptors: muscarinic acetylcholine receptors (mAChRs) and nicotinic 
acetylcholine receptors (nAChRs), whose most known exogenous agonists are muscarine and 
nicotine, respectively (Figure 1). 
 
Figure 1: the endogenous neurotransmitter acetylcholine, the exogenous nAChR agonist (S)-Nicotine 
and mAChRs agonist Muscarine 
mAChRs are seven-transmembrane domain receptors (7TM) and belong to the G-coupled 
receptors superfamily (GPCRs), whose activation, upon neurotransmitter binding, consists in 
an intracellular G-protein mediated metabotropic response.1 
Oppositely, nAChRs are ligand-gated ion channels (LGICs), and are therefore integral 
transmembrane proteins containing a pore that allows a regulated ion flux. Pore opening and, 
consequently, channel gating is triggered by a neurotransmitter (or, more broadly speaking, by 
an agonist).2 
Specifically, nAChRs are homo- or heteropentameric ion channels (pLGICs), composed by 5 
identical or different subunits surrounding a central and axial aqueous pore, permeable to mono- 
and/or divalent- cations. Each subunit is a polypeptide of approximately 500 amino acids, that 
begins with a short C-terminal extracellular domain (CTD), crosses the membrane 4 times with 
helical transmembrane domains (TMD), and ends in a long N-terminal extracellular domain 
(NTD). The NTD contains a loop of approximately 13 amino acids, constrained by a disulphide 
bridge between two cysteines, whose integrity is crucial for the architecture and function of the 
channel (Cys-loop receptors).3 
The orthosteric binding site is located in the ligand binding domain (LBD), contained in the 
extracellular domain, at the interface between two adjacent subunits, provided that they have 
the appropriate architecture to correctly form it. 
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Upon agonist binding at the orthosteric site, the channel opens and cations such as Na+, Ca2+ 
and K+ flux according to their electrochemical gradient (Na+ and Ca2+ inward, K+ outward), 
causing net membrane depolarization (Figure 2). The physiological consequences depend on 
their localization. Originally, nAChRs have been classified according to their tissue distribution 
in muscle nAChRs and neuronal nAChRs. The coordinated activation of postsynaptic neuronal 
nAChRs can elicit an action potential, while presynaptic neuronal nAChRs have a crucial role 
in regulating neurotransmitter release.3,4 Activation of muscle nAChRs in the neuromuscular 
junction allows muscle contraction.  
 
Figure 2: schematic representation of an αβ nAChR. Acetylcholine binds at the two αβ interfaces. 
Adapted from Zoli et al.4 
Nicotinic receptor-mediated synaptic transmission plays pivotal roles both in the CNS and in 
the PNS, by regulating fast synaptic transmission, by controlling the release of other 
neurotransmitters and by influencing cell excitability. As the nicotinic cholinergic system is 
involved in various cognitive and behavioral functions, it is often impaired in CNS associated 
pathological conditions, like epilepsy, anxiety, depression, pain, neurodegenerative disorders 
such as Alzheimer and Parkinson, alcohol addiction and nicotine addiction.5 
Recently, neuronal nicotinic receptors have been also found in non-neuronal tissues, like glial 
cells, endothelial cells, immune system cells, lung epithelia, mesenchymal cells and cancer cells 
where they are involved in cell-cell signaling, cell differentiation, cell proliferation and in 
inflammatory responses.6  
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Classification 
Several classifications and nomenclatures of nAChRs, based both on classical pharmacological 
approaches and on phylogenetic approaches, have been proposed overtime. 
In 1949 Barlow, Ing, Paton and Zaimis pharmacologically distinguished muscle type nicotinic 
receptors, located in the neuromuscular junctions, from neuronal types, originally found in the 
autonomic ganglia and later identified in the nervous system, on the basis of the more effective 
antagonism of decamenthonium (C10) than hexamenthonium (C6) in blocking muscle 
nAChRs, compared to the more effective antagonism of hexamenthonium (C6) at the 
ganglionic nAChRs.7,8 (Figure 3) 
 
Figure 3: non-competitive nAChRs antagonists, originally used to classify nicotinic receptors. 
Structurally, nAChRs are combination of 5 identical or different subunits among 16 subunits 
described in humans to date. Depending on how subunits assemble, they can form many 
different homo- or heteropentamers. These subunits, namely α (α1-7, α9-10), β (β1-4), γ, δ and 
ε, have been originally divided into α, containing a disulphide bridge between two adjacent 
cysteines in the extracellular domain, and non-α. 5 Subunits (α1, β1, γ, δ and ε) assemble to 
form muscle nAChRs, while 11 (α2-7, α9-10 and β2-4) compose neuronal nAChRs.9  
Extraordinary subtype diversity is thus generated by the huge amount of possible combinations 
between subunits (Figure 4). The resulting homomeric or heteromeric receptor subtypes can 
have even profound differences in receptor pharmacology and channel function, even if 
structurally similar.10 
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Figure 4: examples of homomeric and heteromeric nAChRs. Adapted from Bouzat et al.10  
Moreover, nAChRs can be classified according to their sensitivity to the natural neurotoxic 
peptide α-bungarotoxin (α-Bgtx): those that bind α-Bgtx with high affinity and have low affinity 
for (S)-nicotine (homomeric α7 and α9; heteromeric α9α10) and those that do not, but that have 
high affinity to nicotine (heteromeric, combinations of α2-6 and β2-4).11,12 
The protein sequences, the correspondent genes, and further specific information on their 
domains, their functions, annotations etc. can be easily retrieved from the online database 
Uniprot.13 
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Electrophysiology 
Upon binding of an agonist in the orthosteric binding pocket, such as acetylcholine or nicotine, 
a conformational change of the receptor occurs and the channel pore opens, allowing a net 
influx of cations. Continuous or repeated exposure to agonists induces loss of functional 
response of nAChRs. This intriguing phenomenon, called desensitization,14 was investigated 
since 1957, when Katz and Thesleff provided a first comprehensive description of 
desensitization of muscle nAChRs, based on kinetics analysis.15 According to this two-state 
model, the ligand-free nAChRs are an equilibrium between resting and activatable state (R) and 
a desensitized non-conductive state (D). As relatively high concentrations of agonist are 
required to open the channel, the R conformation was considered to have low agonist affinity. 
Oppositely, as very low concentrations of agonist induce desensitization, D was considered a 
high affinity conformation. When even low agonist concentrations are incubated with the 
receptor, the agonist readily binds the pre-existing desensitized state due to its higher affinity, 
shifting the equilibrium toward the agonist-bound desensitized conformation (AD), turning R 
conformations to D conformations to restore the equilibrium (Figure 5A). 
Later, this model was extended and refined until the complete cyclical model Monod-Wyman-
Changeux (MWC) was proposed in 1984.16,17 The MWC model considers all the possible 
transitions between the resting state (R), the opened and activated state (A), an intermediate 
desensitized state (I, that occurs after short exposures and has faster recovery times) and a 
desensitized state (D) (Figure 5B). 
 
Figure 5: A) Kats and Thesleff kinetic model; B) MWC kinetic model. Adapted from Quick and Lester14. 
The transition between a ligand-bound conductive conformation to a ligand-bound non-
conductive desensitized conformation occurs due to a structural reorganization of the channel, 
during which some amino acids move and close into a gate that prevent the ion flux. 
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Even though desensitization is a shared feature among the nicotinic receptors, kinetic properties 
and electrophysiology markedly vary from subtype to subtype. Currently, detailed information 
about desensitization of specific nAChR subtypes are available, thanks to the development of 
specific techniques to investigate this phenomenon.  
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Part 1: α4β2 nAChRs 
1.1 Introduction 
The most abundant nAChR subtypes in the CNS are the homopentameric α7 and the 
heteropentameric α4β2* (the * mark is used to account for an accessory subunit, the α5 subunit 
in 20% of cases, forming (α4)2(β2)2α5 subtypes). The α3β4* subtype is highly expressed in the 
autonomic ganglia, in the adrenal medulla and in special subsets of neurons in the medial 
habenula, dorsal medulla, pineal gland, nucleus interperpendicularis and retina.5,12 
The α4β2 usually assembles with two stoichiometries (2α:3β or 3α:2β), both functional but with 
different distributions, biophysical and pharmacological properties. For instance, (α4)2(β2)3 has 
been demonstrated to have 100 folds higher affinity for both nicotine and acetylcholine, lower 
single channel conductance and calcium permeability (high sensitivity, HS) than the (α4)3(β2)2 
stoichiometry (low sensitivity, LS).18–21 
1.1.1 α4β2 Architecture and electrophysiology 
Nicotinic receptors have always been considered good prototypes of pLGICs. The first 
structural information on the shape and overall architecture of nAChRs came from electron 
microscopy studies reported by Unwin in the ‘80s and ‘90s (resolution ranged from 30 Å in 
198422, to 9 Å in 199323 to 4.6 Å in 199924) . These were performed on postsynaptic membranes 
taken from electric organs of electric rays (species Torpedo Marmorata), which contains 
nAChRs. Further detailed structural information about their three-dimensional architectures 
came, starting from 2001, from the X-Ray models of some snail proteins, the Acetylcholine 
Binding Proteins (AChBPs), which are secreted by molluscan glial cells (i.e. Lymnaea Stagnalis 
or Alypsia Californica) to modulate ACh-mediated synaptic transmission.25 AChBPs are water-
soluble homologs of the extracellular domain of nicotinic receptors, with which they share high 
sequence similarity.26 As water-soluble proteins are much easier to be crystallized than 
transmembrane proteins, their X-Ray 3D structures have been widely used as surrogate models 
or as templates for homology modelling to study not only nicotinic receptors, but also other less 
similar pLGICs, like GABA-A, GABA-C, 5-HT3 and Glycine receptors. 
Obviously, even if the architecture of the ligand binding domain of nicotinic receptors is well 
represented by AChBPs, the sequences of specific subtypes deviate from the sequences of the 
molluscan surrogates. Moreover, since AChBPs aren’t transmembrane proteins, they 
completely lack TM domains and they are consequently unable to mimic the physiological 
processes of channel gating and how ligand binding induces and/or influences it. 
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Despite the huge improvements of homology modelling and other computational techniques, a 
3D X-Ray model of a native nicotinic receptor was highly recommended and sought. 
The goal was achieved in 2016, when the first X-Ray structure of the full-length native nicotinic 
α4β2 receptor was reported by Hibbs (2α:3β stoichiometry).20 
The α4β2 receptor, co-crystallized with nicotine and a cholesterol analogue at 3.9 Å resolution, 
is made of five subunits pseudo-symmetrically arranged around a central channel axis, in an 
overall cylindrical-like shape (Figure 6A). As mentioned above, each subunit comprises a large 
extracellular N-terminal domain, followed by three α-helices which cross the membrane (M1-
M3) and further continue in an intracellular MX helix connected to another transmembrane α-
helix (M4) facing the channel pore, and a short extracellular C-terminal domain. 
If looked from the side, three main portions are easily distinguished: the large extracellular 
domain (ECD), containing the ligand binding domain (LBD), the transmembrane region (TM) 
and the intracellular domain (ICD). In the ECD, each subunit contains an α-helix followed by 
10 strands wrapped inward to form a sandwich. 
The cation permeable pore, easily observable from a top viewpoint of the X-Ray structure, is 
lined by the M4 helix in the TM region (Figure 6B). The channel shows a constriction point of 
3.8 Å diameter close to the cytosol, formed by glutamate side chains at the -1’ position of the 
M2 helices, which are faced on the pore. The diameter of the resulting gate is smaller than the 
minimum consensus diameter of approximately 6.8 Å that would allow the movement of the 
smallest ion (Na+) at least partially hydrated. This structural analysis, together with other 
functional analysis, were used by the authors to state that the X-Ray structure represent a non-
conductive desensitized conformation. 
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Figure 6: A) Side view and B) axial view of the X-Ray 3D structure of the (α4)2(β2)3 co-crystallized with 
nicotine (red) and with a cholesterol analogue (not shown). Na+ is shown in pink. Adapted from 
Morales-Perez et al.20 
Cationic permeability is controlled by the electrostatic properties of the channel: the surface of 
the extracellular vestibule of the pore is strongly electronegative, but becomes more neutral 
proceeding down into the pore until its extracellular end. Afterward, the electronegativity 
increases reaching its maximum at the desensitization gate, formed by 5 glutamate residues. 
This trend probably allows the vestibule to accumulate cations and then to funnel them into the 
pore (Figure 7A). 
In 2018, the same authors reported the Cryo Electron Microscopy (CryoEM) structures of the 
two different stoichiometries of the α4β2 subtypes together with specific antibody fragments 
and nicotine providing deep insights into principles underlying subunits assembly and 
differences in permeation properties between the (α4)2(β2)3 and the (α4)3(β2)2 subtypes.19 
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Figure 7: A) Representation of the pore diameter of the 3α:2β assembly: purple spheres indicate pore 
diameter over 5.6 Å, green between 2.8 and 5.6 Å and red less than 2.8 Å. B) cutaway of the α4β2 
subtype in both stoichiometries (3α:2β on the left side and 2α:3β on the right side). The permeation 
pathway is colored by electrostatic potential. Adapted from Walsh et al.19 
1.1.2 Orthosteric binding site19,20 
In the 2α:3β stoichiometry, the α4 and β2 subunits are ordered as α-β-β-α-β, forming two αβ, 
two βα and one ββ interfaces. Nicotine, acetylcholine and other orthosteric ligands bind only at 
the αβ interfaces, in the classical neurotransmitter orthosteric binding site. The binding pocket 
is lined by the α4 subunit ((+) side) and by the β2 subunit ((-) side). Both sides contribute with 
three loops to the construction of the binding site: A, B and C loops from the (+) side (α4) and 
D, E and F from the (-) side (β2). 
Nicotine is located within a tightly packed so-called “aromatic box”, paved by tyrosine Y100 
(α4 subunit, loop A) and by tryptophan W57 (β2 subunit, β2 strand, loop D). The back walls 
are formed by leucine L121 (β2 subunit, β6 strand, loop E) and by tryptophan W156 (β2 
subunit, β2 strand, loop D), while the front wall is defined by the flexible loop C (α4 subunit), 
tightly packed over the ligand, with its vicinal cysteines C199 and C200 linked with a disulphide 
bond and tyrosines Y197 and Y204 (Figure 8A). 
Nicotine is embedded within the binding site due to several interactions: in addition to the 
hydrophobic and aromatic interactions with the aromatic box, its positively charged pyrrolidine 
nitrogen, protonated at physiological pH, is well placed to interact with a π-cation interaction 
with W156 and to form a hydrogen bond to the backbone carbonyl of the same residue. 
As suggested by the authors, nicotine doesn’t bind to βα or ββ interfaces (β2 as the (+) side), 
because of a profound reorganization of the binding site: the small-sized G154 of the α4 subunit 
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is substituted by the long-chain R149 of β2. The side chain of R149 extends in the binding 
pocket and its guanidinium group remains trapped in a π-cation sustained sandwich between 
Y196 (correspondent to Y197 of α4) and Y95 (correspondent to Y100 in α4), twisting away the 
crucial residue of W151 from the pocket and preventing access to the ligand (Figure 8B and 
8C). 
 
Figure 8: A) Nicotine bound at the α4β2 interface. B) Nicotine doesn’t bind to the β2β2 and C) to the 
β2α4 interface. Adapted from Morales-Perez et al.20 
1.1.3 α4β2 Functions 
nAChRs α4β2* are the most prevalent CNS subtypes and are implicated in a wide range of 
physiological functions, including learning, memory, mood, cognition.27–30 Consequently, they 
are also involved in pathological conditions, like epilepsy, neurodegenerative disorders such as 
Parkinson and Alzheimer, depression, schizophrenia, drug abuse and nicotine addiction.31–33 
1.1.4 α4β2 and nicotine 
Nicotine, a major component of tobacco, is the most known and very abused exogenous 
nicotinic agonist. It exerts its behavioral effects by interacting with nAChRs both in the CNS 
and in the PNS, and after chronic exposure it modulates and alters several neural pathways 
involved in learning, memory and other cognitive functions.34 
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Importantly, nicotine causes a strong psychological addiction. According to the 2018 NIH 
report on “Tobacco, nicotine and e-cigarettes”, approximately 20% of the population smokes 
cigarettes and every year about half of them tries to quit permanently. Yet, only 6% can quit 
within a year.35 
The majority of the population assumes nicotine through cigarette smoke; the combustion of 
tobacco produces more than 7000 chemicals and many of them are carcinogenic.36 Nicotine 
itself has been demonstrated to promote hyperproliferation of carcinoma cells.37 
The pharmacokinetic properties of nicotine, combined with the inhalator “route of 
administration” are perfect match to quickly deliver high amounts of nicotine in the brain. Due 
to pulmonary absorption, nicotine rapidly reaches high blood concentrations and easily crosses 
the blood-brain barrier (BBB) thanks to its lipophilicity. Once in the brain (within 10 seconds 
from the inhalation), 20-100 nM of nicotine is enough to activate and desensitize nAChRs. 
Particularly, nicotine activates the postsynaptic high affinity α4β2* nAChRs located in 
dopaminergic and GABAergic neurons of the midbrain dopamine area or mesostriatal 
dopamine pathway and enhances firing of dopaminergic neurons and release of dopamine in 
the areas where the terminals are located. The mesostriatal dopamine pathway includes the 
ventral mesolimbic pathway, which has cell bodies in the ventral tegmental area (VTA) and 
terminals in the nucleus accumbens (NAc) and olfactory tubercle (OT) and the dorsal 
nigrostriatal pathway, which has cell bodies in the substantia nigra (SN) and terminals in the 
caudate-putamen (CPu) (Figure 9). These circuits are deeply involved in reward systems: 
release of dopamine in the NAc regulates motivation and desire for reward stimuli. The 
addictive properties of nicotine are mainly due to activation of β2* receptors in the VTA and 
the consequent dopamine release in NAc.9,38 
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Figure 9: A) Mesostriatal dopamine pathways: mesolimbic pathway (green), dorsal nigrostriatal 
pathway (red). B) Nicotinic regulation of dopaminergic neurons in the VTA. Adapted from Markou.38 
In the midbrain, nicotine also acts on presynaptic α7 receptors located on glutamatergic 
terminus, stimulating the release of glutamate, an excitatory neurotransmitter that in turn 
stimulates dopamine firing. 
Depolarization and firing of DA neurons also helps to relieve the divalent cation block of 
NMDA receptors enabling them to participate in long-term synaptic potentiation of 
glutamatergic afferents onto midbrain dopamine neurons.9 
Moreover, after an initial activation of the α4β2* in the VTA, the same receptors significantly 
desensitize, preventing the activation of the GABAergic neurons that normally inhibit DA 
firing. 
Nicotine addiction is a severe issue for both individuals and society: according to the WHO 
every year more than 7 million people die for direct consume of tobacco, while around almost 
900,000 die for second-hand smoke. Moreover, the NIH has estimated an overall cost of 
smoking of around 300 billion of $ per year, which include 150 billion $ for direct medical care 
of adults and 150 billion of $ for lost productivity due to premature deaths.35 
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1.2 α4β2 Ligands and selectivity 
During the last decades, due to their widespread distribution in the CNS and their involvements 
in numerous pathological conditions, α4β2 nAChRs have been considered promising 
therapeutic targets for the treatment of CNS disorders like neurodegenerative conditions, pain, 
cognitive dysfunctions, alcohol dependence, anxiety and nicotine dependence.33,39–42 
The high variety of existing nicotinic subtypes, the crucial functions in which they are involved 
and the structural similarities of their binding sites make selectivity over off-target subtypes a 
central but very challenging goal in new ligands development. 
In our specific case, selectivity on α4β2 subtype over α7 (the other major subtype in the CNS) 
and α3β4 (more abundant in the PNS) can be achieved both by designing ligands that do bind 
only to the α4β2 subtype or by exploiting functional differences in electrophysiology at 
different subtypes (i.e. partial agonist with high potency at the α4β2, but low potency at the 
α3β4). 
Depending on their electrophysiological effects, nicotinic orthosteric ligands can be 
functionally classified in full agonists, partial agonists, antagonists, inverse agonists and 
desensitizing agonists. 
A very attractive category is represented by selective α4β2* partial agonists, which have been 
studied up to clinical trials as novel antidepressant, for Alzheimer disease and for nicotine 
addiction. Especially for the last indication, α4β2 partial agonists are recommended: the two 
mechanisms underlying smoking cessation are a “nicotine-like” agonist activity, that reduces 
craving by mimicking nicotine at a smoother extent during a quit attempt, followed by a 
“nicotine-blocking” antagonist activity that, competing for the α4β2 with the inhaled nicotine, 
reduces the reinforcement mechanisms detailed in paragraph 1.1.4. 43 
This dual agonist-antagonist mechanism was initially proposed by Rose and Levin in 1991, 
who suggested to combine a nicotine replacement therapy (NRT) with the non-competitive 
antagonist mecamylamine (Figure 10).44 As the results of a small clinical trials were positive, 
several efforts have been done to gather the two effects in a single drug, such as a partial agonist.  
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Figure 10: schematic representation of the effect of nicotine while smoking, of a nAChR partial agonist 
during a quit attempt and during relapse. Adapted from Rollema et al.43  
Moreover, desensitization induced by agonists contributes to reducing the effect of nicotine 
during a relapse, because the receptors are in a desensitized state due to prior occupancy by the 
nicotinic agonist and therefore they can’t be activated by inhaled nicotine. 
These are the rationales why the α4β2 partial agonist Varenicline tartrate has been approved 
from the FDA and EMA in 2006 with the commercial name of Champix® or Chantix® as a 
tobacco use cessation agent. 
1.2.1 α4β2 Full agonists 
Acetylcholine is the major neurotransmitter at neuromuscular junctions, autonomic ganglia, 
parasympathetic effector junctions, a subset of sympathetic junctions and many parts of the 
CNS. It is synthesized in cholinergic neurons by the enzyme choline acetyltransferase (ChAT) 
starting from choline and acetyl-CoA and it is then transported into storage vesicles by the 
vesicular ACh/H+ antiporter (VAChT), driven by a proton-pumping ATPase. In response to 
membrane depolarization, vesicles are fused with the membrane of the synaptic terminals and 
ACh is released in the synaptic cleft (or neuromuscular junction), where it exerts its 
physiological effects by binding and activating nAChRs and mAChRs located both on the 
presynaptic and on the postsynaptic membranes. ACh is then hydrolyzed in choline and acetate 
by the enzymes acetylcholine esterase (AChE) and choline is reuptaken into cells either by a 
ubiquitous low-affinity choline uptake system or with a cholinergic neuronal specific high-
affinity choline symporter ACh/Na+ (ChT). Acetylcholine is a non-selective full agonist of 
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nicotinic receptors and it is used as a term of comparison for other ligands. It is used in therapy 
only for some ophthalmic applications.27  
Nicotine is an exogenous ligand, regularly assumed by cigarette smokers (and other tobacco 
products users). It is a competitive full agonist at all the nAChRs, but preferentially binds the 
heteromeric α4β2* and other heteromeric combinations of α2-6 and β2-4 (α-Bgtx insensitive) 
rather than to homomeric α7 and heteromeric α9α10 (α-Bgtx sensitive) receptors. 
Epibatidine (Figure 12) was isolated in 1974 by Daly from the skin of the Ecuadorean frog 
Epipdobates Tricolor, whose extract was known to have very potent analgesic properties. Its 
structural determination was hampered by the low availability of the purified alkaloid and it 
was first reported in 1992. The year after, the research group of Corey, at the University of 
Harvard, reported the synthesis of both enantiomers of epibatidine and of some analogues and 
offered them to Daly for biological evaluations. Epibatidine is a non-selective full agonist with 
high affinity and high potency at the α4β2 and α3β4 and, with lower potency, at the α7 and 
muscle subtypes.45,46  
1.2.2 α4β2 Partial agonists 
Cytisine (Figure 12) is a natural alkaloid contained in some plants of the genera such as 
Laburnum or Cytisus of the family Fabaceae and it is extracted from the seeds of Cytisus 
Laburnum. It is a partial agonist at the α4β2 subtype but a full agonist at the α7 and α3β4 
subtypes. Historically, it has been used as a smoking cessation agent since 1964 in Eastern 
Europe with the brand name of Tabex®, but insufficient preclinical and clinical studies on its 
safety and efficacy precluded its approval by FDA or EMA. However, some recent studies 
indicated that cytisine is more efficacious than nicotine replacement therapy in smoking 
cessation.43,47–50 
Recently, in 2018, a direct method via direct C-H functionalization of cytisine by Ir-catalyzed 
borylation to obtain analogues with α4β2 partial agonism activity has been reported by 
Gallagher et al.51 In this work, the core structure of cytisine was decorated with various 
substituents at position C10 with the aim to preserve α4β2 affinity and partial agonism, but to 
enhance selectivity against the α7 and α3β4 subtypes. The C10-substituted variants of cytisine 
(i.e. 10-ethylcytisine) displayed high affinity for the α4β2 subtype, with preference for the 
(α4)2(β2)3 stoichiometry and partial agonist activity. Additionally, they could not bind and/or 
activate the α7 subtype at therapeutically meaningful concentrations and they were weak partial 
agonists at the α3β4 subtype with low affinity. Docking studies at the α4β2, α3β4 and α7 
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subtypes suggested similar binding poses at all the subtypes for the C10-substituted analogues 
of cytisine and cytisine itself, driven by a combination of cation-π interaction and H-bonding 
between the protonated secondary amine N and some residues of the α subunit. The pyridone 
carbonyl oxygen of cytisine or of its analogues pointed toward a small hydrophilic pocket lined 
by the amidic backbone of Leu 121, by the carbonyl backbone of Asn 109 and by the side chain 
of Ser 108 (α4β2) or the correspondent threonine at the other subtypes (α3β4 and α7), with the 
space for bridging a water molecule. The most different interactions between the ligands and 
the three subtypes considered were observed in proximity of position C10, investigated in this 
study. C10 was close to the hydrophobic residue located at position 111, which was the 
relatively small valine in the α4β2, while the bulkier isoleucine and leucine respectively in the 
α3β4 and in the α7 subtype. The authors suggested that selectivity of the bulkier C10-substituted 
analogues of cytisine could be related to their sterically disfavored interactions with the more 
hindered residues of the α3β4 and of the α7 subtypes (Figure 11).  
Therefore, the high selectivity of C10-substituted analogues of cytisine at the α4β2 subtype 
versus the two major off-targets in smoking cessation (α7 and α3β4 subtype) makes these 
compounds the ideal lead candidates for further modifications. 
 
Figure 11: A) Nicotine bound at the α4β2 binding site. B) Cytisine bound at the α4β2, at the C) α3β4 
and at the D) a7 binding sites. Position 10 is represented with a purple sphere. Adapted from Campello 
et al.51 
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Varenicline (Figure 12) was developed by Pfizer as a cytisine analogue and was approved by 
the regulatory authorities in 2006 for smoking cessation with the commercial name of Chantix® 
(USA) or Champix® (EU, Canada). Varenicline is a high affinity partial agonist of the α4β2 
subtype but, as cytisine, it is also active on α3β4, α3β2 and α6 subtypes. Moreover, it is a full 
agonist at the α7 subtype. 52–54 
 
Figure 12: non-selective full agonist epibatidine; non-selective partial agonists cytisine and varenicline; 
selective partial agonist 10-Ethylcytisine. 
1.2.3 α4β2 Antagonists 
α-Conotoxins are competitive nicotinic acetylcholine receptor antagonists and belong to a 
group of neurotoxic peptides (conotoxins) isolated from the venom of the predatory sea snails 
of the genus Conus. Even if more selective at the α3β4 and at the α7 subtype, α-conotoxin GID 
showed high affinity toward the α4β2 subtype and was used as scaffold for the design and 
synthesis of moderately more selective analogues.55 
Peptides or high molecular weight molecules such as conotoxins have been used to investigate 
nicotinic receptors pharmacology in-vitro, but they would encounter several pharmacokinetics 
problems into in-vivo studies or for potential therapeutic applications. For this reason, several 
selective small molecules acting as competitive antagonists have been developed.56–58 
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1.3 State of the art 
In 1996, Abreo reported a series of 3-pyridyl ethers with nano- or subnanomolar affinity for the 
α4β2 subtype, measured as [3H]-(-)-cytisine displacement from whole rat brain, among which 
compounds A-84543 and A-85380 stood out as potent α4β2 full agonists.59 However, although 
A-84543 was shown to be moderately selective in the 86Rb+ efflux assay at the α4β2 subtype 
against the ganglionic α3β4 subtype, several efforts have been done to obtain analogues with 
improved binding and functional selectivity. 60–62 
The same year Elliot from the Abbot laboratories described the affinities of some analogues of 
A-84543 and A-85380 where the pyridine ring was bioisosterically replaced by aryl moieties, 
among which compound (S)-I and (S)-II, which showed good, albeit decreased, binding affinity 
when compared to their pyridyl ether progenitors (Figure 13).63 
 
Figure 13: Phenyl ether analogues (S)-I and (S)-II (right) of the pyridyl ethers A-84543 and A-85480 
(left). Binding affinities were measured as displacement of [3H]-cytisine from whole rat brain 
preparations (rat symbol).64 
In 2005 a series of 5-substituted analogues of A-84543 like (S)-III were reported by 
Kozikowski, who demonstrated that selectivity over rat α3β4 could be improved by introducing 
differently elongated hydrophobic groups such as 5-hexynyl, obtaining further improvements 
when these linkers were terminally OH substituted.61 The year after, the same research group 
synthesized and pharmacologically characterized Sazetidine-A (Saz-A) (Figure 14) as a 
selective α4β2 ligand (both at rat and human receptors), with the particular capability of 
desensitizing the channel without activating it in a 86Rb+-based assay (silent desensitizer).65 
However, since this result was not coherent with the in-vitro dopamine release assays,  more 
detailed investigations were performed demonstrating that Saz-A had different functional 
activities at the two α4β2 stoichiometries: it was a full agonist at the human high affinity 
(α4)2(β2)3 stoichiometry, while a low efficacy partial agonist (6%) at the human (α4)3(β2)2 
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stoichiometry.66 Saz-A showed promising results as antidepressant and was demonstrated to 
decrease alcohol intake and nicotine self-administration and to improve performances in tests 
of attention in an animal model.67–71 
 
Figure 14: Design of Saz-A, a selective α4β2 partial agonist. α4β2 and α3β4 binding affinities were 
measured as displacement of [3H]-epibatidine from heteroguosly expressed rat α4β2 and α3β4 receptors 
(A-84543, (S)-III and Saz-A, rat symbol)61 or human α4β2 and  α3β4 receptors (Saz-A, human 
symbols).65,66 Whereas Saz-A affinity for rat and human α4β2 receptors is similar, Saz-A is much more 
affinitive for human α3β4 than for rat α3β4 receptors. 
The same year, the synthesis of two rigidified analogues of (S)-I, namely N-methyl-2-(2-
pyrrolidinyl)benzodioxanes (S,R)-IV and (R,S)-IV was carried out by Pallavicini et al. and was 
later extended to all the 4 possible stereoisomers in 2009, therefore including (S,S)-IV and 
(R,R)-IV (Figure 15).72,73 These compounds contain two stereocenters in close proximity to the 
pyrrolidine nitrogen, connected by the only rotatable bond of the molecule (pyrrolidine-
benzodioxane). The more favored molecule conformations of the 4 isomers will strongly 
depend on the absolute configurations of the two vicinal stereocenters. As expectable from the 
comparison with other nicotinoids, only the two constrained N-Me-pyrrolidinyl-benzodioxanes 
that maintained the absolute configuration “S” at the pyrrolidine stereocenter (S,S)-IV and 
(S,R)-IV retained α4β2 affinity and moderate selectivity against the α7, with a lower Ki value 
for (S,R)-IV. The very same N-des-methylated analogues showed micromolar affinity values 
and weren’t further considered by the research group. 
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Figure 15: Design of N-Me-pyrrolidinyl-benzodioxanes as selective α4β2 ligands. Only (S,R)-IV and 
(S,S)-IV have sub-micromolar affinities. 
The rigid benzodioxane scaffold of (S,R)-IV represented an optimal platform to probe the 
features of receptor binding pocket and to identify additional pharmacophoric elements: 
substituents at the aromatic ring in such a constrained structure are placed in well-defined region 
of the 3D space if the binding mode is conserved. Intrigued by this opportunity and inspired by 
the known SAR studies on the phenyl- and pyridyl- ethers of prolinol ((S)-I and A-84543), 
according to which substitutions at the meta-position to their methylenoxy linker are the most 
beneficial for affinity and selectivity, the research group synthesized a series of 7-substituted 
analogues of (SR)-IV. The 7- position was chosen because it corresponded to the 5- position of 
A-84543.74 Among the series, compound (S,R)-IVa, stood out as a α4β2 and α6β2* selective 
high affinity ligand, with partial agonist activity (51%) in the dopamine release assay from 
striatal slices  (Figure 16). Since α4β2 and α6β2* subtypes approximately equally contribute to 
nicotine-induced striatal DA release, DA release induced by (S,R)-IVa in presence of a specific 
α6β2* blocker (α-conotoxin αMII) was evaluated. This assay confirmed that (S,R)-IVa acted 
as a partial agonist at both subtypes. Later, in 2015, (S,R)-IVa was shown to be approximately 
50 folds more potent as a partial agonist at the human α4β2 subtype rather than at the human 
α3β4 subtype in eliciting currents in electrophysiological assays.75 These results together 
revealed that (S,R)-IVa had a similar, but more selective, nicotinoid profile to varenicline (non-
selective α4β2 partial agonist, 49% efficacy), the only approved drug up to now for nicotine 
addiction acting on nAChRs.  
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Figure 16: (S,R)-IVa acts as a partial agonist at the α4β2 and α6β2 subtypes: concentration-response 
curves of agonist-induced [3H]DA release from rat striatal slices. The slices were preloaded with 100 
nM [3H]DA and exposed to the indicated concentration of nicotine, (S,R)-IVa alone, or in the presence 
of 100 nM αMII. Results were normalized and expressed as a percentage of 10μM nicotine-induced 
release. The data points represent the mean SEM of 3-4 separate experiments performed in triplicate. 
Interestingly, all the other 7-substitutions of the benzodioxane scaffold were quite detrimental 
for α4β2 affinity, indicating strict structural requirements for binding that region of the binding 
pocket (Figure 17). However, compounds with poor α4β2 affinities provided valuable 
information for SAR analysis: neither small-sized apolar substituents ((S,R)-IVb - methyl), 
medium or bulky lipophilic or aromatic substituents ((S,R)-IVc - bromine, (S,R)-IVd - phenyl) 
nor bulkier but polar ones ((S,R)-IVe - hydroxymethyl, (S,R)-IVf - acetyl, (S,R)-IVg - methoxy) 
were tolerated, thus suggesting the existence of a small and hydrophilic non-conserved 
subpocket that can be reached only through an hydroxyl group. 
Figure 17: design of 7-substituted N-methyl-pyrrolidinyl-benzodioxanes as α4β2 partial agonists. (S,R)-
IVa is a partial agonist with high α4β2 affinity. α4β2 and α3β4 affinities were measured as displacement 
of [3H]-epibatidine respectively from rat brain membranes and heterologuosly expressed human α3β4 
receptors (human symbol).75 Every other 7-substitution substantially decreases α4β2 affinity. EC50 
values relate to electrophysiological assays performed on human α4β2 or α3β4 subtypes.75 
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In 2013, Brown et. al, aiming at potent and selective α4β2 desensitizing agents with enhanced 
physicochemical properties (BBB permeability) in respect of those of Saz-A, synthesized three 
series of Saz-A analogues (Figure 18).76 Among these, they identified compound VMY-2-95 
as the most promising candidate as a therapeutic agent for smoking cessation, due to its better 
brain tissue distribution, high selectivity over more than 40 CNS receptors, including α3β4, α7 
and 5-HT3, high potency associated with low efficacy (30%), high desensitizing capability and 
effectiveness in reducing self-administration of nicotine in animal models. 
 
Figure 18:design of VMY-2-95 as an analogue of Saz-A with improved BBB permeability. 
Although several 5-substituted analogues of the pyridyl-and phenyl-ethers of N-methyl prolinol 
(A-84543 and (S)-I) have been studied (Saz-A, VMY-2-95 and others), the effect of 
hydroxylation at that position had never been reported. Prompted by the considerable 
enhancement of α4β2 affinity obtained by introducing an hydroxyl group at the 7 position of 
the benzodioxane scaffold of (S,R)-IV and by the functional α4β2/α3β4 selectivity of the 
resulting compound (S,R)-IVa, the research group of professor Pallavicini, which I joined for 
my master thesis and later for my PhD, investigated the effect of the same substituent (OH) 
when introduced in the correspondent meta-position of A-84543 and (S)-I. The resulting 
compounds, namely (S)-V and (S)-VI, were shown to be highly potent α4β2 full agonists, but 
only (S)-V showed functional selectivity. Compound (S)-VI can also be considered as a flexible 
analogue of the selective α4β2 and α6β2 partial agonist (S,R)-IVa, obtained by deconstruction 
of its benzodioxane moiety (Figure 19 and Figure 20).75 
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Figure 19: design of the selective full agonist (S)-V and of the unselective full agonist (S)-VI as 
analogues of A-84543 and of (S)-I. 
 
Figure 20: agonist effect of (S,R)-IVa, (S)-V and (S)-VI on transfected human α4β2 and α3β4 subtypes. 
The activation responses are normalized to the maximal response to 1 mM ACh. 
Comparison between partial agonism of the rigid compound (S,R)-IVa and full agonism of the 
flexible (S)-VI suggested that conformational constrain could play a role in functional activity. 
For this reason, a series of semi-rigid analogues of both A-84543 and (S)-VI (for instance (S)-
VII and (S)-VIII) was synthesized, assessed for α4β2, α3β4, α7 affinities75 (data not shown) 
and some selected compounds were tested in electrophysiological assays for α4β2 and α3β4 
activities (Figure 21). The results confirmed that the extended conformation imposed by a semi-
rigid or a rigid structure is correlated with partial agonism activity, whereas flexibility and 
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“compressibility” of the oxymethylene bridge between the aromatic ring and the pyrrolidine 
residue is associated with full agonism. 
 
Figure 21: design of the partial agonists (S)-VII and (S)-VIII as semi-rigid analogues of A-84543, (S)-
VI and (S,R)-IVa.  
Docking studies at a homology model of the α4β2 binding site suggested that the partial agonist 
activity and selectivity could be achieved due to additional interactions between the 7-hydroxy 
of (S,R)-IVa or the meta-hydroxy or meta-basic nitrogen of its semirigid analogues (S)-VII and 
(S)-VIII and a non-conserved small hydrophilic pocket within the β2 subunit (Figure 22). 
 
Figure 22: hypothetic binding modes at the α4β2 subtype suggested by docking of rigid and semi-rigid 
ligands (left) and flexible ligands (right). 
According to this model, rigid and semirigid ligands fit the pocket into an extended 
conformation imposed by their structural constrains, which moves the aromatic ring of the 
benzodioxane moiety away from the aromatic residue of phenylalanine of the binding site, but 
places the terminal hydroxyl pendant within a small and hydrophilic non conserved binding 
pocket.  
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Contrariwise, flexible ligands fold into a compressed conformation and place their aromatic 
rings so that to maintain a π-π interaction with the residue of phenylalanine, but do not reach 
the above mentioned additional pocket. 
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1.4 Outlook 
In this framework, the goals of this part of my project were the: 
• synthesis of novel 5-substituted 3-hydroxyphenyl and 3-nitrophenyl ethers of (S)-
prolinol as α4β2-nicotinic acetylcholine receptor ligands77 
• synthesis of  N-methyl-pyrrolidinyl-pyridodioxanes designed as isosteres of N-
methyl-pyrrolidinyl-benzodioxanes78 
• synthesis of N-methyl-pyrrolidinyl-5-substituted-benzodioxanes 
• computer-aided SARs interpretation 
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1.5 Novel 5-substituted 3-hydroxyphenyl and 3-nitrophenyl ethers 
of (S)-prolinol as α4β2-nicotinic acetylcholine receptor ligands77 
1.5.1 Introduction and aim 
As discussed in the previous chapter 1.3, N-Me-prolinol pyridyl ether A-84543 and its 
azetidinyl analogue A-85380 were reported at the end of the nineties as potent α4β2 full agonists 
with selectivity over α7 and muscle-type nAChRs.59 Later, selectivity over the ganglionic α3β4 
subtype was achieved by Kozikowski and Brown in Sazetidine-A and VMY-2-95, by 
introducing sterically bulky substituents at the 5-position of the pyridyl ether scaffolds.65,76 
Since my research group had already discovered that replacement of the pyridyl ring of A-
84543 with a meta-hydroxyphenyl in compound (S)-VI resulted in comparable affinity, but 
lower selectivity, we aimed at understanding whether we could restore selectivity over the α3β4 
subtype by introducing sterically bulky substituents at the 5-position of compound (S)-VI.75  
We selected, as meta-substituents, 6-hydroxy-1-hexynyl, conferring high α4β2 vs α3β4 
selectivity in Saz-A, and bromine and phenyl, which were reported to preserve high affinity at 
the α4β2 when linked to C5 of A-84543.61,79 Additionally, we enclosed into this series also p-
hydroxyphenyl, with the hypothesis that a terminal hydroxyl group could reinforce the 
interactions of the meta-substituent, like in Saz-A and in (S,R)-IVa (Figure 23). 
Overall, compounds (S)-1a, (S)-1b, (S)-1c and (S)-1d were synthesized. 
 
Figure 23: design of flexible α4β2 selective ligands (S)-1a-d as 5-substituted analogues of (S)-IV. 
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Moreover, since often pyridyl rings can be bioisosterically replaced by nitrophenyl, we decided 
to include in our research compound (S)-IX, whose α4β2 affinity had already been reported 20 
years ago,80 and its 5-substituted analogues (S)-2a, (S)-2b, (S)-2c and (S)-2d (Figure 24).  
 
Figure 24: design of flexible α4β2 selective ligands (S)-2a-d as 5-substituted analogues of (S)-IX, a 
putative bioisoster of A-84543. 
As a term of comparison for (S)-VI, (S)-1d and (S)-2d, we also synthesized compounds (S)-3 
and (S)-4 (Figure 25). 
 
Figure 25: design of flexible α4β2 selective ligands (S)-3 and (S)-4 as meta-substituted analogues of 
(S)-I. 
Based on our previous hypothesis of different binding modes between rigid/semirigid 
compounds (partial agonists) and their flexible analogues (full agonists), we expected 
compounds (S)-1a-d and (S)-2a-d to bind similarly to A-84543. If so, the introduction of the 
listed substituents at the 5-position of the meta-hydroxyphenyl ether and meta-nitrophenyl ether 
scaffolds should result in parallel shifts in affinity and in selectivity when compared to the 5-
substituted pyridyl ether, confirming a bioisosteric relationship between these three scaffolds 
and providing new analogues with good α4β2 affinity and selectivity. 
1.5.2 Synthetic schemes 
Commercial N-Boc protected (S)-prolinol (Sigma Aldrich) was coupled by Mitsunobu reaction 
either with the commercial 3-hydroxy-5-bromophenol or 3-bromo-5-nitrophenol, to obtain 
respectively intermediates (S)-27 and (S)-28, which were directly deprotected to (S)-29 and (S)-
30 respectively with TFA and HCl and then N-methylated with formaldehyde and picoline 
borane to obtain the final compounds (S)-1a and (S)-2a. 
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Intermediates (S)-27 and (S)-28 were coupled in a Suzuki reaction with phenylboronic acid to 
afford (S)-31 and (S)-32, and with 4-hydroxyphenylboronic acid to give (S)-33 and (S)-34, or 
reacted with 5-hexyn-1-ol in a Sonogashira coupling to obtain intermediates (S)-35 and (S)-36. 
Subsequently they were N-Boc deprotected with methanolic HCl to (S)-37-42 and N-
methylated with formaldehyde and picoline borane to obtain the final compounds (S)-1b-d and 
(S)-2b-d (Scheme 1). 
 
Scheme 1: Reagents and conditions. (a) 3-Hydroxy-5-bromophenol, PPh3, DIAD, THF, 130 °C, 30 min, 
microwave, 34% ((S)-27); (b) 3-Bromo-5-nitrophenol, PPh3, DIAD, THF, reﬂux,12 h, 85% ((S)-28); (c) 
TFA, DCM, room temperature, 2 h, 80% ((S)-29); (d) Methanolic 1.25N HCl, room temperature, 12 h, 
42% ((S)-30), 100% ((S)-37), 96% ((S)-39), 80% ((S)-41), 78% ((S)-38), 81% ((S)-40) and 95% ((S)-
42); (e) 37% CH2O, CH3COOH, pic-BH3, CH3OH, room temperature, 4 h, 75% ((S)-1a), 80% ((S)-1b), 
51% ((S)-1c), 87% ((S)-1d), 98% ((S)-2a), 86% ((S)-2b), 80% ((S)-2d), and 79% ((S)-2c); (f) Pd(PPh3)4, 
toluene, 2M aqueous Na2CO3, XB(OH)2, ethanol, reﬂux, 12 h, 75% ((S)-31), 97% ((S)-33), 93%. ((S)-
32) and 63% ((S)-34); (g) Pd(PPh3)4, CuBr, 5-hexyn-1-ol, TEA, reﬂux, 12 h, 80% ((S)-35) and 61% 
((S)-36). 
 The reference compound (S)-3 was synthesized following the same procedure used for the 
synthesis of (S)-1d and (S)-2d, but using 3-bromophenol in the first Mitsunobu coupling step. 
Similarly, the reference compound (S)-4 was synthesized starting from (S)-N-Cbz-prolinol and 
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3-methoxyphenol according to the same procedure used for the synthesis of (S)-1a and (S)-2a 
(Scheme 2). 
 
Scheme 2: (a) 3-Bromophenol or 3-methoxyphenol, PPh3, DIAD, THF, reﬂux,12 h, 48% ((S)-28); (b) 
Pd(PPh3)4, CuBr, 5-hexyn-1-ol, TEA, reﬂux, 12 h, 79%; (c) Methanolic 1.25N HCl, room temperature, 
12 h, 71%; (d) 37% CH2O, CH3COOH, pic-BH3, CH3OH, room temperature, 4 h, 98%; (e) LiAlH4, 
THF, reflux, 90 min, 67%. 
1.5.3 Biology 
We evaluated the binding affinity of (S)-1a-d and (S)-2a-d, (S)-3 and (S)-4 towards the α4β2 
nAChR present on rat cerebral cortex membranes and towards the human α3β4 nAChR 
transiently transfected on HEK 243 cells according to a previously described experimental 
protocol.75 The α4β2 and α3β4 nAChRs were labelled by [3H]-epibatidine and the binding 
affinities (Ki) of the compounds were determined with competition binding experiments. The 
results are listed on Table 1 together with the affinities of (S)-IX and nicotine, used as controls, 
and with those previously reported for the hydroxyphenyl ether (S)-VI.75 
1.5.4 Results and discussion 
 As shown in Table 1, our lead compounds 3-hydroxyphenyl ether (S)-VI and 3-nitrophenyl 
ether (S)-IX had high affinity at the α4β2 subtype (1.1 and 31 nM respectively), higher than 
that determined for the unsubstituted phenyl ether progenitor (S)-I determined in 1995 by Elliot 
using [3H]-cytisine (42 nM). Therefore, the introduction of OH or NO2 at the 3-position of the 
phenyl ether is beneficial for α4β2 affinity and results in a m-hydroxylated ligand (S)-VI, with 
affinity in the same rank of the reference compound A-84543 (1.9 nM) and in a ligand, (S)-IX, 
with intermediate affinity between (S)-I (42 nM) and A-84543. The importance of m-OH is 
further confirmed by the drop of α4β2 affinity when methylated to compound (S)-4 or removed 
from compound (S)-1d to (S)-3. Furthermore, (S)-VI and (S)-IX show moderate α4β2 vs α3β4 
selectivity. 
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Compound 
α4β2 nAChR 
[3H]-Epi 
(nM) 
α3β4 nAChR 
[3H]-Epi 
(nM) 
Selectivity Ki 
α3β4/α4β2 
R1= R2= 
 
H (S)-VI 1.1 (29)a 74 (100)a 67 
Br (S)-1a 186 (25) 147 (30) 0.8 
Ph (S)-1b 528 (32) 200 (28) 0.4 
p-OH-Ph (S)-1c 3.8 (47) 30 (53) 8 
6-OH-1-hexynyl (S)-1d 23.7 (21) 3100 (34) 131 
 
H (S)-IXb 31.2 (32) 946 (33) 30 
Br (S)-2a 55 (26) 415 (49) 8 
Ph (S)-2b 330 (45) 947 (38) 3 
p-OH-Ph (S)-2c 12 (43) 122 (41) 10 
6-OH-hexynyl (S)-2d 14.2 (31) 1200 (32) 85 
 
6-OH-hexynyl (S)-3 4400 (32) 8300 (44) 2 
OMe (S)-4 600 (32) 4500 (41) 7 
  (S)-Nicotine 4 (18) 261 (30) 65 
Table 1: Compounds (S)-1a-d, (S)-IX, (S)-2a-d, (S)-3, (S)-4 and (S)-nicotine: affinity for native α4β2 
nAChR, present in rat brain membranes, labelled by [3H]-epibatidine, and for heterologously expressed 
human α3β4 nAChR, labelled by [3H]-epibatidine and affinity ratios. The numbers in brackets are the % 
coefficient of variation (CV%).75 aAffinity data for (S)-VI from literature.81 bAs the nicotinic affinity data 
reported in literature80 of (S)-IX was not coherent with the rest of the dataset and the α3β4 affinity had 
never been reported, (S)-IX was included in the current binding assays.   
To probe whether bulky substituents at the 5-position of our scaffolds (S)-VI and (S)-IX would 
have led to the same effects observed in A-84543, we introduced the same substituents (Br, Ph, 
4-hydroxyphenyl and 6-hydroxy-1-hexynyl) in the meta- positions of (S)-VI and (S)-IX. 
Interestingly, parallel trends of affinity were found between the two series: 1) meta-bromination 
((S)-1a (S)-2a) and, to a greater extent, meta-phenylation ((S)-1b (S)-2b) lowered the α4β2 
affinity and canceled α4β2/α3β4 selectivity; 2) the meta-4-hydroxyphenyl substituted 
analogues (S)-1c and (S)-2c had the highest affinities in the series (3 and 12 nM respectively) 
but modest selectivity, highlighting the importance of a distal hydroxyl group for affinity, that 
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could enhance α4β2 affinity up to 139 times when compared to the phenyl analogues; 3) both 
the meta-6-hydroxy-1-hexynyl substituted derivatives (S)-1d and (S)-2d showed respectively 
24 and 14 nM affinities and significantly higher α4β2/α3β4 selectivity than the respective parent 
compounds (S)-VI and (S)-IX. 
Proven the parallelism between the two series of compounds, we aimed to reveal the scaffold-
dependent similarities/differences among each series of 5-substituted ligands. The comparison 
could only be drawn for the 5-(6-hydroxy-1-hexynyl) substituted analogues of the three 
scaffolds, namely (S)-1d, (S)-2d and (S)-III, because the 5-(4-hydroxyphenyl)-substituted 
analogue of A-84543 was not reported and the binding data for 5-bromo and 5-phenyl analogues 
were limited to α4β2 affinity and not directly comparable to the Ki of A-84543 (Figure 26). 
 
Figure 26: parallel shifts in α4β2 affinities and selectivities among the series of 5-(6-hydroxy-1-hexynyl) 
substituted analogues. α4β2 and α3β4 affinities of A-84543 and (S)-III were measured as displacement 
of [3H]-epibatidine from heteroguosly expressed rat α4β2 and α3β4 receptors (rat symbols).61 α4β2 and 
α3β4 affinities of (S)-VI, (S)-1d, (S)-IX and (S)-2d were measured as displacement of [3H]-epibatidine 
respectively from rat brain membranes and heterologuosly expressed human α3β4 receptors (human 
symbols).77 
Compound (S)-III, when compared to A-84543, maintained high α4β2 affinity (0.85 nM) and 
had enhanced α4β2/α3β4 selectivity, like (S)-1d and (S)-2d when compared to their parental 
compounds (S)-VI and (S)-IX. The 5-(6-hydroxy-1-hexynyl) substitution similarly affects the 
nicotinic profiles of all the three scaffolds containing, respectively, a pyridyl, a meta-
hydroxyphenyl and a meta-nitrophenyl moiety, suggesting common binding modes at the α4β2 
and a bioisosteric relationship for A-84543, (S)-VI and (S)-IX. 
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As previously proposed and discussed by Pethukov, selectivity on α4β2 over α3β4 can be 
obtained with a long and flexible alkynyl substitutent at C5 of A-84543 thanks to different 
interactions with non-conserved β2 or β4 residues located relatively far away from the charged 
pyrrolidine nitrogen.82 Such different interactions would influence the positioning of the 
pyrrolidine N+ within the aromatic box of the binding site, resulting in favored interactions to 
an α-conserved Trp in the α4β2, but not in the α3β4.  
On the basis of the bioisosteric relationship between A-84543, (S)-VI and (S)-IX, we suggested 
that these binding modes and SARs formulated for (S)-III, could also be extended to (S)-1d and 
(S)-2d, which are in fact new potent and selective α4β2 ligands. 
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1.6 Synthesis of  N-methyl-pyrrolidinyl-pyridodioxanes designed 
as isosteres of N-methyl-pyrrolidinyl-benzodioxanes78 
1.6.1 Introduction and aim 
I collaborated to the synthesis of the SR and SS diastereomers of three regioisomers N-Me-
pyrrolidinyl-pyridodioxanes 5, 6 and 7, designed together with 8 as possible bioisosteres of N-
Me-pyrrolidinyl-benzodioxanes (S,R)-IV and (S,S)-IV and as rigid analogues of compounds A-
84543, (S)-X and (S)-XI (Figure 27). 
Our interest in the challenging synthesis of pyrrolidinyl-pyridodioxanes was stimulated by the 
universally recognized isosteric relationship between pyridine and benzene. In our case, we 
already knew that phenyl and meta-pyridyl ethers of prolinol had similar nicotinic profiles, 
albeit A-84543 was a more potent and selective agonist at the α4β2 subtype than (S)-I.59,63 
Despite the similar activities of the flexible progenitors, we expected different nicotinic profiles 
by the replacement, one by one, of each of the four benzodioxane CH with a nitrogen. Indeed, 
many hints suggested that the position of the nitrogen in the pyridodioxane scaffold would have 
had a great impact on the nicotinic profile: 1) the different affinities of the regioisomers A-
84543, (S)-X and (S)-XI;83,84 2) the differences in affinity between the N-methyl-pyrrolidinyl-
benzofurane (S)-XII and the regioisomers of its furopyridine analogues (S)-XIII, (S)-XIV, (S)-
XV and (S)-XVI85,86 and 3) the known involvement of the aromatic system in π-π and HBA 
interactions, which are both strongly conditioned by the positioning of a heteroatom in the 
system.87  
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Figure 27: design of (S,S)- and (S,R)-N-methyl-pyrrolidinyl pyridodioxanes 5,6,7 and 8 as rigid 
analogues of A-84543, (S)-X and (S)-XI and as potential bioisosters of IV and comparison with their 
N-methyl-pyrrolidinyl-furopyridines analogue (S)-XIII, (S)-XIV, (S)-XV and (S)-XVI.   
According to the known SARs of the flexible pyridylether scaffold of A-84543 and of the rigid 
benzodioxane scaffold of (S,R)-IV, we expected compound (S,R)-7 to have hybrid 
characteristics between A-84543 and (S,R)-IVa: the pyridine nitrogen at position 7, ideally 
superimposable with the pyridine nitrogen of A-84543, might effectively replace the hydroxyl 
pendent of (S,R)-IVa. As a term of comparison, we evaluated the electrophysiological 
functional activity of the “naked” benzodioxane with SR absolute configuration (S,R)-IV. 
1.6.2 Synthetic schemes 
The retrosynthetic analysis of the 4 regioisomers of the pyrrolidinyl-pyridodioxane identified 
as crucial intermediates the correspondent N-protected-pyridyl ethers reported in Figure 28, 
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formally obtained by coupling the phenolic function of appropriate chlorinated 3-
hydroxypyridine to the primary hydroxyl or to the secondary hydroxyl group derived from N-
protected-2-bromoacetylpyrrolidine. Specifically, 8 and 5 could be obtained starting from 2-
chloro-3-hydroxypyridine, connected respectively to the primary and secondary alcohol, while 
6 and 7 starting from 3-hydroxy-4-chloropyridine, coupled respectively with the primary and 
secondary hydroxyl groups. 
 
Figure 28: retrosynthetic analysis of N-methyl-pyrrolidinyl-pyridodioxanes (S,S)- and (S,R)-5-8.  
According to this retrosynthetic analysis, the syntheses of compounds (S,R)- and (S,S)-8 had 
already been reported by a former PhD student and is summarized in Scheme 3.  
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Scheme 3: Reagents and conditions (a) (S)-Proline, NaOH 2M, Cbz-Cl, 3h, rt, 90%; (b) TEA, i-
BuOCOCl, Et2O, -15°C, 1h then CH2N2, 0 °C overnight,  89%; (c) HBr/H2O, Et2O, 25°C, 1h, 85%; (d) 
acetone, rt, 16 h, 81%; (e) LiAlH4, THF, rt, 3 h and then purification through column chromatography 
26% ((S,S)-51) and 43% ((S,R)-51); (f) NaH, DME, 120 °C, 1 h, MW, 28% ((S,R)-8) and 30% ((S,S)-8). 
Initially, a similar strategy was planned also for compounds 5: the bromine of intermediate (S)-
49 was displaced by potassium acetate affording (S)-52, that was reduced by treatment with 
NaBH4 providing the diastereomeric mixture of the N-protected diols (S,S)- and (S,R)-53. Upon 
protection of the primary alcohol with trityl chloride followed by purification through flash 
chromatography to the single diastereomers (S,S)- and (S,R)-54, the etherification of the 
secondary alcohol by Mitsunobu reaction instead of the primary alcohol with the same 2-chloro-
3-hydroxypyridine mentioned above, should have afforded two intermediates, namely (S,R)-55 
and (S,S)-55 that, after deprotection  and cyclization, would have afforded compounds (S,R)- 
and (S,S)-5 (Scheme 4). 
The diastereomer (S,R)-55 was obtained by Mitsunobu reaction with trimethylphosphine and 
DEAD by using microwave irradiation and was further deprotected by reduction with LiAlH4 
followed by hydrolysis in acidic conditions, providing intermediate (S,R)-56, that was then 
cyclized to the final compound (S,R)-5 by treatment with NaH in DME.  
Unfortunately, any attempt to introduce the pyridyl moiety by Mitsunobu reaction on the 
secondary alcohol of (S,R)-54, in the presence of the protecting groups N-Cbz and O-trytyl, was 
unsuccessful, due to steric reasons. The same reaction, performed on the reduced N-Me 
analogue (S,R)-57, lead to introduction of the pyridyl moiety accompanied by a aziridine-
mediated ring-expansion of the pyrrolidine ring to obtain the byproduct (S,R)-58. 
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Scheme 4: Reagents and conditions. (a) CH3COOK, DMSO, rt, 2 h, 98%; (b) NaBH4, THF, rt, 2 h and 
then CH3ONa, MeOH, rt, 1 h 97%; (c) TrCl, TEA, DME, reflux, 4h and then purification through flash 
chromatography 46% ((S,R)-54) and 34% ((S,S)-54); (d) 2-chloro-3-hydroxypyridine, (Me)3P, DEAD, 
THF, 140 °C, 15 min, MW, 43% ((S,R)-55), 0% ((S,S)-55), 75% ((R,R)-58); (e) LiAlH4, THF, reflux, 3 
h and then HCl 1 M, rt, 1 h, 68%; (f) NaH, DME, reflux, 16 h, 75%; (g) CH2O, H2,  Pd/C, MeOH, RT 
12h, 90%. 
This synthetic route was unsuccessful for the synthesis of diastereomer (S,S)-5. To overcome 
this issue, we designed a new synthetic strategy, based on the bicyclic oxazolidinone 
intermediate 60, that could be obtained starting from the diastereomeric mixture of N-Cbz-
protected diol (S,S)-53/(S,R)-53 by benzylation of the primary alcohol with dibutyltin oxide, 
accompanied by transcarbamoylation, providing the desired bicycle. The resulting 
oxazolidinone was synthetically very useful, because it trapped the secondary alcohol into the 
bicyclic moiety, leaving the benzylated primary hydroxyl free to be modified (Scheme 5). 
Procedurally, the benzylation reaction of the diastereomeric mixture of (S,S)-53/(S,R)-53 with 
dibutyltin oxide, partially protected (S,R)-53 into the benzylated opened (S,R)-59 and partially 
transformed it to the bicyclic oxazolidinone (S,R)-60, while it completely converted (S,S)-53 
into the bicyclic intermediate (S,S)-60 by transcarbamoylation. Overall, after chromatography 
separation, a mixture of the two O-Benzylated cyclic carbamates (S,R)-60/(S,S)-60  was 
isolated, while only one diastereomer, (S,R)-59, was obtained in the opened form benzylated at 
the primary alcohol.  
The latter was cyclized to (S,R)-60 by treatment with NaH and, after debenzylation to (S,R)-61 
with H2 on Pd/C, it was pyridylated with 3-benzyloxy-2-bromopyridine, affording (S,R)-62. 
The benzyloxy protecting group was removed by catalytic hydrogenation, providing (S,R)-63 
and the cyclic carbamate was reduced with LiAlH4 obtaining (S,R)-64, which was in turn 
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internally cyclized by Mitsunobu reaction between the two OH groups, affording the final 
compound (S,S)-5. 
 
Scheme 5: Reagents and conditions. (a) Bu2SnO, toluene, reflux, 5 h and then BnBr, TBAI, reflux, 16 h, 
37% ((S,R)-59), 46% ((S,S)-60/(S,R)-60); (b) NaH, DMF, rt, 3 h, 59%; (c) H2, Pd/C, MeOH, rt, 16 h, 
97%; (d) 3-benzyloxy-2-bromopyridine, NaH, DMF, 80 °C, 4 h, 34%; (e) H2, Pd/C, EtOH, rt, 2 h, 99%; 
(f) LiAlH4, THF, rt, 3 h, 77%; (g) (Ph)3P, DIAD, THF, 120 °C, 15 min, MW, 54%. 
A similar synthetic scheme was applied for the synthesis of (S,S) and (S,R)-7, by coupling the 
bicyclic carbamate 61 with 4-hydroxy-3-[(2-methoxyethoxy)methoxy]pyridine 72 (Scheme 6).   
(S,R)-61 had already been isolated as a single diastereomer as described above and was thus 
coupled by Mitsunobu reaction with 4-hydroxy-3-[(2-methoxyethoxy)methoxy]pyridine, 
providing (S,R)-65. Differently, the pure (S,S) diastereomer of 61 was not available. Therefore, 
the diastereomeric mixture of its benzylated precursor (S,S)-60/(S,R)-60 was debenzylated by 
catalytic hydrogenation, providing the mixture (S,S)-61/(S,R)-61, which was subsequently 
coupled with 4-hydroxy-3-[(2-methoxyethoxy)methoxy]pyridine 72 to obtain a mixture of 
(S,S)-65/(S,R)-65, whose purification through flash chromatography afforded the pure 
diastereomer (S,S)-65. 
In both cases, the bicyclic oxazolidinone moieties of (S,R)-65 and of (S,S)-65 were reduced 
with LiAlH4 providing (S,R)-66 and (S,S)-66, whose secondary hydroxyl groups were activated 
by treatment with methanesulphonlyl chloride and TEA in their mesylated analogues, which 
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were further deprotected with TFA to (S,R)-67 and (S,S)-67, and, finally, internally cyclized to 
the final compounds (S,S)-7 and (S,R)-7 by treatment with K2CO3 in DME . 
 
Scheme 6: Reagents and conditions.  (a) H2, Pd/C, MeOH, rt, 16 h, 80%; (b) 4-hydroxy-3-(2-
methoxyethoxy)methoxypyridine 72, (Ph)3P, DIAD, THF, reflux, 12 h, 80% ((S,R)-65) and 54% ((S,S)-
65); (c) LiAlH4, THF, rt, 3 h, 86% ((S,R)-66) and 95% ((S,S)-66); (d) MsCl, TEA, DCM, rt, 30 min and 
then TFA, DCM, rt, 3 h, 59% ((S,R)-67) and 40% ((S,S)-67); (e) K2CO3, DME, reflux, 16 h, 46% ((S,S)-
7) and 69% ((S,R)-7). 
The two diastereomers of the last regioisomer (S,R)- and (S,S)-6 were synthesized according to 
the procedure used for 8 (Scheme 7). (S)-N-Cbz-2-bromoacetylpyrrolidine was coupled with 
the potassium salt of 4-chloro-3-hydroxypyridine 76, providing intermediate (S)-68, which was 
reduced by treatment with NaBH4 to the diastereomeric mixture of secondary alcohols (S,S)-
69/(S,R)-69. Cyclization with NaH in DME provided the final compounds as diastereomeric 
mixture (S,R)-6/(S,S)-6 in a 60:40 ratio (determined by NMR).  
 
Scheme 7: Reagents and conditions. (a) Acetone, rt, 5 h, 48%; (b) LiAlH4, THF, rt, 3 h, 60%; (c) NaH, 
DMF, reflux, 16 h, 35%. 
The absolute configuration of the pyrrolidine stereocenter is S in all the final compounds and 
the intermediates and it is indicated first in their chemical names when there are two 
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stereocenters, while that of the second stereocenter, namely that formed in the course of the 
synthesis and corresponding to dioxane C(2) in the final compounds, is either R or S and was 
assigned to the separated diastereomers of the final compounds and, retrospectively, to the same 
carbon of the respective precursors with the aid of 1H NMR and conformational analysis as 
previously reported for the benzodioxane analogues and the prolinol phenyl ethers. 72,74,75 
Briefly, we assigned R configuration to the pyridodioxane methine, when 1H NMR spectrum 
showed that its proton was anti-disposed to the adjacent methine proton, because such a 
disposition is conformationally disfavored when the dioxane methine has S configuration. The 
anti disposition was revealed by the td (triplet of doublets) pattern of the dioxane methine signal 
resulting from the coupling with pyrrolidine methine proton and one of the two dioxane 
methylene protons with a similar large J, as shown in the 1H NMR spectra of (S,R)-7 reported 
in the Experimental Section and in its magnification in Figure 29A . 
However, such an approach could not be extended to the diastereomers of 5 because of signals 
overlapping. Therefore, we relied on the 1H NMR analysis of an (S,S)-5 precursor, namely 
(S,R)-60 (Scheme 5). In this precursor, where the two adjacent methine stereocenters are 
enclosed into a rigid bicyclic structure, the O-adjacent methine has its proton anti-disposed to 
the proton of the N-adjacent S stereocenter and therefore its configuration has to be R. The anti-
disposition was revealed by the dt (doublet of triplets) pattern of its signal resulting from the 
coupling to the N-adjacent methine proton with a large J and to the exocyclic methylene protons 
with little lower, nearly equal coupling constants (see the 1H NMR spectrum of (S,R)-60 in the 
Experimental section and its magnification in Figure 29B).  
 
Figure 29: magnification of the 1H-NMR spectrum A) focused on the triplet of doublets (td) of the 
dioxane methine hydrogen of (S,R)-7; B) focused on the doublet of triplets (dt) of the O-adjacent methine 
hydrogen of (S,R)-60. 
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As shown in Scheme 5, the absolute configuration of (S,R)-60 is correlated not only to that of 
(S,S)-5, but also to that of (S,S)-7 and this is congruent to the configuration assignment 
previously made to the other diastereomer of 8. 
The enantiomeric excesses of key intermediates (S)-50, (S)-52 and (S)-68, that could in 
principle undergo racemization on the chiral center due to the enhanced acidity of the α-methine 
H were assessed by chiral HPLC and were demonstrated to be higher than 99%. 
The pyridylating agent 72 for the synthesis of 7 was synthesized starting from 3-(2-
methoxyethoxy)methoxypyridine 73. Para-lithiation and lithium-bromine exchange afforded 
70, that was converted to 71 by nucleophilic displacement of bromine with benzylate. Further 
debenzylation provided 72 (Scheme 8). 
 
Scheme 8: Reagents and conditions: (a) n-BuLi, THF,-78 °C, 1 h and then CBr4, -90 °C, 1 h, 72%; (b) 
BnONa, DMSO, rt, 1h, 82%; (c) H2, Pd/C 10%, MeOH, 1 h, 98%. 
The potassium salt of 4-chloro-3-hydroxypyridine 76, necessary for the synthesis of 6, was 
obtained starting from 3-hydroxypyridine, that was O-protected with NaH and MEM-chloride 
(73) and subsequently chlorinated by direct ortho metalation (DOM) with t-BuLi and C2Cl6 
providing 74. Deprotection with hydrogen chloride (75) followed by treatment with KOH 
afforded the appropriate potassium phenate 76 (Scheme 9). 
 
Scheme 9: Reagents and conditions. (a) NaH, MEM-Cl, DMF, 0°C, 3.5 h, 83%; (b) t-BuLi, C2Cl6, diethyl 
ether, -78°C and then rt, 1 h, 90%; (c) HCl, MeOH, rt, 16 h, 90%; (d) KOH, MeOH, rt, 10 min, 95%. 
1.6.3 Biology 
Compounds (S,S)- and (S,R)-5-8 were assayed for binding affinity on native rat α4β2* nAChR 
present on rat cerebral cortex membranes and on human α3β4 nAChR transiently transfected 
into HEK 243 cells according to a previously described experimental protocol. 74,75,88  
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The α4β2 and α3β4 nAChRs were labeled by [3H]-epibatidine ([3H]-Epi) and the binding 
affinities (Ki) of the compounds were determined with competition binding experiments; the 
results are listed in Table 2. As controls in each experiment, we determined the affinity of (S)-
(-)-nicotine for the two subtypes. As a reference, binding affinities of (S,S)- and (S,R)-IV at 
both subtypes were reported.  
Electrophysiological functional assays for α4β2 and α3β4 nAChRs were performed on (S,R)-
IV and on (S,R)-5. Data were collected via whole-cell patch clamp electrophysiology with 
GH4C1 cell line cells transiently expressing human α4β2 and α3β4 subtypes. 
1.6.4 Results and discussion 
The binding studies indicated that (S,R)-5 was the compound with the highest α4β2 affinity and 
highest α4β2/α3β4 selectivity, due to a much lower affinity towards the α3β4 subtype, while its 
diastereomer (S,S)-5 and all the other regioisomers showed supramicromolar α4β2 binding 
affinities.  
 Compound 
α4β2 nAChR 
[3H]-Epi (µM) 
α3β4 nAChR 
[3H]-Epi (µM) 
 (S)-Nicotine 0.004 0.261 
 
(S,R)-IV 0.26 (32) a 1.2 (20) 
(S,S)-IV 0.47 (30) a 8.2 (25) 
 
(S,R)-5 0.41 (20) 16.2 (35) 
(S,S)-5 30.4 (34) 22 (22) 
 
(S,R)-6+(S,S)-6 2.5 (30) 12.3 (37) 
 
(S,R)-7 1.64 (19) 5.8 (27) 
(S,S)-7 3.6 (16) 8.9 (31) 
 
(S,R)-8 43 (29) - 
(S,R)-8 30 (23) - 
Table 2: compounds (S,R)- and (S,S)-5-8, nicotine and (S,R)- and (S,S)-IV: affinity for native α4β2 
nAChR, present in rat brain membranes, labelled by [3H]-epibatidine, and for heterologously expressed 
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human α3β4 nAChR, labelled by [3H]-epibatidine and affinity ratios. The numbers in brackets are the % 
coefficient of variation (CV%).75 a α4β2 affinity data from literature73. 
Particularly, when we compared the moderate affinities of the parent compounds (S,R)-IV  and 
of its epimer (S,S)-IV with the modest supramicromolar or high micromolar affinities of their 
pyridodioxane analogues (S,S)-5, (S,R)-6, (S,S)-6, (S,R)-7, (S,S)-7, (S,R)-8 and (S,S)-8 and with 
the moderate α4β2 affinity of (S,R)-5, we could conclude that the replacement of an aromatic 
CH with a nitrogen was invariably deleterious for affinity with the only exception of (S,R)-5. 
Quite surprisingly, an opposite trend was normally observed for other nicotinoids, like the pairs 
nicotine/nornicotine or A-85453/(S)-I, where the nitrogen-containing one had higher affinity, 
attributed to the presence of a HBA system (Figure 30).  
 
Figure 30: divergent effect of CHN replacement in A) rigid ligands and B) flexible ligands. 
However, this divergent trend in affinity can be explained if we consider the different SARs for 
flexible and rigid compounds, already reported for the effect of meta-hydroxylation of prolinol 
phenyl ethers ad of the 7-hydroxylation of pyrrolidinyl benzodioxanes.  
Whereas flexible ligands like A-84543 and, in a lesser extent, nicotine, can orient their pyridyl 
ring to place the nitrogen in the appropriate position to interact as an HBA with the binding site, 
rigid and bulky ligands like N-Me-pyrrolidinyl-pyridodioxanes are conformationally 
constrained and forcedly place the aromatic nitrogen in regions of the binding site which do not 
necessarily correspond to the ideal position of the HBA system. 
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Indeed, if we compare the pairs A-84543/(S)-I, we see that replacement of the pyridine nitrogen 
with a -CH= results in approximately 300-fold drop of affinity, consistent with a HBA loss. On 
the other hand, if the nitrogen is repositioned, instead of being replaced with a -CH=, a further 
drop in affinity is observed, obtaining analogues (S)-X and (S)-XI with 10000 or 1000-lower 
affinities than A-84543, indicating a simultaneous loss of the HBA system and a weakening of 
π-π interactions.  
Oppositely, the removal of the aromatic nitrogen of (S,R)-5 to (S,R)-IV didn’t decrease affinity, 
but slightly increased it, suggesting that the nitrogen, in that position, is not involved in specific 
interactions beneficial for affinity when compared to (S,R)-IV. However, its repositioning in 
the cycle or the inversion at the pyridodioxane stereocenter is detrimental for α4β2 affinity. 
Together, these evidences, stress the different binding modes and the different roles of the 
pyridyl nitrogen between flexible and rigid ligands. 
In order to determine the effects of (S,R)-5 on α4β2, and α3β4 nAChRs, in vitro, data were 
collected via whole-cell patch clamp electrophysiology with GH4C1 cell line cells transiently 
expressing human α4β2 and α3β4 subtypes. Compound (S,R)-5 did not have any activity at the 
α3β4 subtype, but it was a partial agonist at the α4β2 with an Imax of 24.2% of that elicited by 
1 mM ACh with an effective concentration (EC50) of 10.1 µM (Figure 31). As term of 
comparison, (S,R)-IV was also assayed and, surprisingly, it was found to be a competitive 
antagonist with similar potencies at either the α4β2 (IC50= 5.36 µM) and the α3β4 (IC50= 2.78 
µM) subtypes. 
 
Figure 31: partial agonist activity of (S,R)-5 on transfected human α4β2 and α3β4 subtypes. The 
activation responses are normalized to the maximal response to 1 mM ACh.  
Overall, these findings confirmed our expectations: the four diastereomeric pairs of 
regioisomeric N-Methyl-pyrrolidinyl-pyridodioxanes exhibited very different binding affinities 
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and selectivities depending on the position of the nitrogen. Only compound (S,R)-5, where the 
CH in position 5 of the benzodioxane scaffold was replaced by nitrogen, showed submicromolar 
affinity and good selectivity. Moreover, the electrophysiological assays highlighted that 5CH 
in place of N converted the antagonism activity of (S,R)-IV into a α4β2 selective partial agonist, 
thus exerting a pivotal role in receptor activation. 
This result, together with the α4β2 partial selective agonism of (S,R)-IVa (retested 29%), 
suggested that the naked and rigid antagonist (S,R)-IV can be turned into a selective partial 
agonist by decorating it with an OH group at the 7 position or by replacing the CH in position 
5 with a nitrogen.  
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1.7 Synthesis of N-Methyl-pyrrolidinyl-5-substituted-
benzodioxanes 
1.7.1 Introduction and aim 
As detailed in chapter 1.3, substitution at position 7 of the benzodioxane moiety of IV with a 
small and polar hydroxyl group lead to great enhancement of α4β2 affinity and α4β2 vs α3β4 
functional selectivity in (S,R)-IVa. On the other hand, replacement of CH at position 7 with N 
resulting in the pyridodioxane (S,R)-7 markedly reduced affinity, whereas CH replacement at 
position 5 with N provided a ligand, (S,R)-5, with similar affinity to the benzodioxane parental 
compound and with high α4β2 vs α3β4 selectivity.  
These results prompted us to investigate the effect of the substitution at position 5 of the 
benzodioxane scaffold of IV. Therefore we synthesized the N-methyl-pyrrolidinyl 5-substituted 
benzodioxanes (S,R)- and (S,S)-9a-d, which we expected to have interesting biological profiles 
as those of 5 (Figure 32) 
Moreover, compounds 9a-d were compared to the correspondent 7-substituted analogues IVa, 
10, 11 and IVd. Compounds 10 and 11 were synthesized and characterized previously 
(unpublished data). Nitro-substituted (S,R)-10 and (S,S)-10 had modest micromolar affinities at 
the α4β2 subtype, while, in line with our previous findings, the introduction of a relatively small 
and polar amino substituent provided (S,R)-11, with 27 nM affinity at the α4β2 subtype and 
(S,S)-11, with 144 nM affinity. However, differently from (S,R)-IVa, (S,R)-11 was not selective 
versus the α3β4 subtype. 
 
Figure 32: design of 5-substituted benzodioxanes (S,R)- and (S,S)-9a-d as analogues of IV and 5 
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Compounds 5, 9a and 9b could also be considered as the result of conformational constriction 
of the flexible bioisosteric ligands A-84543, (S)-VI and (S)-IX.77 Ideally, the rigidification of 
such flexible compounds respectively into a pyridodioxane or into a substituted benzodioxane 
moiety, could result into two series of correspondent regioisomers in both diastereomeric pairs 
depending on where the nitrogen or the substituent was constrained. As illustrated in Figure 
33, the first approach constrained the substituent or the nitrogen in position 7 affording 
compounds 7, IVa and 10, while the second approach blocked it in position 5, providing 
compounds 5, 9a and 9b.  
 
Figure 33: design of 5-substituted benzodioxanes (S,R)- and (S,S)-9a,b as constrained analogues of (S)-
VI and of (S)-IX. 
Since we already demonstrated similar binding modes for the meta-pyridyl, the meta-
hydroxyphenyl and meta-nitrophenyl ethers of N-methyl-prolinol parental compounds,77 we 
also aimed at understanding whether the same rationales could be applied to their 
conformational constrained analogues with a pyridodioxane or substituted benzodioxane 
moiety.  
1.7.2 Synthetic schemes 
A key intermediate for the synthesis of compounds (S,S)- and (S,R)-9a-d was (S)-N-Boc-2-
bromoacetylpyrrolidine (S)-79. The commercially available (S)-Proline was N-protected by 
treatment with Boc2O providing (S)-77. The carboxylic group of (S)-77 was activated as a 
mixed anhydride with isobutylchloroformate and converted to the correspondent diazoketone 
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(S)-78 by treatment with diazomethane that was further reacted with aqueous HBr to obtain the 
α-bromoketone (S)-79 (Scheme 10). 
 
Scheme 10: Reagents and conditions. (a) NaOH, Boc2O, rt, 5 h, 95%; (b) TEA, i-BuOCOCl, Et2O, -
15°C, 1h. CH2N2, 0 °C and then overnight at 25 °C, 78%; (c) HBr/H2O, Et2O, 25°C, 1h, 71%. 
The core reaction of all the synthetic routes described below was the nucleophilic displacement 
of the bromine of the bromoketone (S)-79 with the potassium salt of an appropriate substituted 
phenol, exemplified by potassium 2,6-bis((2-methoxyethoxy)methoxy)phenolate 102 for the 
synthesis of (S)-80, an intermediate of the synthetic scheme to afford (S,R)- and (S,S)-9a. 
The stereochemistry of this reaction, and of the corresponding reactions in the following 
schemes, was investigated through chiral HPLC, because the acidity of the methinic hydrogen 
could drive racemization of the chiral center through an enolization process, depending on the 
reaction conditions. Therefore, we developed chiral HPLC methods to evaluate the 
enantiomeric excesses of the coupled ketones, and we identified the most convenient reaction 
conditions to avoid racemization for each intermediate. To assess enantiomeric excesses, the 
syntheses of both the enantiomeric forms of the ketone intermediates were necessary. The R 
enantiomers of each coupled ketone were obtained following the same reaction schemes used 
to synthesize the S enantiomers, but starting from (R)-proline instead of (S)-proline. 
Compounds (S,S)- and (S,R)-9a were obtained starting from the nucleophilic substitution 
between the bromo ketone (S)-79 and potassium 2,6-bis((2-methoxyethoxy)methoxy)phenolate 
102 in acetone overnight at room temperature, which provided intermediate (S)-77. The ketone 
functionality was reduced with NaBH4 to provide a diastereomeric mixture of (S,S)-81/(S,R)-
81, which couldn’t be separated by flash chromatography due to too similar retention times in 
all the eluents tested. The mixture was treated with methansulphonylchloride and TEA, 
providing (S,S)-82/(S,R)-82, whose Boc- and MEM- protecting groups were removed by 
treatment with HCl affording (S,S)-83/(S,R)-83. The intermediates were cyclized by treatment 
with K2CO3 in DME/DMF, to give the benzodioxanes (S,S)-84/(S,R)-84, which were 
methylated to the final compounds (S,S)-9a/(S,R)-9a with formaldehyde and picoline borane. 
Upon chromatography separation, the single diastereomers (S,S)-9a and (S,R)-9a were obtained 
(Scheme 11). 
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Scheme 11: Reagents and conditions. (a) Acetone, rt, overnight, 77%; (b) NaBH4, THF anidro, rt, 3h, 
97%; (c) DCM, TEA, MsCl, rt, 2h, 54%; (d) HCl/MeOH (1.25 M), rt, 2h, 99%; (e) K2CO3, DME, DMF, 
reflux, 3h, 25%; (f) MeOH, CH3COOH, HCOH/H2O 37%, pic-BH3, rt, 3h, HCl/H2O (1M), 30 min and 
then purification through flash chromatography, 46% (S,S)-9a, 36% (R,S)-9a. 
Compounds (S,S)- and (S,R)-9b were obtained starting from the nucleophilic substitution 
between the bromo ketone (S)-79 and potassium 2-((2-methoxyethoxy)-methoxy)-6-
nitrophenolate 106 in acetone overnight at room temperature, which provided intermediate (S)-
85. The ketone functionality was reduced with NaBH4, providing a mixture of diastereomers 
which were separated by chromatography in the single diastereomers (S,S)-86 and (S,R)-86. 
The secondary hydroxyl groups were mesylated with methansulphonyl chloride and TEA to 
give (S,S)-87 and (S,R)-87 which were in turn deprotected with HCl to (S,S)-88 and (S,R)-88, 
cyclized to (S,S)-89 and (S,R)-89 in K2CO3 and DME and then methylated to the final 
compounds (S,S)-9b and (S,R)-9b with formaldehyde and picoline-borane (Scheme 12). 
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Scheme 12: Reagents and conditions. (a) Acetone, 25 °C, overnight, 42%; (b) NaBH4, THF, 25 °C, 3 h, 
80% and then purification through flash chromatography 72% ((S,S)-86) and 28% ((S,R)-28); (c) TEA, 
MsCl, DCM, 25 °C, 1h, 58% ((S,S)-87), 66% ((S,R)-87); (d) HCl/dioxane 4M, MeOH, 25 °C, 2h; (e) 
K2CO3, DME, reflux, 5h, 87% (S,R)-89; 80% ((S,S)-89); (f) CH2O, Pic-BH3, AcOH, MeOH, 25 °C, 3h, 
25% ((S,R)-9b) and 81% ((S,S)-9b). 
Compounds (S,S)- and (S,R)-9c,d were synthesized according to a similar synthetic scheme, 
starting from nucleophilic substitution in acetone at room temperature overnight between (S)-
79 and potassium 2-benzyloxy-6-nitrophenolate 93 for the synthesis of 9c, or potassium 2-
benzyloxy-6-phenylphenolate 114 for 9d. The ketone functionalities of the resulting 
intermediates, respectively (S)-90 and (S)-91 were reduced with NaBH4, providing a mixture 
of diastereomers which were separated by chromatography in the single diastereomers, 
respectively the pair (S,S)-92 and (S,R)-92 and the pair (S,S)-93 and (S,R)-93. The secondary 
hydroxyl groups were mesylated with methanesulphonyl chloride and TEA to give the pair 
(S,S)-94 and (S,R)-94 and the pair (S,S)-95 and (S,R)-95, which were in turn hydrogenated under 
catalytic conditions. In these conditions debenzylation occurred in both cases, but the nitro 
groups of intermediates 94 were reduced to amino groups. Overall, hydrogenation of (S,S)-94 
and (S,R)-94 provided (S,S)-96 and (S,R)-96, while debenzylation of (S,S)-95 and (S,R)-95 
afforded (S,S)-97 and (S,R)-97. Upon cyclization with K2CO3 in DME to give (S,S)- and (S,R)-
98 and (S,S)- and (S,R)-99, the final compounds (S,R)- and (S,S)-9c, and (S,R)- and (S,S)-9d, 
respectively 5-amino and 5-phenyl substituted benzodioxanes were obtained by reduction of 
the N-carbamate with LiAlH4 (Scheme 13). 
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Scheme 13: Reagents and conditions. (a) Acetone, 25 °C, overnight, 81% ((S)-90), 1.5 h, 30%, ((S)-91); 
(b) NaBH4, THF, 25 °C, 3 h, 75% and then purification through flash chromatography, 26% ((S,S)-92) 
and 74% ((S,R)-92), -10 °C, 2 h, 80% and then purification through flash chromatography, 62% ((S,R)-
93) and 24% ((S,S)-93); (c) TEA, Ms-Cl, DCM, 25 °C, 2h, 86% ((S,S)-94), 59% ((S,R)-94), 42% ((S,R)-
80) and 46% ((S,S)-80); (d) H2, Pd/C 5%, MeOH, 25 °C, 6h, 73% ((S,S)-96), 82% ((S,R)-96), 48 h, 77% 
((S,R)-97) and 91% ((S,S)-97); (e) K2CO3, DME, reflux, 7h, 78% ((S,R)-98), 84% ((S,S)-98, 5h, 49% 
((S,S)-99) and 34% ((S,R)-99); (f) LiAlH4, THF dry, reflux, 4h, 100% ((S,R)-9c, 83% ((S,S)-9c), 39% 
((S,S)-9d) and 85% ((S,R)-9d). 
Absolute configuration of the pyrrolidine stereocenter was S in all the final compounds, while 
the absolute configuration of the benzodioxane stereocenter was assigned to the single 
diastereomers of the final compounds and then retrospectively assigned to their precursors, as 
described in paragraph 1.5.2.  
Potassium 2,6-bis((2-methoxyethoxy)methoxy)phenolate 102 was synthesized starting from 
resorcinol, which was protected at its phenolic groups by treatment with MEM-Cl and TEA, 
obtaining 100. The latter was lithiated by DOM by treatment with n-BuLi and oxidized with 
Oxone®, affording 101, which was converted into its potassium salt by treatment with KOH in 
methanol (Scheme 14). 
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Scheme 14: Reagents and conditions. (a) MEM-Cl, DIPEA, DCM, rt, overnight, 46%; (b) THF dry, n-
BuLi, 1h, B(OMe)3, 30 min, NaHCO3 20% in aqueous acetone, Oxone®, 5 min, NaHSO3, 65%; (c) 
KOH/MeOH (1M), rt, 15 min, 95%. 
Potassium 2-((2-methoxyethoxy)-methoxy)-6-nitrophenolate 106 was synthesized reacting the 
commercially available 2-hydroxybenzaldehyde with MEM-Cl and N,N-diisopropylamine, 
obtaining the intermediate 103, which was converted into its correspondent phenolic analogue 
104 through a Baeyer-Villiger reaction with mCPBA followed by hydrolysis. Nitration at its o-
position by treatment with CeNH4(NO3)2 in ACN followed by chromatography purification 
afforded the phenol 105, that was converted into its correspondent potassium salt 106 by 
treatment with KOH 1M in methanol (Scheme 15). 
 
Scheme 15: reagents and conditions. (a) DIPEA, MEM-Cl, DCM, 25 °C, overnight, 87%; (b) mCPBA, 
DCM, 25 °C, 48 h and then KOH 2M, MeOH, 25 °C, 5h, 56%; (c) CAN, acetonitrile, 10 °C, 3h, 40%; 
(d) KOH 1M, MeOH, 25 °C, 15 min, 100%. 
Potassium 2-benzyloxy-6-nitrophenolate 108 was obtained from commercial 2-
benzyloxyphenol, that was nitrated with CAN to 107 that, after chromatography purification, 
was converted into its correspondent potassium phenate 108 (Scheme 16). 
 
Scheme 16: reagents and conditions. (a) CAN, acetonitrile, 10 °C, 3h, 58%; (d) KOH 1M, MeOH, 25 °C, 
15 min, 92%. 
Potassium 2-benzyloxy-6-phenylphenolate 114 was obtained starting from commercial 2-
phenylphenol, that was carbonylated to compound 109 with paraformaldehyde, MgCl2 and 
TEA. The phenolic function was protected by treatment with MEM-Cl, providing intermediate 
110, that was converted in compound 111 by Baeyer Villiger reaction with m-MCPA followed 
by hydrolysis in basic conditions. The free phenolic function was benzylated with benzyl 
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bromide in intermediate 112, that was deprotected in acidic conditions to 113. The potassium 
salt 114 was obtained by treatment with KOH in methanol (Scheme 17). 
 
Scheme 17: reagents and conditions. (a) MgCl2, TEA, dry THF, paraformaldehyde, reflux, 3 h, 88%; 
(b) NaH, dry THF, MEM-Cl, rt, overnight, 71%; (c) m-CPBA, EtOAc, 72 h and then MeOH, NaOH 
2.5M, 2h, rt, 73%; (d) K2CO3, DMF, BnBr, 50 °C, 1.5 h, 78%; (e )HCl 37%, MeOH, 60 °C, 1 h, 96%; 
(f) MeOH, KOH 1M, 30 mins, rt, 91%. 
1.7.3 Biology 
Binding assays were performed on compounds (S,R)- and (S,S)-9a-d as described in paragraph 
1.6.3 and the results are reported in Table 3, together with those of compounds (S,S)- and (S,R)-
IV reported as reference.  
Electrophysiological functional activity was assessed for (S,S)-9c according to the methods 
previously described, and it was compared with the electrophysiological activities of (S,R)-IV, 
(S,R)-IVa and (S,R)-5. 
1.7.4 Results and discussion 
Among the series of 7-substituted benzodioxanes, the (S,R)- diastereomers of compounds with 
a HBA/HBD group such as a hydroxyl or an amine, namely (S,R)-IVa and (S,R)-11, had the 
highest affinities at the α4β2 subtype  (respectively 12 and 27 nM). Differently, nitro-substituted 
benzodioxanes (S,R)-10 and (S,S)-10 and phenyl-substituted benzodioxanes (S,R)-IVb and 
(S,S)-IVb had modest micromolar affinities. 
As the 5-substituted benzodioxanes could be formally considered as analogues of the moderate 
affinitive α4β2 ligand (S,R)-5, we expected them to have similar biological profiles to that of 
(S,R)-5.  
As shown in Table 3, the introduction of relatively small substituents at position 5 of the 
benzodioxane scaffold did not have great impact on binding affinity at the α4β2 subtype when 
compared to the unsubstituted benzodioxane (S,R)-IV. In fact, compounds (S,R)-9a, (S,S)-9b 
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and (S,S)-9c had Ki values respectively of 549 nM, 335 nM and 131 nM, similar to those of 
(S,R)- and (S,S)-IV. Also the introduction of a bulkier phenyl group in (S,R)-9d was tolerated, 
although with a slightly higher Ki value. 
Interestingly, we observed an inverse stereospecificity of binding between 7-substituted and 5- 
substituted benzodioxanes: (S,R)-configuration was required to achieve high affinity in the 7- 
substituted benzodioxanes (S,R)-IVa and (S,R)-11, while (S,S)- configuration was needed for 
the 5-substituted benzodioxanes exhibiting the highest affinities, namely those bearing NO2 
(9b) and NH2 (9c). 
Even though this divergent trend couldn’t be easily explained by classical SAR, we speculated 
that the combination of the absolute stereochemistry and of the positioning of the substituents 
could result in a 3D conformation that oriented the ligands to place similar functional groups in 
the same region of the binding site (see chapter 1.8). 
When (S,R)-IVa was first reported, our group attributed its enhanced α4β2 affinity and its α4β2 
vs α3β4 selectivity to some additional interactions between its hydroxyl group and a small, 
hydrophilic and  non-conserved binding pocket located in the β2 subunit.74 In line with it, the 
amino analogue (S,R)-11, that could in principle interact with the same region, had high affinity 
α4β2, but was found to be non-selective, making the interpretation of the binding data even 
more complicated. Instead, compounds (S,S)-9b,c were α4β2 vs α3β4 selective, achieving 100 
fold selectivity for (S,S)-9c.  
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Compound 
α4β2 nAChR 
[3H]-Epi (µM) 
α3β4 nAChR 
[3H]-Epi (µM) 
Selectivity Ki 
α3β4/α4β2 
R= 
H (S,R)-IV 260 a  1200 a 4.6 
H (S,S)-IV 470 a  8200 a  17.4 
OH (S,R)-9a 549 3900 7.1 
OH (S,S)-9a 1710 100000 58 
NO2 (S,R)-9b 12200 1080 0.09 
NO2 (S,S)-9b 335 6700 20 
NH2 (S,R)-9c 7100 3900 0.55 
NH2 (S,S)-9c 131 13000 99 
Ph (S,R)-9d 636 2660 4.18 
Ph (S,S)-9d 7300 5280 0.72 
Table 3: compounds (S,R)- and (S,S)-9a-d, compared with (S,R)- and (S,S)-IV74: affinity for native α4β2 
nAChR, present in rat brain membranes, labelled by [3H]-epibatidine, and for heterologously expressed 
human α3β4 nAChR, labelled by [3H]-epibatidine and affinity ratios. aBinding affinity data from 
literature.73,89 
When the naked benzodioxane moiety of (S,R)-IV was decorated with a small and hydrophilic 
substituent, such as hydroxyl or amino group, the affinity increased or, at least, it was not 
significantly decreased regardless its 5- or 7 positioning, but depending on the absolute 
configuration at the chiral center.  
These results also suggested divergent structural requirements for 5- and 7- substituted 
benzodioxanes, proving that the bioisosteric relationship between flexible meta-
hydroxyphenyl, meta-nitrophenyl and meta-pyridyl ethers is not preserved into their products 
of rigidification. 
Compound (S,S)-9c was assayed for its electrophysiological activity at the α4β2 and at the α3β4 
subtype and it was found to be an α4β2 partial agonist with a bimodal dose-response curve, that 
could only be interpreted as the combination of different activities at the two stoichiometries of 
the α4β2 subtype (Figure 34). Particularly, the lower EC50 was calculated to be 4.98 nM with 
61 
 
a maximal response of 20%, while the higher EC50 was 8.7 µM with a maximal response of 
60%. From the curve we observed that, overall, when (S,S)-9c was administered at a 
concentration of 100 µM, it elicited a total current equal to 60% of that evoked by acetylcholine 
at 1 mM.  
 
Figure 34: partial agonist activity of (S,S)-9c on transfected human α4β2 subtypes. The activation 
responses are normalized to the maximal response to 1 mM ACh. Data can be only fitted as the sum of 
two sigmoidal dose-response curves, suggesting two different activities at the two α4β2 stoichiometries.  
When compared with the partial agonist (S,R)-IVa, the ligand with highest affinity in the series, 
and with the pyridodioxane (S,R)-5, (S,S)-9c was found to be the most efficacious at the α4β2, 
with a maximal response (60%) almost twice the efficacy of (S,R)-IVa (29%) and of (S,R)-5 
(24.1%). Even though a direct comparison between the two potencies couldn’t be drawn due to 
the bimodal sigmoidal curve of (S,S)-9c, the administration of even low concentrations of (S,S)-
9c (such as 100 nM) elicited approximately 20% of the total current, because the first curve has 
already reached the plateau due to its extremely high potency of 4.9 nM at one stoichiometry. 
Differently, the same concentration of (S,R)-IVa or of (S,R)-5 evoked respectively only 7% and 
0% of the maximal response induced by ACh 1 mM, because of their lower potency of 0.3 µM 
for (S,R)-IVa, and of 10.1 µM for (S,R)-5 (Figure 35). 
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Figure 35: partial agonist activities of (S,R)-IVa and (S,R)-5 on transfected human α4β2 and α3β4 
subtypes. The activation responses are normalized to the maximal response to 1 mM of ACh. 
Furthermore, (S,R)-9c was found to be a very weak antagonist of the α3β4 subtype, with an IC50 
of 54.6 µM, thus having a very high α4β2/α3β4 selectivity, much higher than that of (S,R)-IVa. 
Since binding and functional data alone could not fully explain the SARs of these constrained 
nicotinoids, we applied some computational tools to support their interpretation, which will be 
discussed in the following chapter.  
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1.8 Computer-aided SAR interpretation 
1.8.1 Introduction and aim 
The complexity of the SARs of our constrained nicotinoids, together with the high number of 
pharmacological data, prompted us to use a 3D model of the target to understand structural 
details of the binding modes and of the interactions between the α4β2 receptor and the rigid N-
methyl-pyrrolidinyl- benzodioxanes, -pyridodioxanes and substituted -benzodioxanes. 
Aiming at unrevealing the key elements that drive binding and to obtain some hints about 
α4β2/α3β4 selectivity and functional activity, we performed docking studies of our ligands in 
an adapted binding site of the high affinity α4β2 nAChR subtype. 
1.8.2 Computational methods 
As described in paragraph 1.1.1 , in 2016 a full-lenght X-Ray 3D model of the α4β2 subtype in 
the stoichiometry 2α:3β stoichiometry was reported with a resolution of 3.9 Å.20 
Unfortunately, when in 2018 the cryoEM models of the two stoichiometries of α4β2 were 
reported, our modelling studies had already been completed on the basis of the X-Ray 
structure.19 However, a punctual comparison showed that the X-Ray (5KXI) and the CryoEM 
(6CNJ) structures were very similar. To confirm the findings hereby reported, based on the X-
Ray structure, we performed a preliminary docking study on the binding site derived from the 
CryoEM model, obtaining comparable results.  
Ligand preparation 
Both (S,R)- and (S,S)- diastereomers of compounds IV, IVa, 10, 11, IVd, 5, 7,  and 9a-d were 
built with the 2D sketch editor of Maestro (Schrödinger Release 2017-3: Schrodinger, LCC, 
New York, NY, 2017) and assigned ionization state with LigPrep (Schrödinger Release 2017-
3: Schrodinger, LCC, New York, NY, 2017) using default settings.  
Protein preparation 
The ligand binding domain of the α4β2 was refined starting from the X-Ray structure of the 
full-length α4β2 receptor (5KXI). The pdb structure and the electron density maps of 5KXI 
were retrieved from the online database RSCB and the ligand binding domain was carefully 
inspected with Maestro. The α4β2 dimer, containing nicotine in the binding site, at the interface 
between the two subunits, was extracted from 5KXI and preprocessed, optimized and 
minimized with the Protein Preparation Wizard with default settings (Schrödinger Release 
2017-3: Schrodinger, LCC, New York, NY, 2017).  
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Although the presence of a water molecule in the α4β2 binding site has been observed in X-
Ray crystal structures of AChBPs, neither the X-Ray structure of 5KXI nor the cryoEM 
structure of 6CNJ showed it, probably due to too low resolution. Therefore, the water-
containing X-Ray structure of the homologous AChBP from Lymnaea Stagnalis (1UW6) was 
superimposed to the α4β2 structure.90 Its water molecule was extracted from the AChBP 
binding site and merged with one duplicate of the prepared α4β2 dimer. The resulting water-
containing dimer was preprocessed with the Protein Preparation Wizard with default settings.  
Overall, two models of binding pocket were obtained: a water-free model and a water-
containing model. 
Binding pocket analysis and docking 
Binding pockets analyses were performed using Sitemap (Schrödinger Release 2017-3: 
Schrodinger, LCC, New York, NY, 2017) centered on the ligand, with default settings. 
Next, the bulkiest compound with highest α4β2 affinity of the series, namely (S,R)-IVa, was 
docked in the water-free binding site using the Induced Fit Protocol (Schrödinger Release 2017-
3: Schrodinger, LCC, New York, NY, 2017) to adapt the receptor binding pocket to the shape 
and size of our rigid nicotinoids. The docking center was defined by the present ligand 
(nicotine), scaling was set to 0.8 to avoid profound deformation of the binding site, rescoring 
was performed with Glide-XP (Schrödinger Release 2017-3: Schrodinger, LCC, New York, 
NY, 2017) and otherwise default settings were used. 
The complex α4β2/(S,R)-IVa with the highest Glide XP Score was selected as adapted complex 
and all the prepared compounds were docked within the binding site with Glide XP with the 
grid centered on the ligand and otherwise using default settings. 
The same compounds were also docked in the binding site of the water-containing model with 
GlideXP and otherwise using default settings. 
1.8.3 Results and discussion 
Binding pocket analysis of the X-Ray crystal structure 5KXI confirmed that probably a water 
molecule is included in the binding pocket but is not visible in the X-Ray structure due to low 
resolution. If the water molecule contained in the correspondent 3D position of the homologous  
Lymnaea Stagnalis AChBP (Ls-AChBP) 1UW6 is incorporated in the α4β2 binding site, it 
seems to play a pivotal role in binding: it bridges the pyridine nitrogen of nicotine with a small 
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hydrophilic pocket of the minus β2 side, hydrogen-bonding the -NH backbone of Leu 121, the 
-CO backbone of Asn 109 and the hydroxylated side chain of Ser 108. 
The role of two of these amino acids was investigated in 2010 by Dougherty et al., who proved 
through mutational studies that a water molecule bridges the pyridine nitrogen to the backbone 
amidic -NH of Leu 121 in the β2 subunit (β2L119 according to Dougherty’s numbering) with 
an H-bond in the α4β2 subtype.91 The role of the carbonyl of amino acid Asn 109 (β2N109 
according to Dougherty’s numbering) couldn’t be elucidated due to technical reasons. The third 
amino acid, Ser 108, was not considered by the authors in the mutational study because in the 
AChBPs sequences (the most similar proteins to the α4β2 receptor available at that time) it was 
formally replaced by a glutamine and in the AChBP X-Ray structure the orientation of the entire 
loop was bent by a proline residue that immediately precedes glutamine (Figure 36).  
 
Figure 36: A) extract of the sequence alignment between Ls-AChBP and nAChR β2; major differences 
are indicated by black arrows (Pro“107” vs Tyr107 and Gln”108” vs Ser108). B) 3D alignment 
between the loop of interest of Ls-AChBP and nAChR β2. In Ls-AChBP, Pro 107 bends the entire loop 
and moves Gln 108 out from the binding site. In the β2 subunit, Pro 107 is replaced by Tyr 107, that 
does not twist the loop and orients the side chain of the Ser 108 toward a water molecule in the binding 
site. 
When (S,R)-IVa was docked within the water-free α4β2 binding pocket to adapt it to the size 
and shape of our ligands, it assumed a conformation that maintained all the principal 
interactions of nicotine and surprisingly placed its hydroxyl group in the same small hydrophilic 
pocket mentioned just above. Indeed, if we compare the binding poses of (S,R)-IVa in the 
water-free receptor and nicotine in the water-adapted receptor, we observe a perfect overlay 
between the hydroxyl group of (S,R)-IVa and water (Figure 37A and 37B).  
66 
 
These two premises alone suggested a reasonable explanation of the 20 folds higher affinity of 
(S,R)-IVa compared to its non-hydroxylated precursor (S,R)-IV: whereas the “naked” 
benzodioxane is not able to displace water from the binding site, (S,R)-IVa kicks out water and 
replaces it with its hydroxyl group, that interacts with the side chain of Ser 108 and the backbone 
carbonyl of Gln 109 and NH Leu 121.  Indeed, the unsubstituted benzodioxane (S,R)-IV, 
lacking of any small and polar substituent, fitted the water-containing binding site with a 
docking pose quite different from that of (S,R)-IV, suggesting that the driving force for binding 
with high affinity to the α4β2 subtype in this series of rigid ligands is displacement of water 
accompanied by a new network of H-bond interactions (Figure 37C). 
 
 
Figure 37:A) nicotine bound at the water-containing α4β2 binding site. B) (S,R)-IVa binds maintaining 
comparable interactions to nicotine, displaces water and  fits the small hydrophilic pocket with its 7-
OH substituent. C) (S,R)-IV can’t displace water and assumes a different orientation in the binding site. 
Normally, if water molecules are located in hydrophobic regions of the binding pocket, their 
displacement by lipophilic groups strongly enhance affinity, due both to additional Van Der 
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Waals interactions and to an entropic contribution driven by the release of an ordered and 
“trapped” water molecule to the disordered bulk of the aqueous environment. In our case, 
displacement of the water molecule from a small hydrophilic pocket was more challenging and 
could be only achieved if driven by comparable interactions that could compensate the enthalpic 
loss, such as H-bonds between the hydroxyl group of (S,R)-IVa and the residues of the 
hydrophilic pocket.92 
Moreover, interactions with this small hydrophilic binding pocket seemed to be involved in 
receptor activation: whereas (S,R)-IV is an antagonist, (S,R)-IVa is a partial agonist. A similar 
hypothesis had already been advanced and investigated by Dougherty et al., who observed 
lower potency for nicotine when the hydrogen bonding donor feature of the amidic NH of Leu 
121 was impaired (β2L119 according to Dougherty’s numbering). Thus, we are currently 
designing a mutational study where we will investigate the role of the interaction between (S,R)-
IVa and Ser 108, the residue that was not included in Dougherty’s investigation. According to 
our design of experiments, Ser108 will be mutated to hydrophobic amino acids and binding 
affinities and electrophysiological functional activities of (S,R)-IV and (S,R)-IVa will be 
assayed. 
Afterwards, all the 5-substituted benzodioxanes were docked in the water-free binding site and 
very interestingly, diastereomers with (S,S)- absolute configuration, except for the bulky (S,S)-
9d, fitted it maintaining similar interactions to those of (S,R)-IV, but also interacted through H-
bonding with their 5-substituent with the hydrophilic pocket lined by Gln 107, Ser 108 and Leu 
121, similarly to (S,R)-IVa. In order to reach these residues with the 5-substituent, the core 
benzodioxane moiety had to be twisted of approximately 180° (Figure 38A). Oppositely, the 
(S,R)-diastereomers were predicted to place their 5-substituents far from this pocket, with a 
docking pose almost superimposable with that of (S,R)-IV (Figure 38B).  
These findings, in line with the binding assays, suggested that water displacement, accompanied 
by additional interactions to the small hydrophilic binding pocket at the β2 subunit could be so 
important that, when a suitable H-bond partner is introduced in the 5 position, the ligand 
reorients itself to place the 5-substituent in the additional pocket, resulting in a conformational 
twist of the benzodioxane moiety to keep the pyrrolidine nitrogen within the aromatic box.  
Additionally, N-methyl-pyrrolidinyl-pyridodioxanes (S,R)- and (S,S)-5-8 were docked and, 
among them, compound (S,R)-5 was predicted to hydrogen-bond the water molecule that 
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bridges it with an H-bond network with Leu 121 and Asn 109, in a similar way to nicotine 
(Figure 38C).  
 
Figure 38: A) (S,S)-9c twists its core benzodioxane scaffold to place the 5-amino substituent in the small 
hydrophilic cavity. B) (S,R)-9c places its 5-amino substituent far from the hydrophilic cavity. C) (S,R)-
5 indirectly binds Asn 109 and Leu 121 by H-bonding a water molecule that bridges it with the 
hydrophilic pocket. 
The results of this docking study prompted us to hypothesize a reasonable explanation for the 
differences in the electrophysiological activities of (S,R)-IV, (S,R)-IVa, (S,R)-5 and (S,S)-9c. 
The antagonists (S,R)-IV did not have any hydrophilic substituent that could neither drive the 
expulsion of water from the binding site nor interact with it, while the partial agonists (S,R)-
IVa, (S,R)-5 and (S,S)-9c directly or indirectly interacted, with different extent, with at least 
one residue among Leu 121, Asn 109 and Ser 108, suggesting that this additional interactions 
could be responsible for channel activation. As introduced in the previous paragraph, this 
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hypothesis will be further explored by coupling mutational experiments on Ser 108 with 
electrophysiological assays.   
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Part 2: α7 nAChRs 
2.1 Introduction 
α7 Subunits usually assemble into homopentamers, but in heterologous systems they also form 
functional heteropentameric channels with other nicotinic subunits, like α5, β2 and β3, among 
which the α7β2 heteromeric subtype has been found in rat and human basal forebrain 
cholinergic neurons.5,93  
The α7-containing receptors are largely expressed in the brain, with particularly high abundance 
in the cortex, hippocampus, hypothalamus and some brain stem nuclei. Lower levels can be 
found in thalamic regions and basal ganglia.6,12  
Upon agonist binding, the α7 subtype undergoes rapid activation, followed by quick 
desensitization, and mediates a brief influx of positive cations (Na+ and Ca2+) and an efflux of 
K+. It is localized on presynaptic membranes, where it is involved in the control of 
neurotransmitter release (e.g. glutamate or noradrenaline) and on postsynaptic membranes, 
where it cooperates to the fast synaptic transmission and it can have long-term effects on 
metabolic pathways and gene-expression, due to its high calcium permeability.94 
Even if, historically, the neuronal nicotinic receptors have been thought to be expressed only 
on neuronal cells within the nervous system, the α7 subtype has also been found in non-
excitable cells such as the pulmonary epithelial cells, astrocytes, glial cells, endothelial cells 
and many tumoural cells, where they mediate pro-proliferative, survival and anti-inflammatory 
signalling.6  
2.1.1 α7 Architecture 
The overall architecture of nAChRs is shared among all the subtypes: the homomeric α7 
subtype is a pentameric structure formed by 5 identical α7 subunits (encoded by the CHRNA7 
gene) pseudo-symmetrically arranged around a central aqueous pore.13 Each monomer contains 
a long and folded extracellular N-terminal domain (NTD), three alpha-helices which span the 
cell membrane (TM1-3) connected with a short intracellular loop to the subsequent 
transmembrane alpha-helix (TM4) and a short extracellular C-terminal domain (CTD).3 The 
extracellular domain (ECD) contains 5 identical binding sites at each α7/α7 interface (LBD), 
while the transmembrane region (TM) and the intracellular domain (ICD) are involved in the 
channel gating (Figure 39).  
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Figure 39: Schematic representations of α7 nAChR: topological structure showing the primary 
sequence and the organization in three domains (ECD, TMD and ICD). Adapted from Cheng et al.95 
To date, no X-Ray or CryoEM 3D models of the α7 nAChR are available. The early structural 
information about the architecture of the extracellular domain of the α7 subtype have been 
obtained by combining the 3D X-Ray structures of the homologous proteins AChBPs with 
homology modelling techniques and sequence analysis.  
Later, in 2011, Chen et al. published the crystal structure of the ECD of the receptor chimera 
between the human α7 nAChR and the homologous AChBP of Lymnaea Stagnalis (Ls-AChBP), 
either bound to the agonist epibatidine and in its apo form (Figure 40 and Figure 42).96 
Although still non-identical to the native human α7 ECD and lacking the TMD and ICD, these 
two structures were a more realistic model of the extracellular domain of the α7 nAChRs. 
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Figure 40: A) Top view of the pentameric α7–AChBP chimera; each subunit is shown in a different 
color. B) Surface representation showing α7 residues (blue) and AChBP residues area (beige) on the 
α7–AChBP chimera. Adapted from Li et al.96  
In 2013, the same authors reported on the RCSB database the  the X-Ray structure of the same 
chimera co-crystallized with the α7 antagonist a-bungarotoxin (PDB ID: 4HQP), deepening the 
knowledge about the binding site and its interactions with agonists and antagonists.  
Further structural information on the ligand binding domain and the first insights on the 
potential localization of allosteric binding sites were provided by Ulens et al. in 2015, who 
reported a X-Ray structure of an α7-AChBP chimera co-crystallized with lobeline either alone 
or together with 5 different allosteric fragments.97  
In the meantime, the structures of the TM domain of the α7 nAChRs were determined by 
NMR98 and the full-length structures of some LGIC (i.e. Glutamate-gated chloride channel from 
C. Elegans,99 β3 GABA-A100 and α4β2 nAChR20) structurally similar to the α7 subtype were 
resolved by X-Ray crystallography.  
2.1.2 Orthosteric binding site 
As the orthosteric α7 binding pockets are located in the ECD at each α7/α7 interface, 5 identical 
binding sites exist. However, occupancy of only one binding site is required for activation. Each 
binding cavity is lined by two adjacent α7 subunits, which simultaneously contribute either as 
the principal side (or (+) side) or as the complementary side ((-) side). The principal side 
contributes to the binding pocket with three strands connected by the same number of loops 
(loops A – C), while the complementary subunits lines the binding pocket with three loops 
(loops D – F) (Figure 41).  
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Figure 41: cartoon showing a ribbon representation of an α7α7 dimer. The loops that line the binding 
site are colored. Adapted from Thompson et al.101 
The analysis of the epibatidine-bound α7-AChBP X-Ray crystal structure reported by Chen in 
2011 provided interesting insights on the structural features of the α7 binding site.96 
The crystal structure revealed that the azabicyclo moiety of the agonist epibatidine was 
accommodated into the aromatic cage formed by residues of Tyr 91 from loop A, Trp 145 from 
loop B, Tyr 184 and Tyr 191 from loop C and Trp 53 from loop D (according to the author’s 
numbering).  
The basic nitrogen of epibatidine is protonated at physiological pH and the resulting positively 
charged ammonium group interacts with the indole ring of Trp145 through a π-cation 
interaction and through hydrogen bonds with the backbone carbonyl group of the same amino 
acid and the hydroxyl of Tyr 91. Extensive Van Der Waals contacts between the aliphatic 
portions of the ligand and Tyr184, Cys186, Cys 187 and Trp145 further stabilize the complex. 
Additionally, one of the electropositive carbons directly connected to the cationic nitrogen, is 
near to the aromatic ring of Tyr191. The chloropyridine ring stacks edge-to-face against the 
indole ring of Trp145 and makes Van Der Waals contact with Thr146, Leu104, Leu106 and 
Gln114. The chlorine atom has been suggested to stabilize the complex by halogen-bonding 
Gln114 and Leu104. Trp53 doesn’t directly interact with epibatidine, but keeps Trp145 in lieu 
by mean of face-to-edge π-π stacking (Figure 42A). 
In 2017, a mutational study performed by Ruepp et. al. demonstrated that almost all the residues 
mentioned above were important for epibatidine binding at the α7 nAChRs.101 Differently from 
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the interaction information obtained from the co-crystals between epibatidine and AChBP or 
α7-AChBP chimera, these experiments aimed to clearly determine which amino acids were 
involved in epibatidine binding at human α7 nAChRs. Its binding affinity was 1) impaired with 
the mutations C186A or C187A; 2) completely abolished by W53C, Y91C, N104C, W145C, 
Y184C and Y191C; 3) enhanced by Q114C and S144C and 4) unaffected by the substitutions 
Q55C, L106C, L116C, T146C, D140C and S162C. 
Chen also reported the X-Ray crystal structure of the Apo form of the α7-AChBP and compared 
it with the epibatidine-bound α7-AChBP (Epi). Substantial differences were observed between 
the conformations of loops C. In the Epi structure it was tightly closed on the ligand in all the 
subunits, while in the Apo structure the loop C assumed a range of opened conformations 
(Figure 42).  Loop C was stabilized to an even more open conformation when α7-AChBP is 
bound to a classical antagonist, like methyllicaconitine.102   
 
Figure 42: overlay of the ligand-binding site between the Apo (gold) and Epi (blue) structures. A) Top 
view (B) Side view. Adapted from Li et al.96  
These evidences strengthened the well-established hypothesis that associates closed 
conformations of loop C with agonist-induced activated (A) or desensitized (D) states and open 
conformations with Apo or antagonists-stabilized resting conformations (R).103 
Later, in 2015, Ulens et. al. resolved the X-Ray crystal structures of an α7-AChBP chimera co-
crystallized with lobeline, a ligand of the α7 subtype. Although lobeline, due to its size, binds 
differently to the pocket when compared to epibatidine, the main interaction is maintained: the 
positively charged ammonium group is lodged within the aromatic box at a suitable distance 
for π-cation interactions with the side chain of Trp145. The authors took advantage of the good 
resolution of co-crystals α7/AChBP-lobeline to perform a fragment-library screening coupled 
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with X-Ray analysis to identify potential allosteric binding site. In addition to three putative 
allosteric binding sites, the authors identified an additional subpocket of the orthosteric binding 
site (Figure 43).   
 
Figure 43: X-Ray co-crystal structure of the chimera α7/AChBP with lobeline and fragment 1. 
2.1.3 Allosteric binding site 
Allosteric modulators indirectly influence the effect of an orthosteric ligand, by binding to a 
distinct site from the orthosteric. Positive allosteric modulators (PAMs) increase the agonist 
activity, negative allosteric modulators (NAMs) decrease the agonist activity, while silent or 
null allosteric modulators (SAMs) compete for the allosteric binding site without affecting the 
orthosteric agonist activity. More accurately, allosteric modulation was defined by Ulens as 
“the process that modifies the energetic barriers between the resting and activated state and that 
is caused by binding of a molecule at a site that is different from the orthosteric binding”.97  
α7 nAChRs PAMs have been widely studied overtime. Initial works in this area were performed 
by Bertrand et al. in 1998 and by Sher et al. in 2002, who respectively identified Invermectin 
and 5-hydroxyindole as α7 PAM.104,105 Nowadays, positive allosteric modulators can be 
classified into type I PAM and type II PAM. Type I PAMs, such as invermectin and 5-
hydroxyindole, enhance agonist-evoked peak currents without delaying receptor 
desensitization. Contrariwise, type II PAMs like PNU-120596, the first α7-selective to be 
disclosed, increase the agonist response, decrease receptor desensitization and also reactivate 
desensitized receptors (Figure 44).106,107 
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Figure 44: examples of positive allosteric modulators 5-HI (PAM-I) and PNU-120596 (PAM-II). 
α7 nAChR PAMs arouse great interest for potential therapeutic applications in the fields of 
neurodegenerative disorders and neuroinflammation, and at least one α7 nAChR modulator has 
been tested in clinical trials.108,109   
Although the exact localization of the allosteric binding sites has not been clarified, type-I PAM 
are expected to bind at a site in the extracellular domain, while type-II PAM have been 
suggested to bind in the transmembrane domain.110 In 2015 Ulens et. al. co-crystallized an α7-
AChBP chimera with lobeline and 5 different allosteric fragments, identifying 3 different 
potential binding sites in the ECD, among which one could correspond to the PAM-I binding 
site.97  
In 2018, Arias et al. performed an in-silico study, where they used docking and molecular 
dynamics to identify and study the binding sites of PAM-I and PAM-II. Interestingly, PAM-II 
were predicted to interact with a binding pocket at the ECD-TM interface, while PAM-I with 
the ECD domain.107 
2.1.4 Electrophysiology 
The α7 subtype has been widely studied for its unique electrophysiological properties, which 
make α7 nAChRs pharmacology very complex. Whereas the other major central nAChR 
subtype, the α4β2, has slow activation and desensitization kinetics and low calcium 
permeability, the α7 subtype is rapidly activated upon agonist binding and desensitize 
immediately afterwards (submillisecond time scale) (Figure 45).10,111 Due to its high calcium 
permeability, this brief elapse of time is enough to guarantee an intense influx of calcium, which 
is involved in facilitation of neurotransmitter release from presynaptic terminals, depolarization 
of post-synaptic membranes and initiation of Ca2+-triggered intracellular processes.  
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Figure 45: schematic representation of basic functional and pharmacological properties of the α7 and 
α4β2 nAChR subtypes. Adapted from Dineley et al.112 
The MWC model, described in the general introduction, had been implemented by Papke to 
account for the new insights on the peculiar pharmacology of the α7 nAChR.113–115 When no 
ligands are applied, this receptor can interconvert between four main states: resting or closed 
(C), activated and opened (O*), intermediate desensitized (Di) and desensitized (Ds) non-
conductive states (Figure 46A). Without any ligand, the most stable conformation is the non-
conducting closed state C. As a high energy barrier has to be overcome to reach the opened 
state O*, the receptor spontaneously opens with low probability, as demonstrated by single-
channel experimental data.111,116 After opening, the receptor rapidly converts to a more stable 
desensitized state (Di or Ds) and then relaxes back to the resting conformation. Upon binding 
of an efficacious agonist, the energy landscape is perturbed and both the energy barriers to reach 
the O* state and the energy of the desensitized states (Di and Ds) are reduced (Figure 46B). 
Consequently, the agonist-bound channel either converts into the O* state and then quickly falls 
into a more stable desensitized conformation (Ds or Di) or directly desensitizes. Due to its fast 
desensitization kinetics, the receptor remains opened for very short times, and it mediates very 
fast inward currents. Since the energy barriers to convert back from the desensitized states (Di 
and Ds) to the closed state (C) are quite high, the process is slow. When desensitized, the 
receptor can’t be activated by agonists. 
In 2013, Papke et al. identified a new pharmacological class of α7 nAChR ligands, named silent 
agonists, which bind to the orthosteric binding site but have little or no efficacy in eliciting the 
current.117 Even if in classical electrophysiologic studies they appear as very low efficacy partial 
agonists or antagonists, when they are co-applied with a type-II PAM, they produce marked 
channel activation. According to Papke’s kinetic model, silent agonists alone modify the energy 
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landscape of the α7 by increasing the energy of the O* state (Figure 46C). Consequently, the 
transition C  O* is no longer accessible due to a too high energy barrier, while the transitions 
C  Di or Ds are energetically favored, meaning that the receptor directly converts from a 
closed non-conducting conformation to a desensitized non-conducting conformation, without 
transiting from the opened conductive state. Thus, silent agonists are thought to bind with high 
affinity to a desensitized state. 
Type-II PAMs alone increase the energy of the Di state and reduce the energy of Ds, but they 
don’t modify the energy of O* and therefore they don’t affect channel opening. Moreover, a 
new high energy opened state O’ is virtually accessible, but the energy barrier is too high to be 
reached (Figure 46D). However, when a PAM-II is coapplied with an agonist (Figure 46E) or 
with a silent agonist (Figure 46F) the energy of O’ is lowered, so that the transition Ds  O’ 
is allowed. This model explains why the co-application of a silent agonist, that desensitizes the 
receptor, with a type-II PAM, produces channel opening and current influx. 
 
Figure 46: Hypothetical energy landscapes of the conformational states of the α7 nAChRs A) without 
any ligand or when bound to B) an efficacious agonist; C) a silent agonist; D) a PAM-II alone; E) a 
PAM-II and an efficacious agonist; F) a PAM-II and a silent agonist. Adapted from Papke et al.115  
In 2017, Cottone et. al. constructed a full-length homology model of the α7 receptor and 
performed molecular dynamics simulations of the receptor complexed with the agonist 
epibatidine without any constrains, starting from an opened conformation previously 
described.99,103,118 Interestingly, after a few ns, they observed that the pore was collapsed to a 
very low hydrated conformation, claimed to be a non-conductive conformation. Furthermore, 
in the time scale of the simulation, the LBD-TMD interface underwent conformational changes 
that could be associated with an O*  D transition.  
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2.1.5 α7 Functions 
α7 nAChRs are widely expressed in the CNS where they play crucial roles in several 
physiological processes, such as cognition, learning, attention and memory. Consequently, they 
are also involved in many pathological conditions, like Alzheimer disease, Parkinson disease, 
schizophrenia, ADHD, and autism spectrum disorder.112,119  
In addition to the pivotal role in the brain, the α7 subtype is also expressed in non-excitable 
cells like airway epithelial cells, endothelial cells, pancreatic cells, glial cells, lymphocytes, 
bone narrow cells, monocytes, macrophages and microglia and several tumoral cells. It is 
involved in other biological processes, among which cell-cell signalling, regulation of cell 
survival and of cell death and it is implicated in many pathological conditions, like cancer 
progression, uncontrolled angiogenesis, inflammation and pain.6 
For instance, the autonomous nervous system regulates cytokine production by the immune 
system through an ensemble of neural circuits called “cholinergic anti-inflamatory pathway”. 
Activation of the α7 subtype reduces the production of pro-inflammatory cytokines like tumour-
necrosis factor (TNF-α) or interleukin-1.120  
2.1.6 α7 nAChR and cancer 
Nicotine, the primary addictive component of tobacco, was reported to participate in cancer 
promotion and progression: it promotes cancer cells survival, proliferation, angiogenesis, 
tumour dissemination, invasion and angiogenesis through the activation of nAChRs.121,122 
Cigarette smoking is the predominant risk factor for lung cancer and it has also been related to 
other types of cancers, such as pancreatic cancer and gastric cancer.121,123 During combustion, 
nicotine is partially decomposed to the carcinogenic nitrosamines NNK (4-
(methylnitrosamino)-1-(3-piridyl)-1-butanone), agonist at the α7 nAChRs and NNN (N-
nitrosonornicotine), agonist at the heteromeric αβ nAChRs (Figure 47). These highly reactive 
compounds and their metabolites form toxic adducts with DNA nucleotides, causing deleterious 
mutations to oncogenes or tumour suppressor genes. 
 
Figure 47: main components of cigarette smoke: (S)-nicotine and its combustion byproducts (S)-NNN 
and (S)-NNK. 
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Lung cancers, the leading cause of cancer-related deaths worldwide, are classified in small-cell 
lung cancers (SCLCs), which account for 20% of all lung cancer cases, and in non-small cell 
lung cancers (NSCLCs), which account for 80% of all lung cancer cases.124,125 NSLCLCs are 
further divided into three subtypes: squamous-cell carcinoma (SCC-L), adenocarcinoma and 
large-cells carcinoma. The main subtype that mediates the proliferative and angiogenetic effects 
of nicotine in lung cancer cells is the α7 subtype.37 
The expression of α7 and of α9-α10 nicotinic receptors is upregulated in human SCC-L cell 
lines (NSLCLCs) and in animal models, with expression levels that can vary depending on the 
specific cell line. In 2018, Gotti et al. demonstrated that nicotine or the selective α7 agonist 
ICH3126 increased cell proliferation and viability of adenocarcinoma cell lines expressing high 
level of α7 and α9-α10 nAChR subtypes (A549), while nicotine hadn’t any effect on 
proliferation and viability on adenocarcinoma cell lines expressing none or low levels of the α7 
or α9-α10 subtypes (H1975) (Figure 48A). After nicotine administration, the amount of 
activated pERK and pAkt, two activated proliferative kinases, were increased in A549 cells, 
but not in H1975 cells (Figure 48B). Together, these results confirm that nicotine activates and 
induces the expression of some specific nAChR subtypes, whose activation drives 
hyperproliferation of adenocarcinoma cells through enhancement of intracellular proliferative 
pathways of pERK and pAKT.37  
 
Figure 48: nicotine A) induces hyperproliferation and B) activates the pAkt/Akt pathway of α7 and α9-
α10 containing tumoral cells (A549), but not of tumoral cells with no α7 and low levels of α9-α10 
(H1975).  
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Further studies using either siRNAs or specific α7 and α9-α10 antagonists demonstrated that 
both receptors, the α7 and the a9/a10 subtype are responsible for nicotine-induced 
hyperproliferation of A549 cells. When A549 were treated with the specific antagonists 
methyllicaconitine (MLA) or a-bungarotoxin (a-Bgtx), both nicotine-induced 
hyperproliferation and nicotine-induced activation of pERK and pAKT were reverted (Figure 
49A and 49B). Similarly, but to a lesser extent, administration of α7 selective or α9 selective 
peptidic antagonists (respectively the α-conotoxins ArIB and RgIA4) reduced nicotine-induced 
hyperproliferation (Figure 49C and Figure 49D) and pERK and pAKT activation. The same 
effect was observed by knock-down experiments with α7 or α9 siRNAs.37 
 
Figure 49: antiproliferative effect on A549 cells pre-treated with nicotine of A) the α7 and α9 antagonist 
MLA; C) the selective α9 antagonist RgIA4 and of D) the selective α7 antagonist ArIB; B) MLA reduce 
the activation of the nicotine-induced pAkt/Akt pathway. Adapted from Mucchietto et al.37 
Nicotine- or NNK-stimulated hyperproliferation of SCLC cells in-vitro has been related to the 
activation of α7 nAChRs, via activation of many pro-proliferative intracellular mediators like 
PKC (protein kinase C), RAF1 (serine/threonine kinase), ERK1 and ERK2 (mitogen activated 
kinases) and the transcription factors FOS, JUN and MYC. The same cascade enhances 
production and/or release of the growth factors for SCLCs like serotonin, mammalian 
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bombesins, bradykinin, vasopressin, neurotensin and proangiogenic factors like vascular 
endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF).127 
nAChRs have been also found to be involved in promotion and progression of other types of 
cancer, such as pancreatic cancer, glioma and glioblastoma (unpublished data).128,129 
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2.2 α7 Orthosteric ligands and selectivity 
Since a high number of nicotinic acetylcholine receptor subtypes can be obtained by combining 
different subunits, selectivity on a certain subtype over off-target subtypes is a crucial 
requirement to achieve a desired pharmacological effect. The two subtypes that are usually 
considered for this purpose are the heteropentameric α4β2, the major subtype in the CNS, and 
the α3β4, mainly expressed in autonomic ganglia.  
Despite the huge amount of information that have been collected for the α7 nAChR, the 
structural and functional details of other homopentameric nAChRs have not been deeply 
explored yet. Particularly, the α9 subtype, formed by 5 identically α9 subunits (encoded by the 
gene CHRNA913) shares high sequence similarity with the α7 subtype. Even if the X-Ray 3D 
structure of an α9 monomer co-crystallized with the unspecific antagonists MLA and α-Bgtx 
has been reported, the dimer, containing the entirety of the binding site has never been 
described.  
Probably due to high similarity between the two subtypes, many ligands targeting the α7 
subtype, like the antagonists MLA or α-Bgtx, are not selective versus the α9 subtype. Subtype-
selectivity between the α7 and α9 is therefore desirable. 
The α9 subtype also coassembles with the α10 subunit forming the heteromeric α9α10 subtype. 
As it is quite complicated to express them in heterologous systems, the study of human α9 
subtypes is very limited. α9 nAChRs are expressed in both the inner and outer hair cells of the 
adult cochlea, where they are involved in its function, but they are also expressed in a wide 
variety of non-neuronal tissues, ranging from immune cells to carcinomas.  
2.2.1 α7 Full agonists 
Acetylcholine, nicotine and epibatidine have already been discussed in paragraph number 
1.2.1. 
Anabaseine (Figure 50) is an alkaloid produced by Aphaenogaster ants and by ribbon worms 
Nemertea. It is structurally similar to nicotine and it is a full agonist for the α7 subtype, with 
higher affinity than nicotine, and a partial agonist at the α4β2 subtype with lower affinity than 
nicotine. Anabaseine has been used as a scaffold for the design and synthesis of “functionally” 
selective α7 agonists, like GTS-21, described in the paragraph 2.2.2. These ligands bound to 
both subtypes, but elicited functional responses only at the α7 subtype, meaning that they had 
agonist activity at the α7 receptor, but antagonist activity at the α4β2.130  
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AR-R17779 (Figure 50) is a constrained analogue of acetylcholine with a spirooxazolidinone 
structure and was reported in 2000 as the first “affinity” selective α7 full agonist without any 
non-competitive antagonist activity.131 Prior to AR-R17779, some α7 agonists, derived from 
anabaseine (i.e. GTS-21, described below), were described as “functionally” selective on the 
α7 subtype over the α4β2, but they all had high affinity to the α4β2 subtype, at which they had 
antagonist effect.  
2.2.2 α7 Partial agonists 
GTS-21 (Figure 50). Several analogues of anabaseine were designed to obtain selective α7 
agonists. Among these, compound GTS-21, also known as DMBX-A was reported in 1996 to 
bind both to the α7 and to the α4β2 subtypes with affinity.130,132 However, it was shown to be a 
partial agonist at the α7 subtype, while it had antagonist activity at the α4β2 subtype. Although 
this “functional” selectivity is normally not ideal for therapeutic application, GTS-21 has been 
studied in multiple Phase I studies and in Phase I/II studies for schizophrenia and Alzheimer 
disease.27 
ICH-3 (Figure 50). In 2011, De Micheli et al. reported the synthesis of a series of α7 ligands 
based on the structure of AR-R17779, among which compound ICH-3 stood out as a potent and 
selective α7 partial agonist, which was later investigated for its potential anti-inflammatory 
properties.126 
 
Figure 50: non-selective full agonist anabaseine; α7 functionally selective partial agonist GST-21; α7 
“affinity” selective full agonist AR-R17779 and selective α7 partial agonist ICH-3. 
2.2.3 α7 Antagonists 
α-Conotoxins have been already introduced in paragraph 1.2.3. They are competitive nAChRs 
antagonists isolated from the venom of sea snails of the genus Conus. α-Conotoxin ArIB is a 
selective antagonist for the rat and human α7 subtype, able to block acetylcholine-evoked 
currents in Xenopus Oocytes expressing the human α7 nAChRs and the choline- or AR-R17779- 
evoked currents in SH-SY5Y cells, potentiated by the type II PAM PNU-120596. Although 
ArIB has been widely used as a pharmacological tool for investigation of the α7 pharmacology 
and functions, its peptidic nature and huge size hamper its utility as a potential drug. Conotoxin 
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RgIA4 is a other interesting selective conotoxin, which has been specifically designed to be 
selective at the human α9-containing receptors.133–135 
α-Bungarotoxin is a peptidic α7 antagonist and it was first isolated from the venom of the 
Taiwanese banded krait snake (Bungarus Multicinctus) in 1971.136 It binds with high affinity 
and with slow off- kinetics to the muscle nAChRs at the neuromuscular junctions, causing 
paralysis, respiratory failure and, ultimately, death. It also has antagonist activity at the 
homomeric a9 and α7 subtypes and it is therefore often used as a pharmacological tool to study 
these receptors.  
Methyllicaconitine (MLA) is a diterpene alkaloid isolated from many species of the genus 
Delphinium, plants commonly referred to as “larkspur”. At the neuromuscular junction it blocks 
the α3β4 nAChR with high affinity, causing curare-like effects, while in the CNS it antagonizes 
both the α4β2 and the α7 subtypes. MLA has been widely used as pharmacological tool and 
tested for different applications, such as neurological disorders and nicotine addiction. 
2.3 State of the art 
In 1953 Cavallini et al. reported the synthesis of the oxystilbene compound MG624, formally 
obtained by arylation of the hydroxyl group of triethylcholine, as a molecule with ganglioplegic 
activity (Figure 51).137 
In 1998 Clementi et al. pharmacologically characterized compound MG624 as a high affinity 
ligand at the chick α7 containing receptors, selective against the β2- containing and β4- 
containing subtypes.138 The year after, Gotti et al. demonstrated that MG624 inhibited ACh-
evoked currents in oocyte-expressed chick α7 with an IC50 of 109 nM, while it had 
supramicromolar IC50s at the α4β2 and at the muscle α1β1δ subtypes. The possibility of a 
direct channel blockage was excluded both by competition binding experiments at the 
orthosteric binding site and by finding that the block of MG624was not voltage dependent.139  
 
Figure 51: high affinity α7 orthosteric ligand with moderate selectivity and α7 antagonism activity 
MG624. 
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Recently, as detailed in paragraph 2.1.5, the activation of the α7 and α9-α10 nAChRs has been 
related to cancer promotion and progression and therefore molecules like MG624, able to 
prevent or block their activation, could be promising antitumoral candidates.  
In 2018, Gotti et al. found that MG624, able to block acetylcholine-elicited currents both at the 
α7 and at the α9-α10 subtype by binding at the orthosteric binding sites, not only reverted the 
hyperproliferation induced by nicotine in a similar way to the α7 or α9-α10 selective toxins 
ArIB or RgIA4 or to the use of siRNAs, but also had a dose-dependent cytotoxic effect on 
adenocarcinoma cells (Figure 52).37 
 
Figure 52: A) MG624 blocks ACh elicited currents in transfected Xenopus oocytes expressing α9-α10 
and α7 subunits; B) MG624 decreases A549 proliferation; C) MG624 blocks the nicotine-induced 
activation of the p-Akt pathway.  
In 2008, Paradisi et al. combined the structures of the polyphenol resveratrol with the 
triphenylphosphonium cation (TPP+) by connecting them with a 4 carbons long linker, into 
compound XVII that structurally resembles MG624 (Figure 53).140 Polyphenols like 
resveratrol can act both as pro-oxidants of anti-oxidants depending on the redox potential of the 
polyphenol and on the molecular environment of the subcellular compartment where they are 
localized within cells. As the anti-proliferative and pro-apoptotic effects of resveratrol had 
already been reported and associated with the production of ROS in the mitochondria, the 
authors intended to boost the antiproliferative action by targeting the resveratrol-containing 
molecule to the mitochondria.141–144 TPP+ is a membrane permeable lipophilic cation that drives 
the accumulation of XVII in subcellular compartments held at a negative voltage, like the 
mitochondrial matrix.145 Selectivity over non-tumoral cells can be achieved because of the 
higher transmembrane potential of tumoral cells than that of healthy cells.146 As expected, XVII 
was shown to have mitochondrial tropism and antitumoral activity on rapid-growth cell types. 
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Later, in 2014, Biasutto et al. demonstrated that compound XVII and its methylated analogue 
RDM-4’BTPI, with higher antitumoral activity, killed fast-growing cancer cells through a 
necrosis mechanism.147 Upon accumulation in the mitochondria, they enhanced production of 
reactive oxygen species (especially superoxide anion, then converted to H2O2), causing cellular 
damage and membrane depolarization and therefore acting as mitocans. The same year, 
Biasutto et al. further studied the mechanism of cytotoxicity of these mitochondriotropic 
resveratrol derivatives and discovered that RDM-4’BTPI was a strong inhibitor of the complex 
I and III of the respiratory chain.148 These protein complexes are known to be the major sources 
of ROS in healthy and untreated mitochondria as byproducts of the respiratory chain and it is 
plausible that their inhibition could lead to favour this side reaction. Moreover, RDM-4’BTPI 
was also found to be an inhibitor of the F0F1 ATP synthase, perhaps through a proton slipping 
(decoupling) mechanism. Similarly to RDM-4’BTPI, the mitochondrially targeted derivative 
of vitamin E (VE) analogous -tocopheryl succinate, MitoVES (or MitoVE11S, Figure 53), was 
reported to be inhibit mitochondrial respiratory complex II (CII) leading to ROS generation and 
cell death induction with IC50 values for apoptosis in various malignant cell lines mainly 
ranging between 0.5 and 3 M.149  
 
Figure 53: mitochondriotropic compounds XVII and RDM-4’BTPI and MitoVES with antitumoral 
activity. 
Preliminary results (unpublished data) showed that both MG624 and RDM-4’BTPI had 
respectively micro- and submicromolar antitumoral activity on adenocarcinoma (A549) and 
malignant glioma (U87MG) cell lines. Additionally, RDM-4’BTPI also reduced cell viability 
of neuroblastoma cell lines (SH-SY5Y).  
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The two reference molecules share some common structural features: 1) they both have a 
permanently charged cationic head, that is a triethylammonium moiety in MG624 and 
triphenylphosphonium moiety in RDM-4’BTPI; 2) they both share a stilbenolic core, “naked” 
in MG624 and “decorated” with two meta-methoxy substituents (pterostilbene) in RDM-
4’BTPI; 3) the aromatic moiety and the permanently charged cationic head are connected 
through a flexible alkyl linker, which is an ethyl linker (2 carbons) for MG624, while it is a 
butyl linker (4 carbons) for RDM-4’BTPI.  
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2.4 Potent anti-glioblastoma agents by hybridizing the 
oniumalkyloxy-stilbene based structures of an α7/α9-nAChR 
antagonist and of a pro-oxidant mitocan 
2.4.1 Aim 
As detailed in chapter 2.3, the antitumoral activity of MG624 had been related to α7 and α9-
α10 antagonism, while compound RDM-4’BTPI was described by its inventors as a 
mitocan.37,147 Given the antitumoral activities of MG624 and of RDM-4’BTPI and their 
structural similarities, our first goal was to understand whether the two molecules could share 
some mechanism of actions (MoAs). Then, aiming at elucidating to what extent each 
substructure (onium head/stilbene scaffold/interposed alkylene linker) would address toward 
one MoA or the other, we designed a series of hybrids (Figure 54) between the three constitutive 
portions of RDM-4’BTPI (pterostilbene residue, triphenylphosphonium head and 4 carbons 
linker) and of MG624 (stilbenoxy residue, triethylammonium head and 2 carbons linker). 
Moreover, this design strategy could provide some hybrids where the two MoAs are partially 
merged, obtaining antitumoral compounds with a hybrid pharmacological profile. In principle, 
this systematic hybridization panel should provide 8 compounds: MG624, 12, 13, 14, 15, 16, 
17, RDM-4’BTPI, but the triphenylphosphonium compounds with 2 carbons long linker 12 
and 14 couldn’t be enclosed in this investigation because ready decomposition to stilbenol and 
pterostilbene, respectively, and vinyl-triphenylphosphonium precluded their isolation and 
characterization.  
The compounds were assayed for their binding affinities at the α7 subtype, for their ability to 
block ACh-evoked currents in Xenopus Oocytes expressing human α7 and α9-α10 receptors, 
for their anti-proliferative activity on different tumor cells expressing α7 and/or α9-α10 
nAChRs, for mitochondrial ROS production and for ATP production impairment.  
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Figure 54: design of a series of hybrid compounds between the α7 and α9-α10 antagonist MG624 and 
the mitocan RDM-4’BTPI. 
Furthermore, we were particularly interested in the elongation of the alkylene linker, a structural 
modification expected to be relevant to both nicotinic antagonism, for the increase of steric 
encumbrance, and cytotoxic pro-oxidant activity. Useful information would have been gained 
from α7 and α9-α10 nAChR antagonism comparison between 13 and its two-carbon-elongated 
analogue 17 and between MG624 and the elongated 15, 25 and 26 analogues, while a further 
elongation of the butylene linker of the phosphonium derivatives was strongly suggested by 
evidences from the literature. In fact, RDM-4’BTPI has been suggested to act as mitoVE11S, 
whose activity has been reported to be diminished by shortening its eleven-carbon long 
linker.149 Consistently with such a trend, elongation of the short 4 C linker of 16, the stilbene 
analogue of RDM-4’BTPI, could be beneficial.  Therefore, we extended the series of 
compounds to be investigated over the stilbenoxyalkyl triphenylphosphonium iodides 18 and 
19-24 having alkylene linkers of increasing length (Figure 55). 
91 
 
 
Figure 55: design of elongated analogues of compound 16 and of MG624. 
2.4.2 Synthetic schemes 
The target ammonium compounds 13 and 17 were synthesized starting from commercial 
resveratrol, while ammonium and phosphonium compounds 15, 25, 26, 16 and 18-24 were from 
commercial 4-(E)-stilbenol (Scheme 18).  
Alkylation of resveratrol with 1-bromo-2-choloroethane and 1-bromo-4-chlorobutane  
afforded,  respectively,  the  intermediates  115a and  115c,  whose  free phenolic functions 
were methylated to obtain the O-chloroalkyl pterostilbene intermediates 116a and 116c. These 
were converted into the corresponding iodoalkyl analogues 117a and 117c by Finkelstein 
reaction and then into the final triethylammonium derivatives 13 and 17 by treatment with 
triethylamine.   
The ethers 15, 25, 26, 16 and 18-24 with stilbene scaffold were synthesized by the same  
strategy but using α,ω-dibromoalkanes to O-alkylate 4-(E)-stilbenol. The resulting ω-
bromoalkyl ethers 118b-i were converted into the corresponding ω-iodoalkyl ethers 119b-i. 
Reaction of 119c, 119e and 119g with triethylamine and  triphenylphosphine  afforded  15, 25, 
26 and  16, 20, 22 respectively,  while  reaction  of  119b, 119d, 119f, 119h and 119i  with 
triphenylphosphine provided the corresponding triphenylphosphonium derivatives 18, 19, 21, 
23, 24. MG624  and RDM-4’BTPI were synthesized as previously reported.138,147 
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Scheme 18: reagents and conditions. (a) 1-bromo-2-chloroethane, K2CO3, DMF, 60 °C, overnight, 32% 
(115a); (b) 1-bromo-4-chlorobutane, K2CO3, DMF, 60 °C, overnight, 30% (115c); (c) MeI, CsCO3, 
DMF, rt, overnight, 90% (116a), 63% (116c); (d) NaI sat. in acetone, reflux, overnight, 97% (117a), 
96% (117c), 98% (119b), 99% (119c), 100% (119d), 100% (119e), 100% (119f), 99% (119g), 100% 
(119h), 100% (119i); (e) NEt3, toluene, reflux, 5 h, 89% (15), 92% (25), 92% (26), 81% (13), 75% (17); 
(f) NaOH, DMSO, rt, 3h, dibromopropane, 52% (118b) or dibromobutane, 37% (118c) or 
dibromopentane, 28% (118d) or dibromohexane, 40% (118e) or dibromoheptane, 41% (118f) or 
dibromooctane, 45% (118g) or dibromononane, 84% (118h) or dibromodecane, 37% (118i); (g) PPh3, 
neat, 100 °C, 3 h, 72% (18), 80% (16), 92% (19), 89% (20), 89% (21), 86% (22), 81% (23), 87% (24). 
2.4.3 Biology 
Antiproliferative activity. Nine compounds, namely the three phosphoniums RDM-4’BTPI, 
16 and 24 and all the six ammoniums MG624, 15, 25, 26 and 13, 17, were tested for their 
cytotoxic/cytostatic action using the MTS assay on U87MG glioblastoma, A549 
adenocarcinoma and SH-SY5Y neuroblastoma cell lines (Table 4). The most interesting 
compounds were also tested using the same assay on normal mouse astrocytes. All the other 
phosphonium compounds, namely 18-23, were assayed for their cytotoxic/cytostatic action on 
A549 and U87MG cell lines (Table 5). All of the tumor and control astrocytes were incubated 
with increasing concentrations of the compounds for 72 h and their activity was tested taking 
the absorbance of the control cells (not treated with compounds) as 100%. The dose–response 
curves were fitted by non-linear regression analysis and the concentration that blocked 50% of 
the viability (IC50) was determined. 
Binding affinities. The binding affinity of the synthesized compounds for the human α4β2 or 
α7 subtypes expressed in heterologous cells respectively labelled by [3H]-Epibatidine or [125I]-
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-Bungarotoxin was assayed with competition binding experiments and the results were 
reported in Table 4 and in Table 5. 
In vitro functional activity. Inhibition of respectively 200 µM or 10 µM ACh-evoked currents 
in Xenopus Oocytes expressing human α7 and α9-α10 nAChRs was tested for all the 
triethylammonium compounds MG624, 15, 25, 26, 13, 17 and for the triphenylphosphonium 
RDM-4’BTPI, according to the method previously used for MG624 (Table 4).37 
HepG2 cells permeation. The ability of MG624 to permeate HepG2 cells was evaluated 
exploiting their natural fluorescence. MG624 fluoresces at 350 nm after excitation at 260 nm. 
MG624 was administered in different concentrations (1, 10, 50, 100 µM) to cells and 
fluorescence (RFU 350/620 nm) was measured after 1, 6 and 24 hours. A blank sample was 
included as reference (vehicle alone, DMSO), and its fluorescence (background signal) was 
subtracted from each normalized signal. The same assay was repeated at the single 
concentration of 1 µM with compounds 15, 26 and 22. Cells treated with 100 µM of MG624 
for 24 h were lysed and the cell lysates were analyzed by mass spectrometry, with the aim of 
finding fragments coming from MG624 (Figure 56). 
ROS production. We verified the effects of 1 h exposure of U87MG cells to the phosphonium 
and ammonium compounds on the ROS production as monitored by FACS experiments using 
the fluorescence indicator MitoSOX®. (Figure 57 and Table 5).  
ATP production. The ability of MG624, of RDM-4’BTPI, of the four hybrids (15, 16, 13 and 
17) and of 24 to interfere with ATP production after incubation with U87MG cells in culture 
for 1 or 72 h was determined. The concentrations tested were those determined by the MTS 
assay and in the range of the IC50 values (Figure 58). 
2.4.4 Results and discussion 
Antiproliferative activity. As shown in Table 4, at all the three tumoural cell lines tested, 
linker length elongation from MG624 and 13 respectively to 15 and 17, produced from slight 
(for glioblastoma U87MG and adenocarcinoma A549) to moderate (neuroblastoma SH-SY5Y) 
potency increase. Against adenocarcinoma A549 and neuroblastoma SH-SY5Y, the elongated 
ammonium compounds 15 and 17 were less potent (higher IC50 values, in the range of 3-30 
µM) than the correspondent phosphonium compounds 16 and RDM-4’BTPI (IC50 in the range 
0.3-3 µM), but they were similarly potent at glioblastoma cell lines U87MG.  
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Although phosphonium compounds were generally more potent than ammonium compounds, 
they revealed to be similarly potent against all the tumoral cell lines tested and against non-
tumoral cells (astrocytes) (IC50 in the range 0.5-3 µM). On the other hand, ammonium 
compounds, still active against U87MG and A549 cells, were less potent on SH-SY5Y or on 
control astrocytes cells (in the range of 10-30 µM).  
 
 
Viability 
U87MG 
IC50, µM 
72h 
Viability 
A549 
IC50, µM 
72h 
Viability 
SH-SY5Y 
IC50, µM 
72h 
Viability 
Astrocytes 
IC50, µM 
72h 
Affinity 
α7 Ki, 
nM 
α7 IC50 
nM 
α9-α10 
IC50, 
nM 
R= n= X= Cpd 
H 2 NEt3+ MG624 4.4 4.7 >100 47 104 41 10 
OMe 2 NEt3+ 13 5.3 12 >100 23 189 47 17.2 
H 4 NEt3+ 15 1.8 3.5 31 20 186 6.5 5 
OMe 4 NEt3+ 17 0.57 3.3 11 22 305 24.3 11.9 
H 4 PPh3+ 16 0.64 0.42 3.0 0.4 1638 
Not 
done 
Not 
done 
OMe 4 PPh3+ 
RDM-
4’BTPI 
0.86 0.26 0.55 1.0 1826 >10000 >10000 
H 10 PPh3+ 24 0.06 0.10 0.21 0.6 1930 
Not 
done 
Not 
done 
H 6 NEt3+ 25 3.9 3.6 30 5.8 465 12.3 4.8 
H 8 NEt3+ 26 0.11 0.49 10 2.0 164 92 6.6 
Table 4: MG624, RDM-4’BTPI, their structural hybrids (13, 15, 16, 17) and the elongated analogues 
24, 25 and 26: antiproliferative activity at glioblastoma U87MG, at adenocarcinoma A549, at 
neuroblastoma SH-SY5Y, at normal mouse astrocytes cell lines, α7 binding affinity, α7 and α9-α10 
antagonism. 
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In both ammonium and phosphonium series, the maximum potencies corresponded to the 
maximum linker length, eight and ten methylenes respectively, converging on similar ≤ 100 nM 
U87MG and A549 cytoxicities. Table 5 reports the cytotoxic/cytostatic action of all the 
phosphonium compounds on U87MG glioblastoma and A549 cell lines. The potency of the 
compounds almost monotonically increases along with the length of the alkylene linker from >1  
M (18) to ≤ 100 nM IC50 values (24). 
 
Viability 
U87MG 
IC50, µM 
72h 
Viability 
A549 
IC50, µM 
72h 
Affinity 
α7 receptors 
Ki, nM 
% ROS 
production 
over 0.05 mM 
Antimycin A 
R= n= Compound 
OMe 4 RDM-4’BTPI 0.86 0.26 1826 16.3 
H 3 18 1.4 1. 984 21 
H 4 16 0.64 0.42 1638 1.5 
H 5 19 0.67 0.3 2800 20 
H 6 20 0.38 0.15 559 27.3 
H 7 21 0.36 0.1 617 39.5 
H 8 22 0.07 0.26 909 46.3 
H 9 23 0.09 0.11 1288 56.3 
H 10 24 0.06 0.10 1930 58.2 
Table 5:Phosphonium compounds RDM-4’BTPI, 16 and 18-24: antiproliferative activity at U87MG 
and at A549 cells, binding affinity at the α7 nAChR accompanied by their confidence intervals 
(CI), %ROS production induced by administration of 500 nM of each compound compared with ROS 
production induced by 0.05 mM of Antimycin A. 
Binding affinities. As the antiproliferative activity of MG624 had already been related to its 
α7  and/or α9-α10 nicotinic activity,37 binding affinity at α7 subtype was determined for all the 
reported compounds.  
The six compounds with ammonium head had similar α7 affinities, ranging between 100 and 
500 nM Ki, whereas all the phosphonium compounds had much lower α7 affinities, 
approximately 6-10 times less than that of MG624 (see Table 4 and Table 5). Phosphonium 
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compounds were expected to be poor binders at the nAChRs, because they lacked of the 
important pharmacophoric element of the positively charged ammonium group.  
When tested on the α4β2 subtypes, all the ammonium compounds showed very similar low 
affinities (Ki > 3 µM) (data not shown).  
As single modifications, the linker elongation (compound 15) and the 3’,5’-dimethoxy 
substitution (compound 13) only slightly diminished the high 7 nicotinic affinity of MG624 
(0.104 M Ki), but, together, they led to a greater decrease (compound 17, 0.3 M Ki). Further 
linker elongation to six and eight carbons was accomplished in the stilbene-ammonium series, 
providing 25, with a decreased 7 nicotinic affinity (0.465 M Ki), and 26, that had an 7 
affinity (0.164 M Ki) similar to that of MG624.  
After investigating the antiproliferative activity of the six hybrids on various tumor cells, we 
investigated whether the mechanisms of action underlying their antitumor activity were similar 
to that of MG624 (reported as a 7 and 9 antagonist), to that of RDM-4’BTPI (reported as a 
mitocan), or they had hybrid mechanisms, by considering their nAChR activity and two 
intracellular parameters: the increase in mitochondrial ROS generation and the decrease in ATP 
production. 
Antagonist activities. The six compounds with ammonium head inhibited 10 µM or 200 µM 
ACh-induced currents in oocytes expressing the human α9α10 and α7 subtypes with IC50 values 
<100 nM (Table 4). Increasing the linker length from MG624 to 15, 25 and 26 sensibly 
increased antagonist potency against both subtypes except for 26, whose α7 IC50 remained, 
however, sub-100 nM.  
We also tested the possible antagonist activity of the low affinity binder RDM-4’BTPI on 
nicotinic subtypes; the IC50 was greater than 10 µM at α7 and α9α10 subtypes, confirming that 
phosphonium compounds were not active on nAChRs and meaning that their antitumoural 
activity has to be related to a different MoA.  
Overall, similar trends observed for 7 affinity were observed for 7 and 9-10 antagonism: 
1) the 3’,5’-dimethoxy substitution from MG624 to 13 was irrelevant both for 7 and 9-10 
IC50s; 2) the elongation of the linker from 2 carbons to 4 carbons was beneficial both for 15 and 
for 17. Further elongation in the StN series to 25 (6 carbons) and to 26 (8 carbons) confirmed 
the 9-10 sub-10 nM potency achieved by 15 and, though not ameliorative, the considerable 
sub-100 nM potency of MG624 at the 7 subtype. Overall, as shown in Table 1, elongation of 
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the ethylene linker in the ammonium compounds resulted in generally higher antagonist 
activities at the two nicotinic receptors with non-negligible 9-10 vs 7 selectivity in the case 
of 26.  
As all the ammonium compounds are active in blocking ACh-induced currents mediated by 7 
and 9 subtypes, their moderate to high antitumoral activities could be correlated to their 
nicotinic activity. 
Cell permeation. Prior to determine whether MG624, the structural hybrids between MG624 
and RDM-4’BTPI and their elongated derivatives could at least partially impair the 
mitochondrial functionality as mitocans in a similar way to RDM-4’BTPI, their cell membrane 
permeability had to be ascertained. Whereas the triphenylphosphonium moiety is known to 
confer mitochondrial tropism to molecules due to its lipophilicity and positive charge,145 cell 
permeation of triethylammonium-containing molecule had to be investigated. 
Our findings clearly indicated that MG624 is taken up by HepG2 cells with a concentration and 
time response trend (Figure 56A). Mass spectrometry analysis confirmed MG624 intake from 
HepG2 cells when they were incubated for 24 h with 100 µM of MG624. The MS/MS 
fragmentation pattern of the cell lysate and the observed product ions are completely assigned 
to the product ions generated during the fragmentation. In the MS/MS spectrum the base peak 
at m/z 222.9 corresponds to the loss of the styrene moiety. This experiment clearly showed that 
MG624 permeates the cell membrane and therefore satisfies the first requirement necessary to 
be classified as a mitocan.  
Cell membrane permeability was also tested for the elongated compounds 15, 26 and its 
phosphonium analogue 22. Prior to evaluate their permeability, the compounds were assessed 
for their fluorescence properties and they were found to emit at 350 nM upon irradiation at 260 
nM with the same magnitude of MG624.  Interestingly, they were all found to permeate the cell 
membrane when administered at 1 µM with a time dependent trend (Figure 56B).   
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Figure 56: A) concentration- and time-dependent HepG4 cell membranes permeation of MG624; B) 
time-dependent HepG4 cell membranes permeation of 1 µM of compounds 26, 22, 15, MG624. 
ROS production. The first intracellular parameter that we examined was ROS production in 
the mitochondria. Mitocans like RDM-4’BTPI are driven toward the mitochondrial matrix 
(negative relative voltage) due to their quaternary but lipophilic onium group, where they impair 
mitochondrial functionality by interacting with the respiratory processes. Particularly, RDM-
4’BTPI has been shown to enhance ROS production by inhibiting the complex I and III.148 
Aiming to understand whether MG624, the hybrids between MG624 and RDM-4’BTPI and 
their elongated analogues, could enhance ROS production in the mitochondria, we measured 
mitochondrial ROS production in U87MG cells upon administration of the compounds at a 
concentration similar to the EC50 in the MTS assay.  
None of the triethylammonium compounds increased ROS production, while all the 
triphenylphosphoniums RDM-4’BTPI, 16 and 18-24 enhanced ROS production in a dose-
dependent manner, with potency increasing accordingly to the alkylene linker length (Figure 
57 and Table 5). Therefore, phosphonium compounds permeate the cell membranes and are 
driven toward the mitochondria, where they increase ROS production (acting as mitocans), 
while ammonium compounds, according to this assay, permeate the cell membrane but appear 
not to enhance ROS production. On the other hand, phosphonium compounds have only modest 
affinity and no antagonist activity at the 7 and 9 subtype, while ammonium compounds 
potently block ACh-induced currents mediated by the 7 and 9 subtype.  
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Figure 57: phosphonium compounds RDM-4’BTPI, 16 and 24 increase mitochondrial ROS production 
in a concentration-dependent manner, while the ammonium compounds MG624, 13, 15 and 17 do not 
enhance ROS production. The compounds were tested at concentrations in the range of their EC50. 
According to these results, the antitumoural activity appear to be related to a mitocan-like 
mechanism for phosphonium compounds, while to nicotinic antagonism for ammonium 
compounds. However, among other cytotoxic effects, the mitocan RDM-4’BTPI has been 
reported to impair ATP production, probably by decoupling the respiratory chain from the 
F0F1ATPase. Consequently, enhancement of ROS production alone can’t be used to claim to 
clearly distinct MoAs of the structural hybrids between MG624 and RDM-4’BTPI. 
ATP production. The second intracellular parameter we examined was the decrease in ATP 
production, which is indicative of dysregulated mitochondrial function and antitumor 
activity.150 Tumor cells have to upregulate their inefficient glycolytic ATP production in order 
to satisfy their energy requirements and preventing mitochondrial ATP production has a highly 
toxic and antiproliferative effect. There was a reduction in the ATP production in glioblastoma 
cells, as early as one hour after the administration of RDM-4’BTPI and 15 (Figure 58A), 
whereas ATP was reduced only after 72 hours in the case of the other three ammonium 
derivatives, MG624, 13 and 17 (Figure 58B).  Phosphonium 16, unlike its 3’,5’-dimethoxy 
substituted analogue RDM-4’BTPI, did not affect ATP production. Of note removal of the two 
methoxyls is not necessarily detrimental for such an activity considering that 24, the elongated 
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analogue of 16, is a potent inhibitor of ATP production though devoid of these substituents at 
the distal phenyl ring.  
 
Figure 58: decrease of ATP production in glioblastoma cells after A) 1 hour or B) 72 hours of incubation 
with MG624, RDM-4’BTPI, their structural hybrids and 24. 16 didn’t reduce ATP production after 72 
hours and was further excluded by the assay at 1 hour. 
Overall, the results of these experiments indicate that the mechanism of action underlying the 
antitumor activity of the triphenylphosphonium derivatives is the profound impairment of 
mitochondrial functions, as revealed by the immediate and conspicuous increase in ROS 
production and decrease in ATP production and by their quite indistinct cytotoxicity. On the 
other hand, the antitumor activity of the triethylammonium derivatives seems to be mainly 
connected to their interactions with 7 and 9-10 nAChRs. However, it cannot be excluded 
that, after entering cells, the triethylammonium derivatives, interfere with mitochondria 
function albeit less potently than the phosphonium analogues possibly due to a lower level of 
mitochondriotropism. This may be why, with the exception of 15, our triethylammonium 
derivatives decreased ATP production, only after 72 hours, and induced no immediate increase 
in ROS production.  
As expected, elongation of the alkylene linker in the phosphonium series, importantly 
ameliorated antitumoural activity at glioblastoma U87MG and adenocarcinoma A549 cell lines, 
reaching, on glioblastoma cell lines, an IC50 of 0.06 µM for 24, the longest in the series, due to 
enhanced mitocans properties, as shown by ROS production increase. However, as exemplified 
by 24, phosphonium compounds were also cytotoxic/cytostatic at neuroblastoma cell lines SH-
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SY5Y and at normal mouse astrocytes and therefore they were not selective against specific 
tumoural cell lines or against non-tumoral cells.  
Similarly, elongation of the alkylene linker in the ammonium series markedly enhanced 
antitumoural activity, reaching in 26, the longest term in the series, IC50 of 0.11 µM on 
glioblastoma cells. For the ammonium compounds, the antitumoural activity coincided with 
high capacity of blocking ACh-induced currents in Xenopus Oocytes expressing 7 and 910 
nAChRs, with IC50s in the range of 10-100 nM. Differently from the phosphonium series, 
ammonium compounds had cytotoxic/cytostatic effects on glioblastoma U87MG and on 
adenocarcinoma A549 cells, while they were less toxic at neuroblastoma SH-SY5Y and at 
normal mouse astrocytes. 26, the compound with highest antiproliferative activity, was also a 
very potent and moderately selective 910 antagonist. 
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Concluding remarks and future perspectives 
 
Development of new subtype-selective nAChR ligands with different pharmacological profiles 
will certainly enable further understanding of the molecular mechanisms underlying many 
pathologies, such as nicotine addiction and glioblastoma. The new ligands presented in this 
dissertation provide a new platform for the design and development of other novel α4β2-
selective partial agonists as smoking cessation agents and of α7- and/or α9/α9α10-selective 
antagonists as antiglioblastoma/anticarcinoma agents.  
Part 1: α4β2 nAChRs partial agonists 
Mutational studies 
New α4β2 weak partial agonists could be designed starting from the scaffolds of (S,R)-IV, 
(S,R)-IVa, (S,R)-5 and (S,S)-9c, upon clarification of the role played by the residue Ser108 in 
binding affinity and in receptor activation. Indeed, as introduced in paragraph 1.8, the side chain 
of Ser108 (β2 subunit) seems to be 1) involved in binding the water molecule that bridges either 
(S)-nicotine or (S,R)-5 with the receptors; 2) involved in binding directly the hydroxyl 
appendage of (S,R)-IVa or the amino group of (S,R)-9c; 3) not involved in binding the naked 
benzodioxane moiety of (S,R)-IV. As all the rigid ligands predicted to interact with such a 
residue are partial agonists, while (S,R)-IV is an antagonist, this interaction could also be 
involved in receptor activation. If so, novel partial agonists targeting specifically that residue 
could be designed. To shed light on this pocket, we are currently designing a mutational study 
where we will replace Ser108 with apolar residues (i.e. Phe, Leu, Ala). We will then reveal the 
role of Ser108 by evaluation of binding affinity and electrophysiological activity of (S,R)-IV 
and at least one partial agonist (i.e. (S,R)-IVa, or (S,R)-5 or (S,S)-9c) at the wild type and 
mutated receptors.  
In-vivo activity 
Although the pharmacological profile of (S,R)-IVa and of (S,S)-9c is promisingly similar to that 
of the clinically approved Varenicline, no in-vivo data on (S,R)-IVa and on (S,S)-9c are 
currently available. Upon investigation of the ADMET profiles in-silico and in-vitro, a 
behavioural study on animal models (i.e. Zebrafish) could be performed with the most 
interesting compounds, to probe whether they could be relevant in nicotine addiction or in 
cognitive deficits. 
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Part 2: α7 and α9/α9α10 nAChRs antagonists 
SAR investigation 
The α7 and α9/α9α10 nAChRs antagonists reported in this dissertation will provide an optimal 
platform for further investigation of the structure activity relationships. Particularly, the 
structural requirements to diversificate between α7-selectivity (vs α9/α9α10) and α9/α9α10-
selectivity (vs α7) should be identified. Compound 26 is moderately selective for the α9/α9α10 
and could therefore represent a new lead compound for the development of α9/α9α10-selective 
antagonists. The SAR analysis could be systematically performed on the three moieties of the 
chosen lead compound (i.e. MG624, 15 or 26): 1) development of analogues bearing charged 
ammonium heads with diverse linear or cyclic alkyl substituents, to probe the size of the cavity 
where the positive nitrogen is lodged; 2) development of rigid analogues, where the flexible 
linker is constrained into a cyclic structure, to identify the binding conformation at both 
subtypes; 3) replacement of the stilbene or pterostilbene aromatic moieties with other scaffolds, 
to probe the role of geometry, planarity, lipophilicity and electronic properties. Furthermore, 
these modifications could be designed considering the optimization of physicochemical 
properties.  Homology modelling of the α7 and α9/α9α10 subtype could support the SAR 
investigation.  
Intracellular mechanism of actions 
The structural hybrids between an α7 and α9/α9α10 antagonist and a mitocan developed in this 
thesis could be used to further investigate the MoAs underlying their antiglioblastoma and 
antiadenocarcinoma activities. Specifically, they could be exploited to support the identification 
of intracellular pathways which link the α7 and α9/α9α10 antagonist activity to the 
antiproliferative activity.  
In-vivo activity 
The antiproliferative activity of 24 and of 26 on glioblastoma and adenocarcinoma cell lines is 
very promising and 26 is not toxic on healthy astrocytes. However, ADMET profiles in-silico 
and in-vitro, should be performed with the aim of developing analogues with comparable 
antigloblastoma and antiadenocarcinoma potencies but with pharmacokinetic profiles suitable 
for an in-vivo evaluation of efficacy and safety in animal models of glioblastoma and 
adenocarcinoma. 
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Experimental section 
 
All chemicals and solvents were used as received from commercial sources or prepared as 
described in the literature. Flash chromatography purifications were performed using KP-Sil 
32-63 µm 60 Å cartridges. TLC analyses were carried out on alumina sheets precoated with 
silica gel 60 F254 and visualized with UV light; Rf values are given for guidance. 1H and 13C- 
NMR spectra were recorded at 300 and 75 MHz using an FT-NMR spectrometer. Chemical 
shifts are reported in ppm relative to residual solvent (CHCl3, MeOH or DMSO) as internal 
standard. Melting points were determined by Buchi Melting Point B-540 apparatus. Optical 
rotations were determined in a 1 dm cell of 1 mL capacity. Chiral HPLC analyses were 
performed using Hewlett Packard 1050 instrument. CHN, P and I elemental microanalysis were 
performed. Phosphorous was measured by ICP-AES (Inductively Coupled Plasma Atomic 
Emission Spectroscopy), upon microwave-assisted mineralization of the sample in HNO3. 
Iodine was measured by ionic chromatography, upon thermal decomposition at 1000 °C. High 
Resolution Electrospray Mass Spectra of all the final compounds were acquired with Q-TOF 
Synapt G2 Si (WATERS). 
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Part 1: α4β2 nAChRs  
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Synthesis of (S)-prolinol 
 
Procedure adapted from literature.151 Under nitrogen atmosphere, LiAlH4 (2.96 g – 78.16 
mmol) was suspended in 110 mL of anhydrous THF and refluxed for 15 minutes. The heating 
was suspended and the commercial (S)-proline (5 g – 43.42 mmol) was added stepwise, so that 
to maintain a boiling mixture. Afterward, the reaction was refluxed for 2 hours under vigorous 
stirring. After cooling to 40 °C, the mixture was treated with a 20% aqueous solution of KOH 
and filtered. The filtration cake was resuspended in fresh THF (40 ml), refluxed for 30 minutes 
and then filtered on a small pan of Celite®. The two filtrates were reunited, and the solvent was 
evaporated under vacuum to obtain the desired product as a dark yellow oil (3.8 g – 37.6 mmol, 
87%). [α]D25 = + 31.70° (c1, CHCl3); literature152: [α]D25 = + 35.6° (c1, CHCl3). 1H-NMR (300 
MHz, CDCl3): δ 3.55 – 3.48 (m, 1H), 3.34 – 3.24 (m, 2H), 3.15 – 3.04 (bs, 2H), 2.96 – 2.82 (m, 
2H), 1.86 – 1.66 (m, 3H), 1.45 – 1.34 (m, 1H).153 
Synthesis of (S)-N-tert-butoxycarbonyl-prolinol 
 
Procedure adapted from literature.154 (S)-prolinol (4.21 g – 41.62 mmol) was dissolved in 42 
ml of DCM and the resulting solution was cooled to 0 °C. Afterward, 6 ml of TEA (4.65 g – 
45.82 mmol) and di-tert-butyl dicarbonate (10 g – 45.82 mmol) were added under vigorous 
stirring. The reaction mixture, warmed to room temperature, was vigorously stirred for 30 
minutes. The suspension was diluted with 30 ml of DCM and then washed twice with a 1M 
aqueous solution of HCl. The organic phase was dried over anhydrous sodium sulphate, filtered 
and concentrated under vacuum affording a crude, that was purified by silica gel flash 
chromatography (Cyclohexane/Ethyl Acetate 75:25, Rf=0.4). The pure product was isolated as 
a white solid (6.28g – 31.22 mmol, 75%). TLC (Dichloromethane / Methanol 95:5 + 1% 
NH3(30% in water); stained with KMnO4)): Rf= 0.7. M.p. = 56.0 °C; Literature
155: M.p. = 56.1 - 
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57.4 °C. [α]D25 = - 46.76° (c1, CHCl3); literature156: [α]D20= - 45.9° (c1, CHCl3). 1H-NMR (300 
MHz, CDCl3): δ 3.97 (m, 1H), 3.65 – 3.53 (m, 2H), 3.49 – 3.40 (m, 1H), 3.34 – 3.26 (m, 1H), 
3.01 (bs, 1H), 2.06 – 1.94 (m, 1H), 1.88 – 1.71 (m, 2H), 1.67 – 1.52 (m, 1H), 1.44 (s, 9H). 153 
Synthesis of 3-hydroxy-5-bromophenol 
 
Procedure adapted from literature.157 BBr3 (65.5 mmol – 1M in hexane) was added dropwise 
under anhydrous atmosphere to a solution of 1-bromo-3,5-dimethoxybenzene (7 g – 32.25 
mmol) in 23 ml of anhydrous DCM, previously cooled to -10 °C. The reaction mixture was 
stirred at room temperature for 12 hours. Afterwards, the mixture was cooled to -10° C and the 
excess of BBr3 was quenched by adding dropwise 20 ml of methanol. The solvent was 
evaporated under vacuum and the resulting residue was diluted with ethyl acetate and washed 
with water. The organic phase was dried over anhydrous sodium sulphate, filtered and the 
solvent was removed by rotary evaporation. The resulting crude was purified by silica gel flash 
chromatography, affording the pure product as a pale green solid (3.96 g – 20.96 mmol, 65%). 
TLC (Cyclohexane / Ethyl Acetate 7:3, stained with Cerium Sulphate): Rf = 0.4. M.p.= 
72.0 °C. 1H-NMR (300 MHz, CD3OD): δ 6.41 (d, J= 2.1 Hz, 2H); 6.19 (t, J= 2.1 Hz, 1H).157 
Synthesis of (S)-N-tert-butoxycarbonyl-2-[(3-hydroxy-5-
bromo)phenoxymethyl]pyrrolidine [(S)-27] 
 
3-hydroxy-5-bromo-phenol (705 mg – 3.73 mmol) and (S)-N-tert-butoxycarbonyl-prolinol 
(500 mg – 2.48 mmol), dissolved each in 2 ml of anhydrous THF, were added to a solution of 
triphenylphosphine (787 mg – 3.00 mmol) in 2 ml of anhydrous THF. The reaction mixture was 
cooled to -10°C and DIAD (0.60 mL – 3.00 mmol) was added dropwise, under vigorous stirring. 
The reaction mixture was refluxed for 12 hours. After cooling to room temperature, the mixture 
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was diluted with 10 mL of 1M aqueous solution of NaOH and extracted with DCM twice. The 
organic phase was dried over anhydrous sodium sulphate, filtrated and concentrated in vacuo 
to obtain a crude that was further purified through silica-gel flash column chromatography 
(gradient from cyclohexane to cyclohexane/ethyl acetate 9:1). The pure compound (S)-27 was 
obtained as a white solid (317 mg – 0.85 mmol, 34%). TLC (Cyclohexane / Ethyl Acetate 9:1): 
Rf = 0.5. M.p.= 140.5 °C. [α]D25= -23.87° (c1, CHCl3). 1H-NMR (300 MHz, CDCl3): δ 6.60 
(m, 2H), 6.38 (s, 1H), 4.10 – 4.02 (m, 2H), 3.77 (m, 1H), 3.37 (m, 2H), 2.00 – 1.83 (m, 4H), 
1.48 (s, 9H). 
Synthesis of (S)-2-[(3-hydroxy-5-bromo)phenoxymethyl]pyrrolidine [(S)-29] 
 
(S)-N-tert-butoxycarbonyl-2-[(3-hydroxy-5-bromo)phenoxymethyl]pyrrolidine [(S)-27] (209 
mg – 0.56 mmol) was dissolved in 5 ml of DCM and the resulting solution was cooled to 0 °C. 
Under vigorous stirring, TFA (1 ml) was added dropwise and the reaction mixture was stirred 
at room temperature for 2 hours. Afterward, the mixture was diluted with an aqueous solution 
of HCl 1M (8 ml) and washed with diethyl ether. The aqueous phase was cooled to 0 °C and 
the pH was adjusted to pH 12 by adding dropwise a solution of NaOH 1 M.  After washing 
again with diethyl ether, the aqueous phase was cooled to 0 °C and acidified with acetic acid to 
reach pH 6/7 and extracted with ethyl acetate.  The organic phase was dried over anhydrous 
sodium sulphate, filtered and evaporated in vacuo obtaining the desired product (S)-29 as a 
white sticky solid (122 mg – 0.45 mmol, 80%). TLC (Dichloromethane / Methanol 95:5 + 
0.3 % NH3(30% in water)): Rf= 0.2.  [α]D25 = +9.07° (c1, MeOH). 1H-NMR (300 MHz, CD3OD): 
δ 6.55 (m, 2H), 6.31 (m, 1H), 3.94 (m, 1H), 3.85 (m, 1H), 3.53 (m, 1H), 3.07 – 2.90 (m, 2H), 
2.07 – 1.96 (m, 1H), 1.91 – 1.78 (m, 2H), 1.66 – 1.47 (m, 1H). 
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Synthesis of (S)-N-methyl-2-[(3-hydroxy-5-
bromo)phenoxymethyl]pyrrolidine [(S)-1a] 
 
Under vigorous stirring at 0 °C, an aqueous solution of formaldehyde (37% in water, 0.13 ml) 
was added dropwise to a solution of (S)-2-[(3-hydroxy-5-bromo)phenoxymethyl]pyrrolidine 
[(S)-29] (120 mg – 0.44 mmol) in 8 ml of methanol and 160 µl of glacial acetic acid. Upon 
addition of 2-picolin borane (50 mg – 0.44 mmol), the mixture was reacted for 4 hours at room 
temperature. The solvent was evaporated in vacuo, the residue was diluted with 10 ml of a 1M 
HCl solution and stirred for 1 hour to quench the unreacted 2-picolin-borane. Then, the pH was 
adjusted to 8 by adding an aqueous solution of Na2CO3 2M and the aqueous phase was extracted 
with ethyl acetate (3x30 ml). The organic phase was washed with brine, dried over sodium 
sulphate, filtered and evaporated in vacuo, providing a crude that was purified through silica 
gel flash chromatography. The pure compound (S)-1a was obtained as a yellow sticky solid 
(125 mg – 0.39 mmol, 75%). TLC (Dichloromethane / Methanol 98:2 + 1% NH3(30% in water)): 
Rf= 0.2. [α]D25 = -18.36° (c1, CH3OH). 1H-NMR (300 MHz, CDCl3): δ 6.56 (t, J= 1.9 Hz 1H), 
6.47 (t, J= 1.9 Hz, 1H), 6.28 (t, J= 1.9 Hz, 1H), 4.00 – 3.81 (m, 2H), 3.21 – 3.14 (m, 1H), 2.86 
– 2.79 (m, 1H), 2.60 (s, 3H), 2.42 – 2.31 (m, 1H), 2.12 – 2.00 (m, 1H), 1.93 – 1.89 (m, 2H), 
1.82 – 1.61 (m, 1H). 13C-NMR (75 MHz, CDCl3): δ 159.9, 158.7, 122.8, 113.1, 108.4, 102.6, 
70.7, 64.6, 58.0, 42.8, 28.2, 23.1. HRMS (ESI+): calc. for C12H17NO2
79Br: theor. 286.0443; 
found [M+H]+: 286.0438.  
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Synthesis of (S)-N-tert-butoxycarbonyl-2-[(3-hydroxy-5-
phenyl)phenoxymethyl]pyrrolidine [(S)-31] 
 
Under nitrogen atmosphere, tetrakis(triphenylphosphine)Pd(0) (30 mg – 0.026 mmol) was 
added to a solution of (S)-N-tert-butoxycarbonyl-2-[(3-hydroxy-5-
bromo)phenoxymethyl]pyrrolidine [(S)-27] (250 mg – 0.672 mmol) in 6 ml of toluene. Upon 
stirring for 10 minutes at room temperature, 2 ml of an aqueous solution of Na2CO3 2M and a 
solution of p-hydroxyphenyl boronic acid (90 mg – 0.74 mmol) in ethanol (1.5 ml) were 
sequentially added. The mixture was refluxed for 12 hours. Afterward, the mixture was diluted 
with ethyl acetate (30 ml) and the organic phase was dried over anhydrous sodium sulphate, 
filtered and concentrated in vacuo, providing a crude that was purified through silica gel flash 
chromatography (cyclohexane/ethyl acetate 9:1). The pure product (S)-31 was obtained as a 
white sticky solid (185 mg – 0.50 mmol, 75%). TLC (Cyclohexane / Ethyl Acetate 8:2): Rf= 
0.5. [α]D25 = -17.04 ° (c0.5, CHCl3). 1H-NMR (300 MHz, CDCl3): δ 7.55 (d, J= 9.3 Hz, 2H), 
7.42 – 7.31 (m, 3H), 6.68 (m, 2H), 6.54 (m, 1H), 6.27 (bs, 1H), 4.19 – 4.09 (m, 2H), 3.87 (m, 
1H), 3.40 (m, 2H), 2.04 – 1.84 (m, 4H), 1.47 (s, 9H). 
Synthesis of (S)-2-[(3-hydroxy-5-phenyl)phenoxymethyl]pyrrolidine [(S)-37] 
 
(S)-N-tert-butoxycarbonyl-2-[(3-hydroxy-5-phenyl)phenoxymethyl]pyrrolidine [(S)-31] (185 
mg – 0.50 mmol) was dissolved in 2 ml of methanol and the solution was cooled to 0 °C. Upon 
dropwise addition of 2.5 ml of a 1.25 M methanolic solution of HCl under vigouros stirring, the 
reaction mixture was warmed to room temperature and reacted for 12 hours. Afterward, 
methanol was evaporated in vacuo, the residue was diluted with a 1 M aqueous solution of HCl 
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(5 ml) and washed with DCM.  The aqueous phase was basified to pH 8 with NH3(30% in water) 
and extracted with ethyl acetate. The organic phase was dried over anhydrous sodium sulphate, 
filtrated and evaporated in vacuo, affording the pure product (S)-37 as a yellow solid (135 mg 
– 0.50 mmol, 100%). TLC (Dichloromethane / Methanol 9:1 + 3% NH3(30% in water)): Rf= 0.25. 
[α]D25 = +2.71° (c0.5, CH3OH). 1H-NMR (300 MHz, CD3OD): δ 7.54 (d, J= 7.5 Hz, 2H), 7.37 
(t, J= 7.5, 2H), 7.29 (t, J= 7.5 Hz, 1H), 6.64 (m, 2H), 6.38 (m, 1H), 4.02 (dd, J= 9.3, 4.5 Hz, 
1H), 3.93 (dd, J= 9.3, 7.0 Hz, 1H), 3.57 – 3.48 (m, 1H), 3.07 – 2.90 (m, 2H), 2.08 – 1.91 (m, 
1H), 1.90 – 1.80 (m, 2H), 1.67 – 1.57 (m, 1H). 
Synthesis of (S)-N-methyl-2-[(3-hydroxy-5-
phenyl)phenoxymethyl]pyrrolidine [(S)-1b] 
 
Under vigorous stirring at 0 °C, an aqueous solution of formaldehyde (37% in water, 0.15 ml) 
was added dropwise to a solution of (S)-2-[(3-hydroxy-5-phenyl)phenoxymethyl]pyrrolidine 
(100 mg – 0.35 mmol) [(S)-37] in 3 ml of methanol and 60 µl of glacial acetic acid. Upon 
addition of 2-picolin borane (45 mg – 0.42 mmol), the mixture was reacted for 3 hours. Upon 
vacuo evaporation of methanol the residue is diluted with 5 ml of a 1M HCl solution and stirred 
for 1 hour to quench the unreacted 2-picolin-borane. Then, the pH was adjusted to 8 by adding 
an aqueous solution of Na2CO3 2M and the aqueous phase was extracted with ethyl acetate 
(3x30). The organic phase was washed with brine, dried over anhydrous sodium sulphate, 
filtered and evaporated in vacuo, obtaining a crude that was purified by silica gel flash 
chromatography (Dichloromethane / Methanol 9:1 + 3% NH3(30% in water)), affording the pure 
compound (S)-1b as a yellow sticky solid (80 mg – 0.28 mmol, 80%). TLC (Dichloromethane 
/ Methanol 9:1 + 3% NH3(30% in water)): Rf= 0.45. [α]D25 = -27.8° (c0.5, CH3OH). 1H-NMR (300 
MHz, CD3OD): δ 7.54 (d, J= 7.5 Hz, 2H), 7.39 (t, J= 7.5 Hz, 2H), 7.29 (t, J= 7.5 Hz, 1H), 6.63 
(m, 2H), 6.38 (m, 1H), 4.01 (m, 2H), 3.12 – 3.07 (m, 1H), 2.76 – 2.73 (m, 1H), 2.42 (s, 3H), 
2.40 – 2.33 (m, 1H), 2.13 – 2.07 (m, 1H), 1.88 – 1.70 (m, 3H). 13C-NMR (75 MHz, CD3OD): 
δ 160.4, 158.6, 143.3, 141.1, 128.3, 127.0, 126.5, 106.6, 104.4, 100.4, 69.8, 64.6, 57.3, 40.6, 
27.7, 22.1. HRMS (ESI+): calc. for C18H22NO2: theor. 284.1651; found [M+H]
+: 284.1646.  
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Synthesis of (S)-N-tert-butoxycarbonyl-2-[(3-hydroxy-5-(4-
hydroxyphenyl))phenoxymethyl]pyrrolidine [(S)-33] 
 
Nitrogen was bubbled into a vigorously stirred solution (S)-N-tert-butoxycarbonyl-2-[(3-
hydroxy-5-bromo)phenoxymethyl]pyrrolidine [(S)-27] (278 mg – 0.747 mmol) in 10 ml of 
toluene and tetrakis(triphenylphosphine)Pd (0) (27 mg – 0.023 mmol) was added. Nitrogen was 
flowed for 10 more minutes. Then, 2 ml of a 2M aqueous solution of Na2CO3 and 1 ml of 
ethanolic solution of 4-hydroxy-phenylboronic acid (114 mg – 0.827 mmol) were added. The 
reaction mixture was refluxed for 12 hours. After cooling to room temperature, the mixture was 
diluted with 30 ml of ethyl acetate and the organic phase and, upon anhydrification with sodium 
sulphate and filtration, was concentrated under vacuum. The crude was purified through silica 
gel flash chromatography (cyclohexane/ethyl acetate 6:4) and the pure product (S)-33 was 
isolated as yellow oil (280 mg – 0.727 mmol, 97%). TLC (Cyclohexane / Ethyl Acetate 6:4): 
Rf= 0.28.  [α]D25 = -9.07° (c1, CH3OH). 1H-NMR (300 MHz, CDCl3): δ 7.36 (d, J= 8.2 Hz, 
2H), 6.66 (m, 2H), 6.59 (d J= 8.2 Hz, 2H), 6.44 (m, 1H), 4.13 (m, 2H), 3.85 (m, 1H), 3.40 (m, 
2H), 2.05 – 1.53 (m, 4H), 1.47 (s, 9H). 
Synthesis of (S)-2-[(3-hydroxy-5-(4-
hydroxyphenyl))phenoxymethyl]pyrrolidine [(S)-39] 
 
(S)-N-tert-butoxycarbonyl-2-[(3-hydroxy-5-(4-hydroxyphenyl))phenoxymethyl]pyrrolidine 
[(S)-33] (280 mg – 0.727 mmol) was dissolved in 1 ml of methanol and the solution was cooled 
to 0 °C. Upon dropwise addition of 6 ml of a 1.25 M methanolic solution of HCl under vigorous 
stirring, the reaction mixture was warmed to room temperature and reacted for 12 hours. 
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Afterward, methanol was evaporated in vacuo, the residue was diluted with 5 ml of a 1M 
aqueous solution of HCl and washed with DCM twice. A solution of NH3(30% in water) was added 
to the aqueous phase until pH 8 and the aqueous phase was extracted with ethyl acetate (3x30 
ml). The organic phase was dried over anhydrous sodium sulphate, filtered and concentrated in 
vacuo, providing the pure compound (S)-39 as a white sticky solid. (200 mg – 0.700 mmol, 
96%). TLC (Dichloromethane / Methanol 9:1 + 2% NH3(30% in water)): Rf= 0.17. [α]D25 = +6.16° 
(c1, CH3OH). 1H-NMR (300 MHz, CD3OD): δ 7.39 (d, J= 8.5 Hz, 2H), 6.81 (d, J= 8.5 Hz, 
2H), 6.58 (m, 2H), 6.30 (t, J= 2.3 Hz, 1H), 3.99 (dd, J= 4.7, 9.4 Hz, 1H), 3.90 (dd, J= 7.0, 9.4 
Hz, 1H), 3.48 (m, 1H), 3.02 – 2.89 (m, 2H), 2.02 – 1.87 (m, 1H), 1.83 (m, 2H), 1.62 (m, 1H). 
Synthesis of (S)-N-methyl-2-[(3-hydroxy-5-(4-
hydroxyphenyl))phenoxymethyl]pyrrolidine [(S)-1c] 
 
Under vigorous stirring at 0 °C, an aqueous solution of formaldehyde (37% in water, 0.14 ml) 
was added dropwise to a solution of (S)-2-[(3-hydroxy-5-(4-
hydroxyphenyl))phenoxymethyl]pyrrolidine [(S)-39] (110 mg – 0.386 mmol)in 3 ml of 
methanol and 80 µl of glacial acetic acid. Upon addition of 2-picolin borane (42 mg – 0.386 
mmol), the mixture was reacted for 6 hours. Upon vacuo evaporation of methanol, the residue 
is diluted with 5 ml of a 1M HCl solution and stirred for 1 hour to quench the unreacted 2-
picolin-borane. Then, the pH was adjusted to 8 by adding an aqueous solution of Na2CO3 2M 
and the aqueous phase was extracted with ethyl acetate (3x30). The organic phase was washed 
with brine, dried over sodium sulphate, filtered and evaporated, obtaining a crude that was 
purified by silica gel flash chromatography (dichloromethane/methanol 90:10 + 2% NH3(30% in 
water), affording the pure compound (S)-1c as a dark yellow oil (60 mg – 0.20 mmol, 51%). TLC 
(Dichloromethane / Methanol 9:1 +2% NH3(30% in water)): Rf= 0.3. [α]D25 = -20.93° (c1, CH3OH). 
1H-NMR (300 MHz, CD3OD): δ 7.39 (d, J= 8.6 Hz, 2H), 6.81 (d, J= 8.6 Hz, 2H), 6.58 (m, 
2H), 6.30 (t, J= 1.8 Hz, 1H), 3.99 (m, 2H), 3.10 (m, 1H), 2.75 (m, 1H), 2.50 (s, 3H), 2.36 (m, 
1H), 2.09 (m, 1H), 1.81 (m, 3H). 13C-NMR (75 MHz, CD3OD): δ 160.3, 158.4, 156.9, 143.2, 
132.4, 130.0, 127.5, 115.0, 105.9, 103.8, 99.5, 69.8, 64.5, 57.3, 40.6, 27.8, 22.1. HRMS (ESI+): 
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calc. for C18H22NO3: theor. 300.1600; found [M+H]
+: 300.1593. HRMS (ESI-): calc. for 
C18H20NO3: theor. 298.1443; found [M-H]
-: 298.1448.  
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Synthesis of (S)-N-tert-butoxycarbonyl-2-[(3-hydroxy-5-(6-hydroxy-1-
hexynyl))phenoxymethyl]pyrrolidine [(S)-35] 
 
Under nitrogen atmosphere, CuBr (23 mg – 0.47 mmol) and tetrakis(triphenylphosphine)Pd(0) 
(32 mg – 0.03 mmol) were added to a solution of (S)-N-tert-butoxycarbonyl-2-[(3-hydroxy-5-
bromo)phenoxymethyl]pyrrolidine [(S)-27] (265 mg – 0.71 mmol) in 3 ml of triethylamine. 
Upon stirring for 30 minutes at room temperature, 5-hexyn-1-ol (140 mg – 1.42 mmol) was 
added and the mixture was refluxed for 12 hours. Afterward, the mixture was diluted with 10 
ml of 1M aqueous HCl and extracted with ethyl acetate (3x30 ml). The organic phase was 
washed with brine (15 ml), dried over anhydrous sodium sulphate, filtered on diatomaceous 
earth and concentrated in vacuo, providing a crude that was purified through silica gel flash 
chromatography (cyclohexane/ethyl acetate 6:4). The pure product (S)-35 was obtained as a 
colourless oil (220 mg – 0.57 mmol, 80%). TLC (Dichloromethane / Methanol 98:2): Rf= 0.3. 
[α]D25 = - 18.77° (c1, CHCl3). 1H-NMR (300 MHz, CD3OD) δ: 6.48 (m, 3H), 6.43 (bs, 1H, 
exchange with D2O), 4.11 (m, 1H), 3.80 – 3.69 (m, 2H), 3.36 (m, 2H), 2.43 (m, 2H), 2.00 – 
1.80 (m, 6H), 1.79 – 1.65 (m, 4H), 1.47 (s, 9H). 
Synthesis of (S)-2-[(3-hydroxy-5-(6-hydroxy-1-
hexynyl))phenoxymethyl]pyrrolidine [(S)-41] 
 
(S)-N-tert-butoxycarbonyl-2-[(3-hydroxy-5-(6-hydroxy-1-
hexynyl))phenoxymethyl]pyrrolidine [(S)-35] (194 mg 0.50 mmol) was dissolved in 2 ml of 
methanol and the solution was cooled to 0 °C. Upon dropwise addition of 4 ml of a 1.25 M 
methanolic solution of HCl under vigouros stirring, the reaction mixture was warmed to room 
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temperature and reacted for 12 hours. Afterward, methanol was evaporated in vacuo, the residue 
was diluted with 10 ml of a 10% aqueous solution of NaHCO3 and extracted with DCM. The 
organic phase was dried over anhydrous sodium sulphate, filtered and the solvent was 
evaporated in vacuo, affording a crude that was purified through silica gel flash chromatography 
(dichloromethane/methanol 9:1 + 3% NH3(30% in water)). The pure product (S)-41 was obtained as 
a brown sticky solid (115 mg – 0.40 mmol, 80%).TLC (Dichloromethane / Methanol 9:1 + 3% 
NH3(30% in water)): Rf= 0.16. [α]D25 = +6.3° (c1, CH3OH). 1H-NMR (300 MHz, CD3OD): δ 6.39 
(m, 2H), 6.32 (t, J= 2.2 Hz, 1H), 3.91 (dd, J= 9.2, 4.8 Hz, 1H), 3.83 (dd, J= 9.2, 7.2 Hz, 1H), 
3.60 (m, 2H), 3.46 (m, 1H), 3.07 – 2.80 (m, 2H), 2.40 (t, J= 6.6 Hz, 2H), 2.07 – 1.80 (m, 3H), 
1.73 – 1.58 (m, 5H).  
Synthesis of (S)-N-methyl-2-[(3-hydroxy-5-(6-hydroxy-1-
hexynyl))phenoxymethyl]pyrrolidine [(S)-1d] 
 
Under vigorous stirring at 0 °C, an aqueous solution of formaldehyde (37% in water, 0.09 ml) 
was added dropwise to a solution of (S)-2-[(3-hydroxy-5-(6-hydroxy-1-
hexynyl))phenoxymethyl]pyrrolidine [(S)-41] (66 mg – 0.23 mmol) in 4 ml of methanol and 80 
µl of glacial acetic acid. Upon addition of 2-picolin borane (24 mg – 0.23 mmol), the mixture 
was reacted for 2 hours. The solvent was evaporated in vacuo, the residue was diluted with 10 
ml of a 1M HCl solution and stirred for 1 hour to quench the unreacted 2-picolin-borane. Then, 
the pH was adjusted to 8 by adding an aqueous solution of Na2CO3 2M and the aqueous phase 
was extracted with ethyl acetate (3x30 ml). The organic phase was washed with brine, dried 
over anhydrous sodium sulphate, filtered and the solvent was evaporated in vacuo, providing a 
crude, that was further purified through silica-gel flash chromatography (gradient from 
dichloromethane to dichloromethane/methanol 9:1 + 10% NH3(30% in water)). The pure compound 
(S)-1d was obtained as a yellow sticky solid (60 mg – 0.20 mmol, 87%). TLC 
(Dichloromethane / Methanol 9:1 + 3% NH3(30% in water)): Rf= 0.4. [α]D25 = -19.02° (c0.5, 
CH3OH). 1H-NMR (300 MHz, CD3OD): δ 6.39 (m, 2H), 6.31 (m, 1H), 3.90 (m, 2H), 3.60 (t, 
J= 6.4 Hz, 2H), 3.10 – 3.02 (m, 1H), 2.73 – 2.64 (m, 1H), 2.48 (s, 3H), 2.41 (t, J= 6.7 Hz, 2H), 
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2.31 (m, 1H), 2.09 – 1.99 (m, 1H), 1.84 – 1.61 (m, 7H). 13C-NMR (75 MHz, CD3OD): δ 159.8, 
158.1, 125.3, 110.9, 108.4, 101.7, 88.5, 80.5, 69.7, 64.4, 61.1, 57.3, 40.6, 31.4, 27.7, 24.9, 22.1, 
18.3. HRMS (ESI+): calc. for C18H26NO3: theor. 304.1913; found [M+H]
+: 304.1910.  
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Synthesis of 2-amino-3-bromo-5-nitrophenol 
 
Procedure adapted from literature.158 A solution of 2-amino-5-nitrophenol (500 mg – 3.24 
mmol) in 40 ml of DCM and 20 ml of acetonitrile was cooled to -10 °C and vigorously stirred. 
Br2 (0.29 ml – 5.64 mmol) was carefully added dropwise and the resulting mixture was warmed 
to 35 °C. After 12 hours, the reaction mixture was cooled to room temperature and the excess 
of Br2 was quenched by adding a 10% aqueous solution of Na2S2O5. The organic phase was 
dried over anhydrous sodium sulphate, filtered and concentrated in vacuo, providing a crude 
that was purified through silica gel flash chromatography (cyclohexane/ethyl acetate 7:3). The 
pure product was obtained as a red sticky solid (730 mg – 3.13 mmol, 97%). TLC (Cyclohexane 
/ Ethyl Acetate 6:4): Rf= 0.37. 1H-NMR (300 MHz, DMSO): δ 10.65 (s, exchange with D2O, 
1H), 7.83 (s, 1H), 7.47 (s, 1H), 6.13 (bs, exchange with D2O, 2H).
 159,160 
Synthesis of 3-bromo-5-nitrophenol 
 
Procedure adapted from literature.158 Concentrated H2SO4 (2.18 ml, 96%) was carefully added 
dropwise to a solution of 2-amino-3-bromo-5-nitrophenol (2.62 g – 3.22 mmol) in 63 ml of 
ethanol, previously cooled to -10 °C. Upon heating to 55 °C, NaNO2 (2.73 g – 39.56 mmol) 
was added. The resulting mixture was refluxed for 3 hours. Afterward, the mixture was cooled 
to room temperature and the solvent was evaporated in vacuo. The residue was diluted with 
ethyl acetate (15 ml) and washed with a 1M aqueous solution of NaOH (5 ml) and subsequently, 
with brine (5 ml). The organic phase was dried over sodium sulphate, filtrated and evaporated 
in vacuo, providing a crude that was purified through silica gel flash chromatography 
(cyclohexane/ethyl acetate 6:4). The pure product was obtained as a reddish sticky solid (1.8 g 
– 8.26 mmol, 74%). TLC (Cyclohexane / Ethyl Acetate 6:4): Rf= 0.45. 1H-NMR (300 MHz, 
DMSO): δ 10.92 (s, exchange with D2O, 1H), 7.78 (s, 1H), 7.53 (s, 1H), 7.38 (s, 1H). 161 
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Synthesis of (S)-N-tert-butoxycarbonyl-2-[(3-bromo-5-
nitro)phenoxymethyl]pyrrolidine [(S)-28] 
 
3-bromo-5-nitrophenol (440 mg – 2.02 mmol) and (S)-N-tert-butoxycarbonyl-2-
hydroxymethyl-pyrrolidyne (403 mg – 2.00 mmol), dissolved each in 2 ml of anhydrous THF, 
were added to a solution of triphenylphosphine (630 mg – 2.40 mmol) in 2 ml of anhydrous 
THF. The reaction mixture was cooled to -10°C and DIAD (0.47 mL – 2.40 mmol) was added 
dropwise, under vigorous stirring. The reaction mixture was refluxed for 12 hours.  After 
cooling to room temperature, the mixture was diluted with 10 mL of 1M aqueous solution of 
NaOH and extracted with DCM twice. The organic phase was dried over anhydrous sodium 
sulphate, filtrated and concentrated in vacuo to obtain a crude that was further purified through 
silica-gel flash column chromatography (gradient from cyclohexane to cyclohexane/ethyl 
acetate 9:1). The pure compound (S)-28 was obtained as a dark green oil (685 mg – 1.70 mmol, 
85%). TLC (Cyclohexane / Ethyl Acetate 6:4; stained with cerium sulphate): Rf = 0.55. [α]D25 
= -64.71° (c1, CH3OH). 1H-NMR (300 MHz, CD3OD): δ 7.95 (s, 1H), 7.69 (s, 1H), 7.40 (s, 
1H), 4.16 (m, 2H), 3.99 (m, 1H), 3.39 (m, 2H), 2.05 – 1.86 (m, 4H), 1.53 (s, 4.5H), 1.47 (s, 
4.5H). 
Synthesis of (S)-2-[(3-bromo-5-nitro)phenoxymethyl]pyrrolidine [(S)-30] 
 
 (S)-N-tert-butoxycarbonyl-2-[(3-bromo-5-nitro)phenoxymethyl]pyrrolidine [(S)-28] (385 mg 
– 0.96 mmol) was dissolved in 2 ml of methanol and the solution was cooled to 0 °C. Upon 
dropwise addition of 8 ml of a 1.25 M methanolic solution of HCl under vigouros stirring, the 
reaction mixture was warmed to room temperature and reacted for 12 hours. Afterward, 
methanol was evaporated in vacuo, the residue was diluted with 10 ml of a 10% aqueous 
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solution of NaHCO3 and extracted with DCM. The organic phase was dried over sodium 
sulphate, filtrated and evaporated in vacuo, affording the pure product (S)-30 as a yellow sticky 
solid (120 mg – 0.40 mmol, 42%). [α]D25 = +12.73° (c1, CH3OH). 1H-NMR (300 MHz, 
CD3OD): δ 7.96 (t, J= 2.3 Hz, 1H), 7.77 (t, J= 2.3 Hz, 1H), 7.56 (t, J= 2.3 Hz, 1H), 4.08 (dd, 
J= 4.7, 9.4 Hz, 1H), 3.96 (dd, J= 7.0, 9.4 Hz, 1H), 3.56 – 3.30 (m, 1H), 3.02 – 2.88 (m, 2H), 
2.06 – 1.88 (m, 1H), 1.87 – 1.78 (m, 2H), 1.65 – 1.54 (m, 1H).  
Synthesis of (S)-N-methyl-2-[(3-bromo-5-nitro)phenoxymethyl]pyrrolidine 
[(S)-2a] 
 
Under vigorous stirring at 0 °C, an aqueous solution of formaldehyde (37% in water, 0.12 ml) 
was added dropwise to a solution of (S)-2-[(3-bromo-5-nitro)phenoxymethyl]pyrrolidine [(S)-
30] (117 mg – 0.40 mmol) in 4 ml of methanol and 80 µl of glacial acetic acid. Upon addition 
of 2-picolin borane (43 mg – 0.40 mmol), the mixture was reacted for 3 hours. The solvent was 
evaporated in vacuo, the residue was diluted with 5 ml of a 1M HCl solution and stirred for 1 
hour to quench the unreacted 2-picolin-borane. Then, the pH was adjusted to 8 by adding an 
aqueous solution of Na2CO3 2M and the aqueous phase was extracted with ethyl acetate (3x30 
ml). The organic phase was washed with brine, dried over sodium sulphate, filtered and 
evaporated in vacuo, providing the pure compound (S)-2a as a yellow sticky solid (125 mg – 
0.39 mmol, 98%). TLC (Dichloromethane / Methanol 9:1 +2% NH3(30% in water)): Rf= 0.71. 
[α]D25 = -6.67° (c1, CH3OH). 1H-NMR (300 MHz, CD3OD): δ 7.96 (t, J= 1.8 Hz, 2H), 7.76 (t, 
J= 1.8 Hz, 1H), 7.55 (t, J= 1.8 Hz, 1H), 4.08 (d, J= 5.3 Hz, 2H), 3.12 – 3.06 (m, 1H), 2.80 – 
2.71 (m, 1H), 2.49 (s, 3H), 2.42 – 2.33 (q, J= 9.4 Hz, 4H), 2.13 – 2.03 (m, 1H), 1.88 – 1.70 (m, 
3H). 13C-NMR (75 MHz, CD3OD): δ 160.1, 149.6, 123.7, 122.6, 118.4, 108.3, 70.9, 64.1, 57.2, 
40.6, 27.6, 22.2. HRMS (ESI+): calc. for C12H16N2O3
79Br: theor. 315.0344; found [M+H]
+: 
315.0337.  
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Synthesis of (S)-N-tert-butoxycarbonyl-2-[(3-nitro-5-
phenyl)phenoxymethyl]pyrrolidine [(S)-32] 
 
Under nitrogen atmosphere, tetrakis(triphenylphosphine)Pd(0) (52 mg – 0.045 mmol) was 
added to a solution of (S)-N-tert-butoxycarbonyl-2-[(3-bromo-5-
nitro)phenoxymethyl]pyrrolidine [(S)-28] (260 mg – 0.65 mmol) in 6 ml of toluene. Upon 
stirring for 10 minutes at room temperature, 1 ml of an aqueous solution of Na2CO3 2M and a 
solution of p-hydroxyphenyl boronic acid (88 mg – 0.72 mmol) in ethanol (0.5 ml) were 
sequentially added. The mixture was refluxed for 12 hours. Afterward, the mixture was diluted 
with ethyl acetate (30 ml) and the organic phase was dried over anhydrous sodium sulphate, 
filtered and concentrated in vacuo, providing a crude that was purified through silica gel flash 
chromatography (gradient from cyclohexane/ethyl acetate 8:2 to 6:4). The pure product (S)-32 
was obtained as a yellow oil (241 mg – 0.60 mmol, 93%). TLC (Cyclohexane / Ethyl Acetate 
6:4): Rf= 0.40. [α]D25 = -55.09° (c1, MeOH). 1H NMR (300 MHz, CDCl3): δ 8.05 (s, 1H), 7.71 
(s, 1H), 7.67 – 7.58 (m, 2H), 7.53 – 7.37 (m, 4H), 4.31 – 4.11 (m, 2H), 4.10 – 3.92 (m, 1H), 
3.50 – 3.32 (m, 2H), 2.15 – 1.82 (m, 4H), 1.47 (s, 9H). 
Synthesis of (S)-2-[(3-nitro-5-phenyl)phenoxymethyl]pyrrolidine [(S)-38] 
 
(S)-N-tert-butoxycarbonyl-2-[(3-nitro-5-phenyl)phenoxymethyl]pyrrolidine [(S)-32] (167 mg 
– 0.42 mmol) was dissolved in 5 ml of DCM and the resulting solution was cooled to 0 °C. 
Under vigorous stirring, TFA (0.5 ml) was added dropwise and the reaction mixture was stirred 
at room temperature for 3 hours. Afterward, the mixture was diluted with an aqueous solution 
of HCl 1M (8 ml) and washed with diethyl ether. The aqueous phase was cooled to 0 °C and 
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the pH was adjusted to pH 12 by adding dropwise a solution of NaOH 1 M.  After washing 
again with diethyl ether, the aqueous phase was cooled to 0 °C and acidified with acetic acid to 
reach pH 6/7 and extracted with ethyl acetate.  The organic phase was dried over anhydrous 
sodium sulphate, filtered and evaporated in vacuo obtaining the desired product (S)-38 as 
yellow oil (97 mg – 0.33 mmol, 78%). TLC (Dichloromethane / Methanol 95:5 + 0.3 % NH3(al 
30% in acqua)): Rf= 0.23. 1H NMR (300 MHz, MeOD): δ 8.04 (s, 1H), 7.75 (s, 1H), 7.73 – 7.63 
(m, 2H), 7.58 (s, 1H), 7.55 – 7.37 (m, 3H), 4.14 (dd, J= 9.4, 4.8 Hz, 1H), 4.04 (dd, J= 9.4, 7.0 
Hz, 1H), 3.62 – 3.46 (m, 1H), 3.10 – 2.85 (m, 2H), 2.13 – 1.95 (m, 1H), 1.95 – 1.73 (m, 2H), 
1.73 – 1.53 (m, 1H). 
Synthesis of (S)-N-methyl-2-[(3-nitro-5-phenyl)phenoxymethyl]pyrrolidine 
[(S)-2b] 
 
Under vigorous stirring at 0 °C, an aqueous solution of formaldehyde (37% in water, 0.07 ml) 
was added dropwise to a solution of (S)-2-[(3-nitro-5-phenyl)phenoxymethyl]pyrrolidine [(S)-
38] (68 mg – 0.23 mmol) in 2 ml of methanol and 60 µl of glacial acetic acid. Upon addition of 
2-picolin borane (25 mg – 0.23 mmol), the mixture was reacted for 3 hours. The solvent was 
evaporated in vacuo, the residue was diluted with 5 ml of a 1M HCl solution and stirred for 1 
hour to quench the unreacted 2-picolin-borane. Then, the pH was adjusted to 8 by adding an 
aqueous solution of Na2CO3 2M and the aqueous phase was extracted with ethyl acetate (3x30 
ml). The organic phase was washed with brine, dried over sodium sulphate, filtered and 
evaporated in vacuo, providing a crude that was further purified through silica gel flash 
chromatography (dichloromethane/methanol 95:5). The pure compound (S)-2b was obtained as 
a yellow oil (40 mg – 0.13 mmol, 86%). TLC (Dichloromethane / Methanol 9:1 +2% NH3(30% 
in water)): Rf= 0.24. [α]D25 = –38.42° (c0.5, MeOH). 1H NMR (300 MHz, CDCl3): δ 8.05 (m, 
1H), 7.73 (t, J= 2.1 Hz, 1H), 7.61 (m, 2H), 7.52 – 7.33 (m, 4H), 4.09 (dd, J= 9.3, 5.3 Hz, 1H), 
4.03 (dd, J= 9.3, 5.3 Hz, 1H), 3.14 (m, 1H), 2.81 – 2.61 (m, 1H), 2.51 (s, 3H), 2.39 – 2.25 (m, 
1H), 2.13 – 1.97 (m, 1H), 1.97 – 1.69 (m, 3H). 13C NMR (75 MHz, CDCl3): δ 159.83, 149.55, 
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143.58, 138.72, 129.07, 128.56, 127.09, 120.15, 114.51, 107.32, 71.55, 64.04, 57.75, 41.75, 
28.54, 23.13. HRMS (ESI+): calc. for C18H21N2O3: theor. 313.1552; found [M+H]
+: 313.1547.  
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Synthesis of (S)-N-tert-butoxycarbonyl-2-[(3-nitro-5-(4-
hydroxyphenyl)phenoxymethyl]pyrrolidine [(S)-34] 
 
Under nitrogen atmosphere, tetrakis(triphenylphosphine)Pd(0) (164 mg – 0.14 mmol) was 
added to a solution of (S)-N-tert-butoxycarbonyl-2-[(3-bromo-5-
nitro)phenoxymethyl]pyrrolidine [(S)-28] (820 mg – 2 mmol) in 6 ml of toluene. Upon stirring 
for 10 minutes at room temperature, 3 ml of an aqueous solution of Na2CO3 2M and a solution 
of p-hydroxyphenyl boronic acid (304 mg – 2.2 mmol) in ethanol (0.5 ml) were sequentially 
added. The mixture was refluxed for 12 hours. Afterward, the mixture was diluted with ethyl 
acetate (30 ml) and the organic phase was dried over anhydrous sodium sulphate, filtered and 
concentrated in vacuo, providing a crude that was purified through silica gel flash 
chromatography (gradient from cyclohexane to cyclohexane/ethyl acetate 8:2). The pure 
product (S)-34 was obtained as a yellow oil (522 mg – 1.26 mmol, 63%). TLC (Cyclohexane / 
Ethyl acetate 9:): Rf= 0.38. [α]D25 = -55.27° (c1, MeOH). 1H NMR (300 MHz, CDCl3) δ 7.41 
– 7.32 (m, 2H), 6.90 – 6.80 (m, 2H), 6.64 – 6.56 (m, 2H), 6.43 (s, 1H), 4.19 – 4.10 (m, 2H), 
3.91 – 3.80 (m, 1H), 3.51 – 3.25 (m, 2H), 2.14 – 1.84 (m, 4H), 1.55 – 1.38 (m, 9H). 
Synthesis of (S)-2-[(3-nitro-5-(4-hydroxyphenyl)phenoxymethyl]pyrrolidine 
[(S)-40] 
 
(S)-N-tert-butoxycarbonyl-2-[(3-nitro-5-(4-hydroxyphenyl)phenoxymethyl]pyrrolidine [(S)-
34] (465 mg – 1.12 mmol) was dissolved in 13 ml of DCM and the resulting solution was cooled 
to 0 °C. Under vigorous stirring, TFA (2 ml) was added dropwise and the reaction mixture was 
stirred at room temperature for 3 hours. Afterward, the mixture was diluted with an aqueous 
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solution of HCl 1M (8 ml) and washed with diethyl ether. The aqueous phase was cooled to 
0 °C and the pH was adjusted to pH 12 by adding dropwise a solution of NaOH 1 M.  After 
washing again with diethyl ether, the aqueous phase was cooled to 0 °C and acidified with 
acetic acid to reach pH 6/7 and extracted with ethyl acetate.  The organic phase was dried over 
anhydrous sodium sulphate, filtered and evaporated in vacuo obtaining the desired product (S)-
40 as a yellow oil (285 mg – 0.91 mmol, 81%). TLC (Dichloromethane / Methanol 95:5 + 
0.3 % NH3(30% in water) ): Rf= 0.22. 1H NMR (300 MHz, DMSO-d6): δ 9.80 (bs, 1H, exchange 
with D2O), 7.96 – 7.88 (m, 1H), 7.66 – 7.50 (m, 4H), 6.86 (d, J = 8.2 Hz, 2H), 3.98 (d, J = 6.3 
Hz, 2H), 3.48 – 3.35 (m, 1H), 2.88 – 2.75 (m, 2H), 1.93 – 1.77 (m, 1H), 1.77 – 1.55 (m, 2H), 
1.55 – 1.38 (m, 1H). 
Synthesis of (S)-N-methyl-2-[(3-nitro-5-(4-
hydroxyphenyl)phenoxymethyl]pyrrolidine [(S)-2c] 
 
Under vigorous stirring at 0 °C, an aqueous solution of formaldehyde (37% in water, 0.1 ml) 
was added dropwise to a solution of (S)-2-[(3-nitro-5-(4-
hydroxyphenyl)phenoxymethyl]pyrrolidine [(S)-40] (100 mg – 0.32 mmol) in 3 ml of DMF and 
80 µl of glacial acetic acid. Upon addition of 2-picolin borane (34 mg – 0.32 mmol), the mixture 
was reacted for 3 hours. The solvent was evaporated in vacuo, the residue was diluted with 5 
ml of a 1M HCl solution and stirred for 1 hour to quench the unreacted 2-picolin-borane. Then, 
the pH was adjusted to 8 by adding an aqueous solution of Na2CO3 2M and the aqueous phase 
was extracted with ethyl acetate (3x30 ml). The organic phase was washed with brine, dried 
over sodium sulphate, filtered and evaporated in vacuo, providing a crude that was further 
purified through silica gel flash chromatography (dichloromethane/methanol 95:5 + 2% 
NH3(30% in water)). The pure compound (S)-2c was obtained as a yellow solid (83 mg – 0.25 
mmol, 79%). TLC (Dichloromethane / Methanol 95:5 +2% NH3(30% in water)): Rf= 0.33. M.p.= 
163.8 °C. [α]D25 = -22.49° (c1, MeOH). 1H NMR (300 MHz, DMSO-d6) δ 9.73 (s, exchange 
with D2O, 1H), 7.71 – 7.48 (m, 5H), 6.86 (d, J= 8.3 Hz, 2H), 4.13 (dd, J = 9.6, 5.3 Hz, 1H), 
4.01 (dd, J = 9.6, 5.8 Hz, 1H), 3.02 – 2.90 (m, 1H), 2.68 – 2.52 (m, 1H), 2.37 (s, 3H), 2.28 – 
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2.10 (m, 1H), 2.05 – 1.84 (m, 1H), 1.80 – 1.55 (m, 3H). 13C NMR (75 MHz, CDCl3): δ 159.20, 
157.75, 149.28, 143.11, 129.50, 128.04, 119.61, 116.52, 113.88, 105.67, 69.48, 64.81, 57.65, 
42.01, 27.64, 22.79. HRMS (ESI+): calc. for C18H21N2O4: theor. 329.1501; found [M+H]
+: 
329.1501.  
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Synthesis of (S)-N-tert-butoxycarbonyl-2-[(3-nitro-5-(6-hydroxy-1-
hexynyl))phenoxymethyl]pyrrolidine [(S)-36] 
 
Under nitrogen atmosphere, CuBr (10 mg – 0.07 mmol) and tetrakis(triphenylphosphine)Pd(0) 
(41 mg – 0.035 mmol) were added to a solution of (S)-N-tert-butoxycarbonyl-2-[(3-bromo-5-
nitro)phenoxymethyl]pyrrolidine [(S)-28] (352 mg – 0.877 mmol) in 5 ml of triethylamine. 
Upon stirring for 30 minutes at room temperature, 5-hexyn-1-ol (172 mg – 1.75 mmol) was 
added and the mixture was refluxed for 12 hours. Afterward, the mixture was diluted with 10 
ml of 1M aqueous HCl and extracted with ethyl acetate (3x30 ml). The organic phase was 
washed with brine (15 ml), dried over anhydrous sodium sulphate, filtered on diatomaceous 
earth and concentrated in vacuo, providing a crude that was purified through silica gel flash 
chromatography (dichloromethane/methanol 98:2). The pure product (S)-36 was obtained as a 
yellow oil (265 mg – 0.533 mmol, 61%). TLC (Dichloromethane / Methanol 98:2): Rf= 0.24. 
[α]D25 = -7.08 ° (c1, CH3OH) 1H-NMR (300 MHz, CD3OD): 7.81 (s, 1H), 7.26 (m, 2H), 4.15 
(m, 2H), 3.97 (m, 1H), 3.71 (m, 2H), 3.38 (m, 2H), 2.47 (t, J= 6.4 Hz, 2H), 2.01 – 1.67 (m, 8H), 
1.47 (s, 9H). 
Synthesis of (S)-2-[(3-nitro-5-(6-hydroxy-1-
hexynyl))phenoxymethyl]pyrrolidine [(S)-42] 
 
(S)-N-tert-butoxycarbonyl-2-[(3-nitro-5-(6-hydroxy-1-hexynyl))phenoxymethyl]pyrrolidine 
[(S)-36] (200 mg 0.40 mmol) was dissolved in 2 ml of methanol and the solution was cooled to 
0 °C. Upon dropwise addition of 10 ml of a 1.25 M methanolic solution of HCl under vigorous 
stirring, the reaction mixture was warmed to room temperature and reacted for 12 hours. 
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Afterward, methanol was evaporated in vacuo, the residue was diluted with 10 ml of a 10% 
aqueous solution of NaHCO3 and extracted with DCM. The organic phase was dried over 
sodium sulphate, filtrated and evaporated in vacuo, affording a crude that was purified through 
silica gel flash chromatography (from dichloromethane/methanol 98:2 to 9:1). The pure product 
(S)-42 was obtained as a yellow-brown oil (150 mg – 0.38 mmol, 95%). TLC (Dichloromethane 
/ Methanol 98:2 + 2% NH3(30% in water)): Rf= 0.17. [α]D25 = +7.20° (c1, CH3OH). 1H-NMR (300 
MHz, CD3OD): δ 7.63 (s, 1H), 7.70 (s, 1H), 7.32 (s, 1H), 4.14 (dd, J= 9.6, 4.4 Hz, 1H), 4.03 
(dd J= 9.6, 7.4 Hz, 1H), 3.62 (m, 3H), 3.04 (m, 2H), 2.48 (m, 2H), 2.03 (m, 1H), 1.87 (m, 2H), 
1.70 – 1.63 (m, 5H).  
Synthesis of (S)-N-methyl-2-[(3-nitro-5-(6-hydroxy-1-
hexynyl))phenoxymethyl]pyrrolidine [(S)-2d] 
 
Under vigorous stirring at 0 °C, an aqueous solution of formaldehyde (37% in water, 0.06 ml) 
was added dropwise to a solution of (S)-2-[(3-nitro-5-(6-hydroxy-1-
hexynyl))phenoxymethyl]pyrrolidine [(S)-42] (68 mg – 0.17 mmol) in 4 ml of methanol and 80 
µl of glacial acetic acid. Upon addition of 2-picolin borane (18 mg – 0.17 mmol), the mixture 
was reacted for 6 hours. The solvent was evaporated in vacuo, the residue was diluted with 5 
ml of a 1M HCl solution and stirred for 1 hour to quench the unreacted 2-picolin-borane. Then, 
the pH was adjusted to 8 by adding an aqueous solution of Na2CO3 2M and the aqueous phase 
was extracted with ethyl acetate (3x30 ml). The organic phase was washed with brine, dried 
over sodium sulphate, filtered and evaporated in vacuo, providing a crude, that was further 
purified through silica-gel flash chromatography (gradient from dichloromethane to 
dichloromethane/methanol 9:1). The pure compound (S)-2d was obtained as a yellow oil (56 
mg- 0.14 mmol, 80%). TLC (Dichloromethane / Methanol 9:1 +2% NH3(30% in water)): Rf= 0.57. 
[α]D25 = +30.23° (c1, CH3OH). 1H-NMR (300 MHz, CD3OD): δ 7.76 (s, 1H), 7.70 (s, 1H), 7.31 
(s, 1H), 4.07 (d, J= 5.3 Hz, 2H), 3.61 (t, J= 6.4 Hz, 2H), 3.01 (m, 1H), 2.75 (m, 1H), 2.49 (m, 
5H), 2.38 (m, 1H), 2.05 (m, 1H), 1.86 – 1.67 (m, 7H). 13C-NMR (75 MHz, CD3OD): δ 159.3, 
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149.1, 126.3, 123.0, 118.0, 108.4, 92.3, 78.3, 70.6, 64.2, 61.0, 57.3, 40.6, 31.4, 27.6, 24.6, 22.2, 
18.3. HRMS (ESI+): calc. for C18H25N2O4: theor. 333.1814; found [M+H]
+: 333.1812.  
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Synthesis of (S)-N-tert-butoxycarbonyl-2-(3-
nitrophenoxymethyl)pyrrolidine 
 
Procedure adapted from literature.162 3-nitrophenol (209 mg – 1.50 mmol) and (S)-N-tert-
butoxycarbonyl-2-hydroxymethyl-pyrrolidine (300 mg – 1.50 mmol), dissolved each in 2 ml of 
anhydrous THF, were added to a solution of triphenylphosphine (472 mg – 1.8 mmol) in 2 ml 
of anhydrous THF. The reaction mixture was cooled to -10°C and DIAD (0.35 mL – 1.80 
mmol), was added dropwise, under vigorous stirring. The reaction mixture was refluxed for 12 
hours. After cooling to room temperature, the mixture was diluted with 10 mL of 1M aqueous 
solution of NaOH and extracted with ethyl acetate twice (2x30 ml). The organic phase was 
dried over anhydrous sodium sulphate, filtrated and concentrated in vacuo to obtain a crude that 
was further purified through silica-gel flash column chromatography (gradient from 
cyclohexane/ethylacetate 9:1 to 6:4). The pure compound was obtained as a yellowish - 
brownish oil (400 mg – 1.24 mmol, 82%). TLC (Cyclohexane / Ethyl Acetate 6:4; stained with 
cerium sulphate): Rf = 0.46. [α]D25 = -52.34° (c1, CH3OH). 1H-NMR (300 MHz, CDCl3): δ 
7.78 (m, 2H), 7.42 (t, J= 8.2 Hz, 1H), 7.34 – 7.19 (m, 1H), 4.16 (m, 2H); 3.90 (m, 1H), 3.37 
(m, 2H), 2.03 – 1.86 (m, 4H), 1.55 (s, 4.5H), 1.52 (s, 4.5H). 
Synthesis of (S)-N-tert-butoxycarbonyl-2-(3-
nitrophenoxymethyl)pyrrolidine 
 
(S)-N-tert-butoxycarbonyl-2-(3-nitrophenoxymethyl)pyrrolidine (360 mg – 1.12 mmol) was 
dissolved in 2 ml of methanol and the solution was cooled to 0 °C. Upon dropwise addition of 
8 ml of a 1.25 M methanolic solution of HCl under vigouros stirring, the reaction mixture was 
warmed to room temperature and reacted for 12 hours. Afterward, methanol was evaporated in 
  143 
vacuo, the residue was diluted with 10 ml of a 10% aqueous solution of NaHCO3 and extracted 
with DCM (3x30ml). The organic phase was dried over sodium sulphate, filtrated and 
evaporated in vacuo, affording the pure product as a brownish sticky solid (230 mg – 1.03 
mmol, 100%). TLC (Dichloromethane / Methanol 9:1 + 2% NH3(30% in water)): Rf= 0.5. [α]D25 = 
+7.52 (c1, CHCl3). 1H-NMR (300 MHz, CD3OD): δ 7.82 (ddd, J= 8.2, 2.3, 0.9 Hz, 1H), 7.78 
(t, J= 2.3 Hz, 1H), 7.51 (t, J= 8.2 Hz, 1H), 7.35 (ddd, J= 8.2, 2.3, 0.9 Hz, 1H), 4.10 (dd, J= 9.4, 
4.7 Hz, 1H), 3.99 (dd, J= 9.4, 7.3 Hz, 1H), 3.55 (qd, J= 7.3, 4.7 Hz, 1H), 3.08 – 2.88 (m, 2H), 
2.14 – 1.95 (m, 1H), 1.95 – 1.71 (m, 2H), 1.71 – 1.53 (m, 1H). 
Synthesis of (S)-N-tert-butoxycarbonyl-2-(3-
nitrophenoxymethyl)pyrrolidine 
 
Under vigorous stirring at 0 °C, an aqueous solution of formaldehyde (37% in water, 0.16 ml) 
was added dropwise to a solution of (S)-N-tert-butoxycarbonyl-2-(3-
nitrophenoxymethyl)pyrrolidine (120 mg – 0.540 mmol) in 3 ml of methanol and 80 µl of 
glacial acetic acid. Upon addition of 2-picolin borane (58 mg – 0.540 mmol), the mixture was 
reacted for 3 hours. The solvent was evaporated in vacuo, the residue was diluted with 5 ml of 
a 1M HCl solution and stirred for 1 hour to quench the unreacted 2-picolin-borane. Then, the 
pH was adjusted to 8 by adding an aqueous solution of Na2CO3 2M and the aqueous phase was 
extracted with ethyl acetate (3x30 ml). The organic phase was washed with brine, dried over 
sodium sulphate, filtered and evaporated in vacuo, providing the pure compound as a yellow 
oil (125 mg – 0.53 mmol, 98%). TLC (Dichloromethane / Methanol 9:1 +2% NH3(30% in water)): 
Rf= 0.64. [α]D25 = -33.90° (c1, CH3OH). 1H-NMR (300 MHz, CD3OD): δ 7.82 (ddd, J= 8.2, 
2.2, 0.9 Hz, 1H), 7.77 (t, J= 2.2 Hz, 1H), 7.51 (t, J= 8.2 Hz, 1H), 7.37 (ddd, J= 8.2, 2.2, 0.9 Hz, 
1H), 4.08 (d, J= 5.6 Hz, 2H), 3.30 (m, 1H), 3.09 (m, 1H), 2.76 (m, 1H), 2.42 (s, 3H), 2.37 (q, 
J= 9.4 Hz, 1H), 2.04 – 2.13 (m, 1H), 1.88 – 1.70 (m, 3H).163 13C-NMR (75 MHz, CD3OD): δ 
159.5, 149.2, 130.0, 120.9, 115.3, 108.6, 70.5, 64.2, 57.3, 40.6, 27.7, 22.2. 
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Synthesis of (S)-N-tert-butoxycarbonyl-2-(3-
bromophenoxymethyl)pyrrolidine [(S)-43] 
 
3-bromophenol (429 mg – 2.48 mmol) and (S)-N-tert-butoxycarbonyl-2-hydroxymethyl-
pyrrolidine (500 mg – 2.48 mmol) dissolved each in 2 ml of anhydrous THF, were added to a 
solution of triphenylphosphine (781 mg – 2.976 mmol) in 2 ml of anhydrous THF. The reaction 
mixture was cooled to -10°C and DIAD (0.60 mL – 2.976 mmol) was added dropwise, under 
vigorous stirring.  The reaction mixture was refluxed for 12 hours. After cooling to room 
temperature, the mixture was diluted with 10 mL of 1M aqueous solution of NaOH and 
extracted with ethyl acetate (2x30 ml). The organic phase was dried over anhydrous sodium 
sulphate, filtrated and concentrated in vacuo to obtain a crude that was further purified through 
silica-gel flash column chromatography (gradient from cyclohexane/ethyl acetate 9:1 to 8:2). 
The pure compound (S)-43 was obtained as a yellow oil (420 mg – 1.18 mmol, 48%). TLC 
(Cyclohexane / Ethyl Acetate 8:2): Rf = 0.44. [α]D25 = -42.44° (c1, CHCl3). 1H-NMR (300 
MHz, CDCl3): δ 7.11 (m, 3H), 6.86 (d, J= 8.2 Hz, 1H), 4.10 (d, J= 7.0 Hz, 2H), 3.84 (m, 1H), 
3.37 (m, 2H), 2.02 – 1.83 (m, 4H), 1.54 (s, 4.5H), 1.47 (s, 4.5H).164  
Synthesis of (S)-N-tert-butoxycarbonyl-2-[3-(6-hydroxy-1-
hexynyl)phenoxymethyl]pyrrolidine [(S)-44] 
 
Under nitrogen atmosphere, CuBr (13 mg – 0.09 mmol) and tetrakis(triphenylphosphine)Pd(0) 
(51 mg – 0.044 mmol) were added to a solution of (S)-N-tert-butoxycarbonyl-2-(3-
bromophenoxymethyl)pyrrolidine [(S)-43] (400 mg – 1.12 mmol) in 3 ml of triethylamine. 
Upon stirring for 30 minutes at room temperature, 5-hexyn-1-ol (220 mg – 2.24 mmol) was 
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added and the mixture was refluxed for 12 hours. Afterward, the mixture was diluted with 10 
ml of 1M aqueous HCl and extracted with ethyl acetate (3x30 ml). The organic phase was 
washed with brine (15 ml), dried over anhydrous sodium sulphate, filtered on diatomaceous 
earth and concentrated in vacuo, providing a crude that was purified through silica gel flash 
chromatography (dichloromethane/methanol 98:2). The pure product (S)-43 was obtained as a 
yellow-brown oil (400 mg – 0.88 mmol, 79%). TLC (Dichloromethane / Methanol 95:5): Rf= 
0.44. [α]D25 = -22.68 ° (c1, CH3OH).1H-NMR (300 MHz, CDCl3): 7.16 (m, 1H), 6.96 (m, 2H), 
6.86 (m, 1H), 4.10 (d, J= 7.6 Hz, 2H), 3.90 – 3.76 (m, 1H), 3.71 (t, J= 6.2 Hz, 2H), 3.38 (t, J= 
6.1 Hz, 2H), 2.44 (t, J= 6.7 Hz, 2H), 2.01 – 1.69 (m, 8H), 1.62 – 1.44 (m, 9H). 
Synthesis of (S)-2-[3-(6-hydroxy-1-hexynyl)phenoxymethyl]pyrrolidine [(S)-
45] 
 
(S)-N-tert-butoxycarbonyl-2-[3-(6-hydroxy-1-hexynyl)phenoxymethyl]pyrrolidine [(S)-44]  
(460 mg – 1.02 mmol)  was dissolved in 2 ml of methanol and the solution was cooled to 0 °C. 
Upon dropwise addition of 10 ml of a 1.25 M methanolic solution of HCl under vigorous 
stirring, the reaction mixture was warmed to room temperature and reacted for 12 hours. 
Afterward, methanol was evaporated in vacuo, the residue was diluted with 10 ml of a 10% 
aqueous solution of NaHCO3 and extracted with DCM (3x30ml). The organic phase was dried 
over sodium sulphate, filtrated and evaporated in vacuo, affording the pure product [(S)-45]  as 
a brownish oil (255 mg – 0.72 mmol, 71%). TLC (Dichloromethane / Methanol 9:1 + 2% 
NH3(30% in water)): Rf=0.38. [α]D25 = +5.99° (c1, CH3OH). 1H-NMR (300 MHz, CD3OD): δ 7.20 
(t, J= 8.5 Hz, 1H), 6.95 (m, 2H), 6.82 (dd, J= 2.3, 8.5 Hz, 1H), 3.95 (dd, J= 9.4, 4.9 Hz, 1H), 
3.86 (dd, J= 9.4, 7.0 Hz, 1H), 3.60 (t, J= 6.1 Hz, 2H), 3.52 – 3.37 (m, 1H), 3.06 – 2.82 (m, 2H), 
2.43 (t, J= 6.6 Hz, 2H), 2.01 – 1.90 (m, 1H), 1.90 – 1.76 (m, 2H), 1.76 – 1.49 (m, 5H).  
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Synthesis of (S)-N-methyl-2-[3-(6-hydroxy-1-
hexynyl)phenoxymethyl]pyrrolidine [(S)-3] 
 
Under vigorous stirring at 0 °C, an aqueous solution of formaldehyde (37% in water, 0.22 ml) 
was added dropwise to a solution of (S)-2-[3-(6-hydroxy-1-
hexynyl)phenoxymethyl]pyrrolidine [(S)-45] (255 mg – 0.724 mmol) in 4 ml of methanol and 
80 µl of glacial acetic acid. Upon addition of 2-picolin borane (78 mg – 0.724 mmol), the 
mixture was reacted for 3 hours. The solvent was evaporated in vacuo, the residue was diluted 
with 5 ml of a 1M HCl solution and stirred for 1 hour to quench the unreacted 2-picolin-borane. 
Then, the pH was adjusted to 8 by adding an aqueous solution of Na2CO3 2M and the aqueous 
phase was extracted with ethyl acetate (3x30 ml). The organic phase was washed with brine, 
dried over sodium sulphate, filtered and evaporated in vacuo, providing a crude that was further 
purified through silica gel flash chromatography (dichloromethane/methanol 9:1). The pure 
compound (S)-3 was obtained as a yellow oil (205 mg- 0.56 mmol, 77%). TLC 
(Dichloromethane / Methanol 9:1 +2% NH3(30% in water)): Rf= 0.24. [α]D25 = -5.07° (c1, CHCl3). 
1H-NMR (300 MHz, DMSO-d6): δ 7.21 (m, 1H), 6.90 (m, 3H), 4.40 (m, exchange with D2O, 
1H), 3.94 (dd, J= 9.6, 5.3 Hz, 1H), 3.80 (dd, J= 9.6, 5.9 Hz, 1H), 3.42 (m, 2H), 2.94 (m, 1H), 
2.59 – 2.50 (m, 1H), 2.39 (m, 2H), 2.33 (s, 3H), 2.17 (q, J= 8.6 Hz, 1H), 1.96 – 1.86 (m, 1H), 
1.71 – 1.50 (m, 7H). 13C-NMR (75 MHz, DMSO-d6): δ 158.9, 130.1, 124.8, 124.0, 117.1, 
115.2, 91.0, 81.0, 71.3, 64.0, 60.6, 57.5, 41.8, 32.1, 28.9, 25.3, 23.0, 18.9. HRMS (ESI+): calc. 
for C18H26NO2: theor. 288.1964; found [M+H]
+: 288.1956.  
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Synthesis of (S)-N-carbobenzyloxy-2-(3-methoxyphenoxymethyl)pyrrolidine 
[(S)-46] 
 
3-methoxyphenol (521 mg – 4.2 mmol) and (S)-N-tert-butoxycarbonyl-2-hydroxymethyl-
pyrrolidine (1 g – 4.2 mmol), dissolved each in 5 ml of anhydrous THF, were added to a solution 
of triphenylphosphine (1.3 g – 5.1 mmol) in 8 ml of anhydrous THF. The reaction mixture was 
cooled to -10°C and DIAD (0.83 mL – 5.1 mmol), in 2 ml of anhydrous THF, was added 
dropwise under vigorous stirring. The reaction mixture was refluxed for 12 hours. After cooling 
to room temperature, the mixture was diluted with 10 mL of 1M aqueous solution of NaOH and 
extracted with dichloromethane twice (2x30 ml). The organic phase was dried over anhydrous 
sodium sulphate, filtrated and the solvent was evaporated in vacuo to obtain a crude that was 
further purified through silica-gel flash column chromatography (gradient from 
cyclohexane/ethyl acetate 9:1 to 7:3). The pure compound (S)-46 was obtained as a pale yellow 
oil (901 mg – 2.63 mmol, 63%). TLC (Cyclohexane / Ethyl Acetate 7:3): Rf = 0.7. [α]D25 = -
45.22° (c1, CHCl3). 1H-NMR (300 MHz, CDCl3): δ 7.35 – 7.30 (m, 5H), 7.16 – 7.09 (m, 1H), 
6.56 – 6.42 (m, 3H), 5.15 (s, 2H), 4.20 – 4.17 (m, 2H), 4.08 – 3.95 (m, 1H), 3.78 (s, 3H), 3.49 
(m, 2H), 2.10 – 1.86 (m, 4H).       
Synthesis of (S)-N-methyl-2-(3-methoxyphenoxymethyl)pyrrolidine [(S)-4] 
 
Under inert atmosphere and at -10 °C, a solution of (S)-2-(3-
methoxyphenoxymethyl)pyrrolidine [(S)-47] (250 mg – 0.73 mmol) was added dropwise to a 
vigorously stirred suspension of LiAlH4 (70 mg – 1.84 mmol) in THF (1 ml). The reaction 
mixture was stirred at room temperature for 90 minutes. Afterward, upon cooling to -10 °C, the 
excess of LiAlH4 was quenched by dropwise addition of water. The crude was diluted with a 
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1M aqueous solution of HCl (10 ml) and washed with diethyl ether (2x5 ml) and DCM (5 ml). 
The aqueous phase was basified to pH 12 with an aqueous solution of NaOH and extracted with 
DCM (3x20 ml). the organic phase was dried over anhydrous sodium sulphate, filtered and 
evaporated in vacuo, providing the pure product (S)-4 as a yellow oil (108 mg – 0.49 mmol, 
67%). TLC (Ethyl Acetate + TEA 3%)): Rf= 0.4. [α]D25 = -52.67° (c1, CHCl3). 1H-NMR (300 
MHz, CDCl3): δ 7.17 (t, J= 7.7 Hz, 1 H), 6.50 (m, 3H), 4.00 (dd, J= 9.3, 5.1 Hz, 1H), 3.87 (dd, 
J= 9.3, 6.0, 1H), 3.78 (s, 3H), 3.12 (m, 1H), 2.66 (m, 1H), 2.49 (s, 3H), 2.32 (m, 1H), 2.07 – 
1.98 (m, 1H), 1.89 – 1.71 (m, 3H). 13C-NMR (75 MHz, CDCl3): δ 161.0, 160.4, 130.1, 106.9, 
106.7, 101.2, 70.7, 64.7, 57.9, 55.5, 41.7, 28.9, 23.1. HRMS (ESI+): calc. for C15H20NO2: theor. 
222.1494; found [M+H]+: 222.1493.  
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Synthesis of (S)-N-carbobenzyloxy-proline [(S)-47] 
 
Procedure adapted from literature.165 A solution of (S)-proline (10.0 g – 86.8 mmol) in 40 ml 
of an aqueous solution of NaOH 2M was cooled to 0 °C and benzyloxycarbonil chloride (Cbz-
Cl) (17.5 ml – 116.4 mmol) was added in three sequential portions of 5.9 ml, each followed by 
an addition of 10 ml of NaOH 4 M. The reaction mixture was stirred for 3 hours. Afterward, 
the aqueous layer was washed with diethyl ether (30 ml) and, upon cooling to 0 °C, it was 
acidified to pH 2 and extracted with ethyl acetate. The organic phase was dried over anhydrous 
sodium sulphate, filtered and the solvent was evaporated in vacuo, providing the pure product 
(S)-47 as a white solid (19.5 g – 78.1 mmol, 90%). TLC (Dichloromethane / Methanol 9:1, 
stained with Blue Shift): Rf= 0.26. M.p.= 72.5 °C; literature166: M.p. = 78 °C; literature167: 
M.p. = 60 – 61 °C. [α]D25 = -77.53° (c2, EtOH). 1H-NMR (300 MHz, CDCl3): δ 9.20 (bs, 1H, 
exchange with D2O), 7.33 – 7.26 (m, 5H), 5.20 – 5.00 (m, 2H), 4.30 (m, 1H), 3.60 – 3.40 (m, 
2H), 2.25 – 1.75 (m, 4H).168 
Synthesis of N-methyl-N-nitrosotoluene-p-sulfonamide 
 
A total amount of p-toluensulphonyl chloride of 100 g was divided in three portions of 59.5 g, 
28.1 g and 12.5 g. An aqueous solution of methylamine (52.8 ml – 625 mmol) was mechanically 
stirred at room temperature and the first portion of p-toluensulphonyl chloride (59.4 g – 312 
mmol) was added over 5 minutes. The reaction mixture is heated to 80-90 °C, high enough to 
melt the p-toluene-N-methylsulphonylamide  intermediate and maintain it in the liquid phase, 
but not too high to avoid methylamine loss. After 5 minutes, the pH must be acid. A 50% m/V 
aqueous solution of NaOH was prepared (23.5 g – 587 mmol in 47 ml of H2O ad was used in 
the following steps. Cautiously, the solution of NaOH (15.6 ml) was added, immediately 
followed by the addition of the second portion of p-toluene sulphonyl chloride (28.1 g – 147 
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mmol). Again, the pH was controlled to be acid. 7.8 ml of the same aqueous solution of NaOH 
were added, followed by the addition of the third portion of p-toluene sulphonyl chloride (12.5 
g – 66 mmol). When the pH of the reaction mixture was acid, the spare solution of NaOH was 
added. If the aqueous phase was not basic, methylamine was added until basic pH. The mixture 
was stirred for further 15 minutes and was then poured, still hot, into a round-bottomed flask 
containing glacial acetic acid (470 ml). Glacial acetic acid (80 ml) was also used to carefully 
recover all the residues of the reaction mixture from the first flask. The mixture was cooled at 
5 °C and a solution of NaNO2 (39.1 g – 566 mmol) in 39 ml of water was added dropwise over 
45 minutes. The mixture was stirred for further 15 minutes at 10 °C, diluted with water (155 + 
125 ml) and filtered. The resulting solid was washed and filtered many times with water, until 
removal of whole glacial acetic acid. The resulting solid (103 g – 479 mmol, 91%) was dried 
over P2O5. M.p.= 58.0 °C. 1H-NMR (300 MHz, CDCl3): δ 7.84 (m, 2H), 7.35 (m, 2H), 3.10 (s, 
3H), 2.43 (s, 3H).  
Synthesis of diazomethane 
 
A solution of KOH (12.0 g – 182 mmol) in water (19.2 ml) and ethanol (24 ml) was prepared 
in a round-bottom flask equipped with a Claisen condenser connected at the opposite end to a 
collecting round-bottom flask maintained at – 30 °C. The hydroethanolic solution was heated 
to 55-60 °C and a solution of N-methyl-N-nitroso-p-toluenesulphonamide (12 .0 g – 56 mmol) 
in diethyl ether (110 ml) was added dropwise, to a controlled rate equal to the distillation rate. 
Thus, the ethereal solution of diazomethane was distilled until the distilling fraction appeared 
colourless (diethyl ether alone), collected at – 30 °C and immediately used thereafter for the 
following reaction.   
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Synthesis of (S)-N-carbobenzyloxy-diazoproline [(S)-48] 
 
Procedure adapted from literature.169 Under inert atmosphere, a suspension of (S)-N-
carbobenzyloxy-proline [(S)-47] (6.0 g – 24 mmol) in anhydrous diethyl ether (50 ml) was 
cooled to -15 °C and triethylamine (3.36 ml – 24 mmol) was added dropwise. After 5 minutes, 
isobutylchloroformiate (3.12 ml – 24.1 mmol) was added dropwise, maintaining the 
temperature below -10 °C. After 20 minutes, upon formation of the mixed anhydride, controlled 
by TLC, the mixture was equilibrated to 0 °C and the solid was removed by filtration and 
washed with diethyl ether. The filtrate was cooled to 0 °C and, under inert atmosphere, an 
ethereal solution of diazomethane was carefully added dropwise over 45 minutes 
(approximately 75 mmol in 150 ml of diethyl ether). The reaction mixture was stirred 
vigorously at room temperature overnight. Afterward, the ethereal solution was washed first 
with a saturated solution of NaHCO3 and then with water. The organic phase was dried over 
anhydrous sodium sulphate, filtrated and the solvent was evaporated in vacuo, affording a crude 
that was purified through silica gel flash chromatography (cyclohexane/ethyl acetate 7:3). The 
pure product (S)-48 was isolated as a yellow solid (5.8 g – 18 mmol, 75%). TLC (Cyclohexane 
/ Ethyl Acetate 6:4; staining agent: Blue Shift): Rf= 0.40. M.p.= 64.6 °C; literature170: 58 – 
60 °C; literature171: 66 – 67 °C. [α]D25 = -147.32 (c1, CHCl3); literature171: [α]D25 = -131.8 (c1.1, 
CHCl3). The product shows the typical IR stretching band of CHN2 at 2104 cm
-1. 1H-NMR 
(300 MHz, CDCl3): δ 7.40 – 7.26 (m, 5H), 5.46 – 5.25 (m, 1H), 5.20 – 5.00 (m, 2H), 4.38 – 
4.25 (m, 1H), 3.60 – 3.40 (m, 2H), 2.25 – 1.75 (m, 4H).170  
Synthesis of (S)-N-carbobenzyloxy-2-bromoacetylpyrrolidine [(S)-49] 
 
Procedure adapted from literature.172 Upon cooling to -10 °C, aqueous HBr (2.68 ml – 53.32 
mmol) was added dropwise to a solution of (S)-N-carbobenzyloxy-diazoproline [(S)-48] (4.0 g 
– 14.6 mmol) in diethyl ether (50 ml). The resulting mixture was warmed to room temperature 
and vigorously stirred for 1 hour. Afterward, the mixture is diluted with diethyl ether (40 ml) 
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and washed several times with a saturated solution of NaHCO3 and then with water. The organic 
phase was dried over anhydrous sodium sulphate, filtered and the solvent was evaporated in 
vacuo providing the pure product [(S)-49] was isolated as a pale yellow oil (4.1 g – 12.6 mmol, 
85%). TLC (Cyclohexane / Ethyl Acetate 6:4; stained with Blue Shift): Rf= 0.56. [α]D25 = -
51.59° (c1, MeOH); literature172: [α]D25 = -51° (c1, MeOH). 1H-NMR (300 MHz, CDCl3): δ 
7.36 – 7.25 (m, 5H), 5.18 – 5.02 (m, 2H), 4.64 – 4.50 (m, 1H), 4.15 (d, J = 12.9 Hz, 0.5H), 4.04 
(d, J = 12.9 Hz, 0.5H), 3.80 (s, 1H), 3.63 – 3.52 (m, 2H), 2.26 – 2.18 (m, 1H), 2.07 – 1.88 (m, 
3H).172 
Synthesis of (S)-N-carbobenzyloxy-2-acetoxyacetylpyrrolidine [(S)-52] 
 
(S)-N-carbobenzyloxy-2-bromoacetylpyrrolidine [(S)-49] (545 mg – 1.67 mmol) was added to 
a solution of KOAc (164 mg – 1.67 mmol) in 5 ml of DMSO. The resulting reaction mixture 
was stirred at room temperature for 1.5 hours. Afterward, the mixture was diluted with diethyl 
ether and washed sequentially with water and brine. The organic phase was dried over 
anhydrous sodium sulphate, filtered and the solvent was removed in vacuo, affording the pure 
product [(S)-52] as a colourless oil (499 mg – 1.64 mmol, 98%). The enantiomeric excess was 
assessed by chiral HPLC. [α]D25 = -79.4 (c1, CHCl3). 1H-NMR (300 MHz, CDCl3): δ 7.36 – 
7.25 (m, 5H), 5.18 – 5.09 (m, 2H), 4.83 (s, 1.2H), 4.62 (s, 0.8H), 4.47 – 4.42 (m, 0.6H), 4.41 – 
4.37 (m, 0.4H), 3.62 – 3.46 (m, 2H), 2.23 – 1.86 (m, 4H),  2.15 (s, 3H). e.e. %= 99.28% 
(Chiralcel OJ; hexane/isopropanol 9:1, 2 ml/min, λ=258 nm; RtR= 6.85min, RtS=8.52 min) 
Chiral HPLC analysis: (S)-N-carbobenzyloxy-2-acetoxyacetylpyrrolidine 
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Chiral HPLC analysis: (R)-N-carbobenzyloxy-2-acetoxyacetylpyrrolidine 
 
Chiral HPLC analysis: mixture of (S)- and (R)-N-carbobenzyloxy-2-acetoxyacetylpyrrolidine 
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Synthesis of (S,R)/(S,S)-N-carbobenzyloxy-2-(1,2-
dihydroxyethyl)pyrrolidine [(S,S)-53/(S,R)-53] 
 
A solution of N-carbobenzyloxy-(S)-2-acetoxyacetylpyrrolidine  [(S)-52] (505 mg, 1.65 mmol) 
in anhydrous THF (4 mL) was added dropwise to a suspension of NaBH4 (66 mg – 1.4 mmol) 
in anhydrous THF (4 mL) at -10 °C. The reaction mixture was allowed to reach the room 
temperature and stirred for 3 h at this temperature. Afterwards, dichloromethane was added, 
and the organic phase was washed with water. The separated organic layer was dried over 
Na2SO4, filtered and concentrated in vacuo to provide a residue that was dissolved in methanol 
(20 mL). Sodium methoxide (88 mg, 1.63 mmol) was added to the resulting solution at -10 °C 
and the reaction mixture was stirred for 1 h. Dichloromethane was added, and the organic phase 
was washed with water, separated and filtered through a Celite® plug. The solvent was 
evaporated in vacuo to obtain a mixture of (S,S) and (S,R)-N-carbobenzyloxy-2-(1,2-
dihydroxyethyl)pyrrolidine  [(S,S)-53/(S,R)-53] as a light yellow oil (285 mg –1.07 mmol, 
97%). TLC (Cyclohexane / Ethyl Acetate 1:1): Rf= 0.21. 1H NMR (CDCl3) δ 7.38 – 7.25 (m, 
5H), 5.15 (s, 2H), 4.08 – 3.89 (m, 1H), 3.66 – 3.50 (m, 3H), 3.45 – 3.30 (m, 2H), 3.05 (bs, 2H), 
2.11 – 1.71 (m, 4H).173  
Synthesis of (S,R)-N-carbobenzyloxy-2-(1-hydroxy-2-
benzyloxy)ethylpyrrolidine [(S,R)-59] and of (S,S)/(S,R)-1-
(benzyloxymethyl)tetrahydro-1H,3Hpyrrolo[1,2-c]oxazol-3-one [(S,S)-
60/(S,R)-60] 
 
(S,S)/(S,R)-N-carbobenzyloxy-2-(1,2-dihydroxyethyl)pyrrolidine [(S,S)-53/(S,R)-53] (500 mg 
– 1.88 mmol) was dissolved in anhydrous toluene (10 mL) and dibutyltin oxide (609 mg – 2.45 
mmol) was added. The reaction mixture was refluxed for 5 h and water was azeotropically 
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removed by dean-stark apparatus. Then benzyl bromide (0.25 mL – 2.07 mmol) and 
tetrabutylammonium iodide (35 mg) were added and the mixture was refluxed for additional 
16 h. Afterward, the solvent was evaporated in vacuo and the resulting residue was purified by 
silica gel flash chromatography (cyclohexane/ethyl acetate 1:1). The pure product (S,R)-N-
carbobenzyloxy-2-(1-hydroxy-2-benzyloxy)ethylpyrrolidine [(S,R)-59] was obtained as a 
yellow oil (250 mg – 0.70 mmol, 37%). TLC (Cyclohexane / Ethyl Acetate 1:1): Rf= 0.25. 
[α]D25 = -24.0 (c1, CHCl3). 1H NMR (300 MHz, CDCl3): δ 7.46 – 7.26 (m, 10H), 5.16 – 5.09 
(m, 2H), 4.60 – 4.38 (m, 2H), 4.10 – 3.85 (m, 2H), 3.60 – 3.32 (m, 4H), 2.15 – 1.82 (m, 4H) 
[figure in the next page]. The diastereoisomeric mixture of (S,S)/(S,R)-1-
(benzyloxymethyl)tetrahydro-1H,3Hpyrrolo[1,2-c]oxazol-3-one [(S,S)-60/[(S,R)-59] was 
obtained as an orange oil (198 mg – 0.80 mmol, 46%), in a 60:40 diastereoisomeric ratio. TLC 
(Cyclohexane / Ethyl Acetate 1:1): Rf= 0.30. 1H NMR (300 MHz, CDCl3): δ 7.41 – 7.30 (m, 
5H), 4.82 (dt, J= 7.7, 6.1 Hz, 0.4H), 4.52 – 4.65 (m, 2H), 4.41 – 4.45 (q, J= 5.2 Hz, 0.6H), 3.86 
– 3.94 (m, 0.4H), 3.55 – 3.77 (m, 3.6H), 3.13 – 3.21 (m, 1H), 1.74 – 2.17 (m, 2.4H), 1.43 – 1.58 
(m, 1.6H).  
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 Synthesis of (S,R)-1-(Benzyloxymethyl)tetrahydro-1H,3H-pyrrolo[1,2-
c]oxazol-3-one [(S,R)-60] 
 
A solution of (S,R)-N-carbobenzyloxy-2-(1-hydroxy-2-benzyloxy)ethylpyrrolidine [(S,R)-59] 
(1.5 g – 4.79 mmol) in anhydrous DMF (10 mL) was added dropwise to a suspension of NaH 
(115 mg – 4.79 mmol) in anhydrous DMF (5 mL) at -10 °C under inert atmosphere. The reaction 
was warmed to room temperature and stirred at the same temperature for 3 h. Upon addition of 
dichloromethane, the reaction mixture was washed with water. The organic layer was separated, 
dried over Na2SO4, filtered and evaporated in vacuo providing a residue that was further 
purified by silica gel flash chromatography (cyclohexane/ethyl acetate 4:6). The pure 
compound (S,R)-60 was obtained as a yellow oil (699 mg – 2.83 mmol, 59%). TLC 
(Cyclohexane / Ethyl Acetate 4:6): Rf= 0.45. [α]D25 = - 23.9 (c2, CHCl3). 1H NMR (300 MHz, 
CDCl3): δ 7.41 – 7.30 (m, 5H), 4.82 (dt, J= 7.7, 6.1 Hz, 1H), 4.57 (q, J= 11.8 Hz, 2H), 3.90 
(ddd, J= 10.5, 7.7, 5.5 Hz, 1H), 3.76 – 3.54 (m, 3H), 3.20 – 3.12 (m, 1H), 2.18 – 1.75 (m, 3H), 
1.60 – 1.43 (m, 1H). 13C NMR (75 MHz, CDCl3): δ 161.21, 137.60, 128.75, 128.21, 128.06, 
74.68, 73.97, 68.51, 62.10, 45.72, 25.80, 25.26. 
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Synthesis of (S,R)-1-(hydroxymethyl)tetrahydro-1H,3H-pyrrolo[1,2-
c]oxazol-3-one [(S,R)-61] 
 
A suspension of (S,R)-1-(benzyloxymethyl)tetrahydro-1H, 3Hpyrrolo[1,2-c]oxazol-3-one 
[(S,R)-60] (1.23 g – 4.97 mmol) and 10% Pd/C (245 mg) in methanol (30 ml) was vigorously 
stirred under H2 atmosphere for 8 hours. Afterward, the catalyst was removed by filtration on a 
Celite® pad and the solvent was evaporated in vacuo, affording the pure product (S,R)-61 as a 
white solid (759 mg – 4.82 mmol, 97%). TLC (Ethyl Acetate): Rf= 0.3. M.p.= 60.0 °C. [α]D25 
= -8.60 (c0.4, CHCl3). 1H-NMR (300 MHz, CDCl3): δ 4.78 – 4.70 (m, 1H), 3.99 – 3.79 (m, 
3H), 3.64 – 3.55 (m, 1H), 3.22 – 3.14 (m, 1H), 2.20 – 1.60 (m, 5H).   
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Synthesis of 3-benzyloxy-2-bromopyridine 
 
Procedure adapted from literature.174 A solution of 3-hydoxy-2-bromopyridine (3 g – 17.24 
mmol) in DMF (12 ml) was added dropwise to a suspension of K2CO3 (2.62 g – 18.96 mmol) 
in DMF (8 ml). Upon stirring for 10 minutes, benzyl bromide (2.25 ml – 18.96 mmol) was 
added dropwise. The reaction mixture was stirred overnight at room temperature. Afterward, 
the solvent was concentrated in vacuo, the residue was diluted with DCM and then washed with 
an aqueous solution of NaOH 10%. The organic phase was dried over anhydrous sodium 
sulphate, filtered and the solvent was removed in vacuo. The pure product (4 g – 15.17 mmol, 
88%) was obtained as a light yellow oil. TLC (Cychlohexane / Ethyl Acetate 7:3): Rf= 0.38. 
1H-NMR (300 MHz, CDCl3): δ 7.99 (dd, J= 4.7, 1.7 Hz, 1H), 7.47 – 7.34 (m, 5H), 7.20 – 7.12 
(m, 2H), 5.19 (s, 2H).174 
Synthesis of (S,R)-1-(3-benzyloxy-2-pyridyloxymethyl)tetrahydro-1H,3H-
pyirrolo[1,2-c]ossazol-3-one [(S,R)-62] 
 
A solution of (S,R)-1-(hydroxymethyl)tetrahydro-1H,3H-pyrrolo[1,2-c]oxazol-3-one [(S,R)-
61] (950 mg – 6.04 mmol) in anhydrous DMF (4 mL) was added dropwise to a suspension of 
NaH (148 mg – 6.04 mmol) in anhydrous DMF (1 mL) at -10 °C. Upon addition of 2-bromo-
3-benzyloxypyridine (1.6 g – 6.04 mmol) at the same temperature, the reaction mixture was 
stirred at 80 °C for 4 h. Afterwards the solvent was evaporated in vacuo to give a residue that 
was dissolved in diethyl ether and washed with water. The separated organic phase was dried 
over Na2SO4, filtered and concentrated under vacuum, affording a residue that was purified by 
silica gel flash chromatography (cyclohexane/ethyl acetate 1:1). The pure compound (S,R)-62 
was obtained as a light oil (698 mg – 2.05 mmol, 34%). TLC (Cyclohexane / Ethyl Acetate 
1:1): Rf= 0.40. [α]D25 = -30.1 (c1, CHCl3). 1H NMR (300 MHz, CDCl3): δ 7.70 (dd, J= 5.0, 
1.4 Hz, 1H), 7.39 – 7.26 (m, 5H), 7.12 (dd, J= 7.7, 1.4 Hz, 1H), 6.84 (dd, J= 7.7, 5.0 Hz, 1H), 
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5.26 (dt, J= 9.4, 5.0 Hz, 1H), 5.12 (s, 2H), 4.61 (dd, J= 10.5, 5.0 Hz, 1H), 4.10 (pt, 1H), 3.78 – 
3.70 (dt, J= 9.9, 5.0 Hz, 1H), 3.65 – 3.49 (m, 2H), 2.31 – 2.23 (m, 1H), 2.06 – 1.97 (m, 1H), 
1.89 – 1.66 (m, 2H). 
Synthesis of (S,R)-1-(3-hydroxy-2-pyridyloxymethyl)tetrahydro-1H,3H-
pyirrolo[1,2-c]ossazol-3-one [(S,R)-63] 
 
A suspension of (S,R)-1-(3-benzyloxy-2-pyridyloxymethyl)tetrahydro-1H,3H-pyirrolo[1,2-
c]ossazol-3-one [(S,R)-62] (260 mg – 0.76 mmol) and 10% Pd/C (26 mg) in ethanol (10 ml) 
was vigorously stirred under H2 atmosphere for 2 hours. Afterward, the catalyst was removed 
by filtration on a Celite ® pad and the solvent was evaporated in vacuo, affording the pure 
product (S,R)-63 as a white solid (188 mg – 0.75 mmol, 99%). TLC (Cyclohexane / Ethyl 
Acetate 2:8): Rf= 0.40. M.p.= 154.2 °C. [α]D25 = -49.3 (c0.5, EtOH). 1H NMR (300 MHz, 
CDCl3): δ 7.64 (dd, J= 5.0, 1.4 Hz, 1H), 7.17 (dd, J= 7.7, 1.4 Hz, 1H), 6.86 (dd, J= 7.7, 5.0 Hz, 
1H), 6.12 (bs, 1H, exchange with D2O), 5.30 (dt, J= 9.1, 4.7 Hz, 1H), 4.56 (dd, J= 10.5, 4.7 
Hz, 1H), 4.10 (dd, J= 10.5, 9.1 Hz,1H), 3.73 – 3.48 (m, 3H), 2.30 – 2.23 (m, 1H), 2.06 – 1.98 
(m, 1H), 1.86 – 1.66 (m, 2H). 
Synthesis of (S,R)-N-methyl-2-[2-(3-hydroxy-2-pyridyloxy)-1-
hydroxyethyl]pyrrolidine [(S,R)-64] 
 
A solution of (S,R)-1-(3-hydroxy-2-pyridyloxymethyl)tetrahydro-1H,3H-pyirrolo[1,2-
c]ossazol-3-one [(S,R)-63] (200 mg – 0.8 mmol) in THF (4 mL) was added dropwise to a 
suspension of LiAlH4(92 mg – 2.40 mmol) in THF (4 mL) under inert atmosphere, at -10 °C. 
The reaction mixture was warmed to room temperature and stirred for 2 h. Upon cooling, 
dichloromethane and water were added. The resulting suspension was filtered through a 
Celite® plug and the filtrate was evaporated in vacuo providing a crude that was diluted with 
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an aqueous solution of HCl 1M and washed with DCM. The aqueous phase was basified until 
pH=8 with a 30% solution of NH3 in water and extracted with ethyl acetate. The organic phase 
was dried over anhydrous sodium sulphate, filtered and the solvent was removed in vacuo. The 
pure product (S,R)-64 was isolated as a light yellow sticky solid (147 mg – 0.62 mmol, 77%). 
TLC (Dichloromethane / Methanol 9:1 + 0.5% NH3(30 % in water)): Rf= 0.35. [α]D25 = -17.0 (c0.8, 
CHCl3). 1H NMR (300 MHz, CDCl3): δ 7.67 (dd, J= 4.7, 1.6 Hz, 1H), 7.21 (dd, J= 7.7, 1.6 Hz, 
1H), 6.99 (dd, J= 7.7, 4.7 Hz, 1H), 5.60 (bs, 2H, exchange with D2O), 4.10 (dt, J= 8.8, 2.2 Hz, 
1H), 3.93 (dd, J= 11.8, 8.8 Hz, 1H), 3.66 (dd, J= 11.8, 2.2 Hz, 1H), 3.32 – 3.24 (m, 1H), 2.57 
– 2.42 (m, 1H), 2.41 (s, 4H), 2.19 – 2.12 (m, 1H), 2.02 – 1.85 (m, 3H). 
Synthesis of (S,S)-2-(N-Methyl-2-pyrrolidinyl)-2,3-dihydro-1,4-dioxino[2,3-
b]pyridine [(S,S)-5] 
 
(S,R)-N-methyl-2-[2-(3-hydroxy-2-pyridyloxy)-1-hydroxyethyl]pyrrolidine [(S,R)-64] (150 
mg – 0.63 mmol) was dissolved in anhydrous THF (2 mL) and triphenylphosphine (0.94 mmol) 
was added. The solution was cooled at -10 °C and diisopropyl azodicarboxylate (DIAD) (0.19 
mL) was added. The reaction vessel was placed into a microwave reactor and irradiated at 
120 °C for 15 min at 300 W. The solvent was removed under vacuum affording a residue that 
was purified by silica gel flash chromatography (dichloromethane/methanol 95:5 + 3% NH3(30% 
in water)). The pure compound (S,S)-5 was obtained as a light yellow oil (75 mg – 0.34 mmol, 
54%).TLC (Dichloromethane / Methanol 95:5 + 3% NH3(30% in water)): Rf= 0.15. [α]D25 = -51.5 
(c0.5, CHCl3). 1H NMR (300 MHz, DMSO-d6): δ 7.71 (dd, J= 4.7, 1.6 Hz, 1H), 7.27 (dd, J= 
8.0, 1.6 Hz, 1H), 6.90 (dd, J= 8.0, 4.7 Hz, 1H), 4.34 (dd, J= 11.3, 2.2 Hz, 1H), 4.23 (ddd, J= 
8.0, 4.7, 2.2 Hz, 1H), 3.96 (dd, J= 11.3, 8.0 Hz, 1H), 2.88 – 2.95 (m, 1H), 2.56 – 2.66 (m, 1H), 
2.35 (s, 3H), 2.20 – 2.30 (m, 1H), 1.65 – 1.91 (m, 4H). 13C NMR (75 MHz, CDCl3): δ 151.38, 
140.15, 139.56, 124.66, 118.40, 76.82, 65.53, 65.04, 58.16, 43.18, 28.09, 24.10. Anal. Calc. 
for C12H16N2O2: theor. C= 65.43; H= 7.32; N= 12.72; found C= 65.21; H= 7.34; N= 12.70. 
HRMS (ESI+): calc. for C12H17N2O2: theor. 221.12845; found [M+H]
+: 221.12827. 
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Synthesis of 3-((2-methoxyethoxy)methoxy)pyridine (73) 
 
Procedure adapted from literature.175 Under inert atmosphere and at -10 °C, a solution of 3-
hydroxypyridine (5.00 g – 52.58 mmol) in DMF (40 ml) was added dropwise to a suspension 
of NaH (1.5 g – 63.1 mmol) in DMF (10 ml). Upon stirring at -10 °C for 30 minutes, 2-
methoxyethoxy-methylenchloride (7.85 g – 63.1 mmol) were added dropwise. The reaction 
mixture was equilibrated to 0 °C and stirred for 3.5 hours. Afterward, the mixture was 
concentrated in vacuo and the resulting residue was diluted with DCM and washed with a 10% 
aqueous solution of NaOH. The organic phase was dried over anhydrous sodium sulphate and 
the solvent was evaporated in vacuo. The pure product 73 was obtained as a yellow oil (9.2 g – 
50.21 mmol, 95%). TLC (Cyclohexane / Ethyl acetate 3:7): Rf= 0.25. 1H-NMR (300 MHz, 
CDCl3): δ 8.38 (d, J = 2.7, 1H), 8.23 (dd, J = 5.0, 1.4 Hz, 1H), 7.37 (ddd, J = 8.5, 2.7, 1.4 Hz, 
1H), 7.19 (ddd, J = 8.5, 5.0, 0.5 Hz, 1H), 5.26 (s, 2H), 3.82 – 3.75 (m, 2H), 3.56 – 3.47 (m, 2H), 
3.33 (s, 3H). 
Synthesis of 4-bromo-3-[(2-methoxyethoxy)methoxy]pyridine (70) 
 
Procedure adapted from literature.176 A 2.7 M solution of n-BuLi in heptane (12.13 mL, 32.8 
mmol) was added dropwise to a stirred solution of 3-((2-methoxyethoxy)methoxy)pyridine (73) 
(3.0 g – 16.4 mmol) in THF (60 mL) at -78 °C. After 1 h, the reaction mixture was cooled to -
90 °C and a solution of tetrabromoethane (10.86 g – 32.8 mmol) in THF (15 mL) was added 
dropwise. Upon stirring at this temperature for further 1 h, water (20 mL) was added dropwise. 
The aqueous phase was extracted with ethyl acetate many times. The organic phases were 
combined, dried over anhydrous sodium sulphate, filtered and the solvent was evaporated in 
vacuo, and the resulting crude was purified by silica gel flash chromatography (Cyclohexane / 
Ethyl acetate 3:7). The pure product 70 was isolated as a yellow oil (3.1 g – 11.81 mmol, 72%). 
TLC(Cyclohexane / Ethyl acetate 3:7): Rf= 0.29.1H NMR (300 MHz, CDCl3): δ 8.48 (s, 1H), 
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8.08 (d, J= 5.2 Hz, 1H), 7.48 (d, J= 5.2 Hz, 1H), 5.37 (s, 2H), 3.90 – 3.87 (m, 2H), 3.58 – 3.55 
(m, 2H), 3.36 (s, 3H).  
Synthesis of 4-benzyloxy-3-[(2-methoxyethoxy)methoxy]pyridine (71) 
 
Procedure adapted from literature.177 Under nitrogen atmosphere, a solution of benzyl alcohol 
(3.55 mL – 34.4 mmol) in DMSO (5 mL) was added dropwise to a stirred suspension of NaH 
(1.37 g – 57.2 mmol) in DMSO (15 mL). The mixture was heated at 50 °C for 30 min and then 
cooled to 10 °C. Upon dropwise addition of a solution of 4-bromo-3-[(2-
methoxyethoxy)methoxy]pyridine (70) (6.0 g – 22.9 mmol) in DMSO (40 mL), the temperature 
was increased to 20 °C and the whole reaction mixture was stirred at this temperature for 1 h. 
Afterward, diethyl ether and water were added. The organic phase was separated, washed with 
water, dried over anhydrous sodium sulphate, filtered and the solvent was evaporated in vacuo. 
The resulting crude was purified by silica gel flash chromatography (gradient from 
cyclohexane/ethyl acetate 3:7 to ethyl acetate). The pure product 71 was isolated as a yellow 
oil (5.4 g – 18.78 mmol, 82%). TLC (Cyclohexane / Ethyl acetate 3:7): Rf= 0.23. 1H NMR 
(300 MHz, CDCl3) δ 8.38 (s, 1H), 8.17 (d, J= 5.5 Hz, 1H), 7.41 – 7.31 (m, 5H), 6.84 (d, J= 5.5 
Hz, 1H), 5.29 (s, 2H), 5.16 (s, 2H), 3.88 – 3.86 (m, 2H), 3.55 – 3.52 (m, 2H), 3.39 (s, 3H). 
Synthesis of 4-hydroxy-3-[(2-methoxyethoxy)methoxy]pyridine (72)  
 
A mixture of 4-benzyloxy-3-[(2-methoxyethoxy)methoxy]pyridine (71) (5.2 g – 18.4 mmol) 
and 10% Pd/C (520 mg) in methanol (60 ml) was stirred under H2 atmosphere for 1 h. 
Afterward, the catalyst was filtered off and the filtrate was concentrated in vacuo affording the 
product 72 as a white solid (3.57 g – 18.03 mmol, 98%). M.p.= 89.0 °C. TLC (Ethyl Acetate): 
Rf= 0.3. 1H NMR (300 MHz, CDCl3) δ 7.89 (s, 1H), 7.69 (d, J= 6.9 Hz, 1H), 6.67 (d, J= 6.9 
Hz, 1H), 5.24 (s, 2H), 3.86 – 3.81 (m, 2H), 3.58 – 3.48 (m, 2H), 3.35 (s, 3H).  
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Synthesis (S,R)-1-[3-(2-methoxyethoxy)methoxy-4-
pyridyloxymethyl]tetrahydro-1H,3H-pyrrolo[1,2-c]oxazol-3-one [(S,R)-65] 
 
4-hydroxy-3-(2-methoxyethoxy) methoxypyridine (72) (882 mg – 4.43 mmol) was dissolved 
in anhydrous THF (5 mL). Upon addition of triphenylphosphine (1.74 g – 6.65 mmol), the 
reaction mixture was cooled to -10 °C and a solution of (S,R)-1-(hydroxymethyl)tetrahydro-
1H,3H-pyrrolo[1,2-c]oxazol-3-one [(S,R)-61] (696 mg – 4.43 mmol) in THF (5 mL) was added 
dropwise. Afterwards, diisopropyl azodicarboxylate (DIAD) (210 mg – 6.65 mmol) was added 
and the reaction mixture was refluxed for 12 h. Afterward, the solvent was evaporated in vacuo 
providing a residue that was purified by silica gel flash chromatography 
(dichloromethane/methanol 95:5). The pure compound (S,R)-65 was obtained as an orange oil 
(1.2 g – 3.55 mmol, 80%). TLC (Dichloromethane / Methanol 95:5): Rf= 0.31. [α]D25 = -7.6 
(c1, CHCl3). 1H NMR (300 MHz, CDCl3): δ 8.37 (s, 1H, HA), 8.21 (d, J= 5.5 Hz, 1 H, HC), 
6.81 (d, J= 5.5 Hz, 1H, HB), 5.25 (s, 2H, OCH2O-MEM), 5.12 – 5.00 (m, 1H, C*HO), 4.35 – 
4.22 (m, 1H,CH2O), 4.25 – 4.11 (m, 1H, CH2O), 4.15 – 4.00 (m, 1H, C*HN), 3.88 – 3.84 (m, 
2H, CH2OCH2OPy-MEM), 3.67 – 3.58 (m, 1H, CH2N), 3.57 – 3.53 (m, 2H, CH3OCH2-MEM), 
3.35 (s, 3H, CH3O-MEM), 3.24 – 3.16 (m, 1H, CH2N), 2.17 – 2.09 (m, 1H, CH2CH2C*HN), 
1.98 – 1.82 (m, 2H, CH2CH2C*HN), 1.61 – 1.54 (m, 1H, CH2CH2C*HN). 
 
13C NMR (75 MHz, CDCl3): δ 160.47, 155.02, 145.61, 143.61, 140.21, 108.20, 95.47, 73.46, 
71.71, 68.44, 66.85, 61.77, 59.31, 46.67, 25.94, 25.44.  
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Synthesis of (S,R)-N-Methyl-2-[2-(3-(2-methoxyethoxy)methoxy-4-
pyridyloxy)-1-hydroxyethyl]pyrrolidine [(S,R)-66] 
 
A solution of (S,R)-1-[3-(2-methoxyethoxy)methoxy-4-pyridyloxymethyl]tetrahydro-1H,3H-
pyrrolo[1,2-c]oxazol-3-one [(S,R)-65] (1.1 g – 3.25 mmol) in THF (4 mL) was added dropwise 
to a suspension of LiAlH4 (123 mg – 3.25 mmol) in THF (4 mL) under inert atmosphere, at -
10 °C. The reaction mixture was warmed to room temperature and stirred for 2 h. Upon cooling, 
dichloromethane and water were added. The resulting suspension was filtered through a celite 
plug and the filtrate was evaporated in vacuo providing the pure compound (S,R)-66 as a light-
yellow oil (910 mg – 2.79 mmol, 86%). TLC (Dichloromethane / Methanol 8:2 + 3% NH3(30% 
in water)): Rf= 0.68. [α]D25 = -13.2 (c1, CHCl3). 1H NMR (300 MHz, CDCl3): δ 8.35 (s, 1H), 8.19 
(d, J= 5.5 Hz, 1H), 6.84 (d, J= 5.5 Hz, 1H), 5.27 (s, 2H), 4.18 – 4.06 (m, 2H), 3.97 – 3.88 (m, 
1H), 3.87 – 3.82 (m, 2H), 3.57 – 3.52 (m, 2H), 3.38 (s, 3H), 3.19 – 3.08 (m, 1H), 2.46 – 2.33 
(m, 1H), 2.37 (s, 3H), 2.44 – 2.25 (m, 1H), 1.85 – 1.68 (m, 4H). 
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Synthesis of (S,R)-N-methyl-2-[2-(3-hydroxy-4-pyridyloxy)-1-
mesyloxyethyl]pyrrolidine [(S,R)-67] 
 
Mesyl chloride (0.08 mL – 0.810 mmol) was added to a solution of (S,R)-N-Methyl-2-[2-(3-(2-
methoxyethoxy)methoxy-4-pyridyloxy)-1-hydroxyethyl]pyrrolidine [(S,R)-66] (1.00 g – 2.67 
mmol) and triethylamine (0.085 mL – 0.810 mmol) in dichloromethane (5 mL) at -10 °C. Upon 
stirring for 30 min at room temperature, dichloromethane and 10% aqueous solution of 
NaHCO3 were added. The organic phase was separated, dried over anhydrous sodium sulphate, 
and concentrated, affording a residue (1.00 g – 2.67 mmol) that was dissolved in 
dichloromethane (3 mL) and stirred with TFA at room temperature for 3 h. Afterwards, the 
solvent was evaporated in vacuo and the residue was purified by silica gel flash chromatography 
(dichloromethane/methanol 9:1 + 3%NH3(30% in water)). The pure product (S,R)-67 was obtained 
as a pink sticky solid (500 mg – 1.58 mmol, 59%). TLC (Dichloromethane / Methanol 9:1 + 
3% NH3(30% in water)): Rf= 0.47. [α]D25 = +9.2 (c1, MeOH). 1H NMR (CD3OD): δ 7.97 (s, 1H), 
7.93 (d, J= 5.7 Hz, 1H), 7.08 (d, J= 5.7 Hz, 1H), 4.71 (dd, J= 1.4, 11.0 Hz, 1H), 4.39 (dd, J= 
2.4, 11.0 Hz, 1H), 4.22 – 4.14 (m, 1H), 3.32 (s, 3H), 3.18 – 3.10 (m, 1H), 2.51 – 2.40 (m, 1H), 
2.41 (s, 3H), 2.39 – 2.28 (m, 1H), 1.84 – 1.75 (m, 4H). 
Synthesis of (S,S)-3-(N-methyl-2-pyrrolidinyl)-2,3-dihydro-1,4-dioxino[2,3-
c]pyridine [(S,S)-7] 
 
A solution of (S,R)-N-methyl-2-[2-(3-hydroxy-4-pyridyloxy)-1-mesyloxyethyl]pyrrolidine 
[(S,R)-67] (500 mg – 1.58 mmol) in dimethoxyethane (4 mL) was added to a suspension of 
potassium carbonate (642 mg – 4.64 mmol) in dimethoxyethane (1 mL) under inert atmosphere 
and the resulting mixture was refluxed for 16 h. Then, dichloromethane was added and the 
resulting mixture was washed with a 10% NaHCO3 aqueous solution. The separated organic 
layer was dried over Na2SO4, filtered and evaporated in vacuo affording a crude that was 
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purified by silica gel flash chromatography (Dichloromethane / Methanol 9:1 + 3% NH3(30% in 
water)). The pure compound (S,S)-7 was obtained as a white solid (160 mg – 0.73 mmol, 46%). 
TLC (Dichloromethane / Methanol 9:1 + 3% NH3(30% in water)): Rf= 0.47. M.p.= 57.9 °C. [α]D25 
= -93.4 (c1, CHCl3). 1H NMR (300 MHz, CDCl3): δ 8.21 (s, 1H, HA), 8.00 (d, J= 5.5 Hz, 1H, 
HB), 6.78 (d, J= 5.5 Hz, 1H, HC), 4.41 – 4.28 (m, 1H, CH2O), 4.15 – 4.01 (m, 2H, CH2O + 
C*HO), 3.14 – 3.08 (m, 1H, CH2N), 2.61 – 2.51 (m, 1H, C*HN), 2.42 (s, 3H, CH3N), 2.32 –  
2.24 (m, 1H, CH2N), 1.94 – 1.74 (m, 4H, CH2CH2C*HN). 
 
13C NMR (75 MHz, CDCl3): δ 150.05, 143.29, 141.52, 140.06, 112.17, 74.58, 66.78, 65.28, 
57.91, 42.49, 26.94, 23.75. Anal. Calc. for C12H16N2O2: theor. C= 65.43; H= 7.32; N= 12.72; 
found C= 65.32; H= 7.36; N= 12.69. HRMS (ESI+): calc. for C12H17N2O2: theor. 221.12845; 
found [M+H]+: 221.12824. 
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Synthesis of (S,S)/(S,R)-1-(hydroxymethyl)tetrahydro-1H,3H-pyrrolo[1,2-
c]oxazol-3-one [(S,S)-61/(S,R)-61] 
 
A suspension of (S,S)/(S,R)-1-(benzyloxymethyl)tetrahydro-1H, 3Hpyrrolo[1,2-c]oxazol-3-one 
[(S,S)-60/(S,R)-60] (2.37 g – 9.57 mmol) and 10% Pd/C (473 mg) in methanol (50 ml) was 
vigorously stirred under H2 atmosphere for 8 hours. Afterward, the catalyst was removed by 
filtration on a Celite® pad and the solvent was evaporated in vacuo, affording the pure product 
(S,S)-61/(S,R)-61 as a yellow oil (1.2 g – 7.63 mmol, 80%). TLC (Ethyl Acetate): Rf= 0.3. 1H-
NMR (300 MHz, CDCl3): δ 4.73 – 4.67 (m, 0.2H), 4.38 – 4.33 (m, 0.8H), 3.95 – 3.81 (m, 
0.6H), 3.78 – 3.67 (m, 2.4H), 3.57 – 3.47 (m, 1H), 3.40 – 3.08 (m, 3H, 1bs), 1.59 – 1.37 (m, 
1H), 2.13 – 1.66 (m, 3H).   
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Synthesis of (S,S)-1-[3-(2-methoxyethoxy)methoxy-4-
pyridyloxymethyl]tetrahydro-1H,3H-pyrrolo[1,2-c]oxazol-3-one [(S,S)-65]  
 
4-hydroxy-3-(2-methoxyethoxy) methoxypyridine (72) (633 mg – 3.18 mmol) was dissolved 
in anhydrous THF (5 mL). Upon addition of triphenylphosphine (1.25 g – 4.77 mmol), the 
reaction mixture was cooled to -10 °C and a solution of the diastereoisomeric mixture of 
(S,R)/(S,S)-1-(hydroxymethyl)tetrahydro-1H,3H-pyrrolo[1,2-c]oxazol-3-one [(S,S)-61/(S,R)-
61] (500 mg – 3.18 mmol) in THF (5 mL) was added dropwise. Afterwards, diisopropyl 
azodicarboxylate (DIAD) (151 mg – 4.77 mmol) was added and the reaction mixture was 
refluxed for 12 h. Afterwards, the solvent was evaporated in vacuo providing a residue that was 
purified by silica gel flash chromatography (dichloromethane/methanol 95:5). The pure 
compound (S,S)-65 was obtained as a yellow oil (580 mg – 1.71 mmol, 54%). TLC 
(Dichloromethane / Methanol 95:5): Rf= 0.36. [α]D25 = -31.5 (c1, CHCl3). 1H NMR (300 MHz, 
CDCl3): δ 8.37 (s, 1H, HA), 8.22 (d, J= 5.5 Hz, 1H, HB), 6.83 (d, J= 5.5 Hz, 1H, HC), 5.23 (s, 
2H, OCH2O-MEM), 4.69 – 4.65 (m, 1H, C*HO), 4.30 – 4.19 (m, 2H, CH2O), 3.90 – 3.81 (m, 
3H, C*HN + CH2OCH2OPy-MEM), 3.67 – 3.59 (m, 1H, CH2N), 3.59 – 3.54 (m, 2H, 
CH3OCH2-MEM), 3.36 (s, 3H, CH3O-MEM), 3.23 – 3.16 (m, 1H, CH2N), 2.18 – 1.87 (m, 3H, 
CH2CH2C*HN), 1.63 – 1.50 (m, 1H, CH2CH2C*HN).  
 
13C NMR (75 MHz, CDCl3): δ 160.64, 155.48, 145.76, 143.55, 140.84, 108.46, 95.67, 76.84, 
71.72, 69.14, 68,44, 61.99, 53.32, 45.96, 30.90, 25.89.  
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Synthesis of (S,S)-N-Methyl-2-[2-(3-(2-methoxyethoxy)methoxy-4-
pyridyloxy)-1-hydroxyethyl]pyrrolidine [(S,S)-66] 
 
A solution of (S,S)-1-[3-(2-methoxyethoxy)methoxy-4-pyridyloxymethyl]tetrahydro-1H,3H-
pyrrolo[1,2-c]oxazol-3-one [(S,S)-65] (580 mg – 1.71 mmol) in THF (7 mL) was added 
dropwise to a suspension of LiAlH4 (195 mg – 5.14 mmol) in THF (3 mL) under inert 
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atmosphere, at -10 °C. The reaction mixture was warmed to room temperature and stirred for 2 
h. Upon cooling, dichloromethane and water were added. The resulting suspension was filtered 
through a celite plug and the filtrate was evaporated in vacuo providing the product (S,S)-66 as 
a light yellow oil (523 mg – 1.62 mmol, 95%). TLC (Dichloromethane / Methanol 8:2 + 3% 
NH3(30% in water)): Rf= 0.59. [α]D25 = -18.0 (c1, CHCl3). 1H NMR (300 MHz, CDCl3): δ 8.34 (s, 
1H), 8.19 (d, J= 5.5 Hz, 1H), 6.84 (d, J= 5.5 Hz, 1H), 5.27 (s, 2H), 4.06 – 3.99 (m, 2H), 3.90 – 
3.87 (m, 2H), 3.84 – 3.78 (m, 1H), 3.60 – 3.54 (m, 2H), 3.36 (s, 3H), 3.14 – 3.08 (m, 1H), 2.75 
– 2.69 (m, 1H), 2.50 (s, 3H), 2.46 – 2.38 (m, 1H), 2.26 – 1.95 (m, 1H), 1.83 – 1.37 (m, 3H). 
 
    
Synthesis of (S,S)-N-Methyl-2-[2-(3-hydroxy-4-pyridyloxy)-1-
mesyloxyethyl]pyrrolidine [(S,S)-67] 
 
Mesyl chloride (0.1 mL – 0.85 mmol) was added to a solution of (S,S)-N-Methyl-2-[2-(3-(2-
methoxyethoxy)methoxy-4-pyridyloxy)-1-hydroxyethyl]pyrrolidine [(S,S)-66] (230 mg – 0.71 
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mmol) and triethylamine (0.09 ml – 0.85 mmol) in dichloromethane (5 mL) at -10 °C. Upon 
stirring for 30 min at room temperature, dichloromethane and 10% aqueous solution of 
NaHCO3 were added. The organic phase was separated, dried over anhydrous sodium sulphate, 
and concentrated, affording a residue (180 mg) that was dissolved in dichloromethane (3 mL) 
and stirred with TFA (4.5 mmol)  at room temperature for 3 h. Afterwards, the solvent was 
evaporated in vacuo and the residue was purified by silica gel flash chromatography 
(dichloromethane/methanol 9:1 + 3%NH3(30% in water)). The pure product (S,S)-67 was obtained 
as a yellow oil (56 mg – 0.18 mmol, 40%). TLC (Dichloromethane / Methanol 9:1 + 3%NH3(30% 
in water)): Rf= 0.47. [α]D25 = -33.2 (c1, MeOH). 1H NMR (300 MHz, CD3OD): δ 7.92 – 7.90 (m, 
2H), 7.04 (d, J= 3.0 Hz, 1H), 4.68 – 4.59 (m, 1H), 4.37 – 4.16 (m, 2H), 3.29 (s, 3H), 2.93 – 2.88 
(m, 1H), 2.39 (s, 3H), 2.39 – 2.31 (m, 2H), 2.12 – 1.90 (m, 4H). 
Synthesis of (S,R)-3-(N-Methyl-2-pyrrolidinyl)-2,3-dihydro-1,4-dioxino[2,3-
c]pyridine [(S,R)-7] 
 
A solution of (S,S)-N-Methyl-2-[2-(3-hydroxy-4-pyridyloxy)-1-mesyloxyethyl]pyrrolidine 
[(S,S)-67] (50 mg – 0.16 mmol) in dimethoxyethane (4 mL) was added to a suspension of 
potassium carbonate (65 mg – 0.47 mmol) in dimethoxyethane (1 mL) under inert atmosphere 
and the resulting mixture was refluxed for 16 h. Then, dichloromethane was added, and the 
resulting mixture was washed with a 10% NaHCO3 aqueous solution. The organic layer was 
dried over Na2SO4, filtered and evaporated in vacuo affording a crude that was purified by silica 
gel flash chromatography (dichloromethane/methanol 9:1 + 3% NH3(30% in water)). The pure 
compound (S,R)-7 was obtained as a yellow oil (25 mg – 0.11 mmol, 69%). TLC 
(Dichloromethane / Methanol 9:1 + 3% NH3(30% in water)): Rf= 0.39. [α]D25 = +5.2 (c1, CHCl3). 
1H NMR (300 MHz, CDCl3): δ 8.18 (s, 1H, HA), 8.01 (d, J= 5.5 Hz, 1H, HB), 6.78 (d, J= 5.5 
Hz, 1H, HC), 4.38 (dd, J= 11.6, 2.2 Hz, 1H, CH2O), 4.21 (td, J= 7.7, 2.2 Hz, 1H, C*HO), 4.04 
(dd, J= 11.6, 7.7 Hz, 1H, CH2O), 3.16 – 3.11 (m, 1H, CH2N), 2.73 – 2.66 (m, 1H, C*HN), 2.52 
(s, 3H, CH3N), 2.42 – 2.29 (m, 1H, CH2N), 2.03 – 1.91 (m, 1H, CH2CH2C*HN), 1.84 – 1.67 
(m, 3H, CH2CH2C*HN). 
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13C NMR (75 MHz, CDCl3): δ 149.96, 143.48, 141.18, 139.92, 112.20, 76.03, 66.47, 65.10, 
58.01, 42.85, 27.39, 23.73. Anal. Calc. for C12H16N2O2: theor. C= 65.43; H= 7.32; N= 12.72; 
found C= 65.29; H= 7.35; N= 12.70. HRMS (ESI+): calc. for C12H17N2O2: theor. 221.12845; 
found [M+H]+: 221.12823.  
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Synthesis of 4-Chloro-3-[(2-methoxyethoxy)methoxy]pyridine (74)  
 
Procedure adapted from literature.175 Upon cooling to -78 °C, a 1.7 M solution of tert-
butyllithium in n-pentane (3.4 mL – 5.78 mmol) was added dropwise to a stirred solution of 3-
[(2-Methoxyethoxy)methoxy]pyridine (73) (1 g – 5.46 mmol) in diethyl ether (40 mL). After 
30 min, a solution of hexachloroethane (1.75 g – 6.55 mmol) in diethyl ether (5 mL) was added. 
After 30 min, temperature was increased to 20 °C and the reaction mixture was further stirred 
for 1 h. Afterward, 10% aqueous NaHCO3 was added. The organic phase was separated, washed 
with brine, dried over anhydrous sodium sulphate, filtered and evaporated in vacuo, affording 
a crude that was purified through silica gel flash chromatography (40-60 petroleum 
ether/acetone 8:2). The pure product 74 was isolated as a dark yellow oil (1.0 g – 4.91 mmol, 
90%), which is stable if stored as a 50% v/v solution in MTBE at -28 °C. TLC (Toluene / Ethyl 
Acetate 2:8): Rf= 0.30. 1H NMR (300 MHz, CDCl3): δ 8.55 (s, 1H), 8.20 (d, J= 5.1 Hz, 1H), 
7.34 (d, J= 5.1 Hz, 1H), 5.40 (s, 2H), 3.93 – 3.85 (m, 2H), 3.59 – 3.50 (m, 2H), 3.36 (s, 3H).  
Synthesis of 4-Chloro-3-hydroxypyridine hydrochloride (75)  
 
Procedure adapted from literature.178 Upon cooling to -10 °C, a solution 1.25 M of methanolic 
HCl (9.2 mL – 11.5 mmol) was added dropwise to a stirred solution of 4-Chloro-3-[(2-
methoxyethoxy)methoxy]pyridine (74) (500 mg – 2.3 mmol) in methanol (5 mL). After 1 h, the 
reaction mixture was warmed to 20 °C was stirred for 16 h. Afterward, the solvent was 
evaporated in vacuo and the resulting crude product was crystallized in toluene, providing the 
pure product 75 as a white crystalline solid (342 mg – 2.07 mmol, 90%). TLC (40-60 °C 
Petroleum Ether / Acetone 6:4): Rf= 0.33. M.p.= 205.9 °C. 1H NMR (300 MHz, DMSO-d6): 
δ 12.67 (bs, 2H), 8.52 (s, 1H), 8.30 (d, J= 5.9 Hz, 1H), 7.99 (d, J= 5.9 Hz, 1H).  
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Synthesis of 4-chloro-3-hydroxypyridine potassium salt (76) 
 
Upon complete dissolution of compound 4-chloro-3-hydroxypyridine hydrochloride (75) (460 
mg – 2.8 mmol) in the minimum volume possible of methanol, a 1N methanolic solution of 
KOH (5.3 ml – 5.3 mmol) was added dropwise. After 10 min, the mixture was cooled to 0 °C 
and the resulting suspension was filtered. The solid was dried in open air at room temperature, 
affording the product 76 as a beige powder (440 mg – 2.66 mmol, 95%). 1H NMR (300 MHz, 
DMSO-d6): δ 7.44 (s, 1H), 6.92 (d, J= 4.8 Hz, 1H), 6.81 (d, J= 4.8 Hz, 1H). 
Synthesis of (S)-N-Cbz-2-[(4-chloro-3-pyridyloxy)acetyl]pyrrolidine [(S)-68] 
 
Under inert atmosphere and at -10 °C, a solution of 4-chloro-3-hydroxypyridine potassium salt 
(76) (470 mg – 2.82 mmol) in acetone (30 ml) was added dropwise to a solution of (S)-N-
carbobenxyloxy-2-bromoacetylpyrrolidine [(S)-49] (1.09 g – 3.10 mmol) in acetone (10 ml). 
The reaction mixture was stirred for 5 hours at 15-20 °C. Afterward, the solvent was 
concentrated in vacuo, the residue was diluted in ethyl acetate and washed with an aqueous 
solution of NaOH 1 M and then with water.  The organic phase was dried over anhydrous 
sodium sulphate and the solvent was removed in vacuo, providing a crude that was further 
purified through silica gel flash chromatography (gradient from cyclohexane/ethyl acetate 3:7 
to 1:9). The pure product (S)-68 was obtained as a dark yellow oil (510 mg – 1.36 mmol, 48%). 
The enantiomeric excess was evaluated by chiral HPLC analysis. TLC (Cyclohexane / Ethyl 
Acetate 2:8): Rf= 0.26. [α]D25 = -30.9 (c1, CHCl3). e.e. %= 99.50% (Chiracel OJ, hexane/EtOH 
7:3, F= 1.5 ml/min, λ= 280 nm, RtR= 12.93 min, RtS= 7.60 min). 1H NMR (300 MHz, DMSO-
d6, T= 100 °C): δ 8.27 (s, 1H), 8.16 (d, J= 5.0 Hz, 1H), 7.47 (d, J= 5.0 Hz, 1H), 7.35 – 7.26 (m, 
5H), 5.13 (s, 2H), 5.07 (s, 2H), 4.64 – 4.56 (m, 1H), 3.49 – 3.40 (m, 2H), 2.31 – 2.10 (m, 1H), 
2.04 – 1.85 (m, 3H). 
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Chiral HPLC analysis: (S)-N-carbobenzyloxy-2-[2’-(4-chloro-3-
pyridiniloxy)acetyl]pyrrolidine 
 
 
Chiral HPLC analysis: diastereoisomeric mixture of (S)- and (R)-N-carbobenzyloxy-2-[2’-(4-
chloro-3-pyridiniloxy)acetyl]pyrrolidine 
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Synthesis of (S,S)/(S,R)-N-methyl-2-[1-hydroxy-2-(4-chloro-3-
pyridyloxy)ethyl]pyrrolidine [(S,S)-69/(S,R)-69] 
 
Under a nitrogen atmosphere, at -10 °C, a solution of (S)-N-Cbz-2-[(4-chloro-3-
pyridyloxy)acetyl]pyrrolidine [(S)-68] (300 mg – 0.8 mmol) in anhydrous THF (10 ml) was 
added dropwise to a suspension of LiAlH4 (91 mg – 2.4 mmol) in anhydrous THF (2 ml). The 
reaction mixture was refluxed for 3 hours under vigorous stirring. Afterward, the mixture was 
diluted with dichloromethane and the excess of LiAlH4 was quenched by slowly adding water 
dropwise at 0 °C. The resulting suspension was filtered through Celite® and the solvent was 
concentrated in vacuo, affording a crude that was diluted with an aqueous solution of HCl 1 M 
and washed with diethyl ether. The aqueous phase was basified to pH 9 with an aqueous 
solution of NH3 and extracted with ethyl acetate. The organic phase was dried over anhydrous 
sodium sulphate, filtered and the solvent was evaporated in vacuo, affording a crude that was 
purified through silica gel flash chromatography (dichloromethane/methanol 95:5 + 0.5% 
NH3(30% in water)) providing a diastereoisomeric mixture of (S,S)-69 and (S,R)-69 (123 mg – 0.48 
mml, 60%). TLC (Dichloromethane / Methanol 9:1 + 0.5% NH3(30% in water)): Rf1= 0.27, Rf2= 
0.18. 1H NMR (300 MHz, CDCl3): δ 8.32 (s, 1H), 8.12 – 8.18 (m, 1H), 7.22 – 7.31 (m, 1H), 
4.20 – 4.28 (m, 0.8H), 3.99 – 4.14 (m, 1.2H), 4.00 – 4.08 (m, 0.4H), 3.73 – 3.83 (m, 0.6H), 3.10 
– 3.21 (m, 1H), 2.52 – 2.83 (m, 1H), 2.47 (s, 1.2H), 2.43 (s, 1.8H), 2.35 – 2.46 (m, 1H), 1.86 – 
2.06 (m, 1H), 1.74 – 1.85 (m, 3H),  
Synthesis of (S,R)/(S,S)-2-(N-Methyl-2-pyrrolidinyl)-2,3-dihydro-1,4-
dioxino[2,3-c]pyridine [(S,R)-6/(S,S)-6]  
 
Under inert atmosphere, a solution of the diastereoisomeric mixture of (S,S)/(S,R)-N-methyl-2-
[1-hydroxy-2-(4-chloro-3-pyridyloxy)ethyl]pyrrolidine [(S,S)-69/(S,R)-69] (100 mg – 0.4 
mmol) in DMF (2 ml) was added dropwise to a suspension of NaH (10 mg – 0.4 mmol) in DMF 
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(1 ml). The reaction mixture was refluxed overnight. Afterward, the mixture was cooled to 
room temperature, diluted with ethyl acetate and washed with an aqueous solution of NaOH 
1M. The organic phase was dried over anhydrous sodium sulphate, filtered and the solvent was 
removed in vacuo, providing a crude that was purified through silica gel flash chromatography 
(dichloromethane/methanol 9:1 +0.5% NH3(30% in water)). The diastereoisomeric mixture of (S,R)-
6/(S,S)-6 was obtained as a light yellow sticky solid (30 mg – 0.14 mmol, 35%). TLC 
(Dichloromethane / Methanol 9:1 + 2% NH3(30% in water)): Rf1= 0.48, Rf2= 0.46. 1H NMR (300 
MHz, CDCl3): δ 8.22 (s, 0.4H), 8.18 (s, 0.6H), 8.08 – 7.99 (m, 1H), 6.83 (d, J= 5.3 Hz, 0.6H), 
6.78 (d, J= 5.3 Hz, 0.4H), 4.41 – 4.43 (m, 1.6H), 4.22 – 4.16 (m, 0.4H), 4.12 – 3.98 (m, 1H), 
3.18 – 3.08 (m, 1H), 2.60 – 2.45 (m 1H), 2.42 (s, 3H), 2.38 – 2.28 (m 1H), 1.98 – 1.78 (m, 4H). 
13C NMR (75 MHz, CDCl3): δ 149.99, 149.82, 146.75, 143.38, 143.06, 141.25, 139.80, 139.3, 
112.40, 111.94, 75.07, 74.27, 66.53, 65.76, 65.03, 64.97, 57.64, 57.55, 42.21, 42.08, 26.68, 
26.48, 23.49. Anal. Calc. for C12H16N2O2: theor. C= 65.43; H= 7.32; N= 12.72; found C= 65.33; 
H= 7.39; N= 12.71. HRMS (ESI+): calc. for C12H17N2O2: theor. 221.12845; found [M+H]
+: 
221.12825. 
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Synthesis of N-tert-butoxycarbonyl-(S)-proline [(S)-77] 
 
Procedure adapted from literature.179 Upon addition of (S)-proline (10.0 g – 87 mmol) to a 
solution of NaOH (8.7 g – 218 mmol) in H2O (65 ml), the solution was cooled to 10 °C and di-
tert-butyl-dicarbonate (22.8 g – 104 mmol) was added in portions. The resulting suspension 
was warmed to room temperature and stirred for 5 hours. Afterward, diethyl ether was added 
and, upon phase separation, the aqueous phase was cooled to 0 °C, acidified to pH 2 and 
extracted with ethyl acetate. The organic phase was dried over anhydrous sodium sulphate and 
the solvent was evaporated in vacuo, affording a crude that was crystallized from diisopropyl 
ether and isopropanol. The pure compound (S)-77 was isolated as a white solid (17.8 g – 83 
mmol, 95%). M.p. = 136.56 °C; literature180: M.p. = 133 – 135 °C. [α]D25 = - 84.4° (c1, CHCl3); 
literature181: [α]D25 = -54.5° (c1, CHCl3). 1H-NMR (300 MHz, CDCl3): δ 10.48 (bs, 1H), 4.34 
– 4.23 (m, 1H), 3.53 – 3.34 (m, 2H), 2.26 – 1.89 (m, 4H), 1.47 (s, 4H), 1.41 (s, 5H).180  
Synthesis of N-tert-butoxycarbonyl-(R)-proline [(R)-77]  
 
Procedure adapted from literature.179 (R)-proline (10.0 g -87 mmol) was used to synthesize N-
tert-butoxycarbonyl-(R)-proline, according to the procedure reported for the correspondent 
enantiomer (S). The pure product was obtained as a white solid (18.5 g – 86 mmol, 99%). M.p. 
= 136.92 °C; literature182: M.p. = 132.6 – 135.2 °C. [α]D25 = + 84.2° (c1, CHCl3). 1H-NMR 
(300 MHz, CDCl3): δ 10.48 (bs, 1H), 4.34 – 4.23 (m, 1H), 3.53 – 3.34 (m, 2H), 2.26 – 1.89 (m, 
4H), 1.47 (s, 4H), 1.41 (s, 5H).182 
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Synthesis of (S)-N-tert-butoxycarbonyl-diazoproline [(S)-78] 
 
Procedure adapted from literature.73 Upon cooling to -15 °C, triethylamine (3.5 ml – 24 mmol) 
was added dropwise to a suspension of (S)-N-tert-butoxycarbonylproline [(S)-77] (5 g – 23 
mmol) in anhydrous diethyl ether (40 ml). After 5 minutes, isobutylchloroformiate (3.2 ml – 24 
mmol) was added dropwise, maintaining the temperature below -10 °C. After 20 minutes, upon 
formation of the mixed anhydride, controlled by TLC, the mixture was equilibrated to 0 °C and 
the solid was removed by filtration and washed with diethyl ether. The filtrate was cooled to 
0 °C and, under inert atmosphere, an ethereal solution of diazomethane was carefully added 
dropwise over 45 minutes. The reaction mixture was stirred vigorously at room temperature 
overnight. Afterward, the ethereal solution was washed first with a saturated solution of 
NaHCO3 and then with water. The organic phase was dried over anhydrous sodium sulphate, 
filtrated and the solvent was evaporated in vacuo, affording a crude that was purified through 
silica gel flash chromatography (cyclohexane/ethyl acetate 7:3). The pure product (S)-78 was 
isolated as a yellow solid (4.2 g – 18 mmol, 78%). TLC (Dichloromethane / Methanol 95:5; 
staining agent: Blue Shift): Rf= 0.57. TLC (Cyclohexane / Ethyl Acetate 7:3; staining agent: 
Blue Shift): Rf= 0.27. M.p.= 45 °C; literature73: M.p. = 44 – 46 °C. [α]D25 = -144.6 (c1, CHCl3); 
literature183: [α]D25 = -145 (c1, CHCl3). 1H-NMR (CDCl3): δ 5.51 – 5.35 (m, 1H), 4.31 – 4.16 
(m, 1H), 3.56-3.39 (m, 2H), 2.19-1.85 (m, 4H), 1.43 (s, 9H).184 
Synthesis of N-tert-butoxycarbonyl-(R)-diazoproline [(R)-78]1 
 
Procedure adapted from literature.73 N-tert-butoxycarbonyl-(R)-proline [(R)-77] (5.0 g – 20.9 
mmol) was used to synthesize compound N-tert-butoxycarbonyl-(R)-diazoproline, according 
to the procedure reported for the correspondent enantiomer (S). The pure product [(R)-78] was 
obtained as a yellow solid (4.1 g – 17 mmol, 87%). TLC (Cyclohexane / Ethyl Acetate 7:3; 
stained with Blue Shift): Rf= 0.27. M.p.= 45 °C; literature73: M.p. = 45 – 46 °C. [α]D25 = + 
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141.8 (c1, CHCl3); literature
73: [α]D20 = + 146 (c1, CHCl3). 1H-NMR (CDCl3): δ 5.51 – 5.35 
(m, 1H), 4.31 – 4.16 (m, 1H), 3.56-3.39 (m, 2H), 2.19-1.85 (m, 4H), 1.43 (s, 9H).183 
Synthesis of (S)-N-tert-butoxycarbonyl-2-bromoacetylpyrrolidine [(S)-79] 
 
Upon cooling to -10 °C, aqueous HBr (3.6 g – 21 mmol) was added dropwise to a solution of 
N-tert-butoxycarbonyl-(S)-diazoproline [(S)-78] (4.0 g – 17 mmol) in diethyl ether (80 ml). The 
resulting mixture was warmed to room temperature and vigorously stirred for 1 hour. 
Afterward, the mixture is diluted with diethyl ether (40 ml) and washed several times with a 
saturated solution of NaHCO3 and then with water. The organic phase was dried over anhydrous 
sodium sulphate, filtered and the solvent was evaporated in vacuo, affording a crude that was 
purified through silica gel flash chromatography (cyclohexane/ethyl acetate 7:3). The pure 
product [(S)-79] was isolated as a pale yellow oil (3.53 g – 12 mmol, 71%). TLC 
(Cyclohexane/Ethyl Acetate 7:3; stained with Blue Shift): Rf= 0.50. [α]D25 = -67.0 (c1, 
Acetone); literature73: [α]D25 = -66.4 (c1, Acetone). 1H-NMR (300 MHz, CDCl3): δ 4.55 – 4.45 
(m, 1H), 4.17 – 4.02 (m, 2H), 3.56 – 3.41 (m, 2H), 2.29 – 2.12 (m, 1H), 2.05 – 1.87 (m, 3H), 
1.44 (s, 4.5H), 1.41 (s, 4.5H).73 
Synthesis of (R)-N-tert-butoxycarbonyl-2-bromoacetylpyrrolidine [(R)-79] 
 
N-tert-butoxycarbonyl-(R)-diazoproline [(R)-78] (4.0 g – 17 mmol) was used to synthesize 
compound N-tert-butoxycarbonyl-(R)-2-bromoacetylpyrrolidine, according to the procedure 
reported for the correspondent enantiomer (S). The pure product (S)-79 was obtained as a pale 
yellow oil (3.6 g – 12 mmol, 72%). TLC (Cyclohexane / Ethyl Acetate 7:3; stained with Blue 
Shift): Rf= 0.50. [α]D25 = +66.4 (c1, Acetone); literature73: [α]D25 = +66.4 (c1, Acetone). 1H-
NMR (300 MHz, CDCl3): δ 4.55 – 4.45 (m, 1H), 4.17 – 4.02 (m, 2H), 3.56 – 3.41 (m, 2H), 
2.29 – 2.12 (m, 1H), 2.05 – 1.87 (m, 3H), 1.44 (s, 4.5H), 1.41 (s, 4.5H).73  
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Synthesis of 1,3-bis[(2-methoxyethoxy)methoxy]benzene (100) 
 
Procedure adapted from literature.185 Under a nitrogen atmosphere, at 0 °C, N,N-
diisopropylamine (10.0 g – 80 mmol) was added to a solution of resorcinol (4.0 g – 36 mmol) 
in dichloromethane (20 ml). Upon stirring at 0 °C for 10 minutes, methoxyethoxymethylen 
chloride (10.0 g – 80 mmol) were added dropwise. The reaction mixture was warmed to room 
temperature and stirred overnight. Afterward, the mixture was diluted with dichloromethane 
and then sequentially washed with an aqueous solution of HCl 10% and an aqueous solution of 
NaOH 1M. The organic phase was dried over anhydrous sodium sulphate, filtrated and the 
solvent was evaporated in vacuo affording a crude that was purified through silica gel flash 
chromatography (cyclohexane/ethyl acetate 8:2). The pure product 100 was isolated as a pale 
yellow oil (4.7 g – 17 mmol, 46%). TLC (Cyclohexane / Ethyl Acetate 8:2; stained with Blue 
Shift): Rf= 0.26. 1H-NMR (300 MHz, CDCl3): 7.17 (t, J= 7.9 Hz, 1H), 6.75 – 6.70 (m, 3H), 
5.24 (s, 4H), 3.83 – 3.80 (m, 4H), 3.57 – 3.54 (m, 4H), 3.39 – 3.36 (m, 6H).186 
Synthesis of 2,6-bis((2-methoxyethoxy)methoxy)phenol (101) 
 
Under a nitrogen atmosphere, at 0 °C, n-butyllithium 1.6 M  in hexane (1.9 ml – 3.0 mmol) was 
carefully added dropwise to a solution of 1,3-bis[(2-methoxyethoxy)methoxy]benzene (100) 
(1.0 g – 3.6 mmol) in anhydrous THF (12 ml). Upon stirring for 1 hour at room temperature, 
the mixture was cooled to 0 °C and trimethyl borate (620 mg – 6 mmol) was added and the 
resulting solution was stirred for further 30 minutes. Then, the mixture was concentrated in 
vacuo and the residue was dissolved in a solution of NaHCO3 (3.5 g) in aqueous acetone 
(water/acetone 8:2, 13 ml).  Then, Oxone® (0.9 g – 6 mmol) was added and, upon stirring for 
5 minutes, NaHSO3 (0.5 g) was added. Afterward, the reaction mixture was extracted with ethyl 
acetate (2x20 ml). The organic phase was dried over anhydrous sodium sulphate, filtrated and 
evaporated in vacuo, affording a crude that was purified through silica gel flash chromatography 
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(cyclohexane/ethyl acetate 6:4). The pure product 101 was obtained as a pale yellow oil (0.7 g 
– 2.3 mmol, 65%). TLC (Cyclohexane / Ethyl Acetate 6:4): Rf= 0.28. 1H-NMR (300 MHz, 
CDCl3): δ 6.87 – 6.84 (m, 2H), 6.76 – 6.70 (m, 1H), 5.29 (s, 4H), 3.90 – 3.87 (m, 4H), 3.60 – 
3.55 (m, 4H), 3.39 – 3.36 (m, 6H). 
Synthesis of potassium 2,6-bis((2-methoxyethoxy)methoxy)phenolate (102) 
 
A solution of 2,6-bis((2-methoxyethoxy)methoxy)phenol (101) (2.80 g – 9 mmol) in methanol 
(20 ml) was vigorously stirred and cooled to 0 °C and a 1 M methanolic solution of KOH was 
added dropwise (8.3 ml – 8.3 mmol). After 15 minutes, the solvent is evaporated in vacuo 
providing the pure product as a viscous brown oil (3.0 g – 8.8 mmol, 98%). 1H-NMR (300 
MHz, CD3OD): δ 6.74 – 6.71 (m, 2H), 6.71 – 6.34 (m, 1H), 5.19 (s, 4H), 3.87 – 3.83 (m, 4H), 
3.58 – 3.55 (m, 4H), 3.36 – 3.29 (m, 6H). 
Synthesis of (S)-N-tert-butoxycarbonyl-2-[2’-(2,6-bis((2-
methoxyethoxy)methoxy)phenoxy)acetyl]pyrrolidine [(S)-80] 
 
Under a nitrogen atmosphere, at -10 °C, a solution of N-tert-butoxycarbonyl-(S)-2-
bromoacetylpyrrolidine [(S)-79] (0.96 g – 3.3 mmol) in acetone (6 ml) was added to a solution 
of potassium 2,6-bis((2-methoxyethoxy)methoxy)phenolate (102) (0.86 g – 2.5 mmol) in 
acetone (5 ml). The resulting suspension was stirred overnight at room temperature. Afterward, 
the solvent was evaporated in vacuo and the resulting residue was diluted with ethyl acetate and 
washed with water. The organic phase was dried over anhydrous sodium sulphate, filtered and 
the solvent was evaporated in vacuo, affording a crude that was purified through silica gel flash 
chromatography (cyclohexane/ethyl acetate 7:3). The pure solid (S)-80 was isolated as a pale 
yellow oil (1.0 g – 1.95 mmol, 77%). The enantiomeric excess was evaluated with chiral HPLC 
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analysis. TLC (Cyclohexane / Ethyl Acetate 6:4; stained with Blue Shift): Rf= 0.30. 1H-NMR 
(300 MHz, CDCl3): δ 6.99 – 6.90 (m, 1H), 6.89 – 6.83 (m, 2H), 5.27 (s, 4H), 4.71 – 4.66 (m, 
2H), 3.84 – 3.81 (m, 5H), 3.56 – 3.53 (m, 6H), 3.36 (s, 6H), 2.38 – 1.98 (m, 4H), 1.42 (s, 9H).  
Chiral HPLC analysis: (S)-N-tert-butoxycarbonyl-2-[2’-(2,6-bis((2-
methoxyethoxy)methoxy)phenoxy)acetyl]pyrrolidine 
 
e.e. %= 98.6% (Column 5-Amycoat, n-hexane/ethanol 8:2, F= 1.0 ml/min, λ= 220 nm; RtR= 
7.51 min, RtS= 14.62 min) 
Synthesis of (R)-N-tert-butoxycarbonyl-2-[2’-(2,6-bis((2-
methoxyethoxy)methoxy)phenoxy)acetyl]pyrrolidine [(R)-80] 
 
Potassium 2,6-bis((2-methoxyethoxy)methoxy)phenolate 102 (98 mg – 0.3 mmol) and N-tert-
butoxycarbonyl-(R)-2-bromoacetylpyrrolidine [(R)-79] (111 mg – 0.38 mmol) were used to 
synthesize compound (R)-80, according to the procedure reported for the correspondent 
enantiomer (S). The pure product (R)-80 was obtained as a pale yellow oil (109 mg – 0.2 mmol, 
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74%). 1H-NMR (300 MHz, CDCl3): δ 6.99 – 6.90 (m, 1H), 6.89 – 6.83 (m, 2H), 5.27 (s, 4H), 
4.71 – 4.66 (m, 2H), 3.84 – 3.81 (m, 5H), 3.56 – 3.53 (m, 6H), 3.36 (s, 6H), 2.38 – 1.98 (m, 
4H), 1.42 (s, 9H). 
Chiral HPLC analysis: mixture of (R)- and (S)-N-tert-butoxycarbonyl-2-[2’-(2,6-bis((2-
methoxyethoxy)methoxy)phenoxy)acetyl]pyrrolidine 
 
Synthesis of (S,S)/(S,R)-N-tert-butoxycarbonyl-2-[1’-hydroxy-2’-(2,6-bis((2-
methoxyethoxy)methoxy)phenoxy)ethyl]pyrrolidine [(S,S)-81/(S,R)-81] 
 
Under a nitrogen atmosphere, at -10 °C, a solution of (S)-N-tert-butoxycarbonyl-2-[2’-(2,6-
bis((2-methoxyethoxy)methoxy)phenoxy)acetyl]pyrrolidine [(S)-80] (2.5 g – 4.8 mmol) in 20 
ml of anhydrous THF was added dropwise to a suspension of NaBH4 (180 mg – 4.8 mmol) in 
3 ml of anhydrous THF. Upon warming to room temperature, the reaction mixture was stirred 
for 3 hours. Afterward, the mixture was diluted with dichloromethane and washed with brine 
and then with water. The organic phase was dried over anhydrous sodium sulphate, filtered and 
the solvent was evaporated in vacuo. The resulting crude (2.4 g – 4.60 mmol, 97%) was a 
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diastereomeric mixture of (S,S)-81 and (S,R)-81. The two diasteroisomers were separated at the 
last stage of the synthetic route and were further reacted as a diastereoisomeric mixture. TLC 
(Cyclohexane / Ethyl Acetate 6:4): Rf= 0.16. 1H-NMR (300 MHz, CDCl3): δ 6.95 – 6.85 (m, 
3H), 5.29 (s, 4H), 4.27 – 4.23 (m, 1H), 4.12 (m, 1H), 3.92 (m, 2H), 3.86 – 3.82 (m, 4H), 3.78 – 
3.72 (m, 2H), 3.57 – 3.54 (m, 4H), 3.36 (s, 6H), 2.00 – 1.9 (m, 2H), 1.87 – 1.79 (m, 2H), 1.42 
(s, 9H).  
Synthesis of (S,S)/(S,R)-N-tert-butoxycarbonyl-2-[1’-mesyloxy-2’-(2,6-bis((2-
methoxyethoxy)methoxy)phenoxy)ethyl]pyrrolidine [(S,S)-82/(S,R)-82] 
 
A solution of (S,S)/(S,R)-N-tert-butoxycarbonyl-2-[1’-hydroxy-2’-(2,6-bis((2-
methoxyethoxy)methoxy)phenoxy)ethyl]pyrrolidine [(S,S)-81/(S,R)-81] (0.8 g – 1.5 mmol) in 
dichloromethane (8 ml) was cooled to -10 °C and triethylamine (0.26 ml – 180 mg – 1.80 mmol) 
was added. Upon stirring at that temperature for 10 minutes, methanesulphonylchloride (0.13 
ml – 190 mg – 1.70 mmol) was added dropwise. The reaction mixture was warmed to room 
temperature and stirred for 1 hour. Afterward, the mixture was diluted with dichloromethane 
(30 ml) and washed with a 1M aqueous solution of HCl. The organic phase was dried over 
anhydrous sodium sulphate, filtered and the solvent was evaporated in vacuo, affording a crude 
that was purified through silica gel flash chromatography (cyclohexane/ethyl acetate 6:4). The 
diastereoisomeric mixture of (S,S)-82 and (S,R)-82 was isolated as pale yellow oil (460 mg – 
0.80 mmol, 54%). TLC (Cyclohexane / Ethyl Acetate 6:4): Rf= 0.21. 1H-NMR (300 MHz, 
CDCl3): δ 6.99 – 6.89 (m, 1H), 6.86 – 6.82 (m, 2H), 5.27 (s, 4H), 4.21 – 4.11 (m, 1H), 4.12 – 
3.97 (m, 3H), 3.86 – 3.82 (m, 4H), 3.59 – 3.51 (m, 6H), 3.37 (s, 6H), 3.22 (s, 1.5H), 3.18 (s, 
1.5H), 2.10 – 1.9 (m, 2H), 1.83 – 1.79 (m, 2H), 1.42 (s, 9H).   
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Synthesis of (S,S)/(S,R)-2-[1’-mesyloxy-2’-(2,6-
dihydroxy)phenoxyethyl]pyrrolidine [(S,S)-83/(S,R)-83] 
 
Upon cooling to 0 °C, a 1.25 M solution of HCl in methanol (10 ml) were added to a solution 
of (S,S)/(S,R)-N-tert-butoxycarbonyl-2-[1’-mesyloxy-2’-(2,6-bis((2-
methoxyethoxy)methoxy)phenoxy)ethyl]pyrrolidine [(S,S)-82/(S,R)-82] (1.0 g  – 1.6 mmol) in 
methanol (10 ml). The reaction mixture was warmed to room temperature and stirred for 2 
hours. Afterward, the solvent was evaporated in vacuo and the residue was diluted with a 
saturated aqueous solution of NaHCO3 and extracted with ethyl acetate. The organic phase was 
dried over anhydrous sodium sulphate, filtered and the solved was removed in vacuo, providing 
a crude diastereoisomeric mixture of (S,S)-83 and (S,R)-83 as a light yellow oil, which was 
directly used for the following reaction (507 mg – 1.6 mmol, 99%). 
Synthesis of (S,R)/(S,S)-2-(2’-pyrrolidinyl)-5-hydroxy-1,4-benzodioxane 
[(S,R)-84/(S,S)-84] 
 
Under nitrogen atmosphere, at 0 °C, a solution of (S,S)/(S,R)-2-[1’-mesyloxy-2’-(2,6-
dihydroxy)phenoxyethyl]pyrrolidine [(S,S)-83/(S,R)-83] (730 mg – 2.3 mmol) in 
dimethoxyethane (15 ml) and dimethylformamide (10 ml) was added dropwise to a suspension 
of K2CO3 (625 mg – 4.5 mmol) in dimethoxyethane (15 ml). The reaction mixture was refluxed 
under vigorous stirring for 3 hours. Afterward, the solvent was concentrated in vacuo, the 
residue was diluted with diethyl ether and washed with brine. The organic phase was dried over 
anhydrous sodium sulphate, filtered and the solvent was evaporated in vacuo, affording a crude 
that was purified through silica gel flash chromatography (dichloromethane/methanol 97:3 + 
1.5% NH3(30% in water)). The pure diastereoisomeric mixture of (S,R)-84/(S,S)-84 was isolated as 
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a light yellow oil (133 mg – 0.6 mmol, 25%). TLC (Dichloromethane / Methanol 97:3 + 1.5% 
NH3(30% in water)): Rf= 0.20. 1H-NMR (300 MHz, CDCl3): δ 6.57 (t, J= 8.2 Hz, 1H), 6.50 – 6.43 
(m, 2H), 4.36 – 4.15 (m, 1H), 4.12 – 3.98 (m, 2H), 3.35 – 3.22 (m, 1H), 3.15 – 2.84 (m, 3H), 
1.98 – 1.59 (m, 4H). 
Synthesis of (S,R)/(S,S)-2-(N-methyl-2’-pyrrolidinyl)-5-hydroxy-1,4-
benzodioxane [(S,R)-9a/(S,S)-9a] 
 
Under vigorous stirring at 0 °C, an aqueous solution of formaldehyde (37% in water, 0.20 ml – 
69 mg – 2.3 mmol) was added dropwise to a solution of (S,R)/(S,S)-2-(2’-pyrrolidinyl)-5-
hydroxy-1,4-benzodioxane [(S,R)-84/(S,S)-84] (51 mg – 0.23 mmol) in methanol (4 ml) and 
glacial acetic acid (0.02 ml) . Upon addition of 2-picolin borane (25 mg – 0.23 mmol), the 
mixture was warmed to room temperature and stirred for 3 hours. The solvent was evaporated 
in vacuo at 40 °C, the residue was diluted with 5 ml of a 1M HCl solution and stirred for 30 
minutes to quench the unreacted 2-picolin-borane. Then, the aqueous solution was washed 
twice with diethyl ether. The aqueous phase was cooled to 0 °C, basified to pH 9 with NaHCO3 
and extracted with ethyl acetate. The organic phase was dried over anhydrous sodium sulphate, 
filtered and evaporated in vacuo, providing a diastereomeric mixture of (S,R)-9a/(S,S)-9a in a 
44:56 ratio (43 mg – 0.18 mmol), that was further purified through silica gel flash column 
chromatography (dichloromethane/methanol 97:3 + 1.5% NH3(30% in water)). TLC= 
(Dichloromethane / Methanol 97:3 + 1.5% NH3(30% in water)): Rf1= 0.37; Rf2= 0.30. 
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Synthesis of (S,R)-2-(N-methyl-2’-pyrrolidinyl)-5-hydroxy-1,4-
benzodioxane [(S,R)-9a] 
 
The pure (S,R) diastereoisomer (S,R)-9a was obtained as a white solid (15.4 mg – 0.065 mmol, 
36%). TLC= (Dichloromethane / Methanol 97:3 + 1.5% NH3(30% in water)): RfSR= 0.30. M.p.= 
105.2 °C. [α]D25 = +5.97 (c1, MeOH). 1H-NMR (300 MHz, CDCl3): δ 6.71 (t, J= 8.2 Hz, 1H), 
6.50 (dd, J= 8.2, 1.4 Hz, 1H), 6.46 (dd, J= 8.2, 1.4 Hz, 1H), 5.56 (bs, 1H, exchange with D2O), 
4.36 (dd, J= 11.1, 2.1 Hz, 1H), 4.20 (td, J= 7.2, 2.1 Hz, 1H), 4.02 (dd, J= 11.1 Hz, 7.2 Hz, 1H), 
3.12 (m, 1H), 2.67 (m, 1H), 2.50 (s, 3H), 2.30 (q, J= 8.7 Hz, 1H), 2.04 – 1.90 (m, 1H), 1.83 – 
1.68 (m, 3H). 13C-NMR (75 MHz, CDCl3): δ 145.8, 143.9, 131.8, 121.3, 109.5, 107.9, 76.2, 
66.1, 65.1, 57.9, 42.9, 27.1, 23.8. HRMS (ESI+): calc. for C13H18NO3: theor. 236.1287; found 
[M+H]+: 236.1286  
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Synthesis of (S,S)-2-(N-methyl-2’-pyrrolidinyl)-5-hydroxy-1,4-benzodioxane 
[(S,S)-9a] 
 
The pure (S,S) diastereoismer (S,S)-9a was obtained as a white solid (19.6 mg – 0.08 mmol, 
46%). TLC= (Dichloromethane / Methanol 97:3 + 1.5% NH3(30% in water)): RfSS= 0.37. M.p.= 
130.3 °C. [α]D25 = -57.15 (c1, MeOH). 1H-NMR (300 MHz, CDCl3): δ 6.71 (t, J= 8.3 Hz, 1H), 
6.51 (d, J= 8.3, 2H), 5.50 (bs, 1H, exchange with D2O), 4.36 (dd, J= 10.5, 1.4 Hz, 1H), 4.12 
(m, 1H), 4.05 (dd, J= 10.5, 8.0, 1H), 3.13 (m, 1H), 2.56 (m, 1H), 2.44 (s, 3H), 2.37 – 2.18 (m, 
1H), 1.95 – 1.75 (m, 4H). 13C-NMR (75 MHz, CDCl3): δ 145.5, 143.9, 131.4, 121.3, 109.1, 
107.8, 74.1, 66.2, 64.6, 57.9, 42.8, 27.3, 23.7. HRMS (ESI+): calc. for C13H18NO3: theor. 
236.1287; found [M+H]+: 236.1286. 
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Synthesis of 2-((2-methoxyethoxy)methoxy)benzaldehyde (103)  
 
Procedure adapted from literature.187 Under a nitrogen atmosphere, at 0 °C, N,N-
diisopropylamine (9.97 ml – 7.40 g – 57.26 mmol) were added to a stirred solution of 2-
hydroxybenzaldheyde (5 g – 40.9 mmol) in dichloromethane (100 ml). Upon stirring at 0 °C 
for 10 minutes, methoxyethoxymethylen chloride (5.60 ml – 6.11 g – 49.08 mmol) was added 
dropwise and the reaction mixture was warmed to room temperature and stirred overnight. 
Afterward, the reaction mixture was quenched with an aqueous saturated solution of NH4Cl. 
Upon phase separation, the aqueous phase was extracted with dichloromethane (2x25 ml) and 
the organic phases were combined. The latter were subsequently washed with a saturated 
solution of NaHCO3 (3x10 ml), a 1M aqueous solution of NaOH (2x10 ml) and brine (2x10 
ml). The organic phase was dried over anhydrous sodium sulphate, filtered and the solvent was 
evaporated in vacuo, providing the pure product 103 as a light yellow oil (7.43 g – 35.85 mmol, 
87%). TLC (Cyclohexane / Ethyl Acetate 7:3): Rf= 0.42. 1H-NMR (300 MHz, CDCl3) δ 10.49 
(s, 1H), 7.83 (dd, J= 7.8 Hz, J= 1.8 Hz, 1H), 7.53 (dt, J= 8.0 Hz, J= 1.8 Hz, 1H), 7.26 (m, 1H), 
7.08 (dt, J= 7.8 Hz, J= 0.8 Hz, 1H), 5.40 (s, 2H), 3.87 (m, 2H), 3.56 (m, 2H), 3.37 (s, 3H).188  
Synthesis of 2-((2-methoxyethoxy)-methoxy)phenol (104) 
 
Under a nitrogen atmosphere, m-chloro perbenzoic acid (8.49 g – 49.18 mmol) was added to a 
solution of 2-((2-methoxyethoxy)methoxy)benzaldehyde (103) (7.43 g – 35.38 mmol) in 
dichloromethane (30 ml). The resulting reaction mixture was stirred at room temperature for 48 
hours. Afterward, the mixture was cooled to 0 °C, the suspension was filtered through Celite® 
and the white solid was removed. The filtrate was diluted with dichloromethane (20 ml) and 
washed with a saturated aqueous solution of Na2S2O3 and then with brine. The organic phase 
was dried over anhydrous sodium sulphate, filtered and the solvent was evaporated in vacuo. 
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The resulting residue was suspended in a methanolic (31 ml) solution of KOH (3.10 g – 55.20 
mmol) and the resulting reaction mixture was stirred for 5 hours at room temperature. 
Afterward, the mixture was concentrated in vacuo and the resulting residue was diluted with 
water (40 ml) and washed with diethyl ether (3x15 ml). Upon phase separation, the aqueous 
phase was acidified with formic acid until pH 5, extracted with ethyl acetate (3x15 ml) which 
was in turn washed with a saturated solution of NaHCO3. The organic phase was dried over 
anhydrous sodium sulphate, fitrated and the solvent was evaporated in vacuo, providing the 
pure product 104 as a transparent light yellow oil (3.93 g – 19.86 mmol, 56%). TLC 
(Cyclohexane / Ethyl Acetate 7:3): Rf= 0.35. 1H-NMR (300 MHz, CDCl3): δ 7.05 (m, 1H), 
6.94 (m, 2H), 6.81 (m, 1H), 6.35 (bs, 1H), 5.26 (s, 2H), 3.88 (m, 2H), 3.60 (m, 2H), 3.41 (s, 
3H). 
Synthesis of 2-((2-methoxyethoxy)-methoxy)-6-nitrophenol (105) 
 
A solution of 2-((2-methoxyethoxy)-methoxy)phenol (104) (3.93 g – 19.86 mmol) in 
acetonitrile (30 ml) was cooled to 10 °C and a solution of (NH4)2Ce(NO3)6 in acetonitrile (40 
ml) was added dropwise. The reaction mixture was stirred at the same temperature for 3 hours. 
Afterward, the mixture was diluted with water and extracted with ethyl acetate. The organic 
phase was dried over anhydrous sodium sulphate, filtered and the solvent was evaporated in 
vacuo, affording a crude that was purified through silica gel flash chromatography 
(cyclohexane/ethyl acetate 8:2). The pure compound 105 was obtained as a bright yellow oil 
(1.92 g – 7.89 mmol, 40%). TLC (Cyclohexane / Ethyl Acetate 7:3): Rf= 0.33. 1H-NMR (300 
MHz, CDCl3):  10.73 (bs, 1H), 7.78 (dd, J= 8.5 Hz, J= 1.5 Hz, 1H), 7.48 (dd, J= 8.5 Hz, J= 
1.5 Hz, 1H), 6.90 (t, J= 8.5 Hz, 1H), 5.36 (s, 2H), 3.90 (m, 2H), 3.57 (m, 2H), 3.36 (s, 3H).  
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Synthesis of potassium 2-((2-methoxyethoxy)-methoxy)-6-nitrophenolate 
(106) 
 
A solution of 2-((2-methoxyethoxy)-methoxy)-6-nitrophenol (105) (1.92 g – 7.90 mmol) in 
methanol (20 ml) was vigorously stirred and cooled to 0 °C and a 1 M methanolic solution of 
KOH was added dropwise (7.10 ml – 7.10 mmol), forming an orange solution. After 15 minutes, 
the solvent is evaporated in vacuo providing the pure product as an orange solid (2.22 g – 7.90 
mmol, 100%). M.p.= 197.6 °C. 1H-NMR (300 MHz, MeOD):  7.49 (dd, J= 7.0 Hz, J= 0.9 
Hz, 1H), 7.00 (dd, J= 7.0 Hz, J= 0.9 Hz, 1H), 6.15 (t, J= 7.0 Hz, 1H), 5.20 (s, 2H), 3.83 (m, 
2H), 3.56 (m, 2H), 3.29 (s, 3H). 
Synthesis of (S)-N-tert-butoxycarbonyl-2-[2’-(2-(2-methoxyethoxymethoxy)-
6-nitrophenoxy)acetyl]pyrrolidine [(S)-85] 
 
Under a nitrogen atmosphere, at -10 °C, a solution of N-tert-butoxycarbonyl-(S)-2-
bromoacetylpyrrolidine [(S)-79] (2.77 g – 9.50 mmol) in acetone (15 ml) was added to a 
solution of potassium 2-((2-methoxyethoxy)-methoxy)-6-nitrophenolate (106) (2.22 g – 7.90 
mmol) in acetone (20 ml). The resulting suspension was stirred overnight at room temperature. 
Afterward, the solvent was evaporated in vacuo and the resulting residue was diluted with ethyl 
acetate and washed with water. The organic phase was dried over anhydrous sodium sulphate, 
filtered and the solvent was evaporated in vacuo, affording a crude that was purified through 
silica gel flash chromatography (cyclohexane/ethyl acetate 7:3). The pure product (S)-85 was 
isolated as a pale yellow oil (1.49 g – 3.28 mmol, 42%). The enantiomeric excess was evaluated 
with chiral HPLC analysis. TLC (Cyclohexane / Ethyl Acetate 1:1): Rf= 0.45. [α]D25 = -12.30 
(c1, MeOH). 1H-NMR (300 MHz, CDCl3):  7.46 – 7.39 (m, 2H), 7.20 – 7.13 (m, 1H), 5.35 (s, 
0.9H), 5.32 (s, 1.1H), 4.91 (s, 1.1H), 4.86 (s, 0.9H), 4.71 (m, 0.45H), 4.61 (m, 0.55H), 3.84 (m, 
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2H), 3.51 (m, 4H), 3.36 (s, 3H), 2.26 – 2.14 (m, 1H), 2.08 – 2.02 (m, 1H), 1.94 – 1.85 (m, 2H), 
1.45 (s, 4.95H), 1.42 (s, 4.05H). 
Chiral HPLC analysis: (S)-N-tert-butoxycarbonyl-2-[2’-(2-(2-methoxyethoxymethoxy)-6-
nitrophenoxy)acetil]pyrrolidine 
 
e.e. %= 100% (Column Lux 3 µ Cellulose-2, n-hexane/ethanol 8:2, F= 1.0 ml/min, λ=276 nm 
(RtS= 7.75 min, RtR= 8.45 min) 
Synthesis of (R)-N-tert-butoxycarbonyl-2-[2’-(2-(2-methoxyethoxymethoxy)-
6-nitrophenoxy)acetyl]pyrrolidine [(R)-85] 
 
(R)-N-tert-butoxycarbonyl-2-bromoacetylpyrrolidine [(R)-79] (220 mg – 0.75 mmol) and 
potassium 2-(2-methoxyethoxymethoxy)-6-nitrophenolate (106) (236 mg – 0.84 mmol) were 
coupled to synthesize compound (R)-85, according to the procedure reported for the 
correspondent enantiomer (S). The pure product (R)-85 was obtained as a pale yellow oil (90 
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mg – 0.22 mmol, 30%). A mixture of (S)- and (R)- (S)-N-tert-butoxycarbonil-2-[2’-(2-(2-
methoxyethoxymethoxy)-6-nitrophenoxy)acetyl]pyrrolidine was analyzed by chiral HPLC to 
measure the retention times of the two enantiomers. TLC (Cyclohexane / Ethyl Acetate 1:1): 
Rf= 0.45. [α]D25 = +11.92 (c1, MeOH). 1H-NMR (300 MHz, CDCl3):  7.46 – 7.39 (m, 2H), 
7.20 – 7.13 (m, 1H), 5.35 (s, 0.9H), 5.32 (s, 1.1H), 4.91 (s, 1.1H), 4.86 (s, 0.9H), 4.71 (m, 
0.45H), 4.61 (m, 0.55H), 3.84 (m, 2H), 3.51 (m, 4H), 3.36 (s, 3H), 2.26 – 2.14 (m, 1H), 2.08 – 
2.02 (m, 1H), 1.94 – 1.85 (m, 2H), 1.45 (s, 4.95H), 1.42 (s, 4.05H). 
Chiral HPLC analysis: mixture of (R)- and (S)-N-tert-butoxycarbonyl-2-[2’-(2-(2-
methoxyethoxymethoxy)-6-nitrophenoxy)acetyl]pyrrolidine 
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Synthesis of (S,S)/(S,R)-N-tert-butoxycarbonyl-2-[1’-hydroxy-2’-(2-(2-
methoxyethoxymethoxy)-6-nitrophenoxy)ethyl]pyrrolidine [(S,S)-86/(S,R)-
86] 
 
Under a nitrogen atmosphere, at -10 °C, a solution of (S)-N-tert-butoxycarbonyl-2-[2’-(2-(2-
methoxyethoxymethoxy)-6-nitrophenoxy)acetyl]pyrrolidine [(S)-85] (1.19 g – 2.62 mmol) in 
10 ml of anhydrous THF was added dropwise to a suspension of NaBH4 (104.1 mg – 2.75 
mmol) in 2 ml of anhydrous THF. Upon warming to room temperature, the reaction mixture 
was stirred for 3 hours. Afterward, the mixture was diluted with dichloromethane and washed 
with brine and then with water. The organic phase was dried over anhydrous sodium sulphate, 
filtered and the solvent was evaporated in vacuo. The resulting crude (958.6 mg – 2.10 mmol, 
80%) was a diastereomeric mixture of (S,S)-86/(S,R)-86, in a 70:30 ratio. The diastereoisomers 
were separated through silica gel flash chromatography (cyclohexane/ethyl acetate 1:1). TLC 
(Cyclohexane / Ethyl Acetate 3:7): RfSS= 0.62;  RfSR= 0.57. 
Synthesis of (S,S)-N-tert-butoxycarbonyl-2-[1’-hydroxy-2’-(2-(2-
methoxyethoxymethoxy)-6-nitrophenoxy)ethyl]pyrrolidine [(S,S)-86] 
 
The pure (S,S) diastereoisomer (S,S)-86 was obtained as a viscous yellow-ochre oil (680 mg – 
1.49 mmol, 72%). [α]D25 = -63.90 (c1, MeOH). 1H-NMR (300 MHz, CDCl3):  7.43 – 7.36 (m, 
2H), 7.10 (m, 1H), 5.34 (s, 2H), 4.33 (m, 1H), 4.15 – 4.08 (m, 2H), 3.88 – 3.85 (m, 3H), 3.57 – 
3.54 (m, 2H), 3.54 – 3.40 (m, 1H), 3.37 (s, 3H), 3.37 – 3.30 (m, 1H), 2.00-1.89 (m, 3H), 1.83 – 
1.79 (m, 1H), 1.45 (s, 9H).   
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Synthesis of (S,R)-N-tert-butoxycarbonyl-2-[1’-hydroxy-2’-(2-(2-
methoxyethoxymethoxy)-6-nitrophenoxy)ethyl]pyrrolidine [(S,R)-86] 
 
The pure (S,R) diastereoismer (S,R)-86 was obtained as a viscous yellow-ochre viscous oil (270 
mg – 0.59 mmol, 28%). [α]D25 = -19.65 (c1, MeOH). 1H-NMR (300 MHz, CDCl3):  7.45 – 
7.36 (m, 2H), 7.11 (t, J= 8.0 Hz, 1H), 5.34 (s, 2H), 4.34 (m, 1H), 4.12 – 4.02 (m, 2H), 3.87 – 
3.84 (m, 3H), 3.57 – 3.54 (m, 3H), 3.44 (m, 1H), 3.37 (s, 3H), 2.10 (m, 1H), 1.97 – 1.79 (m, 
3H), 1.45 (s, 9H).  
Synthesis of (S,S)-N-tert-butoxycarbonyl-2-[1’-mesyloxy-2’-(2-(2-
methoxyethoxymethoxy)-6-nitrophenoxy)ethyl]pyrrolidine [(S,S)-87] 
 
A solution of (S,S)-N-tert-butoxycarbonyl-2-[1’-hydroxy-2’-(2-(2-methoxyethoxymethoxy)-6-
nitrophenoxy)ethyl]pyrrolidine [(S,S)-86] (660 mg – 1.45 mmol) in dichloromethane (10 ml) 
was cooled to -10 °C and triethylamine (0.40 ml – 293 mg – 2.90 mmol) was added. Upon 
stirring at that temperature for 10 minutes, methanesulphonylchloride (0.22 ml – 332 mg – 2.90 
mmol) were added dropwise. The reaction mixture was warmed to room temperature and stirred 
for 1 hour. Afterward, the mixture was diluted with dichloromethane (30 ml) and washed with 
a 1M aqueous solution of HCl. The organic phase was dried over anhydrous sodium sulphate, 
filtered and the solvent was evaporated in vacuo, affording a yellowish waxy crude that was 
purified through silica gel flash chromatography (cyclohexane/ethyl acetate 6:4). The pure 
product (S,S)-87 was isolated as a white sticky solid (445 mg – 0.83 mmol, 58%). TLC 
(Toluene / Ethyl Acetate 1:1): Rf= 0.62. [α]D25 = -31.77 (c1, MeOH). 1H-NMR (300 MHz, 
CDCl3)  7.41 (m, 2H), 7.15 (m, 1H), 5.35 (s, 2H), 5.20 (m, 1H), 4.39 (m, 1H), 4.26 (m, 2H), 
3.87 – 3.84 (m, 2H), 3.57 – 3.54 (m, 4H), 3.36 (s, 3H), 3.10 (s, 3H), 2.06 (m, 3H), 1.84 (m, 1H), 
1.45 (s, 9H).   
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Synthesis of (S,R)-N-tert-butoxycarbonyl-2-[1’-mesyloxy-2’-(2-(2-
methoxyethoxymethoxy)-6-nitrophenoxy)ethyl]pyrrolidine [(S,R)-87] 
 
A solution of (S,R)-N-tert-butoxycarbonyl-2-[1’-hydroxy-2’-(2-(2-methoxyethoxymethoxy)-
6-nitrophenoxy)ethyl]pyrrolidine [(S,R)-86] (270 mg – 0.59 mmol) in dichloromethane (7 ml) 
was cooled to -10 °C and triethylamine (0.12 ml – 89.5 mg – 0.88 mmol) was added. Upon 
stirring at that temperature for 10 minutes, methanesulphonylchloride (0.07 ml – 101 mg – 0.88 
mmol) were added dropwise. The reaction mixture was warmed to room temperature and stirred 
for 1 hour. Afterward, the mixture was diluted with dichloromethane (30 ml) and washed with 
a 1M aqueous solution of HCl. The organic phase was dried over anhydrous sodium sulphate, 
filtered and the solvent was evaporated in vacuo, affording a yellowish waxy crude that was 
purified through silica gel flash chromatography (cyclohexane/ethyl acetate 6:4). The pure 
product (S,R)-87 was isolated as a yellow-ochre viscous oil (208 mg – 0.39 mmol, 66%). TLC 
(Toluene / Ethyl Acetate 7:3): Rf= 0.45. [α]D25 = -20.81 (c1, MeOH). 1H-NMR (300 MHz, 
CDCl3):  7.47 – 7.38 (m, 2H), 7.19 – 7.12 (m, 1H), 5.55 (m, 1H), 5.39 (s, 2H), 4.40 (m, 1H), 
4.27 (m, 1H), 4.08 (m, 1H), 3.90 (m, 2H), 3.56 (m, 4H), 3.37 (s, 3H), 3.04 (s, 3H), 2.17 – 2.00 
(m, 3H), 1.84 (m, 1H), 1.58 (s, 2.43H), 1.47 (6.57H).  
Synthesis of (S,S)-2-[1’-mesyloxy-2’-(2-hydroxy-6-
nitrophenoxy)ethyl]pyrrolidine [(S,S)-88] 
 
Upon cooling to 0 °C, a 4 M solution of HCl in dioxane (4.15 ml) was added to a solution of 
(S,S)-N-tert-butoxycarbonyl-2-[1’-mesyloxy-2’-(2-(2-methoxyethoxymethoxy)-6-
nitrophenoxy)ethyl]pyrrolidine (S,S)-87 (445 mg – 0.83 mmol) in methanol (3 ml). The reaction 
mixture was warmed to room temperature and stirred for 2 hours. Afterward, the solvent was 
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evaporated in vacuo and the residue was diluted with a saturated aqueous solution of NaHCO3 
and extracted with ethyl acetate. The organic phase was dried over anhydrous sodium sulphate, 
filtered and the solved was removed in vacuo, providing a crude product as a light yellow oil, 
which was directly used for the following reaction (330 mg – 0.95 mmol). TLC 
(Dichloromethane / Methanol 95:5 + 1%NH3(30% in water)): Rf= 0.17 
Synthesis of (S,R)-2-[1’-mesyloxy-2’-(2-hydroxy-6-
nitrophenoxy)ethyl]pyrrolidine [(S,R)-88] 
 
Upon cooling to 0 °C, a 4 M solution of HCl in dioxane (1.0 ml) was added to a solution of 
(S,R)-N-tert-butoxycarbonyl-2-[1’-mesyloxy-2’-(2-(2-methoxyethoxymethoxy)-6-
nitrophenoxy)ethyl]pyrrolidine [(S,R)-87] (208 mg – 0.39 mmol) in methanol (3 ml). The 
reaction mixture was warmed to room temperature and stirred for 2 hours. Afterward, the 
solvent was evaporated in vacuo and the residue was diluted with a saturated aqueous solution 
of NaHCO3 and extracted with ethyl acetate. The organic phase was dried over anhydrous 
sodium sulphate, filtered and the solved was removed in vacuo, providing a crude product as a 
viscous green oil, which was directly used for the following reaction (175 mg – 0.50 mmol). 
TLC (Dichloromethane / Methanol 95:5 + 1%NH3(30% in water)): Rf= 0.15. 
Synthesis of (S,R)-2-(2’-pyrrolidinyl)-5-nitro-1,4-benzodioxane [(S,R)-89] 
 
Under nitrogen atmosphere, at 0 °C, a solution of (S,S)-2-[1’-mesyloxy-2’-(2-hydroxy-6-
nitrophenoxy)ethyl]pyrrolidine [(S,S)-88] (330 mg – 0.95 mmol) in dimethoxyethane (5 ml) 
was added dropwise to a suspension of K2CO3 (236.36 – 1.90 mmol) in dimethoxyethane (3 
ml). The reaction mixture was refluxed under vigorous stirring for 5 hours. Afterward, the 
solvent was concentrated in vacuo, the residue was diluted with dichloromethane and washed 
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with water and then brine. The organic phase was dried over anhydrous sodium sulphate, 
filtered and the solvent was evaporated in vacuo, affording a crude that was purified through 
silica gel flash chromatography (ethyl acetate+ 5% TEA). The pure product (S,R)-89 was 
isolated as a dark yellow oil (207 mg – 0.83 mmol, 87%). TLC (Ethyl Acetate + 5% TEA): 
Rf= 0.40. [α]D25 = -100.49 (c1, MeOH). 1H-NMR (300 MHz, CDCl3):  7.47 (dd, J= 8.2 Hz, 
J= 1.6 Hz, 1H), 7.11 (dd, J= 8.2 Hz, J= 1.6 Hz, 1H), 6.89 (t, J= 8.2 Hz, 1H), 4.54 – 4.50 (m, 
1H), 4.20 – 4.04 (m, 2H), 3.35 (m, 1H), 2.53 (m, 2H), 2.04 – 1.78 (m, 4H). 
Synthesis of (S,S)-2-(2’-pyrrolidinyl)-5-nitro-1,4-benzodioxane [(S,S)-89] 
 
Under nitrogen atmosphere, at 0 °C, a solution of (S,R)-2-[1’-mesyloxy-2’-(2-hydroxy-6-
nitrophenoxy)ethyl]pyrrolidine [(S,R)-88] (174 mg – 0.50 mmol) in dimethoxyethane (5 ml) 
was added dropwise to a suspension of K2CO3 (138.21 mg – 1.0 mmol) in dimethoxyethane (2 
ml). The reaction mixture was refluxed under vigorous stirring for 5 hours. Afterward, the 
solvent was concentrated in vacuo, the residue was diluted with dichloromethane and washed 
with water and then brine. The organic phase was dried over anhydrous sodium sulphate, 
filtered and the solvent was evaporated in vacuo, affording a crude that was purified through 
silica gel flash chromatography (ethyl acetate+ 5% TEA). The pure product (S,S)-89 was 
isolated as a yellow oil (100 mg – 0.40 mmol, 80%). TLC (Ethyl Acetate + 5% TEA): Rf= 
0.42. [α]D25 = -14.74 (c1, MeOH). 1H-NMR (300 MHz, CDCl3):  7.47 (dd, J= 8.2 Hz, J= 1.8 
Hz, 1H), 7.10 (dd, J= 8.2 Hz, J= 1.8 Hz, 1H), 6.88 (t, J= 8.2 Hz, 1H), 4.52 (dd, J= 11.7 Hz, J= 
2.3 Hz, 1H), 4.16 (dd, J= 11.7 Hz, J= 7.6 Hz, 1H), 4.02 (dt, J= 7.6 Hz, J= 2.3 Hz, 1H), 3.37 – 
3.31 (m, 1H), 2.98 – 2.94 (m, 2H), 2.01 – 1.72 (m, 4H). 
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Synthesis of (S,R)-2-(N-methyl-2’-pyrrolidinyl)-5-nitro-1,4-benzodioxane 
[(S,R)-9b] 
 
Under vigorous stirring at 0 °C, an aqueous solution of formaldehyde (37% in water, 0.62 ml – 
249 mg – 8.3 mmol) was added dropwise to a solution of (S,R)-2-(2’-pyrrolidinyl)-5-nitro-1,4-
benzodioxane [(S,R)-89] (207 mg – 0.83 mmol) in methanol (10 ml) and glacial acetic acid 
(0.05 ml) . Upon addition of 2-picolin borane (89 mg – 0.83 mmol), the mixture was warmed 
to room temperature and stirred for 3 hours. The solvent was evaporated in vacuo at 40 °C, the 
residue was diluted with 10 ml of a 1M HCl solution and stirred for 30 minutes to quench the 
unreacted 2-picolin-borane. Then, the aqueous solution was washed twice with diethyl ether. 
The aqueous phase was cooled to 0 °C, basified to pH 11 and extracted with ethyl acetate. The 
organic phase was dried over anhydrous sodium sulphate, filtered and evaporated in vacuo, 
providing a crude that was further purified through preparative TLC (ethyl acetate + 5% TEA). 
The pure compound (S,R)-9b was isolated as orange solid (50.0 mg- 0.19 mmol, 25%). TLC 
(Ethyl Acetate + 5% TEA): Rf= 0.64. M.p.= 77.0 °C. [α]D25 = +40.39 (c1, MeOH). 1H-NMR 
(300 MHz, CDCl3): δ 7.48 (dd, J= 8.3 Hz, J= 1.5 Hz, 1H), 7.12 (dd, J= 8.3 Hz, J= 1.5 Hz, 1H), 
6.88 (t, J= 8.3 Hz, 1H), 4.50 (dd, J= 11.3 Hz, J= 2.1 Hz, 1H), 4.21 (dt, J= 8.0 Hz, J= 2.1 Hz, 
1H), 4.06 (dd, J= 11.3 Hz, J= 8.0 Hz, 1H), 3.13 – 3.07 (m, 1H), 2.71 – 2.64 (m, 1H), 2.48 (s, 
3H), 2.31 (q, J= 9.0 Hz, 1H), 2.01 – 1.91 (m, 1H), 1.82 – 1.65 (m, 3H). 13C-NMR (300 MHz, 
CDCl3): δ 144.93, 138.99, 138.80, 122.11, 120.03, 117.71, 76.19, 66.28, 64.58, 57.88, 42.77, 
27.30, 23.67. HRMS (ESI+): calc. for C13H17N2O4: theor. 265.1188; found [M+H]
+: 265.1183.  
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Synthesis of (S,S)-2-(N-methyl-2’-pyrrolidinyl)-5-nitro-1,4-benzodioxane 
[(S,S)-9b] 
 
Under vigorous stirring at 0 °C, an aqueous solution of formaldehyde (37% in water, 0.30 ml – 
120 mg – 4.0 mmol) was added dropwise to a solution of (S,S)-2-(2’-pyrrolidinyl)-5-nitro-1,4-
benzodioxane [(S,R)-89] (100 mg – 0.40 mmol) in methanol (5 ml) and glacial acetic acid (0.03 
ml). Upon addition of 2-picolin borane (43 mg – 0.40 mmol), the mixture was warmed to room 
temperature and stirred for 3 hours. The solvent was evaporated in vacuo at 40 °C, the residue 
was diluted with 5 ml of a 1M HCl solution and stirred for 30 minutes to quench the unreacted 
2-picolin-borane. Then, the aqueous solution was washed twice with diethyl ether. The aqueous 
phase was cooled to 0 °C, basified to pH 11 and extracted with ethyl acetate. The organic phase 
was dried over anhydrous sodium sulphate, filtered and evaporated in vacuo, providing a crude 
that was further purified through preparative TLC (ethyl acetate + 5% TEA). The pure 
compound (S,S)-9b was isolated as bright yellow oil (50.0 mg- 0.19 mmol, 81%). TLC (Ethyl 
Acetate + 5% TEA): Rf= 0.72. [α]D25 = -90.12 (c1, MeOH). 1H-NMR (300 MHz, CDCl3): δ 
7.46 (dd, J= 8.3 Hz, J= 1.6 Hz, 1H), 7.17 (dd, J= 8.3 Hz, J= 1.6 Hz, 1H), 6.88 (t, J= 8.3 Hz, 
1H), 4.47 (dd, J= 11.3 Hz, J= 2.0 Hz, 1H), 4.20 (ddd, J= 8.3 Hz, J= 3.9 Hz, J= 2.0 Hz, 1H), 
4.07 (dd, J= 11.3 Hz, J= 8.3 Hz, 1H), 3.15 – 3.09 (m, 1H), 2.60 – 2.54 (m, 1H), 2.43 (s, 3H), 
2.32 – 2.24 (m, 1H), 1.94 – 1.24 (m, 4H). 13C-NMR (300 MHz, CDCl3): δ 145.19, 139.09, 
138.80, 122.20, 120.05, 117.59, 73.97, 66.57, 65.00, 57.56, 42.02, 26.36, 23.46. HRMS (ESI+): 
calc. for C13H17N2O4: theor. 265.1188; found [M+H]
+: 265.1185. 
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Synthesis of 2-benzyloxy-6-nitrophenol (107) 
 
Procedure adapted from literature.189 A solution of 2-benzyloxyphenol (5 g – 25 mmol) in 
acetonitrile (40 ml) was cooled to -10 °C. Then, a solution of (NH4)2Ce(NO3)6 (10 g – 18.2 
mmol) in acetonitrile (60 ml) was added dropwise. The reaction mixture was stirred for 3 hours 
at – 10 °C. Afterward, the reaction was diluted with water and extracted three times with ethyl 
acetate. The combined organic phases were dried over anhydrous sodium sulphate, filtrated and 
the solvent was evaporated in vacuo. The resulting crude was purified through silica gel flash 
chromatography (cyclohexane/ethyl acetate 95:5). The pure product 107 was isolated as a bright 
yellow solid (3.56 g – 14.52 mmol, 58%). TLC (Cyclohexane / Ethyl Acetate 7:3): Rf= 0.65. 
M.p.= 97.7 °C. 1H-NMR (300 MHz, CDCl3): δ 10.76 (bs, 1H), 7.71 (dd, J= 8.8 Hz, J= 1.7 Hz, 
1H), 7.47 – 7.33 (m, 5H), 7.16 (dd, J= 8.8 Hz, J= 1.7 Hz, 1H), 6.85 (t, J= 8.8 Hz, 1H), 5.20 (s, 
2H). 
Synthesis of potassium 2-benzyloxy-6-nitrophenolate (108) 
 
A solution of 2-benzyloxy-6-nitrophenol (107) (2.8 g – 11.42 mmol) in methanol (30 ml) was 
vigorously stirred and cooled to 0 °C and a 1 M methanolic solution of KOH was added 
dropwise (17.13 ml – 17.13 mmol). After 15 minutes, the solid is filtered at 0 °C, washed with 
water and air-dried. The pure product 108 was isolated as a bright red solid (2.97 g – 10.49 
mmol, 92%). M.p.= 114.7 °C. 1H-NMR (300 MHz, MeOD): δ 7.47 – 7.39 (m, 3H), 7.35 – 7.22 
(m, 3H), 6.77 (dd, J= 7.7 Hz, J= 1.7 Hz, 1H), 6.18 (t, J= 7.7 Hz, 1H), 5.10 (s, 2H).  
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Synthesis of (S)-N-tert-butoxycarbonyl-2-[2’-(2-benzyloxy-6-
nitrophenoxy)acetyl]pyrrolidine [(S)-90] 
 
Under a nitrogen atmosphere, at -10 °C, a solution of N-tert-butoxycarbonyl-(S)-2-
bromoacetylpyrrolidine [(S)-79] (2.76 g – 9.45 mmol) in acetone (15 ml) was added to a 
suspension of potassium 2-benzyloxy-6-nitrophenolate (108) (2.97 – 10.49 mmol) in acetone 
(20 ml). The resulting suspension was stirred overnight at room temperature. Afterward, the 
solvent was evaporated in vacuo and the resulting residue was diluted with ethyl acetate and 
washed with water. The organic phase was dried over anhydrous sodium sulphate, filtered and 
the solvent was evaporated in vacuo, affording a crude that was purified through silica gel flash 
chromatography (cyclohexane/ethyl acetate 8:2). The pure product (S)-90 was isolated as a 
viscous yellow-ochre oil (3.49 g – 7.64 mmol, 81%). The enantiomeric excess was evaluated 
with chiral HPLC analysis. TLC (Cyclohexane / Ethyl Acetate 7:3): Rf= 0.43. [α]D25 = -15.37 
(c1, MeOH). 1H-NMR (300 MHz, CDCl3): δ 7.38 – 7.31 (m, 6H), 7.20 – 7.09 (m, 2H), 5.17 (s, 
0.66H), 5.12 (s, 1.34H), 4.95 (s, 0.66H), 4.86 (s, 1.34H), 4.61 (m, 0.33H), 4.52 (m, 0.67H), 3.47 
– 3.36 (m, 2H), 2.13 – 2.04 (m, 1H), 1.82 – 1.69 (m, 3H), 1.44 (s, 3H), 1.37 (s, 6H). 
Chiral HPLC analysis: (S)-N-tert-butoxycarbonyl-2-[2’-(2-benzyloxy-6-
nitrophenoxy)acetyl]pyrrolidine 
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e.e. %= 100% (Column Lux 3 µ Cellulose-2, n-hexane/ethanol 8:2, F= 1 ml/min, λ=276 nm 
(RtS= 8.20 min, RtR= 9.05 min) 
Synthesis of (R)-N-tert-butoxycarbonyl-2-[2’-(2-benzyloxy-6-
nitrophenoxy)acetyl]pyrrolidine [(R)-90] 
 
N-tert-butoxycarbonyl-(R)-2-bromoacetylpyrrolidine [(R)-79] (400 mg – 1.37 mmol) and 
potassium 2-benzyloxy-6-nitro-phenolate (108) (430 mg – 1.52 mmol) were coupled to 
synthesize compound (R)-90, according to the procedure reported for the correspondent 
enantiomer (S). The pure product (R)-90 was obtained as a pale yellow oil (326 mg – 0.71 
mmol, 47%). A mixture of (S)- and (R)-N-tert-butoxycarbonyl-2-[2’-(2-benzyloxy-6-
nitrophenoxy)acetyl]pyrrolidine was analyzed by chiral HPLC to measure the retention times 
of the two enantiomers. TLC (Cyclohexane / Ethyl Acetate 7:3): Rf= 0.43.  [α]D25 = +17.41 
(c1, MeOH). 1H-NMR (300 MHz, CDCl3): δ 7.38 – 7.31 (m, 6H), 7.20 – 7.09 (m, 2H), 5.17 (s, 
0.66H), 5.12 (s, 1.34H), 4.95 (s, 0.66H), 4.86 (s, 1.34H), 4.61 (m, 0.33H), 4.52 (m, 0.67H), 3.47 
– 3.36 (m, 2H), 2.13 – 2.04 (m, 1H), 1.82 – 1.69 (m, 3H), 1.44 (s, 3H), 1.37 (s, 6H). 
Chiral HPLC analysis: mixture of (S)- and (R)- N-tert-butoxycarbonyl-2-[2’-(2-benzyloxy-6-
nitrophenoxy)acetyl]pyrrolidine  
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Synthesis of (S,S)/(S,R)-N-tert-butoxycarbonyl-2-[1’-hydroxy-2’-(2-
benzyloxy-6-nitrophenoxy)ethyl]pyrrolidine [(S,S)-92/(S,R)-92] 
 
Under a nitrogen atmosphere, at -10 °C, a solution of (S)-N-tert-butoxycarbonyl-2-[2’-(2-
benzyloxy-6-nitrophenoxy)acetyl]pyrrolidine [(S)-90] (3.49 g – 7.64 mmol) in 30 ml of 
anhydrous THF was added dropwise to a suspension of NaBH4 (300 mg – 8.02 mmol) in 5 ml 
of anhydrous THF. Upon warming to room temperature, the reaction mixture was stirred for 3 
hours. Afterward, the mixture was diluted with dichloromethane and washed with brine and 
then with water. The organic phase was dried over anhydrous sodium sulphate, filtered and the 
solvent was evaporated in vacuo. The resulting crude (3.32 g – 7.25 mmol, 75%) was a 
diastereomeric mixture of (S,S)-92 and (S,R)-92, in a 25:75 ratio. The diastereoisomers were 
separated through silica gel flash chromatography (cyclohexane/ethyl acetate 9:1). TLC 
(Cyclohexane / Ethyl Acetate 7:3): RfSR= 0.51; RfSS= 0.42. 
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Synthesis of (S,S)-N-tert-butoxycarbonyl-2-[1’-hydroxy-2’-(2-benzyloxy-6-
nitrophenoxy)ethyl]pyrrolidine [(S,S)-92] 
 
The pure (S,S) diastereoismer (S,S)-92 was obtained as a viscous yellow oil (674 mg – 1.47 
mmol, 26%). [α]D25 = -42.56 (c1, MeOH). 1H-NMR (300 MHz, CDCl3): δ 7.44 – 7.34 (m, 6H), 
7.16 – 7.06 (m, 2H), 5.16 (s, 2H), 4.37 – 4.30 (m, 1H), 4.14 – 4.08 (m, 2H), 3.85 (m, 1H), 3.48 
– 3.39 (m, 1H), 3.29 – 3.21 (m, 1H), 2.03 – 1.98 (m, 1H), 1.92 – 1.67 (m, 3H), 1.42 (s, 9H). 
Synthesis of (S,R)-N-tert-butoxycarbonyl-2-[1’-hydroxy-2’-(2-benzyloxy-6-
nitrophenoxy)ethyl]pyrrolidine [(S,R)-92] 
 
The pure (S,R) diastereoismer [(S,R)-92] was obtained as a viscous yellow oil (1.95 g – 4.26 
mmol, 74%). [α]D25 = -52.04 (c1, MeOH). 1H-NMR (300 MHz, CDCl3): δ 7.46 – 7.35 (m, 6H), 
7.16 – 7.05 (m, 2H), 5.16 (s, 2H), 4.36 (m, 1H), 4.14 (m, 1H), 4.02 (m, 1H), 3.92 (m, 1H), 3.45 
(m, 1H), 3.28 (m, 1H), 1.93 – 1.80 (m, 3H), 1.78 – 1.72 (m, 1H), 1.44 (s, 9H). 
Synthesis of (S,S)-N-tert-butoxycarbonyl-2-[1’-mesyloxy-2’-(2-benzyloxy-6-
nitrophenoxy)ethyl]pyrrolidine [(S,S)-94] 
 
A solution of (S,S)-N-tert-butoxycarbonyl-2-[1’-hydroxy-2’-(2-benzyloxy-6-
nitrophenoxy)ethyl]pyrrolidine [(S,S)-92] (660 mg – 1.44 mmol) in dichloromethane (7 ml) was 
cooled to -10 °C and triethylamine (0.40 ml – 291.43 mg – 2.88 mmol) was added. Upon stirring 
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at that temperature for 10 minutes, methanesulphonylchloride (0.22 ml – 329.90 mg – 2.88 
mmol) were added dropwise. The reaction mixture was warmed to room temperature and stirred 
for further 2 hours. Afterward, the mixture was diluted with dichloromethane (30 ml) and 
washed with a 1M aqueous solution of HCl. The organic phase was dried over anhydrous 
sodium sulphate, filtered and the solvent was evaporated in vacuo, affording a yellowish waxy 
crude that was purified through silica gel flash chromatography (toluene/ethyl acetate 9:1). The 
pure product (S,S)-94 was isolated as a viscous yellow oil (665 mg – 1.24 mmol, 86%). TLC 
(Toluene / Ethyl Acetate 9:1): Rf= 0.31. [α]D25 = -24.53 (c1, MeOH). 1H-NMR (300 MHz, 
CDCl3): δ 7.44 – 7.34 (m, 6H), 7.22 – 7.13 (m, 2H), 5.33 (m, 1H), 5.16 (s, 2H), 4.41 (m, 1H), 
4.01 (m, 1H), 3.47 – 3.30 (m, 3H), 2.94 (s, 3H), 2.02 – 1.84 (m, 3H), 1.78 – 1.74 (m, 1H), 1.45 
(s, 9H). 
Synthesis of (S,R)-N-tert-butoxycarbonyl-2-[1’-mesyloxy-2’-(2-benzyloxy-6-
nitrophenoxy)ethyl]pyrrolidine [(S,R)-94] 
 
A solution of (S,R)-N-tert-butoxycarbonyl-2-[1’-hydroxy-2’-(2-benzyloxy-6-
nitrophenoxy)ethyl]pyrrolidine [(S,R)-92] (1.70 g – 3.71 mmol) in dichloromethane (20 ml) 
was cooled to -10 °C and triethylamine (0.93 ml – 675.95 mg – 6.68 mmol) was added. Upon 
stirring at that temperature for 10 minutes, methanesulphonylchloride (0.52 ml – 765.20 mg – 
6.68 mmol) were added dropwise. The reaction mixture was warmed to room temperature and 
stirred for further 2 hours. Afterward, the mixture was diluted with dichloromethane (30 ml) 
and washed with a 1M aqueous solution of HCl. The organic phase was dried over anhydrous 
sodium sulphate, filtered and the solvent was evaporated in vacuo, affording a yellowish waxy 
crude that was purified through silica gel flash chromatography (cyclohexane/ethyl acetate 8:2). 
The pure product (S,R)-94 was isolated as a viscous yellow oil (1.17 g – 2.18 mmol, 59%). 
TLC (Cyclohexane / Ethyl Acetate 7:3): Rf= 0.38. [α]D25 = -46.47 (c1, MeOH). 1H-NMR (300 
MHz, CDCl3): δ 7.43 – 7.33 (m, 6H), 7.16 – 7.10 (m, 2H), 5.26 (m, 1H), 5.13 (s, 2H), 4.48 – 
4.42 (m, 1H), 4.29 (m, 1H), 4.08 (m, 1H), 3.40 (m, 1H), 3.23 (m, 1H), 3.02 (s, 3H), 1.90 (m, 
2H), 1.76 (m, 2H), 1.47 (s, 9H). 
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Synthesis of (S,S)-N-tert-butoxycarbonyl-2-[1’-mesyloxy-2’-(2-benzyloxy-6-
aminophenoxy)ethyl]pyrrolidine [(S,S)-96] 
 
A suspension of (S,S)-N-tert-butoxycarbonyl-2-[1’-mesyloxy-2’-(2-benzyloxy-6-
nitrophenoxy)ethyl]pyrrolidine [(S,S)-94] (616 mg – 1.15 mmol) and 5% Pd/C (123.2 mg) in 
methanol (10 ml) was vigorously stirred under H2 atmosphere for 6 hours. Afterward, the 
catalyst was removed by filtration on a Celite® pad and the solvent was evaporated in vacuo, 
affording a crude that was purified through silica gel flash chromatography (cyclohexane/ethyl 
acetate 8:2). The pure product [(S,S)-96] was isolated as a pale yellow oil (350 mg – 0.84 mmol, 
73%). TLC (Cyclohexane / Ethyl Acetate 1:1): Rf= 0.52. [α]D25 = -37.35 (c1, MeOH). 1H-
NMR (300 MHz, CDCl3): δ 6.80 (t, J= 8.0 Hz, 1H), 6.38 (dd, J= 8.0 Hz, J= 1.7 Hz, 1H), 6.28 
(dd, J= 8.0 Hz, J= 1.7 Hz, 1H), 4.95 (m, 1H), 4.45 (m, 1H), 4.07 (m, 2H), 3.43 (m, 1H), 3.28 
(m, 1H), 3.15 (s, 3H), 2.10 – 2.00 (m, 1H), 1.99 – 1.85 (m, 3H), 1.45 (s, 9H). 
Synthesis of (S,R)-N-tert-butoxycarbonyl-2-[1’-mesyloxy-2’-(2-benzyloxy-6-
aminophenoxy)ethyl]pyrrolidine [(S,R)-96] 
 
A suspension of (S,R)-N-tert-butoxycarbonyl-2-[1’-mesyloxy-2’-(2-benzyloxy-6-
nitrophenoxy)ethyl]pyrrolidine [(S,R)-94] (1.07 g – 2.0 mmol) and 5% Pd/C (214 mg) in 
methanol (20 ml) was vigorously stirred under H2 atmosphere for 6 hours. Afterward, the 
catalyst was removed by filtration on a Celite® pad and the solvent was evaporated in vacuo, 
affording a crude that was purified through silica gel flash chromatography (cyclohexane/ethyl 
acetate 8:2). The pure product (S,R)-96 was isolated as a white sticky solid (680 mg – 1.63 
mmol, 82%). TLC (Cyclohexane / Ethyl Acetate 1:1): Rf= 0.58. [α]D25 = -34.43 (c1, MeOH). 
1H-NMR (300 MHz, CDCl3): δ 6.80 (t, J= 8.0 Hz, 1H), 6.38 (dd, J= 8.0 Hz, J= 1.7 Hz, 1H), 
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6.30 (dd, J= 8.0 Hz, J= 1.7 Hz, 1H), 5.09 (m, 1H), 4.48 (m, 1H), 4.15 – 4.00 (m, 2H), 3.50 (m, 
1H), 3.34 (m, 1H), 3.12 (s, 3H), 2.20 – 2.05 (m, 1H), 2.04 – 1.85 (m, 3H), 1.48 (s, 9H). 
Synthesis of (S,R)-2-(N-tert-butoxycarbonyl-2’-pyrrolidinyl)-5-amino-1,4-
benzodioxane [(S,R)-98] 
 
Under nitrogen atmosphere, a solution of (S,S)-N-tert-butoxycarbonyl-2-[1’-mesyloxy-2’-(2-
benzyloxy-6-aminophenoxy)ethyl]pyrrolidine [(S,S)-96] (350 mg – 0.84 mmol) in 
dimethoxyethane (5 ml) was added dropwise to a suspension of K2CO3 (116.23 mg – 0.84 
mmol) in dimethoxyethane (5 ml). The reaction mixture was refluxed under vigorous stirring 
for 7 hours. Afterward, the solvent was concentrated in vacuo, the residue was diluted with 
dichloromethane and washed with brine. The organic phase was dried over anhydrous sodium 
sulphate, filtered and the solvent was evaporated in vacuo, affording a crude that was purified 
through silica gel flash chromatography (cyclohexane/ethyl acetate 8:2). The pure product 
(S,R)-98 was isolated as a creamy-white sticky solid (210 mg – 0.65 mmol, 78%). TLC 
(Cyclohexane / Ethyl Acetate 1:1): Rf= 0.73. [α]D25 = -7.84 (c1, MeOH). 1H-NMR (300 MHz, 
CDCl3): δ 6.69 (t, J= 8.0 Hz, 1H), 6.53 (dd, J= 8.0 Hz, J= 1.7 Hz, 1H), 6.44 (dd, J= 8.0 Hz, J= 
1.7 Hz, 1H), 4.46 – 4.37 (m, 1H), 4.29 – 4.21 (m, 2H), 3.93 (m, 1H), 3.55 – 3.34 (m, 2H), 2.05 
(m, 3H), 1.89 (m, 1H), 1.46 (s, 9H). 
Synthesis of (S,S)-2-(N-tert-butoxycarbonyl-2’-pyrrolidinyl)-5-amino-1,4-
benzodioxane [(S,S)-98] 
 
Under nitrogen atmosphere, a solution of (S,R)-N-tert-butoxycarbonyl-2-[1’-mesyloxy-2’-(2-
benzyloxy-6-aminophenoxy)ethyl]pyrrolidine [(S,R)-96] (680 mg – 1.63 mmol) in 
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dimethoxyethane (8 ml) was added dropwise to a suspension of K2CO3 (225.83 mg – 1.63 
mmol) in dimethoxyethane (5 ml). The reaction mixture was refluxed under vigorous stirring 
for 7 hours. Afterward, the solvent was concentrated in vacuo, the residue was diluted with 
dichloromethane and washed with brine. The organic phase was dried over anhydrous sodium 
sulphate, filtered and the solvent was evaporated in vacuo, affording a crude that was purified 
through silica gel flash chromatography (cyclohexane/ethyl acetate 8:2). The pure product 
[(S,S)-98] was isolated as a white viscous oil (440 mg – 1.37 mmol, 84%). TLC (Cyclohexane 
/ Ethyl Acetate 1:1): Rf= 0.78. [α]D25 = -146.92 (c1, MeOH). 1H-NMR (300 MHz, CDCl3): δ 
6.65 (t, J= 8.0 Hz, 1H), 6.36 (dd, J= 8.0 Hz, J= 1.4 Hz, 1H), 6.33 (dd, J= 8.0 Hz, J= 1.4 Hz, 
1H), 4.36 (m, 1H), 4.08 (m, 1H), 3.97 (m, 2H), 3.49 (m, 1H), 3.38 (m, 1H), 2.21 (m, 1H), 2.02 
– 1.91 (m, 3H), 1.48 (s, 9H). 
Synthesis of (S,R)-2-(N-methyl-2’-pyrrolidinyl)-5-amino-1,4-benzodioxane 
[(S,R)-9c] 
 
Under a nitrogen atmosphere, at -10 °C, a solution of (S,R)-2-(N-tert-butoxycarbonyl-2’-
pyrrolidinyl)-5-amino-1,4-benzodioxane [(S,R)-98] (200 mg – 0.62 mmol) in anhydrous THF 
(5 ml) was added dropwise to a suspension of LiAlH4 (70.6 mg – 1.86 mmol) in anhydrous 
THF (2 ml). The reaction mixture was refluxed for 4 hours under vigorous stirring. Afterward, 
the mixture was diluted with dichloromethane and the excess of LiAlH4 was quenched by 
slowly adding water dropwise at 0 °C. The resulting suspension was filtered through celite and 
the solvent was concentrated in vacuo, affording a crude that was purified through silica gel 
flash chromatography (dichloromethane/methanol 95:5 + 0.5% NH3(30% in water)). The pure 
compound (S,R)-9c was isolated as a beige solid (145 mg – 0.62 mmol, 100%). TLC 
(Dichloromethane / Methanol 95:5 + 0.5% NH3(30% in water)): Rf= 0.23. M.p.= 59.1 °C. [α]D25 = 
+26.86 (c1, MeOH). 1H-NMR (300 MHz, CDCl3): δ 6.64 (t, J= 7.8 Hz, 1H), 6.34 (dd, J= 7.8 
Hz, J= 1.5 Hz, 1H), 6.30 (dd, J= 7.8 Hz, J= 1.5 Hz, 1H), 4.34 (dd, J= 11.1 Hz, J= 2.1 Hz, 1H), 
4.13 (dt, J= 7.3 Hz, J= 2.1 Hz, 1H), 4.00 (dd, J= 11.1 Hz, J= 7.3 Hz, 1H), 3.72 (bs, 2H), 3.12 – 
3.06 (m, 1H), 2.67 – 2.60 (m, 1H), 2.48 (s, 3H), 2.27 (q, J= 8.6 Hz, 1H), 2.00 – 1.89 (m, 1H), 
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1.81 – 1.61 (m, 3H). 13C-NMR (300 MHz, CDCl3): δ 143.50, 135.88, 131.48, 120.95, 107.74, 
107.35, 76.29, 65.62, 64.74, 57.93, 42.65, 27.20, 23.44. HRMS (ESI+): calc. for C13H19N2O2: 
theor. 235.1447; found [M+H]+: 235.1448.  
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Synthesis of (S,S)-2-(N-methyl-2’-pyrrolidinyl)-5-amino-1,4-benzodioxane 
[(S,S)-9c] 
 
Under a nitrogen atmosphere, at -10 °C, a solution of (S,S)-2-(N-tert-butoxycarbonyl-2’-
pyrrolidinyl)-5-amino-1,4-benzodioxane [(S,S)-98] (227 mg – 0.72 mmol) in anhydrous THF 
(5 ml) was added dropwise to a suspension of LiAlH4 (82 mg – 2.13 mmol) in anhydrous THF 
(2 ml). The reaction mixture was refluxed for 4 hours under vigorous stirring. Afterward, the 
mixture was diluted with dichloromethane and the excess of LiAlH4 was quenched by slowly 
adding water dropwise at 0 °C. The resulting suspension was filtered through celite and the 
solvent was concentrated in vacuo, affording a crude that was purified through silica gel flash 
chromatography (dichloromethane/methanol 95:5 + 0.5% NH3(30% in water)). The pure compound 
(S,S)-9c was isolated as a beige solid (140 mg – 0.60 mmol, 83%). TLC (Dichloromethane / 
Methanol 95:5 + 0.5% NH3(30% in water)): Rf= 0.25. M.p.= 104.45 °C. [α]D25 = -127.83 (c1, 
MeOH). 1H-NMR (300 MHz, CDCl3): δ 6.64 (t, J= 8.1 Hz, 1H), 6.39 (dd, J= 8.1 Hz, J= 1.5 
Hz, 1H), 6.30 (dd, J= 8.1 Hz, J= 1.5 Hz, 1H), 4.32 (dd, J= 10.8 Hz, J= 1.8 Hz, 1H), 4.10 (ddd, 
J= 8.0 Hz, J= 4.2, J= 1.8 Hz, 1H), 4.02 (dd, J= 10.8 Hz, J= 8.0 Hz, 1H), 3.72 (bs, 2H), 3.15 – 
3.10 (m, 1H), 2.54 – 2.48 (m, 1H), 2.43 (s, 3H), 2.30 – 2.21 (m, 1H), 1.94 – 1.74 (m, 4H). 13C-
NMR (300 MHz, CDCl3): δ 143.82, 135.94, 131.53, 120.93, 107.65, 107.50, 74.07, 66.00, 
65.29, 57.70, 42.10, 26.46, 23.37. HRMS (ESI+): calc. for C13H19N2O2: theor. 235.1447; found 
[M+H]+: 235.1445.  
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Synthesis of 2-hydroxy-3-phenylbenzaldehyde (109) 
 
Procedure adapted from literature.190 Under inert atmosphere, a solution of 2-phenylphenol (3.4 
g – 20.0 mmol), anhydrous triethylamine (10 ml) and anhydrous MgCl2 (2.9 g – 30.0 mmol) in 
anhydrous THF (60 ml) was stirred for 20 minutes. Paraformaldehyde (4.0 g) was added in 8 
portions (500 mg each) every 6 minutes and the reaction mixture was refluxed for 3 hours. 
Afterwards, upon cooling to room temperature, an aqueous solution 2M of HCl was added to 
reach pH 5 and the mixture was stirred for further 5 minutes. The product was extracted with 
ethyl acetate (3x40 ml) and the organic phase was washed with brine, dried over anhydrous 
sodium sulphate, filtered and the solvent was evaporated under vacuo, affording a crude that 
was purified through silica-gel flash chromatography (cyclohexane/ethyl acetate 9:1). The pure 
product 109 was isolated as a yellow solid (3.49 g – 17.6 mmol, 88%). TLC= (Cyclohexane / 
Ethyl Acetate 9:1): Rf= 0.41. M.p.= 44 °C; literature190: M.p. = 45 °C. 1H-NMR (300 MHz, 
CDCl3) δ 11.54 (s, 1H), 9.97 (s, 1H, exchange with D2O), 7.70 – 7.53 (m, 4H), 7.46 (m, 2H), 
7.38 (m, 1H), 7.12 (t, J = 7.6 Hz, 1H).190 
Synthesis of 2-((2-methoxyethoxy)methoxy)-3-phenylbenzaldehyde (110) 
 
Procedure adapted from literature.191 Under inert atmosphere at 0 °C, a solution of  2-hydroxy-
3-phenylbenzaldehyde (109) (3.0 g – 15.1 mmol) in THF (10 ml) was added dropwise to a 
stirred suspension of NaH (399 mg – 16.6 mmol) in THF (40 ml) and the resulting mixture was 
stirred for 30 minutes. Upon dropwise addition of 2-methoxyethoxymethyl chloride (5.79 g – 
5.31 ml – 46.5 mmol), the mixture was stirred overnight. Afterwards, the solvent was 
evaporated under vacuo, the residue was diluted with an aqueous solution 2M of KOH (50 ml) 
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and the product was extracted with diethyl ether. The organic phase was dried over anhydrous 
sodium sulphate, filtered and the solvent was removed under vacuo, affording a crude that was 
purified through silica gel flash chromatography (gradient cyclohexane/ethyl acetate from 9:1 
to 7:3). The pure product 110 was obtained as a yellow oil (3.07 g – 10.72 mmol, 71%). TLC= 
(Cyclohexane / Ethyl Acetate 9:1): Rf= 0.18. 1H-NMR (300 MHz, CDCl3): δ 10.49 (s, 1H), 
7.87 (dd, J= 7.7, 1.8 Hz, 1H), 7.61 (dd, J= 7.5, 1.8 Hz, 1H), 7.58 – 7.50 (m, 2H), 7.50 – 7.28 
(m, 4H), 4.81 (s, 2H), 3.56 (m, 2H), 3.35 (m, 2H), 3.29 (s, 3H). 
Synthesis of 2-((2-methoxyethoxy)methoxy)-3-phenylphenol (111) 
 
At 0 °C, m-CPBA (964 mg – 5.59 mmol) was added to a solution of 2-((2-
methoxyethoxy)methoxy)-3-phenylbenzaldehyde (110) (640 mg – 2.24 mmol) in ethyl acetate 
(15 ml). The resulting mixture was stirred at room temperature for 72 hours. Afterwards, the 
solvent was evaporated under vacuo and the resulting crude was diluted in DCM (15 ml), 
washed with a saturated solution of NaHCO3 (3x10 ml) and water (10 ml). The organic phase 
was dried over anhydrous sodium sulphate, filtered and the solvent was evaporated under 
vacuo. The resulting crude was dissolved in MeOH and a 2.5 M aqueous solution of NaOH was 
added. Upon stirring for 2 hours, methanol was removed under vacuo and the resulting aqueous 
residue was washed with diethyl ether. The aqueous phase was acidified to pH 5 with aqueous 
formic acid and the product was extracted with diethyl ether. The organic phase was dried over 
anhydrous sodium sulphate, filtered and the solvent was removed under vacuo, affording the 
pure product 111 as a brownish oil (450 mg – 1.64 mmol, 73%). TLC= (Cyclohexane / Ethyl 
Acetate 9:1): Rf= 0.19. 1H-NMR (300 MHz, CDCl3) δ 7.56 (bs, 1H, exchange with D2O), 7.54 
– 7.47 (m, 2H), 7.40 (t, J = 7.6 Hz, 2H), 7.33 (m, 1H), 7.08 (dd, J= 8.1, 7.6 Hz, 1H), 6.97 (dd, 
J= 8.1, 1.7 Hz), 6.84 (dd, J= 7.6, 1.7 Hz, 1H), 4.71 (s, 2H), 3.81 (m, 2H), 3.58 (m, 2H), 3.44 (s, 
3H). 
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Synthesis of 2-((2-methoxyethoxy)methoxy)3-benzyloxy-biphenyl (112) 
 
A solution of 2-((2-methoxyethoxy)methoxy)-3-phenylphenol (111) (570 mg – 2.08 mmol) in 
DMF (10 ml) was added to a suspension of K2CO3 (574 mg – 4.16 mmol) in DMF (20 ml) and 
the resulting mixture was vigorously stirred for 20 minutes. Upon dropwise addition of benzyl 
bromide (462 mg – 0.32 ml – 2.7 mmol), the reaction mixture was warmed to 50 °C and stirred 
for 1.5 hours. Afterwards, the mixture was cooled to room temperature and the solvent was 
concentrated under vacuo. The resulting residue was diluted with diethyl ether and sequentially 
washed with brine, with an aqueous solution of NaOH 2.5 M (2x20 ml), with an aqueous 
solution of HCl 10% and then with water. The organic phase was dried over anhydrous sodium 
sulphate, filtered and the solvent was removed under vacuo, providing the pure compound 112 
as an orange oil (590 mg – 1.62 mmol, 78%). TLC= (Cyclohexane / Ethyl Acetate 9:1): Rf= 
0.29. 1H-NMR (300 MHz, CDCl3): δ 7.58 – 7.50 (m, 2H), 7.49 – 7.27 (m, 8H), 7.13 – 7.05 (m, 
1H), 7.00 – 6.93 (m, 2H), 5.13 (s, 2H), 4.99 (s, 2H), 3.23 – 3.16 (m, 5H), 3.14 – 3.05 (m, 2H). 
Synthesis of 2-benzyloxy-6-phenylphenol (113) 
 
A concentrated (37 %) aqueous solution of HCl (1 ml) was added dropwise to a solution of 2-
((2-methoxyethoxy)methoxy)3-benzyloxy-biphenyl (112) (255 mg – 0.70 mmol) in methanol 
(50 ml). The resulting solution was vigorously stirred at 60 °C for 1 hour. Afterwards, the 
reaction mixture was cooled to room temperature and quenched by carefully adding dropwise 
a saturated aqueous solution of NaHCO3. Methanol was removed in vacuo and the resulting 
aqueous phase was extracted with ethyl acetate. The organic phase was dried over anhydrous 
sodium sulphate, filtered and the solvent was evaporated under vacuo, providing the pure 
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product as a white solid (186 mg – 0.67 mmol, 96%). TLC= (Cyclohexane / Ethyl Acetate 9:1): 
Rf= 0.5. M.p.= 86 °C. 1H-NMR (300 MHz, CDCl3) δ 7.62 (m, 2H), 7.48 – 7.29 (m, 8H), 7.00 
(dd, J= 5.2, 3.2 Hz, 1H), 6.95 – 6.84 (m, 2H), 5.93 (s, 1H, exchange with D2O), 5.17 (s, 2H). 
Synthesis of potassium 2-benzyloxy-6-phenylphenolate (114) 
 
A methanolic solution 1M of KOH (2.52 ml – 2.52 mmol) was added to a solution of 2-
benzyloxy-6-phenylphenol (113) (735 mg – 2.66 mmol) in methanol (0.5 ml). Upon stirring for 
30 minutes, the solvent was removed under vacuo and the residue was diluted with water. The 
resulting suspension was filtered and the pure product 114 was obtained as an grey solid (761 
mg – 2.42 mmol, 91%). M.p.= 83 °C. 1H-NMR (300 MHz, CDCl3) δ 7.5 (d, J= 7.3 Hz, 2H), 
7.47 – 7.26 (m, 8H), 6.98 (dd, J = 7.2, 1.5 Hz, 1H), 6.95 – 6.83 (m, 2H), 5.13 (s, 2H). 
Synthesis of (S)-N-tert-butoxycarbonyl-2-[(2-benzyloxy-6-
phenylphenoxy)acetyl]pyrrolidine [(S)-91] 
 
Under a nitrogen atmosphere, at -10 °C, a solution of N-tert-butoxycarbonyl-(S)-2-
bromoacetylpyrrolidine [(S)-79] (515 mg – 1.76 mmol) in acetone (5 ml) was added to a 
solution of potassium 2-benzyloxy-6-phenylphenolate 114 (530 mg – 1.69 mmol) in acetone (5 
ml). The resulting suspension was stirred at room temperature for 1.5 hours. Afterward, the 
solvent was evaporated in vacuo and the resulting residue was diluted with DCM and washed 
with brine. The organic phase was dried over anhydrous sodium sulphate, filtered and the 
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solvent was evaporated in vacuo, affording a crude that was purified through silica gel flash 
chromatography (gradient from cyclohexane/ethyl acetate 9:1 to ethyl acetate). The pure 
product (S)-91 was isolated as a pale yellow oil (1.49 g – 3.28 mmol, 30%). The enantiomeric 
excess was evaluated with chiral HPLC analysis. TLC (Dichloromethane / Toluene 9:1): Rf= 
0.15. [α]D25 = -5.88 ° (c1, MeOH). 1H-NMR (300 MHz, CDCl3) δ 7.54 (d, J = 7.1 Hz, 2H), 
7.48 – 7.28 (m, 8H), 7.23 – 7.04 (m, 1H), 6.99 (m, 2H), 5.12 (s, 2H), 4.50 (m, 1H), 4.39 (m, 
2H), 3.35 (m, 2H), 1.99 – 1.67 (m, 4H), 1.23 (s, 9H). 
Chiral HPLC analysis: (S)-N-tert-butoxycarbonyl-2-[(2-benzyloxy-6-
phenylphenoxy)acetyl]pyrrolidine 
 
e.e. %= 100% (Column Lux 3 µ Cellulose-1, n-hexane/ethanol 8:2, F= 0.5 ml/min, λ=276 nm 
(RtS= 7.59 min, RtR= 8.45 min) 
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Synthesis of (R)-N-tert-butoxycarbonyl-2-[(2-benzyloxy-6-
phenylphenoxy)acetyl]pyrrolidine [(R)-91] 
 
N-tert-butoxycarbonyl-(R)-2-bromoacetylpyrrolidine [(S)-79] (537 mg – 1.84 mmol) and 
potassium 2-benzyloxy-6-phenylphenolate (114) (550 mg – 1.75 mmol) were coupled to 
synthesize compound (R)-91, according to the procedure reported for the correspondent 
enantiomer (S). The pure product was obtained as a pale yellow oil (299 mg – 0.61 mmol, 35%). 
A mixture of (S)-91 and (R)-91 was analyzed by chiral HPLC to measure the retention times of 
the two enantiomers. TLC (Dichloromethane / Toluene 9:1): Rf= 0.15. 1H-NMR (300 MHz, 
CDCl3) δ 7.54 (d, J = 7.1 Hz, 2H), 7.48 – 7.28 (m, 8H), 7.23 – 7.04 (m, 1H), 6.99 (m, 2H), 5.12 
(s, 2H), 4.50 (m, 1H), 4.39 (m, 2H), 3.35 (m, 2H), 1.99 – 1.67 (m, 4H), 1.23 (s, 9H). 
Chiral HPLC analysis: mixture of (R)- and (S)-N-tert-butoxycarbonyl-2-[(2-benzyloxy-6-
phenylphenoxy)acetyl]pyrrolidine 
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Synthesis of (S,S)/(S,R)-N-tert-butoxycarbonyl-2-[1’-hydroxy-2’-(2-
benzyloxy-6-phenylphenoxy)ethyl]pyrrolidine [(S,S)-93/(S,R)-93] 
 
Under a nitrogen atmosphere, at -10 °C, a solution of (S)-N-tert-butoxycarbonyl-2-[(2-
benzyloxy-6-phenylphenoxy)acetyl]pyrrolidine [(S)-91] (1.48 g – 3.04 mmol) in 9 ml of 
anhydrous THF was added dropwise to a suspension of NaBH4 (209 mg – 8.71 mmol) in 6 ml 
of anhydrous THF. The reaction was stirred for 2 hours at -10 °C. Afterwards, the mixture was 
diluted with dichloromethane and washed with an aqueous solution of HCl 1 M and then with 
water. The organic phase was dried over anhydrous sodium sulphate, filtered and the solvent 
was evaporated in vacuo. The resulting crude (1.31g – 2.68 mmol, 80%) was a diastereomeric 
mixture of (S,S)-93 and (S,R)-93, in a 60:40 ratio. The diastereoisomers were separated through 
silica gel flash chromatography (toluene/ethyl acetate 8:2). TLC (Toluene / Ethyl Acetate 9:1): 
RfSR= 0.45;  RfSS= 0.33.  
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Synthesis of (S,S)-N-tert-butoxycarbonyl-2-[1’-hydroxy-2’-(2-benzyloxy-6-
phenylphenoxy)ethyl]pyrrolidine [(S,S)-93] 
 
The pure (S,S) diastereoisomer (S,S)-93 was obtained as a white sticky solid (360 mg – 0.74 
mmol, 24%). [α]D25 = -22.06 (c1, CHCl3). 1H-NMR  (300 MHz, CDCl3): δ 7.54 (d, J= 7.9 Hz, 
2H), 7.50 – 7.27 (m, 8H), 7.07 (m, 1H), 7.02 – 6.89 (m, 2H), 5.16 (s, 2H), 3.72 (m, 2H), 3.65 – 
3.41 (m, 2H), 3.27 (m, 1H), 3.13 (m, 1H), 1.73 – 1.50 (m, 4H), 1.30 (s, 9H). 
Synthesis of (S,R)-N-tert-butoxycarbonyl-2-[1’-hydroxy-2’-(2-benzyloxy-6-
phenylphenoxy)ethyl]pyrrolidine [(S,R)-93] 
 
The pure (S,R) diastereoisomer (S,R)-93 was obtained as a colourless oil (915 mg – 1.87 mmol, 
62%). [α]D25 = -20.62 (c1, CHCl3). 1H-NMR  (300 MHz, CDCl3) δ 7.57 – 7.53 (m, 2H), 7.48 
(m, 2H), 7.45 – 7.29 (m, 6H), 7.09 (dd, J= 8.5, 7.3 Hz, 1H), 6.99 – 6.94 (m, 2H), 5.15 (s, 2H), 
3.83 (m, 2H), 3.61 (m, 2H), 3.31 (m, 1H), 3.12 (m, 1H), 1.95 – 1.55 (m, 4H), 1.36 (s, 9H). 
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Synthesis of (S,S)-N-tert-butoxycarbonyl-2-[1’-mesyloxy-2’-(2-benzyloxy-6-
phenylphenoxy)ethyl]pyrrolidine [(S,S)-95] 
 
Under inert atmosphere, a solution of (S,S)-N-tert-butoxycarbonyl-2-[1’-hydroxy-2’-(2-
benzyloxy-6-phenylphenoxy)ethyl]pyrrolidine [(S,S)-93] (320 mg – 0.65 mmol) in 
dichloromethane (7 ml) was cooled to 0 °C and triethylamine (0.2 ml – 145 mg – 1.43 mmol) 
was added. Upon stirring at that temperature for 10 minutes, methanesulphonylchloride (0.1 ml 
– 148 mg – 1.29 mmol) was added dropwise. The reaction mixture was warmed to room 
temperature and stirred for further 2 hours. Afterward, the mixture was diluted with 
dichloromethane (30 ml) and washed with a 1M aqueous solution of HCl. The organic phase 
was dried over anhydrous sodium sulphate, filtered and the solvent was evaporated in vacuo, 
affording a yellowish waxy crude that was purified through silica gel flash chromatography 
(gradient from toluene to toluene/ethyl acetate 9:1). The pure product (S,S)-95 was isolated as 
a viscous yellow oil (170 mg – 0.30 mmol, 46%). TLC (Toluene / Ethyl Acetate 9:1): Rf= 0.41. 
[α]D25 = -44.81 (c0.5, CHCl3).1H-NMR (300 MHz, CDCl3) δ 7.41 (m, 10H), 7.10 (m, 1H), 6.97 
(m, 2H), 5.12 (s, 2H), 5.08 – 4.95 (m, 1H), 4.14 – 4.02 (m, 1H), 3.78 (m, 2H), 3.27 (m, 1H), 
3.14 (m, 1H), 2.74 (s, 1.5H), 2.67 (s, 1.5H), 1.94 – 1.73 (m, 2H), 1.73 – 1.55 (m, 2H), 1.44 (s, 
9H).  
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Synthesis of (S,R)-N-tert-butoxycarbonyl-2-[1’-mesyloxy-2’-(2-benzyloxy-6-
phenylphenoxy)ethyl]pyrrolidine [(S,R)-95] 
 
Under inert atmosphere, a solution of (S,R)-N-tert-butoxycarbonyl-2-[1’-hydroxy-2’-(2-
benzyloxy-6-phenylphenoxy)ethyl]pyrrolidine [(S,R)-93] (605 mg – 1.24 mmol) in 
dichloromethane (10 ml) was cooled to 0 °C and triethylamine (0.38 ml – 276 mg – 2.73 mmol) 
was added. Upon stirring at that temperature for 10 minutes, methanesulphonylchloride (0.21 
ml – 310 mg – 2.71 mmol) was added dropwise. The reaction mixture was warmed to room 
temperature and stirred for further 2 hours. Afterward, the mixture was diluted with 
dichloromethane (30 ml) and washed with a 1M aqueous solution of HCl. The organic phase 
was dried over anhydrous sodium sulphate, filtered and the solvent was evaporated in vacuo, 
affording a yellowish waxy crude that was purified through silica gel flash chromatography 
(gradient from toluene to toluene/ethyl acetate 9:1). The pure product (S,R)-95 was isolated as 
a viscous yellow oil (296 mg – 0.52 mmol, 42%). TLC (Toluene / Ethyl Acetate 9:1): Rf= 0.39. 
[α]D25 = -15.10 (c0.5, CHCl3). 1H-NMR (300 MHz, CDCl3): δ 7.58 – 7.29 (m, 10H), 7.14 – 
7.05 (m, 1H), 6.97 (m, 2H), 5.12 (s, 2H), 4.86 (m, 1H), 4.14 (m, 1H), 3.92 (m, 2H), 3.50 – 3.01 
(m, 2H), 2.77 (s, 2H, rotamers), 2.70 (s, 1H, rotamer), 2.01 – 1.68 (m, 4H), 1.38 (s, 9H). 
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Synthesis of (S,S)-N-tert-butoxycarbonyl-2-[1’-mesyloxy-2’-(2-hydroxy-6-
phenylphenoxy)ethyl]pyrrolidine [(S,S)-97] 
 
A suspension of (S,S)-N-tert-butoxycarbonyl-2-[1’-mesyloxy-2’-(2-benzyloxy-6-
phenylphenoxy)ethyl]pyrrolidine [(S,S)-95] (200 mg – 0.35 mmol) and 5% Pd/C (60 mg) in 
methanol (10 ml) was vigorously stirred under H2 atmosphere for 48 hours. Afterward, the 
catalyst was removed by filtration on a Celite® pad and the solvent was evaporated in vacuo, 
affording a crude that was partially purified through silica gel flash chromatography 
(toluene/ethyl acetate 9:1). The product (S,S)-97 was isolated as an oil (154 mg – 0.32 mmol, 
91%) and was further used as a crude for the next step. TLC (Toluene / Ethyl Acetate 9:1): Rf= 
0.13 
Synthesis of (S,R)-N-tert-butoxycarbonyl-2-[1’-mesyloxy-2’-(2-hydroxy-6-
phenylphenoxy)ethyl]pyrrolidine [(S,R)-97] 
 
A suspension of (S,R)-N-tert-butoxycarbonyl-2-[1’-mesyloxy-2’-(2-benzyloxy-6-
phenylphenoxy)ethyl]pyrrolidine [(S,R)-95] (390 mg – 0.69 mmol) and 5% Pd/C (80 mg) in 
methanol (10 ml) was vigorously stirred under H2 atmosphere for 48 hours. Afterward, the 
catalyst was removed by filtration on a Celite® pad and the solvent was evaporated in vacuo, 
affording a crude that was partially purified through silica gel flash chromatography 
(toluene/ethyl acetate 9:1). The product (S,R)-97 was isolated as a brown oil (254 mg – 0.53 
mmol, 77%) and further used as a crude for the next step. TLC (Toluene / Ethyl Acetate 9:1): 
Rf= 0.37. 
  246 
Synthesis of (S,R)-2-(N-tert-butoxycarbonyl-2’-pyrrolidinyl)-5-phenyl-1,4-
benzodioxane [(S,R)-99] 
 
Under nitrogen atmosphere, at 0 °C, a solution of (S,S)-N-tert-butoxycarbonyl-2-[1’-mesyloxy-
2’-(2-hydroxy-6-phenylphenoxy)ethyl]pyrrolidine [(S,S)-97] (154 mg – 0.32 mmol) in 
dimethoxyethane (10 ml) was added dropwise to a suspension of K2CO3 (53 mg – 0.38 mmol) 
in dimethoxyethane (5 ml). The reaction mixture was refluxed under vigorous stirring for 5 
hours. Afterwards, the solvent was concentrated in vacuo, the residue was diluted with 
dichloromethane and washed with water and then brine. The organic phase was dried over 
anhydrous sodium sulphate, filtered and the solvent was evaporated in vacuo, affording a crude 
that was purified through silica gel flash chromatography (gradient toluene/ethyl acetate from 
9:1 to 1:1). The pure product (S,R)-99 was isolated as a brown oil (42 mg –  0.11 mmol, 34%). 
TLC (Toluene / Ethyl Acetate 9:1): Rf= 0.50. [α]D25 = +5.86 ° (c0.5, MeOH). 1H-NMR  (300 
MHz, CDCl3): δ 7.56 – 7.51 (m, 2H), 7.41 (t, J= 7.3 Hz, 2H), 7.34 (m, 1H), 6.92 – 6.86 (m, 
3H), 4.27 (m, 3H), 3.91 (m, 1H), 3.63 – 3.29 (m, 2H), 2.18 – 2.03 (m, 3H), 1.97 – 1.83 (m, 1H), 
1.44 (s, 9H). 
Synthesis of (S,S)-2-(N-tert-butoxycarbonyl-2’-pyrrolidinyl)-5-phenyl-1,4-
benzodioxane [(S,S)-99] 
 
Under nitrogen atmosphere, at 0 °C, a solution of (S,R)-N-tert-butoxycarbonyl-2-[1’-mesyloxy-
2’-(2-hydroxy-6-phenylphenoxy)ethyl]pyrrolidine [(S,R)-97] (240 mg – 0.50 mmol) in 
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dimethoxyethane (10 ml) was added dropwise to a suspension of K2CO3 (83 mg – 0.60 mmol) 
in dimethoxyethane (5 ml). The reaction mixture was refluxed under vigorous stirring for 5 
hours. Afterwards, the solvent was concentrated in vacuo, the residue was diluted with 
dichloromethane and washed with water and then brine. The organic phase was dried over 
anhydrous sodium sulphate, filtered and the solvent was evaporated in vacuo, affording a crude 
that was purified through silica gel flash chromatography (gradient toluene/ethyl acetate from 
9:1 to 1:1). The pure product (S,S)-99 was isolated as a white oil (93 mg – 0.25 mmol, 49%). 
TLC (Toluene / Ethyl Acetate 9:1): Rf= 0.44. [α]D25 = -88.37 (c0.5, MeOH). 1H-NMR (300 
MHz, CDCl3) δ 7.53 (d, J = 7.2 Hz, 2H), 7.41 (t, J= 7.2 Hz, 2H), 7.37 – 7.30 (m, 1H), 6.93 – 
6.87 (m, 3H), 4.35 (dd, J= 11.4, 1.7 Hz , 1H), 4.12 (m, 1H), 4.03 – 3.86 (m, 2H), 3.43 – 3.31 
(m, 2H), 2.31 – 2.21 (m, 1H), 2.02 – 1.85 (m, 3H), 1.45 (s, 9H). 
Synthesis of (S,R)-2-(N-methyl-2’-pyrrolidinyl)-5-phenyl-1,4-benzodioxane 
[(S,R)-9d] 
 
Under a nitrogen atmosphere, at -10 °C, a solution of (S,R)-2-(N-tert-butoxycarbonyl-2’-
pyrrolidinyl)-5-phenyl-1,4-benzodioxane [(S,R)-99] (42 mg – 0.11 mmol) in anhydrous THF 
(2 ml) was added dropwise to a suspension of LiAlH4 (60 mg – 1.58 mmol) in anhydrous THF 
(3 ml). The reaction mixture was refluxed for 2 hours under vigorous stirring. Afterward, the 
mixture was diluted with dichloromethane and the excess of LiAlH4 was quenched by slowly 
adding water dropwise at 0 °C. The resulting suspension was filtered through Celite® and the 
solvent was concentrated in vacuo, affording the pure compound (S,R)-9d as a white oil (28 mg 
– 0.09 mmol, 85%). TLC (Toluene / Ethyl Acetate 9:1 + 0.5% TEA): Rf= 0.26. [α]D25 = 
+14.12 ° (c0.5, CHCl3). 1H-NMR (300 MHz, CDCl3): δ 7.55 (d, J= 7.3 Hz, 2H), 7.42 (t, J= 7.3 
Hz, 2H), 7.33 (t, J= 7.3 Hz, 1H), 6.96 – 6.87 (m, 3H), 4.32 (dd, J= 11.2, 1.8 Hz, 1H), 4.22 (td, 
J = 7.2, 1.8 Hz, 1H), 4.00 (dd, J= 11.2, 7.2 Hz, 1H), 3.21 – 3.07 (m, 1H), 2.68 (m, 1H), 2.54 (s, 
3H), 2.32 (m, 1H), 2.05 – 1.88 (m, 1H), 1.88 – 1.59 (m, 3H). 13C-NMR (75 MHz, CDCl3): δ 
143.58, 140.56, 137.66, 130.57, 129.83, 129.41, 128.02, 127.11, 125.53, 122.58, 121.09, 
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116.67, 76.12, 65.70, 64.88, 57.94, 42.72, 30.31, 29.71, 27.30, 23.42. HRMS (ESI+): calc. for 
C19H22NO2: theor. 296.1651; found [M+H]
+: 296.1645.  
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Synthesis of (S,S)-2-(N-methyl-2’-pyrrolidinyl)-5-phenyl-1,4-benzodioxane 
[(S,S)-9d] 
 
Under a nitrogen atmosphere, at -10 °C, a solution of (S,S)-2-(N-tert-butoxycarbonyl-2’-
pyrrolidinyl)-5-phenyl-1,4-benzodioxane [(S,S)-99] (90 mg – 0.26 mmol) in anhydrous THF (2 
ml) was added dropwise to a suspension of LiAlH4 (44 mg – 1.15 mmol) in anhydrous THF (3 
ml). The reaction mixture was refluxed for 2 hours under vigorous stirring. Afterward, the 
mixture was diluted with dichloromethane and the excess of LiAlH4 was quenched by slowly 
adding water dropwise at 0 °C. The resulting suspension was filtered through Celite® and the 
solvent was concentrated in vacuo, affording a crude that was purified through silica gel flash 
chromatography (toluene/ethyl acetate 9:1 + 0.5% TEA). The pure compound (S,S)-9d was 
isolated as a brownish oil (33 mg – 0.11 mmol, 39%). TLC (Toluene / Ethyl Acetate 9:1 + 
0.5% TEA): Rf= 0.3. [α]D25 = -64.74 ° (c0.5, CHCl3). 1H-NMR  (300 MHz, CDCl3): δ 7.57 – 
7.50 (m, 2H), 7.45 – 7.37 (m, 2H), 7.32 (t, J= 7.3 Hz, 1H), 6.97 (dd, J= 5.7, 4.2 Hz, 1H), 6.90 
(d, J= 5.7 Hz, 1H),  6.89 (d, J= 4.2 Hz, 1H), 4.30  (dd, J= 11.2, 2.2 Hz, 1H), 4.18 (ddd, J = 8.0, 
4.1, 2.2 Hz, 1H), 3.99 (dd, J = 11.2, 8.0 Hz, 1H), 3.23 – 3.05 (m, 1H), 2.59 – 2.47 (m, 1H), 2.45 
(s, 3H), 2.26 (q, J = 8.4 Hz, 1H), 1.99 – 1.70 (m, 4H). 13C-NMR (75 MHz, CDCl3): δ 143.89, 
140.58, 137.69, 130.67, 129.83, 129.40, 128.01, 127.11, 122.57, 121.09, 116.81, 73.45, 65.99, 
65.28, 57.64, 41.86, 29.71, 26.26, 23.33. HRMS (ESI+): calc. for C19H22NO2: theor. 296.1651; 
found [M+H]+: 296.1645. 
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Part 2: α7 nAChRs  
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Synthesis of (E)-3,5-dihydroxy-4’-(2-chloroethyloxy)stilbene (115a) 
 
Procedure adapted from literature.140 K2CO3 (152 mg – 1.1 mmol) was added to a solution of 
resveratrol (228 mg – 1 mmol) in 1.2 ml of anhydrous DMF. After stirring for 20 minutes, 1-
bromo-2-chloroethane (215 mg – 1.5 mmol) was added dropwise and the reaction was stirred 
overnight at 60 °C. After an HCl/AcOEt extraction, the organic phase was dried over NaSO4, 
filtered and evaporated under vacuum. The crude was then purified by flash column 
chromatography (gradient dichloromethane/ethyl acetate from 9:1 to 8.2), affording the desired 
intermediate 115a as a brownish solid (93 mg – 0.32 mmol, 32%). TLC (Dichloromethane / 
Ethyl Acetate 9:1): Rf= 0.22. M.p.= 161 °C. 1H NMR (300 MHz, DMSO): δ 9.20 – 9.13 (s, 
2H, exchange with D2O), 7.49 (d, J = 8.8 Hz, 2H), 7.02 – 6.81 (m, 4H), 6.38 (d, J = 2.2 Hz, 
2H), 6.10 (t, J = 2.2 Hz, 1H), 4.29 – 4.20 (m, 2H), 3.97 – 3.87 (m, 2H). 
Synthesis of (E)-3,5-dimethoxy-4’-(2-chloroethyloxy)stilbene (116a) 
 
Cs2CO3 (717 mg – 2.2 mmol) was added to a stirred solution of (E)-3,5-dihydroxy-4’-(2-
chloroethyloxy)stilbene (115a) (290 mg – 1 mmol) in anhydrous DMF (1.5 ml). The resultant 
mixture was stirred for 20 minutes. Afterward, MeI (312 mg – 2.2 mmol) was added dropwise 
and the reaction mixture was stirred overnight at room temperature. After HCl/EtOAc 
extraction, the organic phase was dried over NaSO4, filtered and concentrated under vacuum. 
The crude residue was then purified by flash column chromatography (cyclohexane/ethyl 
acetate 9:1), affording the desired intermediate 116a as a white solid (287 mg – 0.9 mmol, 
90%). TLC (Cyclohexane / Ethyl acetate 9:1): Rf= 0.37. M.p.= 87 °C. 1H NMR (300 MHz, 
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CDCl3): δ 7.44 (d, J = 8.7 Hz, 2H), 7.03 (d, J = 16.3 Hz, 1H), 6.96 – 6.85 (m, 3H), 6.64 (d, J = 
2.2 Hz, 2H), 6.37 (t, J = 2.2 Hz, 1H), 4.25 (t, J = 5.9 Hz, 2H), 3.85 – 3.79 (m, 8H). 
Synthesis of (E)-3,5-dimethoxy-4’-(2-iodoethyloxy)stilbene (117a) 
 
Procedure adapted from Literature.140 Intermediate (E)-3,5-dimethoxy-4’-(2-
chloroethyloxy)stilbene (116a) (319 mg – 1 mmol) was dissolved in a saturated solution of NaI 
in acetone (10 ml), which was then refluxed overnight. After concentrating under vacuum, the 
residue was diluted with diethyl ether and subsequently washed with 10% aqueous Na2S2O5 
and then with brine. The organic phase was dried over Na2SO4, filtered, and the solvent was 
evaporated under vacuum to give the desired intermediate 117a as a white solid (398 mg – 0.97 
mmol, 97%). TLC (Cyclohexane / Ethyl acetate 9:1): Rf= 0.43. M.p.= 83 °C. 1H NMR (300 
MHz, CDCl3): δ 7.44 (d, J = 8.8 Hz, 2H), 7.03 (d, J = 16.3 Hz, 1H), 6.91 (m 3H), 6.64 (d, J = 
2.2 Hz, 2H), 6.38 (t, J = 2.2 Hz, 1H), 4.27 (t, J = 6.9 Hz, 2H), 3.82 (s, 6H), 3.45 – 3.39 (t, J = 
6.9 Hz, 2H). 
Synthesis of (E)-3,5-dimethoxy-4’-(2-triethylammoniumethyloxy)stilbene 
iodide (13) 
 
The intermediate (E)-3,5-dimethoxy-4’-(2-iodoethyloxy)stilbene (117a) (410 mg – 1 mmol) 
was dissolved in 3 ml of triethylamine and 3 ml of toluene and stirred at reflux temperature for 
5 hours. Upon concentration under vacuum, the residue was diluted with diethyl ether and the 
obtained suspension was filtered, affording the desired product 13 as a solid (455 mg – 0.89 
mmol, 89%). M.p.= 169 °C. 1H NMR (300 MHz, DMSO): δ 7.56 (d, J = 8.7 Hz, 2H), 7.22 (d, 
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J = 16.4 Hz, 1H), 7.02 (m,  3H), 6.73 (d, J = 2.2 Hz, 2H), 6.38 (t, J = 2.2 Hz, 1H), 4.40 (t, J = 
4.6 Hz, 2H), 3.76 (s, 6H), 3.67 (t, J = 4.6 Hz, 2H), 3.37 (q, J = 7.1 Hz, 6H), 1.22 (t, J = 7.1 Hz, 
9H). 13C NMR (75 MHz, DMSO): δ 161.11, 157.55, 139.75, 130.90, 128.79, 128.29, 127.11, 
115.35, 104.69, 100.04, 61.51, 55.66, 53.37, 7.76. Anal. Calc. for C24H34INO3: theor. C= 56.36; 
H= 6.70; N= 2.74; I= 24.81; found C= 56.20; H= 6.72; N= 2.73; I= 24.66. HRMS (ESI+): calc. 
for C24H34NO3: theor. 384.2539; found [M]
+: 384.2538.  
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Synthesis of (E)-3,5-dihydroxy-4’-(4-chlorobutyloxy)stilbene (115c) 
 
Procedure adapted from literature.140 K2CO3 (152 mg – 1.1 mmol) was added to a solution of 
resveratrol (228 mg – 1 mmol) in 1.2 ml of anhydrous DMF. After stirring for 20 minutes, 1-
bromo-4-chlorobutane (257 mg – 1.5 mmol) was added dropwise and the reaction was stirred 
overnight at 60 °C. After an HCl/AcOEt extraction, the organic phase was dried over NaSO4, 
filtered and evaporated under vacuum. The crude was then purified by flash column 
chromatography (gradient from dichloromethane to dichloromethane/methanol 9:1), affording 
the desired intermediate 115c as a brownish solid (95 mg – 0.30 mmol, 30%). TLC 
(Dichloromethane / Methanol 9:1): Rf= 0.54. M.p.= 148 °C. 1H NMR (300 MHz, DMSO): δ 
9.18 (s, 2H, exchange with D2O), 7.48 (d, J = 8.7 Hz, 2H), 6.91 (m, 4H), 6.38 (d, J = 2.0 Hz, 
2H), 6.10 (t, J = 2.0 Hz, 1H), 4.00 (t, J = 5.9 Hz, 2H), 3.70 (t, J = 5.9 Hz, 2H), 1.97 – 1.70 (m, 
4H).140 
Synthesis of (E)-3,5-dimethoxy-4’-(4-chlorobutyloxy)stilbene (116c) 
 
Cs2CO3 (701 mg – 2.2 mmol) was added to a stirred solution of (E)-3,5-dihydroxy-4’-(4-
chlorobutyloxy)stilbene (115c) (319 mg – 1 mmol) in anhydrous DMF (1.5 ml). The resultant 
mixture was stirred for 20 minutes. Afterward, MeI (312 mg – 2.2 mmol) was added dropwise 
and the reaction mixture was stirred overnight at room temperature. After HCl/EtOAc 
extraction, the organic phase was dried over NaSO4, filtered and concentrated under vacuum. 
The crude residue was then purified by flash column chromatography (cyclohexane/ethyl 
acetate 95:5), affording the desired intermediate 116c as a pale yellow solid (219 mg – 0.63 
mmol, 63%). TLC (Cyclohexane / Ethyl acetate 95:5): Rf= 0.22. M.p.= 77 °C. 1H NMR (300 
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MHz, CDCl3): δ 7.43 (d, J = 8.6 Hz, 2H), 7.03 (d, J = 16.2 Hz, 1H), 6.95 – 6.81 (m, 3H), 6.65 
(d, J = 1.9 Hz, 2H), 6.37 (t, J = 1.9 Hz, 1H), 4.03 (d, J = 5.8 Hz, 2H), 3.83 (s, 6H), 3.63 (t, J = 
5.8 Hz, 2H), 1.97 (m, 4H). 
Synthesis of (E)-3,5-dimethoxy-4’-(4-iodobutyloxy)stilbene (117c) 
 
Procedure adapted from literature.140 Intermediate (E)-3,5-dimethoxy-4’-(4-
chlorobutyloxy)stilbene (116c) (347 mg – 1 mmol) was dissolved in a saturated solution of NaI 
in acetone (10 ml), which was then refluxed overnight. After concentrating under vacuum, the 
residue was diluted with diethyl ether and subsequently washed with 10% aqueous Na2S2O5 
and then with brine. The organic phase was dried over Na2SO4, filtered, and the solvent was 
evaporated under vacuum to give the desired intermediate 117c as a white solid (421 mg – 0.96 
mmol, 96%). TLC (Cyclohexane / Ethyl acetate 9:1): Rf= 0.36. M.p.= 87 °C. 1H NMR (300 
MHz, CDCl3): δ 7.43 (d, J = 8.7 Hz, 2H), 7.03 (d, J = 16.3 Hz, 1H), 6.96 – 6.76 (m, 3H), 6.65 
(d, J = 2.2 Hz, 2H), 6.38 (t, J = 2.2 Hz, 1H), 4.01 (t, J = 6.0 Hz, 2H), 3.83 (s, 6H), 3.27 (t, J = 
6.8 Hz, 2H), 2.14 – 1.85 (m, 4H). 
Synthesis of (E)-3,5-dimethoxy-4’-(4-triethylammoniumbutyloxy)stilbene 
iodide (17) 
 
The intermediate (E)-3,5-dimethoxy-4’-(4-iodobutyloxy)stilbene (117c) (438 mg – 1 mmol) 
was dissolved in 3 ml of triethylamine and 3 ml of toluene and stirred at reflux temperature for 
5 hours. Upon concentration under vacuum, the residue was diluted with diethyl ether and the 
obtained suspension was filtered, affording the desired product 17 as a solid (496 mg – 0.92 
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mmol, 92%). M.p.= 138 °C. 1H NMR (300 MHz, MeOD): δ 7.54 – 7.43 (m, 2H), 7.10 (d, J = 
16.3 Hz, 1H), 7.01 – 6.86 (m, 3H), 6.69 (d, J = 2.2 Hz, 2H), 6.37 (t, J = 2.2 Hz, 1H), 4.05 (t, J= 
5.4 Hz, 2H), 3.79 (s, 6H),  3.37 – 3.25 (m, 8H), 1.85 (m, 4H), 1.26 (t, J = 7.4, 9H). 13C NMR 
(75 MHz, MeOD): δ 161.12, 158.53, 139.74, 130.20, 128.27, 127.60, 126.29, 114.44, 103.96, 
99.13, 66.56, 56.24, 54.49, 52.57, 25.59, 18.30, 6.47. Anal. Calc. for C26H38INO3: theor. C= 
57.88; H= 7.10; N= 2.60; I= 23.52; found C= 57.69; H= 7.10; N= 2.59; I= 23.58. HRMS 
(ESI+): calc. for C26H38NO3: theor. 412.2852; found [M]
+: 412.2849.  
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Synthesis of (E)-4-(3-bromopropyloxy)stilbene (118b) 
 
Procedure adapted from literature.192 A solution of trans-4-hydroxystilbene (196 mg – 1 mmol) 
in DMSO (1.4 ml) was added to a stirred suspension of finely ground NaOH (85 mg – 2.1 
mmol) in DMSO (5.6 ml). The mixture was stirred at room temperature for 30 minutes and then 
the 1,3-dibromopropane (403 mg – 2 mmol) was added dropwise. When stilbenol was reacted, 
the reaction mixture was filtered and 1M aqueous solution of HCl was added dropwise to the 
filtrate to reach pH 3. The crude product was precipitated by slowly adding cold water. The 
precipitate was isolated by filtration, dried under vacuum and recrystallized from ethanol 
affording a crude that was further purified through silica gel flash chromatography (gradient 
from hexane to hexane/acetonitrile 9:1). The pure product 118b was obtained as a beige solid 
(165 mg – 0.52 mmol, 52%). TLC (cyclohexane/ethyl acetate 9:1): Rf= 0.61. M.p.= 109 °C; 
literature192: M.p. = 108 – 109 °C. 1H NMR (300 MHz, CDCl3): δ 7.54 – 7.41 (m, 4H), 7.35 
(t, J = 6.7 Hz, 2H), 7.26 – 7.19 (m, 1H), 7.08 (d, J = 15.5 Hz, 1H), 7.03 – 6.87 (m, 3H), 4.14 (t, 
J = 6.4 Hz, 2H), 3.62 (t, J = 7.0 Hz, 2H), 2.34 (m, 2H).192 
Synthesis of (E)-4-(3-iodopropyloxy)stilbene (119b) 
 
Procedure adapted from literature.140 Intermediate (E)-4-(3-bromopropyloxy)stilbene (118b) 
(317 mg – 1 mmol) was dissolved in a saturated solution of NaI in acetone (10 ml), which was 
then refluxed overnight. After concentrating under vacuum, the residue was diluted with diethyl 
ether and subsequently washed with 10% aqueous Na2S2O5 and then with brine. The organic 
phase was dried over Na2SO4, filtered, and the solvent was evaporated under vacuum to give 
the desired intermediates 119b as a white solid (357 mg – 0.98 mmol, 98%). TLC 
(cyclohexane/ethyl acetate 9:1): Rf= 0.69. M.p.= 117 °C. 1H NMR (300 MHz, CDCl3): δ 7.47 
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(m, 4H), 7.34 (t, J = 7.4 Hz, 2H), 7.23 (m, 1H), 7.07 (d, J = 16.2 Hz, 1H), 6.97 (d, J = 16.2 Hz, 
1H), 6.89 (d, J = 8.8 Hz, 2H), 4.07 (t, J = 5.4 Hz, 2H), 3.38 (t, J = 6.2 Hz, 2H), 2.29 (m, 2H). 
Synthesis of (E)-4-(3-triphenylphosphoniumpropyloxy)stilbene iodide (18) 
 
Procedure adapted from literature.140 A solid mixture of PPh3 (5.25 g – 20 mmol) and 
intermediate (E)-4-(3-iodopropyloxy)stilbene (119b) (364 mg – 1 mmol) was heated to 100 °C 
so as to obtain a solution of the starting material in molten PPh3. The reaction mixture was 
slowly stirred at 100 °C for 3 hours and then cooled to room temperature without stirring any 
further. The re-solidified mixture was dissolved in the smallest possible volume of 
dichloromethane and diethyl ether was added dropwise under vigorous stirring. Afterwards, the 
solid precipitate was isolated by filtration affording the desired product 18 as a pale yellow 
solid (451 mg – 0.72 mmol, 72%). M.p.= 107 °C. 1H NMR (300 MHz, CDCl3): δ 7.96 – 7.62 
(m, 15H), 7.55 – 7.31 (m, 6H), 7.27 – 7.19 (m, 1H), 7.04 (d, J = 16.3 Hz, 1H), 6.95 (d, J = 16.3 
Hz, 1H), 6.91 – 6.82 (m, 2H), 4.35 (t, J = 5.7 Hz, 2H), 4.03 – 3.87 (m, 2H), 2.30 – 2.13 (m, 
2H). 13C NMR (75 MHz, CDCl3) δ 157.78, 137.55, 135.20, 135.17, 133.79, 133.69, 130.67, 
130.50, 128.65, 128.09, 127.77, 127.26, 126.81, 126.26, 118.57, 117.42, 114.92, 66.71, 66.49, 
22.90, 22.86, 20.37, 19.67. Anal. Calc. for C35H32IOP: theor. C= 67.10; H= 5.15; P= 4.94; I= 
20.26; found C= 66.91; H= 5.15; P= 4.90; I= 20.20. HRMS (ESI+): calc. for C35H32OP: theor. 
499.2191; found [M]+: 499.2193.  
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Synthesis of (E)-4-(4-bromobutyloxy)stilbene (118c) 
 
Procedure adapted from literature.192 A solution of trans-4-hydroxystilbene (196 mg – 1 mmol) 
in DMSO (1.4 ml) was added to a stirred suspension of finely ground NaOH (85 mg – 2.1 
mmol) in DMSO (5.6 ml). The mixture was stirred at room temperature for 30 minutes and then 
the 1,4-dibromobutane (431 mg – 2 mmol) was added dropwise. When stilbenol was reacted, 
the reaction mixture was filtered and 1M aqueous solution of HCl was added dropwise to the 
filtrate to reach pH 3. The crude product was precipitated by slowly adding cold water. The 
precipitate was isolated by filtration, dried under vacuum and recrystallized from ethanol 
affording the pure compound 118c as a white solid (123 mg – 0.37 mmol, 37%). TLC 
(cyclohexane/ethyl acetate 9:1): Rf= 0.61. M.p.= 115 °C; literature192: M.p. = 108 – 110 °C. 
1H NMR (300 MHz, CDCl3): δ 7.50 – 7.43 (m, 4H), 7.34 (t, J = 7.7 Hz, 2H), 7.23 (m, 1H), 
7.06 (d, J = 16.3 Hz, 1H), 6.97 (d, J = 16.3 Hz, 1H), 6.88 (d, J = 8.7 Hz, 2H), 4.02 (t, J = 5.9 
Hz, 2H), 3.50 (t, J = 6.5 Hz, 2H), 2.16 – 2.02 (m, 2H), 2.00 – 1.93  (m, 2H).192 
 Synthesis of (E)-4-(4-iodobutyloxy)stilbene (119c) 
 
Intermediate (E)-4-(4-bromobutyloxy)stilbene (118c) (331 mg – 1 mmol) was dissolved in a 
saturated solution of NaI in acetone (10 ml), which was then refluxed overnight. After 
concentrating under vacuum, the residue was diluted with diethyl ether and subsequently 
washed with 10% aqueous Na2S2O5 and then with brine. The organic phase was dried over 
Na2SO4, filtered, and the solvent was evaporated under vacuum to give the desired intermediate 
119c as a white solid (374 mg – 0.99 mmol, 99%). TLC (cyclohexane/ethyl acetate 9:1): Rf= 
0.66. M.p.= 124 °C. 1H NMR (300 MHz, CDCl3): δ 7.47 (m, 4H), 7.34 (t, J = 7.6 Hz, 2H), 
7.23 (m, 1H), 7.06 (d, J = 16.3 Hz, 1H), 6.97 (d, J = 16.3 Hz, 1H), 6.88 (t, J = 8.7 Hz, 2H), 4.01 
(t, J = 6.0 Hz, 2H), 3.27 (t, J = 6.8 Hz, 2H), 2.12 – 1.98 (m, 2H), 1.98-1.83 (m, 2H). 
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Synthesis of (E)-4-(4-triethylammoniumbutyloxy)stilbene iodide (15) 
 
Intermediate (E)-4-(4-iodobutyloxy)stilbene (119c) (378 mg – 1 mmol) was dissolved in 3 ml 
of triethylamine and 3 ml of toluene for 5 hours. Upon concentration under vacuum, the residue 
was diluted with diethyl ether and the obtained suspension was filtered, affording the desired 
product 15 as a beige solid (441 mg – 0.92 mmol, 92%). M.p.= 159 °C. 1H NMR (300 MHz, 
DMSO): δ 7.57 – 7.49 (m, 4H), 7.34 (t, J = 7.6 Hz, 2H), 7.26 – 7.13 (m, 2H), 7.07 (d, J = 16.4 
Hz, 1H), 6.95 (d, J = 8.7 Hz, 2H), 4.03 (m, 2H), 3.23 (m, 8H), 1.76 (m, 4H), 1.16 (t, J = 7.0 Hz, 
9H). 13C NMR (75 MHz, DMSO): δ 158.58, 137.78, 130.24, 129.12, 128.82, 128.44, 128.26, 
127.67, 126.63, 126.61, 115.20, 67.10, 56.08, 52.53, 52.49, 52.45, 46.24, 25.86, 18.41, 7.62. 
Anal. Calc. for C24H34INO: theor. C= 60.12; H= 7.15; N= 2.92; I= 26.47; found C= 59.92; H= 
7.18; N= 2.89; I= 26.58. HRMS (ESI+): calc. for C24H34NO: theor. 352.2640; found [M]
+: 
352.2644.  
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Synthesis of (E)-4-(4-triphenylphosphoniumbutyloxy)stilbene iodide (16) 
 
Procedure adapted from literature.140 A solid mixture of PPh3 (5.25 g – 20 mmol) and 
intermediate (E)-4-(4-iodobutyloxy)stilbene (119c) (378 mg – 1 mmol) was heated to 100 °C 
so as to obtain a solution of the starting material in molten PPh3. The reaction mixture was 
slowly stirred at 100 °C for 3 hours and then cooled to room temperature without stirring any 
further. The re-solidified mixture was dissolved in the smallest possible volume of 
dichloromethane and diethyl ether was added dropwise under vigorous stirring. Afterwards, the 
solid precipitate was isolated by filtration affording the desired product (16) as a white solid 
(512 mg – 0.80 mmol, 80%). M.p.= 109 °C. 1H NMR (300 MHz, CDCl3): δ 7.91 – 7.60 (m, 
15H), 7.54 – 7.27 (m, 6H), 7.27 – 7.17 (m, 1H), 7.03 (d, J = 16.3 Hz, 1H), 6.94 (d, J = 16.3 Hz, 
1H), 6.87 – 6.76 (d, J = 8.7 Hz, 2H), 4.08 (t, J = 5.6 Hz, 2H), 3.84 – 3.68 (m, 2H), 2.21 (p, J = 
6.4 Hz, 2H), 1.98 – 1.79 (m, 2H). 13C NMR (75 MHz, CDCl3) δ 158.36, 137.55, 135.18, 135.16, 
135.14, 133.75, 130.65, 130.65, 130.49, 130.22, 128.10, 127.75, 127.25, 126.67, 126.23, 
118.59, 117.45, 114.73, 66.47, 29.38, 29.16, 22.76, 22.09, 19.36, 19.31. Anal. Calc. for 
C36H34IOP: theor. C= 67.50; H= 5.35; P= 4.84; I= 19.81; found C= 67.32; H= 5.37; P= 4.81; 
I= 19.73. HRMS (ESI+): calc. for C36H34OP: theor. 513.2347; found [M]
+: 513.2348.  
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Synthesis of (E)-4-(5-bromopentyloxy)stilbene (118d) 
 
Procedure adapted from literature.192 A solution of trans-4-hydroxystilbene (196 mg – 1 mmol) 
in DMSO (1.4 ml) was added to a stirred suspension of finely ground NaOH (85 mg – 2.1 
mmol) in DMSO (5.6 ml). The mixture was stirred at room temperature for 30 minutes and then 
the 1,5-dibromopentane (458 mg – 2 mmol) was added dropwise. When stilbenol was reacted, 
the reaction mixture was filtered and 1M aqueous solution of HCl was added dropwise to the 
filtrate to reach pH 3. The crude product was precipitated by slowly adding cold water. The 
precipitate was isolated by filtration, dried under vacuum and recrystallized from ethanol 
affording the pure compound 118d as a white solid (97 mg – 0.28 mmol, 28%). TLC 
(cyclohexane/ethyl acetate 9:1): Rf= 0.62. M.p.= 98 °C; literature192: M.p. = 83 – 85 °C. 1H 
NMR (300 MHz, CDCl3): δ 7.46 (m, 4H), 7.34 (t, J = 7.6 Hz, 2H), 7.22 (m, 1H), 7.07 (d, J = 
16.4 Hz, 1H), 6.97 (d, J = 16.4 Hz, 1H), 6.88 (d, J = 8.7 Hz, 2H), 3.99 (t, J = 6.3 Hz, 2H), 3.45 
(t, J = 6.7 Hz, 2H), 2.02 – 1.89 (m, 2H), 1.89 – 1.77 (m, 2H), 1.65 (m, 2H). 
Synthesis of (E)-4-(5-iodopentyloxy)stilbene (119d) 
 
Procedure adapted from literature.140 Intermediate (E)-4-(5-bromopentyloxy)stilbene (118d) 
(345 mg – 1 mmol) was dissolved in a saturated solution of NaI in acetone (10 ml), which was 
then refluxed overnight. After concentrating under vacuum, the residue was diluted with diethyl 
ether and subsequently washed with 10% aqueous Na2S2O5 and then with brine. The organic 
phase was dried over Na2SO4, filtered, and the solvent was evaporated under vacuum to give 
the desired intermediate 119d as a white solid (392 mg – 1.00 mmol, 100%). TLC 
(cyclohexane/ethyl acetate 9:1): Rf= 0.68. M.p.= 102 °C. 1H NMR (300 MHz, CDCl3): δ 7.47 
(m, 4H), 7.34 (t, J = 7.5 Hz, 2H), 7.23 (m, 1H), 7.06 (d, J = 16.3 Hz, 1H), 6.96 (d, J = 16.3 Hz, 
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1H), 6.88 (d, J = 8.7 Hz, 2H), 3.99 (t, J = 6.3 Hz, 2H), 3.23 (t, J = 7.0 Hz, 2H), 1.99 – 1.74 (m, 
4H), 1.68 – 1.56 (m, 2H). 
Synthesis of (E)-4-(5-triphenylphosphoniumpentyloxy)stilbene iodide (19) 
 
Procedure adapted from literature.140 A solid mixture of PPh3 (5.25 g – 20 mmol) and 
intermediate (E)-4-(5-iodopentyloxy)stilbene (392 mg – 1 mmol) was heated to 100 °C so as to 
obtain a solution of the starting material in molten PPh3. The reaction mixture was slowly stirred 
at 100 °C for 3 hours and then cooled to room temperature without stirring any further. The re-
solidified mixture was dissolved in the smallest possible volume of dichloromethane and 
diethyl ether was added dropwise under vigorous stirring. Afterwards, the solid precipitate was 
isolated by filtration affording the desired product 19 as a white solid (602 mg – 0.92 mmol, 
92%). M.p.= 99 °C. 1H NMR (300 MHz, DMSO): δ 7.94 – 7.68 (m, 15H), 7.58 – 7.45 (m, 4H), 
7.34 (t, J = 7.6 Hz, 2H), 7.27 – 7.12 (m, 2H), 7.06 (d, J = 16.4 Hz, 1H), 6.85 (d, J = 8.7 Hz, 
2H), 3.93 (t, J = 6.0 Hz, 2H), 3.62 – 3.54 (m, 2H), 1.72 (m, 2H), 1.60 (m, 4H). 13C NMR (75 
MHz, DMSO): δ 158.71, 137.80, 135.37, 135.33, 134.12, 133.99, 130.79, 130.63, 130.04, 
129.11, 128.47, 128.26, 127.63, 126.61, 126.50, 119.55, 118.42, 115.09, 67.69, 28.25, 27.22, 
27.00, 22.09, 21.02, 20.36. Anal. Calc. for C37H36IOP: theor. C= 67.89; H= 5.54; P= 4.73; I= 
19.39; found C= 67.61; H= 5.58; P= 4.67; I= 19.27. HRMS (ESI+): calc. for C37H36OP: theor. 
527.2504; found [M]+: 527.2511.  
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Synthesis of (E)-4-(6-bromohexyloxy)stilbene (118e)  
 
Procedure adapted from literature.193 A solution of trans-4-hydroxystilbene (196 mg – 1 mmol) 
in DMSO (1.4 ml) was added to a stirred suspension of finely ground NaOH (85 mg – 2.1 
mmol) in DMSO (5.6 ml). The mixture was stirred at room temperature for 30 minutes and then 
the 1,6-dibromohexane (488 mg – 2 mmol) was added dropwise. When stilbenol was reacted, 
the reaction mixture was filtered and 1M aqueous solution of HCl was added dropwise to the 
filtrate to reach pH 3. The crude product was precipitated by slowly adding cold water. The 
precipitate was isolated by filtration, dried under vacuum and recrystallized from ethanol 
affording the pure compound 118e as a white solid (144 mg – 0.40 mmol, 40%). TLC 
(Cyclohexane / Ethyl acetate 9:1): Rf= 0.62. M.p.= 111 °C; literature193: M.p. = 89 – 91 °C. 
1H NMR (300 MHz, CDCl3): δ 7.46 (m, 4H), 7.34 (t, J = 7.6 Hz, 2H), 7.25 – 7.18 (m, 1H), 
7.06 (d, J = 16.4 Hz, 1H), 6.96 (d, J = 16.4 Hz, 1H), 6.88 (d, J = 7.9 Hz, 2H), 3.98 (t, J = 6.4 
Hz, 2H), 3.42 (t, J = 6.7 Hz, 2H), 1.96 – 1.73 (m, 4H), 1.55 – 1.44 (m, 4H). 
Synthesis of (E)-4-(6-iodohexyloxy)stilbene (119e) 
 
Procedure adapted from literature.140 Intermediate (E)-4-(6-bromohexyloxy)stilbene (118e) 
(359 mg – 1 mmol) was dissolved in a saturated solution of NaI in acetone (10 ml), which was 
then refluxed overnight. After concentrating under vacuum, the residue was diluted with diethyl 
ether and subsequently washed with 10% aqueous Na2S2O5 and then with brine. The organic 
phase was dried over Na2SO4, filtered, and the solvent was evaporated under vacuum to give 
the desired intermediate 119e as a white solid (406 mg – 1.00 mmol, 100%). TLC 
(cyclohexane/ethyl acetate 9:1): Rf= 0.76. M.p.= 126 °C. 1H NMR (300 MHz, CDCl3): δ 7.47 
(m, 4H), 7.34 (t, J = 7.6 Hz, 2H), 7.23 (m, 1H), 7.06 (d, J = 16.3 Hz, 1H), 6.96 (d, J = 16.3 Hz, 
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1H), 6.88 (d, J = 8.6 Hz, 2H), 3.98 (t, J = 6.4 Hz, 2H), 3.20 (t, J = 6.7 Hz, 2H), 1.93 – 1.72 (m, 
4H), 1.50 – 1.37 (m, 4H). 
Synthesis of (E)-4-(6-triphenylphosphoniumhexyloxy)stilbene iodide (20) 
 
Procedure adapted from literature.140 A solid mixture of PPh3 (5.25 g – 20 mmol) and 
intermediate (E)-4-(6-iodohexyloxy)stilbene (119e) (406 mg – 1 mmol) was heated to 100 °C 
so as to obtain a solution of the starting material in molten PPh3. The reaction mixture was 
slowly stirred at 100 °C for 3 hours and then cooled to room temperature without stirring any 
further. The re-solidified mixture was dissolved in the smallest possible volume of 
dichloromethane and diethyl ether was added dropwise under vigorous stirring. Afterwards, the 
solid precipitate was isolated by filtration affording the desired product 20 as a white solid (595 
mg – 0.89 mmol, 89%).M.p.= 88 °C. 1H NMR (300 MHz, CDCl3): δ 7.90 – 7.63 (m, 15H), 
7.50 – 7.36 (m, 4H), 7.33 (t, J = 7.4 Hz, 2H), 7.25 – 7.16 (m, 1H), 7.04 (d, J = 16.4 Hz, 1H), 
6.94 (d, J = 16.4 Hz, 1H), 6.88 – 6.79 (d, J = 8.8 Hz, 2H), 3.93 (t, J = 6.2, 2H), 3.76 (m, 2H), 
1.71 (m, 6H), 1.48 (m, 2H). 13C NMR (75 MHz, DMSO) δ 158.79, 137.81, 135.38, 135.33, 
134.13, 133.99, 130.79, 130.63, 130.00, 129.12, 128.49, 128.26, 127.64, 126.61, 126.49, 
119.58, 118.45, 115.10, 67.76, 30.13, 29.90, 28.78, 25.21, 22.22, 20.97, 20.31. Anal. Calc. for 
C38H38IOP: theor. C= 68.26; H= 5.73; P= 4.63; I= 18.98; found C= 68.08; H= 5.76; P= 4.57; 
I= 18.81. HRMS (ESI+): calc. for C38H38OP: theor. 541.2660; found [M]
+: 541.2663.  
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Synthesis of (E)-4-(6-triethylammoniumhexyloxy)stilbene iodide (25) 
 
Intermediate (E)-4-(6-iodohexyloxy)stilbene (119e) (406 mg – 1 mmol) was dissolved in 3 ml 
of triethylamine and 3 ml of toluene for 5 hours. Upon concentration under vacuum, the residue 
was diluted with diethyl ether and the obtained suspension was filtered, affording the desired 
product 25 as a beige solid (411 mg – 0.81 mmol, 81%). M.p.= 166 °C. 1H NMR (300 MHz, 
CDCl3): δ 7.52 – 7.38 (m, 4H), 7.33 (t, J = 7.6 Hz, 2H), 7.24 – 7.18 (m, 1H), 7.05 (d, J = 16.5 
Hz, 1H), 6.95 (d, J = 16.5 Hz, 1H), 6.88 (d, J = 7.3 Hz, 2H), 3.99 (t, J = 6.0 Hz, 2H), 3.44 (q, J 
= 7.0 Hz, 6H), 3.34 – 3.22 (m, 2H), 1.94 – 1.67 (m, 4H), 1.57 – 1.48 (m, 4H), 1.39 (t, J = 7.0 
Hz, 9H). 13C NMR (75 MHz, CDCl3): δ 158.72, 137.58, 130.03, 128.67, 128.16, 127.77, 
127.25, 126.57, 126.24, 114.82, 67.65, 57.77, 53.85, 28.98, 26.22, 25.69, 22.21, 8.36. Anal. 
Calc. for C26H38INO: theor. C= 61.53; H= 7.55; I= 25.01; N= 2.76; found C= 61.33; H= 7.57; 
I= 25.11; N= 2.74. HRMS (ESI+): calc. for C26H38NO: theor. 380.2953; found [M]
+: 380.2950.  
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Synthesis of (E)-4-(7-bromoheptyloxy)stilbene (118f) 
 
Procedure adapted from literature.193 A solution of trans-4-hydroxystilbene (196 mg – 1 mmol) 
in DMSO (1.4 ml) was added to a stirred suspension of finely ground NaOH (85 mg – 2.1 
mmol) in DMSO (5.6 ml). The mixture was stirred at room temperature for 30 minutes and then 
the 1,7-dibromoeptane (516 mg – 2 mmol) was added dropwise. When stilbenol was reacted, 
the reaction mixture was filtered and 1M aqueous solution of HCl was added dropwise to the 
filtrate to reach pH 3. The crude product was precipitated by slowly adding cold water. The 
precipitate was isolated by filtration, dried under vacuum and recrystallized from ethanol 
affording the pure compound 118f as a white solid (153 mg – 0.41 mmol, 41%). TLC 
(cyclohexane/ethyl acetate 9:1): Rf= 0.62. M.p.= 111 °C. 1H NMR (300 MHz, CDCl3): 7.45 
(m, 4H), 7.33 (t, J = 7.3 Hz, 2H), 7.23 (m, 1H), 7.05 (d, J = 16.3 Hz, 1H), 6.95 (d, J = 16.3 Hz, 
1H), 6.87 (d, J = 8.5 Hz, 2H), 3.96 (t, J = 6.2 Hz, 2H), 3.40 (t, J = 6.7 Hz, 2H), 1.95 – 1.70 (m, 
4H), 1.47 (s, 6H). 
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Synthesis of (E)-4-(7-iodoheptyloxy)stilbene (119f) 
 
Procedure adapted from literature.140 Intermediate (E)-4-(7-bromoheptyloxy)stilbene (118f) 
(373 mg – 1 mmol) was dissolved in a saturated solution of NaI in acetone (10 ml), which was 
then refluxed overnight. After concentrating under vacuum, the residue was diluted with diethyl 
ether and subsequently washed with 10% aqueous Na2S2O5 and then with brine. The organic 
phase was dried over Na2SO4, filtered, and the solvent was evaporated under vacuum to give 
the desired intermediate 119f as a white solid (420 mg – 1.00 mmol, 100%). TLC 
(cyclohexane/ethyl acetate 9:1): Rf= 0.76. M.p.= 84 °C. 1H NMR (300 MHz, CDCl3): δ 7.47 
(m, 4H), 7.34 (t, J = 7.7 Hz, 2H), 7.22 (m, 1H), 7.06 (d, J = 16.3 Hz, 1H), 6.96 (d, J = 16.3 Hz, 
1H), 6.88 (d, J = 8.6 Hz, 2H), 3.97 (t, J = 6.5 Hz, 2H), 3.19 (t, J = 6.0, J = 4.2 Hz, 2H), 1.89 – 
1.72 (m, 4H), 1.44 (m, 6H).  
Synthesis of (E)-4-(7-triphenylphosphoniumheptyloxy)stilbene iodide (21) 
 
Procedure adapted from literature.140 A solid mixture of PPh3 (5.25 g – 20 mmol) and 
intermediate (E)-4-(7-iodoheptyloxy)stilbene (119f) (420 mg – 1 mmol) was heated to 100 °C 
so as to obtain a solution of the starting material in molten PPh3. The reaction mixture was 
slowly stirred at 100 °C for 3 hours and then cooled to room temperature without stirring any 
further. The re-solidified mixture was dissolved in the smallest possible volume of 
dichloromethane and diethyl ether was added dropwise under vigorous stirring. Afterwards, the 
solid precipitate was isolated by filtration affording the desired product 21 as a white solid (608 
mg – 0.89 mmol, 89%). M.p.= 76 °C. 1H NMR (300 MHz, CDCl3): δ 7.91 – 7.76 (m, 9H), 7.76 
– 7.64 (m, 6H), 7.52 – 7.39 (m, 4H), 7.34 (t, J = 7.5 Hz, 2H), 7.26 – 7.18 (m, 1H), 7.05 (d, J = 
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16.3 Hz, 1H), 6.95 (d, J = 16.3 Hz, 1H), 6.85 (d, J = 8.8 Hz, 2H), 3.93 (t, J = 6.4 Hz, 2H), 3.80 
– 3.65 (m, 2H), 1.81 – 1.66 (m, 6H), 1.48 – 1.29 (m, 4H). 13C NMR (75 MHz, DMSO): δ 
158.82, 137.81, 135.36, 135.32, 134.11, 133.98, 130.79, 130.62, 129.96, 129.28, 129.11, 
128.49, 128.25, 127.62, 126.60, 126.45, 119.58, 118.45, 115.09, 67.80, 30.32, 30.10, 28.94, 
28.27, 25.65, 22.18, 22.13, 20.95, 20.29. Anal. Calc. for C39H40IOP: theor. C= 68.62; H= 5.91; 
P= 4.54; I= 18.59; found C= 68.49; H= 5.92; P= 4.47; I= 18.53. HRMS (ESI+): calc. for 
C39H40OP: theor. 555.2817; found [M]
+: 555.2805.  
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Synthesis of (E)-4-(8-bromooctyloxy)stilbene (118g) 
 
Procedure adapted from literature.193 A solution of trans-4-hydroxystilbene (196 mg – 1 mmol) 
in DMSO (1.4 ml) was added to a stirred suspension of finely ground NaOH (85 mg – 2.1 
mmol) in DMSO (5.6 ml). The mixture was stirred at room temperature for 30 minutes and then 
the 1,8-dibromooctane (544 mg – 2 mmol) was added dropwise. When stilbenol was reacted, 
the reaction mixture was filtered and 1M aqueous solution of HCl was added dropwise to the 
filtrate to reach pH 3. The crude product was precipitated by slowly adding cold water. The 
precipitate was isolated by filtration, dried under vacuum and recrystallized from ethanol 
affording the pure compound 118g as a white solid (174 mg – 0.45 mmol, 45%). TLC 
(Cyclohexane / Ethyl acetate 9:1): Rf= 0.63. M.p.= 110 °C. 1H NMR (300 MHz, CDCl3): δ 
7.46 (m, 4H), 7.34 (t, J = 7.5 Hz, 2H), 7.2 (m, 1H), 7.07 (d, J = 16.3 Hz, 1H), 6.96 (d, J = 16.3 
Hz, 1H), 6.88 (d, J = 8.6 Hz, 2H), 3.97 (t, J = 6.5 Hz, 2H), 3.41 (t, J = 6.8 Hz, 2H), 1.92 – 1.72 
(m, 4H), 1.52 – 1.27 (m, 8H). 
Synthesis of (E)-4-(8-iodooctyloxy)stilbene (119g) 
 
Procedure adapted from literature.140 Intermediate (E)-4-(8-bromooctyloxy)stilbene (118g) 
(387 mg – 1 mmol) was dissolved in a saturated solution of NaI in acetone (10 ml), which was 
then refluxed overnight. After concentrating under vacuum, the residue was diluted with diethyl 
ether and subsequently washed with 10% aqueous Na2S2O5 and then with brine. The organic 
phase was dried over Na2SO4, filtered, and the solvent was evaporated under vacuum to give 
the desired intermediate 119g as a white solid (430 mg – 0.99 mmol, 99%). TLC (Cyclohexane 
/ Ethyl Acetate 9:1): Rf= 0.74. M.p.= 120 °C. 1H NMR (300 MHz, CDCl3): δ 7.46 (m, 4 H), 
7.33 (t, J = 7.5 Hz, 2H), 7.22 (m, 1H), 7.06 (d, J = 16.3 Hz, 1H), 6.95 (d, J = 16.3 Hz, 1H), 6.88 
  289 
(d, J = 8.7 Hz, 2H), 3.97 (t, J = 6.5 Hz, 2H), 3.18 (t, J = 7.0 Hz, 2H), 1.79 (m, 4H), 1.43 - 1.31 
(m, 8H). 
Synthesis of (E)-4-(8-triphenylphosphoniumoctyloxy)stilbene iodide (22) 
 
Procedure adapted form literature.140 A solid mixture of PPh3 (5.25 g – 20 mmol) and 
intermediate (E)-4-(8-iodooctyloxy)stilbene (119g) (434 mg – 1 mmol) was heated to 100 °C 
so as to obtain a solution of the starting material in molten PPh3. The reaction mixture was 
slowly stirred at 100 °C for 3 hours and then cooled to room temperature without stirring any 
further. The re-solidified mixture was dissolved in the smallest possible volume of 
dichloromethane and diethyl ether was added dropwise under vigorous stirring. Afterwards, the 
solid precipitate was isolated by filtration affording the desired product 22 as a white solid (599 
mg – 0.86 mmol, 86%). M.p.= 80 °C. 1H NMR (300 MHz, CDCl3): δ 7.89 – 7.74 (m, 9H), 7.74 
– 7.65 (m, 6H), 7.52 – 7.38 (m, 4H), 7.33 (t, J = 7.5 Hz, 2H), 7.27 – 7.16 (m, 1H), 7.05 (d, J = 
16.3 Hz, 1H), 6.94 (d, J = 16.3 Hz, 1H), 6.85 (d, J = 8.8 Hz, 2H), 3.93 (t, J = 6.5 Hz, 2H), 3.78 
– 3.63 (m, 2H), 1.78 – 1.66 (m, 6H), 1.47 – 1.25 (m, 6H). 13C NMR (75 MHz, CDCl3): δ 158.83, 
137.63, 135.17, 135.13, 133.70, 133.57, 130.66, 130.50, 129.84, 128.61, 128.24, 127.66, 
127.15, 126.39, 126.19, 118.65, 117.51, 114.71, 67.94, 30.43, 30.23, 29.09, 29.01, 28.87, 25.82, 
23.44, 22.77, 22.60, 22.54. Anal. Calc. for C40H42IOP: theor. C= 68.96; H= 6.08; P= 4.45; I= 
18.22; found C= 68.88; H= 6.08; P= 4.39; I= 18.16. HRMS (ESI+): calc. for C40H42OP: theor. 
569.2973; found [M]+: 569.2976.  
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Synthesis of  (E)-4-(8-triethylammoniumoctyloxy)stilbene iodide (26) 
 
Intermediate (E)-4-(8-iodooctyloxy)stilbene (119g) (434 mg – 1 mmol) was dissolved in 3 ml 
of triethylamine and 3 ml of toluene for 5 hours. Upon concentration under vacuum, the residue 
was diluted with diethyl ether and the obtained suspension was filtered, affording the desired 
product 26 as a beige solid 402 mg – 0.75 mmol, 75%). M.p.= 163 °C. 1H NMR (300 MHz, 
CDCl3): δ 7.53 – 7.38 (m, 4H), 7.33 (t, J = 7.6 Hz, 2H), 7.25 – 7.17 (m, 1H), 7.05 (d, J = 16.4 
Hz, 1H), 6.95 (d, J = 16.4 Hz, 1H), 6.87 (d, J = 8.8 Hz, 2H), 3.95 (t, J = 6.4 Hz, 2H), 3.44 (q, J 
= 7.2 Hz, 6H), 3.31 – 3.19 (m, 2H), 1.84 – 1.58 (m, 4H), 1.53 – 1.27 (m, 17H). 13C NMR (75 
MHz, CDCl3): δ 158.84, 137.62, 129.95, 128.64, 128.21, 127.70, 127.20, 126.50, 126.21, 
114.76, 67.91, 57.80, 53.82, 29.12, 29.04, 26.37, 25.83, 22.21, 8.32. Anal. Calc. for C28H42INO: 
theor. C= 62.80; H= 7.90; I= 23.70; N= 2.62; found C= 62.58; H= 7.92; I= 23.80; N= 2.59. 
HRMS (ESI+): calc. for C28H42NO: theor. 408.3266; found [M]
+: 408.3264.  
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Synthesis of (E)-4-(9-bromononyloxy)stilbene (118h) 
 
Procedure adapted form literature.193 A solution of trans-4-hydroxystilbene (196 mg – 1 mmol) 
in DMSO (1.4 ml) was added to a stirred suspension of finely ground NaOH (85 mg – 2.1 
mmol) in DMSO (5.6 ml). The mixture was stirred at room temperature for 30 minutes and then 
the 1,9-dibromononane (572 mg – 2 mmol) was added dropwise. When stilbenol was reacted, 
the reaction mixture was filtered and 1M aqueous solution of HCl was added dropwise to the 
filtrate to reach pH 3. The crude product was precipitated by slowly adding cold water. The 
precipitate was isolated by filtration, dried under vacuum and recrystallized from ethanol 
affording the pure compound 118h as a white solid (337 mg – 0.84 mmol, 84%). TLC 
(Cyclohexane / Ethyl acetate 9:1): Rf= 0.63. M.p.= 111 °C. 1H NMR (300 MHz, CDCl3): δ 
7.46 (m, 4H), 7.34 (t, J = 7.5 Hz, 2H), 7.23 (m, 1H), 7.07 (d, J = 16.3 Hz, 1H), 6.96 (d, J = 16.3 
Hz, 1H), 6.88 (d, J = 8.7 Hz, 2H), 3.97 (t, J = 6.5 Hz, 2H), 3.41 (t, J = 6.8 Hz, 2H), 1.95 – 1.68 
(m, 4H), 1.49 – 1.24 (m, 10H). 
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Synthesis of (E)-4-(9-iodononyloxy)stilbene (119h) 
 
Procedure adapted form literature.140 Intermediate (E)-4-(9-bromononyloxy)stilbene (118h) 
(401 mg – 1 mmol) was dissolved in a saturated solution of NaI in acetone (10 ml), which was 
then refluxed overnight. After concentrating under vacuum, the residue was diluted with diethyl 
ether and subsequently washed with 10% aqueous Na2S2O5 and then with brine. The organic 
phase was dried over Na2SO4, filtered, and the solvent was evaporated under vacuum to give 
the desired intermediate 119h as a white solid (448 mg – 1.00 mmol, 100%). TLC 
(cyclohexane/ethyl acetate 9:1): Rf= 0.74. M.p.= 100 °C. 1H NMR (300 MHz, CDCl3): δ 7.46 
(m, 4H), 7.34 (t, J = 7.5, 2H), 7.22 (m, 1H), 7.06 (d, J = 16.3 Hz, 1H), 6.96 (d, J = 16.3 Hz, 
1H), 6.88 (d, J = 8.8 Hz 2H), 3.97 (t, J = 6.5 Hz, 2H), 3.19 (t, J = 7.0 Hz, 2H), 1.92 – 1.68 (m, 
4H), 1.49 – 1.18 (m, 10H).  
Synthesis of (E)-4-(9-triphenylphosphoniumnonyloxy)stilbene iodide (23) 
 
A solid mixture of PPh3 (5.25 g – 20 mmol) and intermediate (E)-4-(9-iodononyloxy)stilbene 
(119h) (448 mg – 1 mmol) was heated to 100 °C so as to obtain a solution of the starting material 
in molten PPh3. The reaction mixture was slowly stirred at 100 °C for 3 hours and then cooled 
to room temperature without stirring any further. The re-solidified mixture was dissolved in the 
smallest possible volume of dichloromethane and diethyl ether was added dropwise under 
vigorous stirring. Afterwards, the solid precipitate was isolated by filtration affording the 
desired product 23 as a white solid (647 mg – 0.91 mmol, 91%). M.p.= 72 °C. 1H NMR (300 
MHz, CDCl3): δ 7.83 – 7.72 (m, 9H), 7.72 – 7.62 (m, 6H), 7.48 – 7.34 (m, 4H), 7.30 (t, J = 7.5 
Hz, 2H), 7.18 (m, 1H), 7.01 (d, J = 16.3 Hz, 1H), 6.91 (d, J = 16.3 Hz, 1H), 6.84 (d, J = 8.7 Hz, 
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2H), 3.91 (t, J = 6.5 Hz, 2H), 3.59 (m, 2H), 1.79 – 1.51 (m, 6H), 1.45 – 1.12 (m, 8H). 13C NMR 
(75 MHz, CDCl3): δ 158.86, 137.63, 135.17, 135.13, 133.70, 133.57, 130.66, 130.50, 129.84, 
128.61, 128.24, 127.67, 127.14, 126.38, 126.19, 118.65, 117.51, 114.71, 68.01, 30.48, 30.28, 
29.15, 29.13, 29.04, 29.01, 25.89, 23.45, 22.79, 22.59, 22.53. Anal. Calc. for C41H44IOP: theor. 
C= 69.29; H= 6.24; P= 4.36; I= 17.86; found C= 69.02; H= 6.26; P= 4.30; I= 17.78. HRMS 
(ESI+): calc. for C41H44OP: theor. 583.3130; found [M]
+: 583.3129.  
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Synthesis of (E)-4-(10-bromodecyloxy)stilbene (118i) 
 
Procedure adapted from literature.193 A solution of trans-4-hydroxystilbene (196 mg – 1 mmol) 
in DMSO (1.4 ml) was added to a stirred suspension of finely ground NaOH (85 mg – 2.1 
mmol) in DMSO (5.6 ml). The mixture was stirred at room temperature for 30 minutes and then 
the 1,4-dibromobutane (600 mg – 2 mmol) was added dropwise. When stilbenol was reacted, 
the reaction mixture was filtered and 1M aqueous solution of HCl was added dropwise to the 
filtrate to reach pH 3. The crude product was precipitated by slowly adding cold water. The 
precipitate was isolated by filtration, dried under vacuum and recrystallized from ethanol 
affording the pure compound 118i as a white solid (153 mg – 0.37 mmol, 37%). TLC 
(Cyclohexane / Ethyl Acetate 9:1): Rf= 0.63. M.p.= 112 °C. 1H NMR (300 MHz, CDCl3): δ 
7.46 (m, 4H), 7.34 (t, J = 7.6 Hz, 2H), 7.23 (m, 1H), 7.06 (d, J = 16.3 Hz, 1H), 6.96 (d, J = 16.3 
Hz, 1H), 6.89 (d, J = 8.7 Hz, 2H), 3.97 (t, J = 6.5 Hz, 2H), 3.41 (t, J = 6.9 Hz, 2H), 1.93 – 1.71 
(m, 4H), 1.49 – 1.23 (m, 12H).  
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Synthesis of (E)-4-(10-iododecyloxy)stilbene (119i) 
 
Procedure adapted from literature.140 Intermediate (E)-4-(10-bromodecyloxy)stilbene (118i) 
(415 mg – 1 mmol) was dissolved in a saturated solution of NaI in acetone (10 ml), which was 
then refluxed overnight. After concentrating under vacuum, the residue was diluted with diethyl 
ether and subsequently washed with 10% aqueous Na2S2O5 and then with brine. The organic 
phase was dried over Na2SO4, filtered, and the solvent was evaporated under vacuum to give 
the desired intermediate 119i as a white solid (462 mg – 1.00 mmol, 100%). TLC (Cyclohexane 
/ Ethyl Acetate 9:1): Rf= 0.74. M.p.= 122 °C. 1H NMR (300 MHz, CDCl3): δ 7.46 (m, 4H), 
7.34 (t, J = 7.5 Hz, 2H), 7.22 (m, 1H), 7.06 (d, J = 16.4 Hz, 1H), 6.96 (d, J = 16.4 Hz, 1H), 6.92 
– 6.85 (m, 2H), 3.97 (t, J = 6.5 Hz, 2H), 3.19 (t, J = 7.0 Hz, 2H), 1.88 – 1.70 (m, 4H), 1.51 – 
1.22 (m, 12H).  
Synthesis of (E)-4-(10-triphenylphosphoniumdecyloxy)stilbene iodide (24) 
 
Procedure adapted from literature.140 A solid mixture of PPh3 (5.25 g – 20 mmol) and 
intermediate (E)-4-(10-bromodecyloxy)stilbene (119i)  (448 mg – 1 mmol) was heated to 
100 °C so as to obtain a solution of the starting material in molten PPh3. The reaction mixture 
was slowly stirred at 100 °C for 3 hours and then cooled to room temperature without stirring 
any further. The re-solidified mixture was dissolved in the smallest possible volume of 
dichloromethane and diethyl ether was added dropwise under vigorous stirring. Afterwards, the 
solid precipitate was isolated by filtration affording the desired product 24 as a white solid (647 
mg – 0.87 mmol, 87%). M.p.= 67 °C. 1H NMR (300 MHz, CDCl3): δ 7.90 – 7.74 (m, 9H), 
7.79 – 7.63 (m, 6H), 7.53 – 7.38 (m, 4H), 7.33 (t, J = 7.5 Hz, 2H), 7.31 – 7.17 (m, 1H), 7.06 (d, 
J = 16.3 Hz, 1H), 6.95 (d, J = 16.3 Hz, 1H), 6.88 (d, J = 8.7 Hz, 2H), 3.95 (t, J = 6.5 Hz, 2H), 
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3.73 (m, 2H), 1.82 – 1.60 (m, 6H), 1.42 (m, 2H), 1.25 (m, 8H). 13C NMR (75 MHz, CDCl3): δ 
158.87, 137.64, 135.18, 135.14, 133.72, 133.59, 130.67, 130.50, 129.84, 128.63, 128.53, 
128.43, 128.25, 127.68, 127.16, 126.38, 126.20, 118.67, 117.53, 114.71, 68.03, 30.54, 30.34, 
29.36, 29.24, 29.20, 29.13, 29.12, 29.09, 25.94, 23.46, 22.80, 22.62, 22.56. Anal. Calc. for 
C42H46IOP: theor. C= 69.61; H= 6.40; P= 4.27; I= 17.51; found C= 69.54; H= 6.39; P= 4.19; 
I= 17.39. HRMS (ESI+): calc. for C42H46OP: theor. 597.3286; found [M]
+: 597.3295. 
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